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Atherosclerosis remains one the main causes of mortality and contributes significantly to 
the increase of morbidity in the western world. The origin of this problem is initiated by 
changes in the endothelial layer caused by dyslipidemia, hypertension, and pro-inflammatory 
mediators that lead to the exposure of adhesion molecules and infiltration of circulating 
leukocytes into the arterial wall. The recognition of modified lipids, parts from damaged cells 
or modified matrix components by immune cells cause an ongoing inflammatory process that 
contributes to lesion and plaque formation.[1-3] Early atherosclerotic plaques consist of lipid 
depositions, foam cells and T cells and resides most in the large and middle arteries such as 
aorta, coronary arteries, carotid arteries and femoral arteries.[1] During progression of the 
plaque a fibrous cap is formed overlying the necrotic core of the plaque. This fibrous cap is 
formed by migration and proliferation of smooth muscle cell (SMC) and extracellular matrix 
depositions. Progression in growth of the atherosclerotic plaques narrows the vessel, limiting 
blood flow and thereby essential oxygen provision to the organs and tissues[4, 5]. A major 
problem occurs when the fibrous cap ruptures and the core of the plaque is exposed to the 
blood. This will cause platelets to aggregate and to form blood clots that will close up the total 
vessel causing immediate ischemia, an infarction[6]. This requires intervention strategies 
to re-open the vessel to restore bloodflow. Due to increased possibilities for the treatment 
and the prevention of a myocardial infarction (MI) survival chances of these patients have 
increased significantly.
Percutaneous Coronary Intervention
The invention of Percutaneous Coronary Intervention, also known as balloon angioplasty, 
has ensured that closed vessels could be re-opened without the requirement of heart surgery. 
Unfortunately, the results are not always satisfactory because in a significant number of 
patients the re-opened vessel narrows again at the place of initial treatment. This process 
is called restenosis a problem strongly mediated by inflammation, proliferation and matrix 




Intravascular ultrasound images of the various stages of coronary artery disease. Indicated are the outer border 
of the vessel (green), the lumen (red), and the coronary stent (pink). Schematic representations are shown to 
the right of these images. The processes occurring in the vessel immediately after PCI with stent placement are 
highlighted in detail. Abbreviations: ADMA, asymmetric dimethylarginine; ECM, extra cellular matrix; MMPs, 
matrix metalloproteinases; mTOR, mammalian target of rapamycin; PAI-1, plasminogen activator inhibitor 1; PCI, 
percutaneous coronary interventions; TNF, tumor necrosis factor; VSMC, vascular smooth muscle cell. (Jukema et 
al. Nature Reviews Cardiology 9, 53-62 2012)[7]
Risk factors of restenosis development are diabetes, smoking, stent type, lesion complexity 
and off-label use of stents. Although strong evidence for influence of inflammation has been 
provided, the exact pathophysiology of restenosis has not been fully elucidated yet. Gaining 
more insight in this process may be fundamental for the development of novel therapeutic 
strategies 
In the late 70s rates of restenosis and procedural failures were still around 40%. As 
interventional cardiologist gained more experience with the procedure the number of failed 
procedures was significantly reduced. Restenosis rates however began to decline only after 
introduction of the stent. A stent is a small tube inserted into a natural passage/conduit to 
prevent or counteract a disease-induced, localized flow constriction. This stent prohibits the 
early phase of restenosis in which elastic recoil of the vessel after balloon angioplasty narrows 
the lumen. The intermediate phase of intimal hyperplasia and late phase of atherosclerosis 
formation however are not sufficiently prohibited by the stent. The vascular injury and 
presence of a foreign body even may cause a stronger inflammatory reaction leading to platelet 
aggregation, proliferation of smooth muscle cells in the vessel wall and influx of lipids and 
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immune cells derived from the circulation that all contribute to the formation of intimal 
hyperplasia, accelerated atherosclerosis and thereby the incidence of restenosis[7, 9, 10]. A 
novel invention to overcome this problem is the use of stents that secrete specific drugs, which 
inhibit the proliferation of cells, the so-called drug eluting stents (DES)[11, 12]. As a result 
restenosis numbers further decreased. Unfortunately, the reverse side is an increased risk for 
in-stent-thrombosis caused by a reduction in re-endothelialisation, activation of coagulation 
mediators such as tissue factor and is associated with high morbidity and mortality rates[7, 
11, 13]. Therefore patients with DES have to take medication that inhibits platelet aggregation 
such as Ascal and Clopidogrel for longer periods, thereby increasing bleeding risk but also 
experience a greater risk of in-stent thrombosis, and thus infarction, when they undergo non-
cardiac surgery within one year after stent placement[14, 15]. Nowadays PCI is a safe and 
effective treatment of atherosclerotic coronary artery disease however restenosis remains an 
important complication after PCI with rates in daily practise of 5-15%.
Vein graft remodeling
The trade-off for the choice of intervention type is associated with the severity of the 
stenosis, strictures, and the number of occluded vessels[16]. In some cases it is not possible 
or unbeneficial to perform PCI and an alternative intervention strategy is provided by the 
use of a bypass. Nowadays thoracic surgeons make mainly use of arterial grafts, such as the 
left and right mammary artery. In some cases, however, when these vessels are unavailable 
or unusable, venous conduits offer an alternative. So vein grafts are still important conduits 
for revascularization during both coronary but also peripheral bypass surgery. Unfortunately 
vein graft failure is not an uncommon event.[17] Early graft failure is usually due to 
thrombosis, but long-term graft failure is caused by vein graft disease (VGD) induced by the 
wall thickening due to intimal hyperplasia, which is part of an inflammatory reaction. Vein 
graft wall thickening is in part characterized by smooth muscle cell (SMC) proliferation, 
matrix turnover, and an influx of lipids and inflammatory cells. When this process continues 
and additional atherosclerosis formation takes place the lumen slowly closes the vessel 
leading to a poor long-term graft patency[18-20]. The disadvantage of the vein is that it is 
rather weak with a thin vessel wall with limited musculature and is not adapted to the high 
pressures that are present in the arterial circuit. Via hyperplasia of smooth muscle cells in the 
vessel wall partial arterialization takes place, which ensures that the vein does not collapse 
under the increased pressure[21]. Due to the pressure differences however the endothelium 
is severely damaged offering a substrate for lipid and inflammatory cell influx and thereby 
atherosclerotic plaque formation[22]. This process together with the proliferation of the 
smooth muscle cells, that also may become foam cells, will severely narrow the lumen. 
Inflammation
For many years the assumption was that atherosclerosis is merely a passive accumulation of 
cholesterol in the vessel wall[1] Nowadays, atherosclerosis and other vascular remodeling 
processes such as restenosis and vein graft remodeling, are considered to be chronic 
inflammatory diseases mediated by the immune system[3, 23]. The innate immune system is 
considered to be the first line of defence and to be non-specific. This means that the cells of 
the innate system recognize and respond to pathogens in a generic way without a long-lasting 
memory. Cells of the innate immunity such as dendritic cells, monocytes and macrophages 
recognize pathogens via their pattern recognition receptors (PRR) that bind pathogen 




not by host cells or tissues[24, 25]. Activation of innate immunity by PAMPs will result in 
cytokine/chemokine releases that further mediate the initiated inflammatory cascade[26]. On 
the other hand cell stress or tissue damage cause a release of host molecules that are known as 
Damage Associated Molecular Patterns (DAMPs) and are thought to mediate non-infectious 
“sterile” inflammatory responses in reaction to cell stress, apoptosis or necrosis[27]. 
Acquired or adaptive immunity consists of B and T lymphocytes and is considered to be the 
specific immune system. T-cell responses to immunogenic antigens are regulated by antigen 
recognition signals provided by peptide-MHC antigen complexes on antigen-presenting cells 
(APCs) that bind to the T-cell antigen receptor (TCR), which operates in concert with co-
stimulatory signals[28]. In multiple vascular remodeling processes infiltration of multiple 
leukocyte subsets from both innate and adaptive immunity such as monocytes, macrophages, 
T cells, B cells and Mast cells can be appreciated in the vessel wall[1]. 
 
Figure 2: Activation of innate immune responses in the atheroma
From Göran K Hansson & Andreas Hermansson Nature Immunology 12, 204–212 (2011) [1]
Over time processes of cellular stress, apoptosis, necrosis and calcification take place within 
the plaque with the release of several DAMPs and multiple inflammatory cells can be 
appreciated that may further enhance the ongoing inflammation and luminal narrowing.
Toll Like Receptors
Toll Like Receptors are pattern recognition receptors (PRR) of the immune system known 
to recognize exogenous ligands that originate from bacteria or viruses (PAMPs) as well 
as endogenous ligands derived from host-cells (DAMPs). TLR4 is the most investigated 
TLR as a membrane bound receptor located on a variety of immune and non-immune cells 
including macrophages, endothelial cells and SMCs. It is the only TLR that makes use of all 
four adaptor proteins. The discovery by Dr. Beutler that TLR4 recognizes lipopolysacharide 
(LPS), part of the cell membrane of gram negative bacteria, has had important implications 
and for which he was awarded the Nobel Price in 2011 shared with Jules A. Hoffmann and 
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Ralph M. Steinman for their discoveries concerning the activation of innate immunity[29, 
30]. Later TLR4 was found to be capable of initiating inflammatory responses upon DAMP 
activation[31-34]. The role of TLR4 in vascular remodeling, especially arterial remodeling has 
previously been demonstrated in various studies either directed at atherogenesis and plaque 
(de)stabilization or directed at the role of TLR4 in post-interventional arterial remodeling 
after angioplasty[35-38]. The TLR family consists of 13 members that all recognize multiple 
ligands from different source[24]. TLRs can reside in the cell membrane or endosomal. 
Endosomal TLRs comprising TLR3, TLR7, TLR8 and TLR9 recognize nucleic acid derived 
from viruses as well as endogenous nucleic acids (self DNA and RNA) while the other TLRs 
recognize mostly bacterial components and endogenous matrix components as hyaluronic 
acid, fibronectin EDA but also oxLDL[35, 39, 40]. These DAMPs may be released after 
tissue damage or cell stress initiated upon PCI, vein graft placement or myocardial infarction. 
TLRs make use of four different adaptor proteins of which Myd88 is considered to be the 
most important. Myd88 depended TLR signaling leads to NFκB activation and up regulation 
of several pro-inflammatory cytokines also those that are considered to be important in 
vascular disease such as TNF and MCP1. The Myd88-independent or TRIF-pathway is only 
used by TLR3 and 4 and leads to phosphorylation of Interferon Regulating Factors (IRF) that 
after translocating to the nucleus cause the release of type 1 interferons[39]. Meanwhile a 
late response of TRIF activation may, via RIP1 and TAK1, initiate NFκB activation and up 
regulation of several pro-inflammatory cytokines via a mechanism comparable to that of the 
Myd88-dependent pathway. Altogether TLRs regulate over more than thousand genes and 
subsequent processes[41, 42]. 
Specific accessory proteins or cofactors can regulate the complex mechanism of signaling 
that reflects and emphasizes the complexity and diversity of TLR ligand interaction and 
activation. Such molecules have different roles, for example as cofactors, signalling adaptors 
and molecules, and regulators of TLR function[43]. Activation of TLR4 is dependent on 
the presence of accessory molecule MD2 that is capable of binding LPS and a variety of 
other known endogenous ligands [44-46]. Next to MD2, RP105 (CD180) is an important 
accessory molecules acting as a regulator of TLR4[46-49]. Interestingly the role of RP105 in 
modulating inflammatory responses depends on the cell type making it unique in its role of 
either enhancing or suppressing TLR regulated inflammation in different cell types[43] This 
underlines the complex mechanism of TLR signalling which should be taken into account 
during the design of therapeutic strategies focused on TLR or DAMP interference. 
Outline of the thesis
Studying pathophysiological processes in a pre-clinical setting requires resembling animal 
models. Chapter 2 reviews animal models that can be used for the study of post-interventional 
remodeling highlighting the murine arterial cuff model either or not incombination with a 
hypercholesterolemic pro-atherosclerotic background. This model not only allows studying 
this process but also the application of local therapy mimicking drug eluting balloons or 
drug eluting stents. Furthermore effects of local and systemic drug therapy are reviewed. 
The continuing problems of vascular remodeling and restenosis emphasize the need for 
specific biomarkers so that these processes can be detected early and / or can be treated in 
time. The underlying immune regulated inflammatory reactions may offer such biomarkers, 
which are discussed in chapter 3 with special interest in Damage Associated Molecular 
Patterns (DAMPs). A distinction in potential biomarkers is made between circulating, local 




important recognizers of multiple DAMPs, in vein graft remodeling . TLR4 was up-regulated 
in reperfused human venous segments and was shown to serve as a potential local therapeutic 
target to reduce accelerated atherosclerosis in vein grafts in mice. 
TLR7 and TLR9 are recognizers of PAMPs (CpG and DNA fragments) of viruses and 
DAMPs derived from the cell nucleus  of dying cells and known to be involved in several 
autoimmune  disorders. Chapter 5 shows the efficacy of a novel synthesized dual TLR7/9 
antagonist on the prevention of accelerated atherosclerosis. The antagonist reduced restenosis 
via reduced leukocyte infiltration, hampered foam cell formation and an increase in anti-
inflammatory cytokine IL10. TLR7 and TLR9 use signaling routes via Myd88 to release type 
I interferons that are known to be capable of succefully target virusses. Actually all TLRs 
make use of the Myd88 dependent pathway exept for TLR3. TLR3 signals via the TIR-
domain-containing adapter-inducing interferon-β (TRIF) and interferon regulatory factor 
(IRF)3 and IRF7 resulting in induction of type I interferons (IFNs). Chapter 6 describes the 
protective effects of TLR3 and downstream IRF factors on vein graft remodeling while other 
TLRs traditionally linked to vascular disease were shown to increase vein graft remodeling. 
Via pathway analysis we showed that the TLR and type 1 Interferon pathway belonged to 
the top 15 of regulated pathways in vein graft remodelling. Presence of intact TLR3, IRF3 or 
IRF7 resulted in reduced influx of inflammatory cell types compared to mice in which these 
genes were deleted. 
TLR signalling is strongly mediated by TLR accessory molecules. RP105 is a TLR4 homolog 
and important regulator of TLR4 signalling. It is unique in its role of either enhancing or 
suppressing TLR4 signalling in different cell types. The function of RP105 in restenosis was 
studied in Chapter 7 were RP105 deficiency revealed enhanced restenosis rates. Analysis on the 
protein structure of purified MD1/RP105 showed a unique protein structure that is consistent 
with a hetero- tetrameric RP1052MD12 complex, as was observed in the recently published 
crystal structures of the RP105-MD1 complex. This orientation is opposite to that of known 
ligand-induced TLR-homodimers. The soluble form of this protein was capable of reducing 
TLR induced inflammation ex-vivo and restenosis in vivo. The effects of RP105 deficiency 
on myocardial remodeling were described in Chapter 8. RP105 deficient mice showed a more 
prominent cardiac dilation after MI, but remained relatively good hemodynamic parameters 
by adequate compensation. No effects however were found on inflammatory cell infiltration. 
Chapter 9 describes the role of RP105 deficiency on haematopoetic cells in atherosclerotic 
plaque formation with an unexpected reduction of lesion size. Differences were found on B 
cell activation status, antibody production against oxLDL and cytokine expression profiles. 
Only moderate effects were detected on cells that are traditionally linked to TLR involvement 
in atherosclerosis. 
In the supplemental material to chapter 2 it is shown how potential therapeutic therapies 
can be tested and mechanistic insights can be obtained by using the murine arterial cuff 
model. First the importance of T cell and co-stimulatory and co-inhibitory pathways in 
restenosis making use of knockout mice, antibodies and Abatacept is described. Abatacept, a 
recombinant CTLA4-Ig fusion protein, is registered for treatment of clinical-RA and prevents 
CD28 mediated T cell activation.
Furthermore the use of Annexin A5 to block the DAMP phosphatidylserine (PS) is descirbed 
and reduced restenosis can be appreciated. Additionally associations were found between 
polymorphisms in the Annexin A5 gene and restenosis rates in humans making it highly 
relevant for the medical clinic.
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Summary 
In-stent restenosis remains the major drawback of coronary interventions and is a highly 
complex process, initiated by the induction of vascular injury and stent deployment, ultimately 
leading to negative vascular remodeling and reoccurrence of symptoms. Development, testing 
and validation of new therapies strongly depends on the availability of animal models that 
closely mimic human restenotic pathophysiology. Moreover, for a better understanding of 
the pathophysiology of the restenosis process adequate animal models mimicking the human 
restenosis process are essential.
Here, we review various animal models, predominately humanized mouse models, currently 
used to study the pathophysiology of restenosis. Larger animal models such as pigs and 
rabbits that are used for testing new therapeutic strategies such as new drug-eluting stents, 
will not be discussed in this chapter. 
We will discuss the involvement of inflammatory and immune modulatory factors in the 
development and progression of restenosis. Furthermore, we will discuss in detail several 
new therapeutic options based on modulation of their anti-proliferative, anti-inflammatory or 
proteinase-interference abilities.
We can conclude highly-reproducible animal models for post-interventional vascular 






Pathophysiology of restenosis in humans and animals
Restenosis is defined angiographically in patients when neointimal tissue comprises over 
50% of the luminal surface at the site of intervention of the affected artery. Restenosis is 
characterized by acute elastic recoil, negative remodeling and intimal hyperplasia due to 
inflammation, deposition of granulation tissue and extracellular matrix remodeling.
Intracoronary stenting has virtually eliminated elastic recoil and negative remodeling. 
However, after balloon angioplasty and stent placement neointimal formation still occurs 
due to de-endothelization and injury of the vessel wall including the atherosclerotic plaque. 
Together, these effects lead to activation of the remaining endothelium, platelet adhesion and 
subsequent activation, fibrin formation and the expression of adhesion molecules, leukocyte 
adherence and infiltration. Adhered leukocytes release an array of inflammatory cytokines, 
chemokines, proteases such as matrix metalloproteinases and growth factors which not 
only promote inflammation, but also cause medial smooth muscle cell migration and 
proliferation, matrix degradation, local proteoglycan deposition and subsequent extracellular 
matrix remodeling. Under hypercholesterolemic conditions this is accompanied by influx 
and accumulation of low-density lipoprotein (LDL) cholesterol in the vessel wall. This will 
be taken up by macrophages, that become foam cells and initiate a process of accelerated 
atherosclerosis in these vessel segments1.Patients receive platelet-inhibitors throughout 
interventional procedures to prevent arterial thrombosis and end-organ ischemia due to 
thrombotic occlusion of the affected vessel.  Furthermore, this therapy partly prevents the 
initial pathophysiological events that eventually lead to restenosis development. Nonetheless, 
in patients limited local inflammatory processes are related to the healing of the vascular 
injury triggered by mechanical dilation, stent deployment and the continuous presence of stent 
struts against the arterial wall and their exposure to flowing blood2, 3. However, uncontrolled 
inflammatory processes may induce intimal hyperplasia.
Intravascular injury to diseased vessels with a hypercholesterolemic background is common 
in patients, but severely difficult to reproduce in healthy vessels of mainly young animals 
with a normocholesterolemic phenotype. Therefore, transgenic mouse models with a pro-
atherosclerotic or hypercholesterolemic phenotype have attracted attention as humanized 
mouse models for mechanistic and pathophysiological restenosis research.
Animal models for restenosis and vascular remodeling
Various animal models, mainly in mice, are currently available to mimic human restenosis, 
extensively based on perivascular injury, aimed to induce local coagulation and subsequent 
inflammation, leading to accelerated atherosclerosis formation.
Balloon angioplasty of rat carotid arteries
A model of balloon-induced injury to the carotid artery in rats was described in 1983 by 
Clowes et al.4 and used many studies there after, amongst others by Ohlstein et al.5, in which 
an arterial embolectomy catheter is inserted into the common carotid artery and a balloon 
is inflated and drawn along the vessel wall to induce mechanical injury. Afterwards, the 
external carotid artery is ligated. This leads to severe SMC migration and proliferation and 
intimal thickening. 
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Common carotid artery ligation in mice
Neointimal formation can be elicited by completely ligating the common carotid artery just 
proximal to the carotid bifurcation to disrupt blood flow as has been described by Kumar et al.6 
and since then has frequently been used by several groups. After 4 weeks, intimal thickening 
occurs and consists of both SMCs and leukocytes, indicating the pivotal role of inflammation 
in the formation of neointimal tissue. The model is hampered by its reproducibility, since 
morphometric analysis is very critical. The degree of the intimal hyperplasia depends on the 
position the analyzed section in regard to the point of ligation.
Mouse model of femoral artery denudation injury
Femoral artery transluminal injury can be induced by passage of a 0.25-mm diameter 
angioplasty guide wire in mice7. Four weeks after injury, neointima formation can be analyzed 
and consist predominately of migrated and proliferated SMCs, although inflammatory cells 
can already be observed early after injury.
Perivascular electrocoagulation injury
Electrocoagulation-induced injury to the femoral artery of mice was introduced in 1997 by 
Carmeliet et al.8, leading to loss of all endothelial and medial smooth muscle cells (SMCs) and 
formation of a mural non-occlusive platelet-rich thrombus. This leads to inflammatory cell 
recruitment and SMC migration and proliferation, eventually leading to intimal thickening. 
Photochemical intravascular injury
Photochemical endothelial injury to the femoral artery of mice injected with rose Bengal 
solution using transluminal green light has been used by Kikuchi et al.9 in 1998 to induce a 
local thrombus formation, followed by endothelial denudation and medial SMC apoptosis 
and eventually intimal thickening. Unfortunately, the reproducibility of this model remains 
rather low. 
Perivascular chemical injury
Chemical perivascular injury to the carotid artery of dyslipidemic mice using a filter paper 
saturated with a 10% ferric chloride solution was used by Zhu et al.10 to induce formation 
of an occlusive platelet-rich thrombus due to endothelial cell loss and medial SMC necrosis, 
triggering inflammatory cell recruitment and SMC migration and proliferation. Eventually, 
this promotes intimal thickening.
Inter-arterial venous engraftment
Accelerated atherosclerosis and vascular remodeling also appear in engrafted vascular 
segments, which are performed frequently to bypass occluded arterial segments in patients.  
Although bypass models do not mimic the pathophysiology of restenosis completely, they 
can be used excellently to study various aspects of restenotic disease.  Models have been 
developed for several animal species. Only relatively recently have mouse models for vein 
graft disease become available, developed by Xu et al., (7), most often based on the model 
described by Lardenoye et al.11, in which a venous interposition is made within the carotid 
artery of a mouse. For this, an inferior caval vein is harvested from littermate donor mice and 
preserved in a 0.9% NaCl solution containing 100U of heparin at 4°C, to prevent thrombosis. 
Afterwards, the carotid artery is dissected free from its surroundings, ligated twice and 




ligatures to allow haemostatic control to the surgeon throughout the procedure, leaving free 
arterial ends over which a cuff can be placed. Next, the free arterial ends are everted over 
the cuffs and ligated with an 8.0 silk ligature, after which the harvested inferior caval vein is 
interpositioned between the ends of the artery. The connections are ligated together with an 
8.0 silk suture and visible pulsations confirm successful engraftment. 
When performed in hypercholesterolemic mice, concentric lesions are formed within 4 weeks 
and are friable, with extracellular lipid deposition and foam cell accumulation, underneath a 
poorly developed or absent fibrous cap. This morphology highly resembles the morphology 
observed in arterially-engrafted veins in patients. All aspects of rapid post-interventional 
vascular remodeling and accelerated atherosclerosis development are present in this very 
reproducible animal model. 
Intravascular balloon dilatation injury
Intravascular injury models resembling invasive coronary procedures have been developed 
recently, but remain technically very demanding. 
Kwak et al.12 described a mouse model in which intravascular carotid balloon distension 
injury is performed, which a balloon catheter was introduced through an arteriotomy on 
the proximal external carotid artery and advanced into the common carotid artery and 
subsequently distended to induce controlled vessel wall distension. In this elegant model, 
distention could be matched to the animal’s weight and the balloon was expanded using a 
water-filled inflation device. Vessel wall damage led to endothelial denudation, followed by 
leukocyte recruitment and medial SMC activation, leading to intimal thickening and luminal 
stenosis. Although this model is technically difficult to perform, vascular injury highly 
resembles the human situation and leads to a similar pathophysiological vessel wall response. 
Inter-arterial stented-arterial engraftment
Ali et al.13 have taken intravascular stenting in mouse models a step further, which they 
reported in 2007. Donor mice receiving aspirin underwent stenting using a stainless-steel 
stent crimped onto an angioplasty balloon catheter, which was guided into place retrograde 
through the thoracic aorta, leaving the balloon and stent in the descending thoracic aorta. 
The balloon was inflated for 30 seconds until 8 times atmospheric pressure to induce stent 
deployment. Next, the stented-aorta was removed and kept in heparinised PBS solution, before 
being engrafted within the ligated carotid artery of a hypercholesterolemic recipient mouse, 
similarly to the vein graft procedure. After 28 days, intimal thickening was significantly 
increased in the stented arterial graft, when compared to the aorta and balloon-inflated aortic 
grafts. Lesions consisted predominately of SMCs, macrophages and foam cells, similarly to 
human coronary lesions after interventions.
Perivascular femoral arterial cuff placement
Already in 1989, it was shown by Booth et al.14 that placement of a perivascular non-
constrictive plastic cuff around the common carotid artery of hypercholesterolemic rabbits 
results in intimal thickening based on SMC migration and proliferation, cholesterol deposition 
and foam cell formation as seen in human restenotic lesions. This is due to mechanical 
vascular damage and an inflammatory response evoked by the cuff. There was no need for 
endothelial cell damage and the formation of a transient occlusive thrombus in this model.
When this attractive model was downscaled to mice15, this offered the unique opportunity to 
employ a mechanically-induced inflammatory-based restenosis model in an animal species of 
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which an enormous range of strains with genetic variations existed, including atherosclerosis 
prone transgenic strains. 
Since like the human genome, the murine genome has currently been completely mapped 
and multiple humanized-mouse models have been developed, this has allowed researchers 
to investigate the role of specific genotypic and general phenotypic traits in restenosis 
development. The aim was to identify pathophysiological changes leading to restenosis and 
accelerated atherosclerosis development, and subsequently identify key targets for prevention 
and treatment of restenosis in patients in a clinical setting.
The technical procedure of perivascular cuff placement15 is described in detail in the next 
section. 
Before surgery, mice are anaesthetized with an intraperitoneal injection with a combination of 
5 mg/kg Midazolam (Roche, Basel, Switzerland), 0.5 mg/kg Medetomidine (Orion, Helsinki, 
Finland) and 0.05 mg/kg Fentanyl (Janssen, Geel, Belgium). This combination of anesthetics 
gives complete narcosis, lasting minimally one hour and can be antagonized using Antisedan 
2.5 mg/kg (Orion), Anexate 0.5 mg/kg (Roche) and Buprenorphine 0.08 mg/kg (Schering-
Plough, Kenilworth, NJ, USA). 
A microscope with 10-15x total magnification is used during the microsurgery procedures 
(Olympus SZX9 microscope). Basic instruments required are a blunt micro forceps (length: 
10.5cm, height: 0.3mm, Medicon Instruments, Tuttlingen, Germany), a sharp micro forceps 
(length: 10.5cm, height: 0.3mm, Medicon Instruments), a micro scissor (length: 12.5cm, 
height: 10mm, Medicon Instruments) and a micro needle holder (length: 18.5cm, Medicon 
Instruments). 
A longitudinal incision is made at the internal side of the thigh and the femoral artery is 
dissected from the femoral nerve and vein. The femoral artery is looped twice with a ligature 
(USP: 6/0, Metric: 0.7., Silkam natural silk, B. Braun, Melsungen, Germany) and a non-
constrictive fine bore polyethylene tubing (0.40mm inner diameter, 0.80mm outer diameter, 
Portex, Kent, UK) is cut 2.0mm length and longitudinally opened and sleeved loosely around 
the femoral artery. The cuff is closed with two 6/0 ligature knots in the extremities of the 
cuff. Finally, the skin incision is closed with a running suture (USP: 6/0, Metric: 0.7., Silkam 
silk, B. Braun). After surgery, animals are placed in a clean cage on top of a heating pad 
for four hours. A schematic representation and photomicrograph of the femoral arterial cuff 
placement are shown in figure 1.
For histological analysis, animals are typically sacrificed 2-3 weeks after cuff placement. 
After anesthesia, the thorax is opened and a mild pressure-perfusion (100 mmHg) with 4% 
formaldehyde in 0.9% NaCl is performed for 5 minutes by cardiac puncture. After perfusion, 
a longitudinal incision is made in the internal side of the thigh and the cuffed femoral artery 




Figure 1. Schematic representation of non-constrictive cuff placed loosely around a murine femoral artery, held 
in place by two ligatures (A) and a photomicrograph (B) of a positioned cuff in vivo. (C) Photomicrograph of the 
restenosis lesion in the cuffed femoral artery in the mouse. Indicated are the internal elastic lamina (IEL) and the 
neointima (NI) formed within the vessel wall.
Preclinical application of drug-eluting stents and balloons
Intracoronary stenting decreased restenosis rates by preventing elastic recoil and negative 
remodeling, although in-stent restenosis due to neointimal proliferation remains the major 
limiting factor of the success rate for coronary interventions as treatment for coronary artery 
disease. Drug-eluting stents with a polymer coating have been developed which are loaded 
with various types of drugs designed to prevent in-stent restenosis. These drugs, some 
originally used as chemotherapeutic agents, against transplant rejection or as
immunosuppressive drugs, tend to prevent the local inflammatory reaction, SMC proliferation 
and migration or promote local healing due to a slow local release. 
Drug-eluting balloons are coated with similar drugs, but are designed to deliver the drug only 
for a very short period of time whilst the balloon is left inflated, to prevent solely the initial 
local responses to balloon inflation and vessel wall distention. 
Limited (post-mortem) pathological data is available from stented human coronary arteries, 
since histology is usually not readily available. All in vitro and in vivo effects of new drug-
eluting stents should be evaluated for safety and efficiency before being applied in human 
studies. Preclinical animal studies can also provide insight in the method-of-action, dose-
response and side-effects of these new stents. Additionally, they can be used for investigation 
into specific genes involved in restenosis development. Genes of interest can be found in 
large prospective follow up studies, such as the GENDER study16, in which the association 
between gene polymorphisms and clinical outcome can be studied. Additionally, these 
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highly-reproducible models can be used to screen candidate compounds, without the need 
for expensive, large, long-lasting and time-consuming clinical trials.  
Drug-eluting stents can be mimicked in mice by placement of a perivascular non-constrictive 
drug-eluting cuff17, comprised of a poly(ε-caprolactone) (PCL) polymer and non-toxic 
polyethylene glycol, loaded with the candidate drug, shown in figure 2. This polymer cuff 
allows encapsulation and local sustained release of compounds over a longer period of time. 
Depending on the ratio between PCL and polyethylene glycol, the duration of drug-release 
can be extended up until 21 days after cuff placement, to allow local vessel wall drug-
exposure throughout the entire study period, even in non-hypercholesterolemic mice which 
develop restenotic lesions relatively slowly. 
An alternative for local delivery of active compounds to the mouse vessel wall is the use of 
local administration of the compound dissolved in pluronic gel or gelatin in and around the 
cuff. This allows short period of delivery of compounds locally in the murine cuff model as 
the gelatin or the pluronic gel will degrade in a short period of time. The set-up of this local 
application of pluronic gel in the cuff is shown in figure 3.
In patients, drug-eluting stents release the drug intraluminally, whilst in this model drugs are 
released from the adventitial side of the vessel wall. However, the vessel wall in the mouse 
is smaller, therefore penetration of the compound will be efficient, although applied via the 
adventitia. Nonetheless, this drug-eluting PCL cuff is certainly an extremely useful and 
practical tool to evaluate the effects of new candidate anti-restenotic drugs on local vessel 
wall pathology and intimal thickening as part of post-interventional vascular remodeling.
Figure 2. Schematic representation of a drug-eluting femoral arterial cuff and method-of-action
Suitable mouse strains
Contrary to patients, wild-type mouse strains have low levels of pro-atherosclerotic low-
density-lipoprotein and high plasma levels of anti-atherosclerotic high-density lipoprotein 




accelerated atherosclerosis and restenosis tend to respond to restenotic stimuli by displaying 
either a type 1 or type 2 helper T cell (Th1 or Th2) response. The Th1 response, typical 
of the C57BL/6 mouse strain, leads to macrophage differentiation into proatherogenic M1 
macrophages and production of inflammatory cytokines and chemokines, which promote 
lesion formation18. The Th2 response, typical of the BALB/C mouse strain, promotes the 
differentiation of macrophages into anti-inflammatory M2 macrophages, which produce anti-
inflammatory and anti-atherogenic cytokines, eventually leading to a healing response within 
the damaged vessel wall. For this reason, mouse strains with a C57BL/6 background a favored 
for studying pathophysiological changes leading to restenosis. When the perivascular non-
constrictive cuff procedure is performed in this mouse strain19, concentric lesions develop 
within 21 days after surgery and typically consist of collagen and α-actin positive SMCs.
Figure 3. Schematic representation of non-constrictive cuff around a murine femoral artery, covered by hardened 
pluronic gel (A). Photomicrograph cuff in vivo, with hardened (40%) pluronic gel applied to the cuffed vessel 
segment, loaded with an anti-restenotic drug (yellow) (B).
Dyslipidemic mouse strains
Intravascular injury by balloon inflation and stent placement in diseased human vessels in 
hypercholesterolemic patients can be mimicked by cuff placement in hypercholesterolemic 
knock-out or transgenic mouse strains.
Apolipoprotein (Apo) E is an important part of circulating very (V) LDL and LDL cholesterol 
and acts as a ligand for the LRL-R, thus leading to uptake of proatherosclerotic cholesterol 
from the circulation. Genetic ApoE deficiency therefore leads to hypercholesterolemia due 
to insufficient LDL-receptor(R)-mediated VLDL and LDL clearance, especially when fed 
a high-cholesterol diet, and spontaneous atherosclerotic and interventional-induced lesion 
formation. Drawbacks of this mouse strain are plasma cholesterol levels that are mainly 
determined by the VLDL fraction, that exceed by far any physiological level and that all 
other atheroprotective (anti-inflammatory, anti-platelet and anti-proliferative) properties of 
ApoE are lost20.
Patients with familial hypercholesterolemia display mutations in the LDL-R gene, leading 
to insufficient LDL clearance and dyslipidemia. Similarly, LDL-R knockout mice develop 
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mild hypercholesterolemia, which increases strongly when fed a high-cholesterol diet. 
Since cholesterol elevation is mainly determined by the LDL fraction and spontaneous 
atherosclerotic lesions develop more slowly than in ApoE knockout mice, this is classified 
as a more moderate model. Nonetheless, both mouse strains can be used to study post-
interventional restenosis development20. 
Mutations in the ApoE3 gene are associated with dysbetaproteinemia in patients. One of 
these mutations is the ApoE3Leiden mutation21. By introducing an ApoE3 and ApoC1 gene 
construct in the C57BL/6 mice, the transgenic ApoE3*Leiden mouse strain was generated 
22. Since the animals still express endogenous ApoE proteins, contrary to the ApoE knockout 
animals, the uptake of ApoE-containing lipoproteins is merely reduced and not completely 
inhibited. Animals have diet-induced increased plasma cholesterol concentrations, mainly 
in VLDL and LDL fractions. They are very responsive to high-cholesterol feeding.  
Desired plasma cholesterol concentrations can be obtained by varying dietary cholesterol 
content. Additionally, since both ApoE and LRL-R are still present, plasma cholesterol levels 
are subject to modulation by lipid-lowering drugs that influence endogenous chylomicron 
and VLDL production and indirectly affect LDL-R expression, such as statins. Restenotic 
lesions after cuff placement develop moderately and consist predominately of SMCs, foam 
cells and extracellular matrix formation, very similar to human lesions15. 
New mechanistic and therapeutic insights
Agents currently used or under investigation to prevent and treat restenosis can be divided 
between either drugs with cytotoxic/anti-proliferative and anti-inflammatory effects or drugs 
that target proteolytic systems. Here we give an overview how animal models may contribute 
to gain further insight into the mechanism of restenosis and to test new therapeutic strategies.
Proliferation
Rapamycin (sirolimus)
Immunosuppressive drugs like rapamycin are currently widely used in drug-eluting stents 
to prevent the development of in-stent restenosis. Rapamycin is a macrolide antibiotic 
drug with anti-proliferative and immunosuppressive effects that targets protein translation, 
resulting in a G1 arrest of the cell cycle which is known to inhibit vascular SMC proliferation 
and migration in vitro by inhibiting DNA synthesis and cell growth23-25. Rapamycin has 
been shown to effectively inhibit the arterial proliferative response after PCTA in a porcine 
restenosis model, without toxicity in low doses. Local rapamycin application in the murine 
cuff model was performed using a rapamycin-eluting cuff and it was observed that locally 
released rapamycin led to an inhibition of neointima formation by 75±6% for all tested 
concentrations. Experiments demonstrated that perivascular sustained release was restricted 
to the cuffed vessel segment, with no systemic adverse effects. Moreover, when applying the 
rapamycin eluting cuff to a diseased atherosclerotic vessel segment in ApoE3Leiden mice, no 
progression of the atherosclerotic lesion development could be observed, nor any systemic 
side effects 
Paclitaxel
Paclitaxel belongs to the taxanes, which are potent anti-proliferatives widely used to treat 
patients suffering from cancer. It leads to polymerization of the α- and β-units of tubulin 
and thus stabilizes microtubules, which are necessary for the G2 transition of a dividing 




proliferation and migration by targeting cytoskeleton structure. SMC proliferation and 
migration are both induced by balloon inflation and stent placement during interventional 
procedures. In a murine femoral arterial cuff model, drug-eluting cuffs containing high 
paclitaxel concentrations (1–5%) have been shown to reduce intimal thickening by 76±2%. 
When placing the paclitaxel eluting cuff in hypercholesterolemic mice or even over an 
existing atherosclerotic lesion in mice, dose dependent negative side effects were observed.  
High dosage of placlitaxel significantly increased apoptosis (also in the media), disruption of 
the elastic laminas and decrease medial and intimal smooth muscle cell as well as collagen 
content. These findings show elegantly the added value of testing drug eluting devices in 
atherosclerotic animal model. Many clinical trials26-28 have investigated the effectiveness of 
(non) polymer-based paclitaxel-eluting stents and have shown to be very effective in the 
prevention of restenosis development, however, negative effects on the vascular pathology 
were not detected, emphasizing that the femoral arterial cuff model is of high predictive value 
in the screening for new candidate drugs for efficacy and local adverse side effects. 
Inflammation
Although neointima formation is characterized by proliferation and migration of smooth 
muscle cells (SMC) and extracellular matrix turnover it is now broadly accepted that these 
processes are triggered by inflammatory activation of the vessel wall16. Evidence that 
inflammation is the initial trigger for vascular remodeling has accumulate over the past years 
and the role of various cytokines and chemokines as pro-inflammatory factors as well as 
immune modulation in general has been the focus of many studies on vascular remodeling and 
restenoses. In the next section we would like to illustrate this with a couple of representative 
examples. Starting with the description of the effects of the general anti-inflammatory factor 
dexamethason, we will further zoom in on the effects of specific cytokines (TNFa, IL10), 
chemokines (MCP-1) and the role of the innate immune system (complement, Toll-like 
receptors) on restenosis in the mouse models.
Dexamethason
Dexamethason is a corticosteroid with strong glucocortocoid properties and is widely used 
as a broad anti-inflammatory and immunosuppressant drug. Prolonged systemic delivery is 
associated with multiple side effects in humans and animals. These effect could be abolished 
by local delivery using a drug-eluting cuff (DEC), mimicking the potential effect of drug 
eluting stents. Local delivery of dexamethason via DEC delivery inhibited neointima 
formation drastically without systemic side effects, indicating a beneficial effect of local 
suppression of inflammation over systemic delivery as was tested by applying dexamethason 
via the drinking water in the same model. However pathobiological examination of the murine 
arteries revealed a dose-dependent medial atrophy, a reduction in vascular smooth muscle 
cells and collagen content, an increase in apoptotic cell count and disruption of the internal 
elastic lamina29. Short term systemic delivery in a model for vein graft remodeling showed 
a reduction in intimal hyperplasia formation without serious side effects probably due to the 
short period of delivery30. These results not only emphasize the importance of the immune 
system and the role of inflammation in restenosis more specifically and systematically, but 
also show that the use of small (hypercholesterolemic) animal models does have predictive 
value in regard to negative side effects on vascular pathology after local drug application.
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Innate immunity
Innate immunity is very important in triggering inflammation and can be divided into a 
humoral and a cellular component. It comprises multiple cell types, receptors and mechanisms 
such as the Complement system and Toll like receptors (TLRs) that are very important in 
host defense. The innate immune system is considered to be highly involved in regulation 
of intimal hyperplasia and atherogenesis. This could very elegantly be demonstrated using 
specific mouse models in combination with cuff placement or vein grafting as described in 
the section below.
Complement
The complement system comprises the humoral mechanism of the innate immune system. 
C3 cleavage plays a central role in the complex regulation of complement activation and 
can be initiated via the classical, alternative or the lectin pathway. The role of complement 
was studied in the model of vein graft restenosis combined with accelerated atherosclerosis 
in the ApoE3*Leiden mouse. The expression of complement components C1q, C3, and 
the regulatory proteins CD59 and complement receptor-related gene y (Crry) could be 
detected on the protein and mRNA level in the grafts. A reduction in vein graft thickening 
and intimal hyperplasia was accomplished after interference with C3 activation by systemic 
administration of either Cobra Venom Factor or Crry-Ig protein. The latter was associated 
with a reduced number of inflammatory cells in the vessel wall31, indicating that blocking 
the central factor in the complement activation cascade, C3, results in a profound reduction 
of vascular remodeling. This underscores a role of the innate immune system in restenosis 
related vascular remoding.
Toll-like Receptors 
TLRs are membrane bound receptors located on a variety of immune and non-immune cells 
including macrophages, endothelium and SMCs. Cell stress and tissue damage may cause 
a release of Damage Associated Molecular Patterns (DAMPs) that function as endogenous 
TLR ligands. Balloon inflation and stent placement or bypass grafting lead to injury to the 
vessel wall and may cause up regulation of DAMPs such as Heat Shock Protein 60 (HSP60), 
Fibronectin-EDA, Tenascin C and Biglycan. HSP60 binds directly to TLR2 or TLR4 thereby 
initiating proliferation of VSMC32. In response to peri-adventitial cuff induced injury TLR4 
expression is up regulated in the vessel wall during at least 7 days (unpublished data).  A 
causal role for TLR4 in restenosis was demonstrated by a reduced cuff induced neointima 
formation in TLR4 deficient mice33. Moreover, local adventitial TLR4 activation by LPS 
application strongly augmented neointima formation in both mouse models, so with and 
without involvement of accelerated atherosclerosis34. The same method was used to stimulate 
TLR2 with Pam3Cys and resulted in an increase in neointima formation in C57/B6 mice and 
in APOE-/- mice that develop atherosclerotic lesions35.
We believe that the release upon vascular injury of specific DAMPs as endogenous TLR 
ligands is one of the earliest triggers in vascular remodeling in restenosis and are convinced 
that the TLR signaling pathway has a crucial function in the restenosis process. This is 
supported by the SNPs found in the TLR4 gene that correlate with in increased risk for 
cardiovascular event and/or restenosis after an initial PCI 36-38 
Cytokines




cytokines. These cytokines can be seen as hormones of the immune system that communicate, 
can attract and activate different cell types importantly involved in restenosis and 
atherosclerosis like SMC and macrophages. A disturbance in the cytokine balance, locally or 
systemically, alters the inflammatory status thereby mediating inflammatory processes. Since 
many cytokines have their role in multiple inflammatory reactions it is important to know 
whether they are involved, can be a therapeutic target or may function as biomarker for the 
process of restenosis.
TNFα
Tumor Necrosis Factor alpha (TNFα) is a cytokine that regulates immune cells and promotes 
the inflammatory response. It is produced by many cells including endothelial cells, VSMCs 
and macrophages. The GENDER project systematically genotyped for six polymorphisms 
in the TNFα gene and found associations with an increased clinical and angiographic risk 
for restenosis in humans39. In a rat balloon-injury model blockade of the TNFα caused a 
reduction in neointima formation via acceleration of endothelium repair40. In mice, after 
common carotid artery (CCA) ligation, TNFα mRNA expression was found in intimal 
lesions itself. Application of the same model in knockout mice showed a decrease in lesion 
size41. After peri-adventitial cuff placement TNFα mRNA is rapidly up regulated to levels 
4000 times to original mRNA levels  and deficiency of TNFα in a murine study of restenosis 
with accelerated atherosclerosis, performed in ApoE*3-Leiden-TNFalpha knockout mice, 
caused a marked reduction in neointima formation. Interestingly, the use of a DEC for local 
delivery of thalidomide as a potent TNFalpha biosynthesis inhibitor demonstrated a powerful 
reduction  of the neointima formation after cuff placement to levels similar to those observed 
in the ApoE*3-Leiden-TNFalpha knockout model39. TNFalpha is clearly an important 
cytokine in the inflammatory process that take place in the vessel wall during restenosis and 
its role can be studied in detail using the specific mouse models for restenosis, cuff and drug 
eluting cuff placement.
CCR2/MCP1
The chemokine Monocyte Chemoattractant Protein1 (MCP1) or CCL2 is a cytokine that 
is capable of attracting immune cell types like monocytes that are known to infiltrate the 
vessel wall as a one of the first in neointima formation. Furthermore MCP1 influences SMC 
proliferation and is expressed in various stages of vascular remodeling. MCP1 binds to its 
receptor CC chemokine receptor 2 (CCR2) that belongs to the family of G-coupled receptors. 
Femoral artery transluminal injury by passage of a 0.25-mm diameter angioplasty guide 
wire was done in a CCR2-/- mice7.Four weeks after injury, CCR2-/- mice showed a 61.4% 
reduction in neointima formation and a 62% reduction in intima/media ratio. The effects 
of MCP1 in vivo were studied in the murine vein graft model as well as in the femoral 
cuff model. Systemic overexpression of a dominant negative form of MCP-1, 7ND-MCP, by 
electroporation of a plasmid into the calf muscle resulted in circulating levels of this MCP-1 
inhibitor that were sufficient to decrease intimal hyperplasia significantly, both in the cuff 
model42 as well as in the vein graft model43. 
In addition, in the mouse vein graft restenosis model perivascular local vector application 
for lentiviral shRNA targeting CCR2 reduced intimal hyperplasia in the vein grafts by 




Interleukin 10 (IL-10) is one of the most prominent anti-inflammatory cytokines and 
functions pleiotropic. It may suppress antigen presentation and is capable of inhibiting pro-
inflammatory cytokine production. These capacities make IL-10 a very attractive candidate 
for anti restenotic and anti atherosclerotic therapy. Three polymorphisms significantly 
increased the risk of restenosis in patients and demonstrate that IL-10 is associated with 
restenosis. This set interest for anti-inflammatory genes to be involved in the development of 
restenosis45. The functional role of IL-10 in restenosis was assessed by Feldman et al.46 and 
showed beneficial effects of recombinant human IL-10 after balloon angioplasty or stenting 
in hypercholesterolemic rabbits. Per-adventitial cuff placement in hypercholesterolemic 
APOE*3-Leiden-IL-10-/- mice (hypercholesterolemic mice deficient for IL-10) resulted in 
an increased neointima formation indicating a protective role for IL-10 in a murine model 
for restenosis and accelerated atherosclerosis47. Electroporation of an IL-10 plasmid into the 
calf muscle resulted in IL-10 overexpression in ApoE3*Leiden mice and caused a reduction 
in cholesterol and neointima formation two weeks after cuff placement, underscoring the 
therapeutic potential of IL10 in restenosis. 
Protease inhibition in restenosis
Proteases of the Matrix metalloproteinase (MMP) system and of the plasminogen activator 
system are thought to play an important role in the matrix degradation and smooth muscle 
cell migration during vascular remodeling and are upregulated after coronary angioplasty48. 
Studies in mice showed a decreased neointima formation in MMP2-/-, MMP9-/- mice and 
augmented neointima formation in TIMP1-/- mice49-51. By use of the electrocoagulation 
vascular injury model Lijnen et al.52 studied whether the plasminogen activation system, 
a system that also may activate the MMP system, and the MMP system itself play a role in 
neointima formation using knockout mice. Neointima formation was reduced in urokinase-
type plasminogen activator knockout (uPA-/-) and Plasminogen (Plg) knockouts (Plg-/-) but no 
effect was seen in the tissue-type Plg activator knockout (tPA-/-) mice. 
To study the therapeutic potential of these findings a hybrid protein consisting of the receptor-
binding amino-terminal fragment of uPA (ATF), linked to the potent protease inhibitor 
bovine pancreas trypsin inhibitor (BPTI) was constructed and cloned into an adenoviral 
vector53 Mice were infected with the combined ATF.BPTI vector or single vectors for ATF 
or BPTI and cuffs were placed around the femoral arteries to induce neointima formation. 
Only the ATF.BPT showed a strong inhibition of neointima formation by selective binding 
to the uPA receptor and inhibiting plasmin activity54. Infection with the same vector in a 
balloon injury model also showed significant inhibition of neointima formation in rats55 
as well as in mice after cuff placement53. In 2002 a novel hybrid protein consisting of the 
tissue inhibitor of metalloproteinase-1 (TIMP-1) domain, as MMP inhibitor, linked to ATF 
(TIMP-1.ATF) was constructed. By binding to the u-PA receptor this protein blocks binding 
of u-PA and attaches TIMP-1 directly to the cell surface. This construct was able to inhibit 
SMC migration and neointima formation in vitro56. In vivo intimal hyperplasia combined 
with accelerated atherosclerosis was studied in murine vein grafts. Plasmids encoding ATF, 
TIMP-1, TIMP-1.ATF, were injected and electroporated (non-viral gene transfer) in both 
calf muscles of hypercholesterolemic ApoE*3Leiden mice. Although all constructs reduced 
vein graft thickening compared with the controls, the luminal area was best preserved in the 
TIMP-1.ATF-treated mice57.




was constructed and validated. After four weeks, vein graft thickening was significantly 
inhibited in mice treated with the single domains TIMP-1, ATF or BPTI. In the TAB treated 
mice vein graft thickening was reduced and was also significantly stronger as compared to 
the individual domains58. 
Conclusions
For restenosis research animal models are definitely essential for testing new anti-
restenosis devices, such as new drug eluting stent, as well as for unraveling the underlying 
pathophysiological mechanism and identifying new therapeutic targets.
It is important to work with models that mimic the human situation as good as possible, either 
in vascular anatomical aspects (size, diameter, wall thickness) or disease stage related aspects 
(hypercholesterolemia, vessel with atherosclerotic lesions).
In the current chapter we have focused on the later group of animal models, those humanized 
models that have the best predictive value for the pathophysiological process in the 
development of restenosis, intimal hyperplasia and accelerated atherosclerosis in the lesions. 
Various vascular interventions in transgenic mouse models have been described, with a 
strong focus on the mouse femoral artery cuff model and these mouse models have proven to 
be technically suitable for the study into restenosis development. 
Next, to study effects of (local) drug therapy, animals should be susceptible to the treatment 
of interest, have similar metabolic levels, coagulatory phenotype and react in a human-like 
fashion. The use of humanized (transgenic) animal models has extensively increased the 
similarity between human and animal lesions and the translation of new therapies into in the 
clinical setting.
Mechanistic and pathophysiologal studies have shown that local vessel wall inflammation, 
proliferation and proteolysis play important roles in the post-interventional vascular 
remodeling, both in humans and in the animal models used. 
In addition, these animal models are extremely suitable to identify new potential therapeutic 
targets to prevent restenosis and test new experimental strategies for therapy, e.g. based on 
systemic or local gene delivery of inhibitory factors (anti-proliferative, anti-inflammatory 
or anti-proteolytic). These studies clearly demonstrate the importance and value of animal 
models for clinical medicine.
We can conclude that highly-reproducible animal models for post-interventional vascular 
remodeling remain essential for studying the process of restenosis and the development of 
future anti-restenotic therapies.
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Abstract
New circulating and local arterial biomarkers may help the clinician with risk stratification or 
diagnostic assessment of patients and selecting the proper therapy for a patient. Additionally 
they may be used for follow-up and testing efficacy of therapy, which is not provided by 
current biomarkers. Processes  leading to post-interventional restenosis and accelerated 
atherosclerosis are complex due to many biological variables mediating the specific 
inflammatory and immunogenic responses involved. Adequate assessment of these processes 
requires different and more specific biomarkers. Post-interventional remodeling is associated 
with cell stress and tissue damage causing apoptosis, release of damage-associated molecular 
patterns (DAMPs) and upregulation of specific cyto/chemokines that could serve as suitable 
clinical biomarkers. Furthermore, plasma titers of pathophysiological process-related (auto)
antibodies could aid in the identification of restenosis risk or lesion severity. This review 
provides an overview of a number of potential biomarkers selected on the basis of their role 
in the remodeling process.
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The current concept that inflammation plays a key role in the development of (post-
interventional) atherosclerotic vascular remodeling has led to the investigation of inflammatory 
factors to serve as biomarkers for cardiovascular risk prediction. Multiple local arterial and 
blood-based biomarkers have been identified and selected for their association with a more 
adverse cardiovascular risk profile independently of known traditional risk factors such 
as dyslipidemia, hypertension, diabetes and smoking. Many of these markers have been 
incorporated into risk prediction models to improve risk assessment accuracy in addition 
to current diagnostic strategies [1]. Of these, C-reactive protein (CRP) is currently the best-
validated inflammatory biomarker. Despite the value of plasma lipoprotein profiling and CRP 
measurements the picture is not yet clear. Many patients but not all continue to develop 
vascular remodeling following revascularization procedures and ongoing investigations into 
newer and more accurate or combined biomarker risk profiles remain necessary[2]. This 
review retracts the underlying pathophysiology of atherosclerosis and post-interventional 
vascular remodeling and the value of recently discovered inflammatory biomarkers[3] in 
the prediction of cardiovascular events in the biological context that require target lesion 
revascularization, highlighting their potential clinical value. Other biomarkers including 
genetic differences such as polymorphisms are not taken into account in this review.
Background of atherosclerosis and restenosis
Native atherosclerosis
Atherosclerosis is a chronic inflammatory disease of the large and medium-sized arteries and 
is initiated by a qualitative change in the endothelial monolayer by irritative stimuli such 
as dyslipidemia, hypertension, and pro-inflammatory mediators that lead to the exposure of 
adhesion molecules and infiltration of circulating leukocytes into the arterial wall[4]. Such 
mediators could be of high value when measured as biomarkers of lesion progression and 
stage of severity. Changes in endothelial permeability provoke the retention of cholesterol-
containing low-density lipoprotein (LDL) particles that are endocytosed by monocytes-
derived macrophages leading to foam cell and atheromatous lesion formation in the arterial 
tree(5, 6). Tunica media-derived smooth muscle cell (SMC) migration and proliferation and 
extracellular matrix deposition lead to the formation of a fibrous cap overlying a necrotic 
core due to inefficient efferocytosis[5, 7]. Physical disruption of the plaque exposes the 
underlying thrombogenic material to the circulation triggering thrombosis formation, that 
may be monitored as biomarkers, and luminal occlusion with progressing ischemia in distal 
tissues[6], eventually leading to infarction requiring angioplasty or bypass-grafting[6, 8].
Post-interventional restenosis
Restenosis following angioplasty and stent implantation has been the major problem limiting 
the success rate of coronary interventions and tremendous efforts have been made to target this 
problem[9]. Acute and long-term vessel occlusion requiring target lesion revascularization 
following balloon angioplasty occurred in 30-60% of all patients due to elastic recoil and 
negative remodeling. The introduction of bare-metal stents (BMS) prevented elastic recoil 
and has reduced this incidence of restenosis to 16-44%, but also led to the development of 
neointimal hyperplasia[10]. Drug-eluting stents (DES) have been developed to counter this 
phenomenon, although incidence rates of 5-10% of in-stent restenosis (ISR) are still reported, 
encompassing over 200.000 revascularizations annually in the United States alone[11]. 
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Inflammation has been shown to be the driving factor behind these remodeling processes, 
pointing to a role as biomarker for this factor in the analysis of disease progression.  DES 
have been successful in the prevention of neointimal hyperplasia, but have not been able to 
completely prevent the process of ISR. These figures support the need for development of 
new biomarker assays that allow careful screening of patients at risk for restenosis.
Restenosis is defined as more than 50% luminal loss at follow-up angiography with 
clinical restenosis defined as recurrence of symptoms such as angina pectoris or ischemia 
at rest, requiring repeat revascularization[12]. It has been proposed to be the result of an 
overshooting healing response that originally occurred in three distinctive phases: early loss 
due to elastic recoil, which occurs within minutes and has been successfully countered by 
the application of intracoronary stenting, followed by neointimal hyperplasia and eventually 
accelerated atherosclerosis development[13]. Neointimal hyperplasia is evoked by injury 
to the endothelium and underlying atherosclerotic plaque, with exposure of thrombogenic 
content to flowing blood, supporting the adhesion and activation of thrombocytes and 
thrombosis. Platelets release mitogens, which can be traced throughout the plasma to serve 
as biological markers of thrombosis extent, and promote SMC migration and proliferation to 
the tunica intima with local extracellular matrix deposition]14]. This process is prevented or 
delayed (e.g. by many years) by DES compared to BMS implantation through the release of 
drugs that affect SMC migration and proliferation. This process is ultimately followed by a 
phase of vascular remodeling, in which accelerated atherosclerosis and concentric adventitial 




Underlying causes of restenosis
The underlying causes of restenosis can be divided into four general causes, namely 
biological, arterial, stent and implantation factors[10, 12]. Biological factors encompass the 
natural (genetic) vascular wall resistance to anti-proliferative drugs and the development of 
a sustained hypersensitivity reaction directed towards the polymer or metallic stent platform. 
Additionally, the initial levels of proteinases that determine SMC proliferation and migration 
are of great importance to treatment success[10]. These effects of proteinase of SMC 
proliferation and migration may be direct or indirect effects. In vascular remodeling matrix 
metalloproteinases may regulate migration, proliferation, and death of vascular smooth muscle 
cells by degrading matrix and non-matrix substrates[15], but also may play a role in activating 
other factors such as growth factor or other pericellular proteases[16]. Arterial factors that 
influence the vascular response are comprised of factor regulated by local wall shear stress 
levels, the progression of original atherosclerosis lesions growth within a stented segment, but 
also previous positive vascular remodeling. Stent factors that contribute to the development 
of ISR are the specific type of coating used, drug concentration and sustained period of 
release and to a lesser extent the drug of choice[17, 18]. Differences between effectiveness 
rates of specific drugs are determined by their ability to meet the biological threshold that 
exists and determines the initiation of an inflammatory response and the eventual occurrence 
of neointimal hyperplasia, which could be tracked with biomarker levels in plasma[10]. The 
stent gap, strut thickness and possible polymer disruption or cracking and eventual fractures 
are all important for proper stent effectiveness in the prevention of ISR[10]. Finally, technical 
implantation factors can limit therapeutic effectiveness that stenting could offer, such as an 
incomplete stent expansion and geographical misses, where the stent is deployed short of or 
beyond the complete lesion area[12]. During every interventional procedure the eventually 
of barotrauma to unstented segments and the deployment of a DES in a clot-laden arterial 
segment remains, that raise the chance of ISR after discontinuation of anti-thrombotic drugs. 
These factors support the search for biomarkers that could offer diagnostic insight at the time 
of procedure. These markers should be an adequate reflection of acute vessel injury. 
Inflammation status as biomarker
The overall requirement of a cardiovascular disease biomarker is to enhance the ability 
to optimally manage the patient, identification of patients, to differentiate patients, assess 
the likelihood of a therapeutic response, the risk of future recurrences and progression of 
disease[19]. The use of BMS or DES may have different effects on the pathophysiological 
process initiated and thereby on the inflammatory response and eventual potential biomarkers 
related to restenosis or in-stent thrombosis. For potential novel biomarkers it would be of 
major importance to be easily detectable and that levels correlate with disease progression. 
Since inflammation is importantly involved in vascular disease many studies focused on CRP 
as a biomarker. CRP is a strong marker of inflammation and upregulated in response to pro-
inflammatory cytokines. No association was found for major cardiovascular events and high 
sensitivity-CRP, IL6 or TNFα by Sukhija and co-workers[20]. However, CRP seemed to be 
an excellent marker for post-stenting inflammation since it was produced mostly in response 
to pro-inflammatory cytokines released as a response upon the vascular damage initiated by 
the procedure(1). In addition pre-procedural serum CRP-level proved to be an independent 
predictor of adverse outcome after coronary stent implantation, suggesting that a systemically 
detectable inflammatory activity is associated with proliferative responses within successfully 
implanted stents[21]. Higher baseline CRP levels of patients undergoing BMS implantation 
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are a predictor of restenosis[22]. Interactions were also found between CRP levels, statin 
treatment and restenosis-incidence[23]. No clear association of CRP and restenosis was 
found during application of drug-eluting stents[1]. A study on first cardiovascular events 
and death based on the Framingham Offspring Study by Wang and co-workers showed 
that the most informative circulating biomarkers for predicting death proved to be B-type 
natriuretic peptide, C-reactive protein, homocysteine, renin, and the urinary albumin-to-
creatinin ratio[2]. Other studies focused on CRP levels did not find a direct relation with 
restenosis[24]. Currently the limitation of existing biomarkers is that even in combination, 
they only add moderately to the prediction of risk in an individual person[2]. This statement 
is confirmed by Ware who explains that a risk factor must have a much stronger association 
with the disease outcome than we ordinarily see in etiologic research if it is to provide a basis 
for early diagnosis or prediction in individual patients. Most studies are of limited value for 
the risk stratification of individual patients as we have discovered new biologic variables that 
lie on the complex pathway leading to chronic disease and death[25].  Therefore the role of 
experimental research is very important in identifying novel biomarkers since it provides the 
tools to focus more specifically on the pathophysiological process.
Currently a lot of contradicting data is available of using CRP as a biomarker in cardiovascular 
disease, a notion merely worsened by the use of different stents types. The approaches thus 
far may not be specific enough to serve as good reflectors of the pathophysiological process 
that is initiated by the interventional procedure. CRP is possibly just an indirect reflection 
of inflammation which is easily become upregulated by other underlying inflammatory 
processes. The application of individual biomarkers only contributes moderately to risk 
assessment of individual patients. The prospect of combining multiple known markers 
could possibly contribute significantly more to the optimization of patient selection and 
individual tailor-made treatment[1]. The future success of biomarker strategies in this field 
could possibly depend on the discovery of new biomarkers to complement the current 
markers and diagnostic strategies. The identification of patients at elevated risk based upon 
biomarker assessment could be of additive value for the management of patients receiving 
stent implantation. In this review, we provide an overview of considered novel potential 




Several factors involved in the pathophysiological process of post-interventional remodeling 
may be detected in the circulation soon after the interventional damage, thereby forming 
potential biomarkers that are easily available such as damage-associated molecular patterns 
(DAMPs). DAMPs are endogenous structures that can be released upon tissue damage and 
can be recognised by receptors on inflammatory cells e.g. Toll Like Receptors. Balloon 
angioplasty with or without stent placement will cause damage to the vessel wall that will 
cause al release of DAMPs and activate toll-like receptors that cause a release of several 
inflammatory cytokines and chemokines[26, 27]. Also antibodies may be formed upon (auto-
) antigens that become present after the intervention. Original papers on this subject are 





Annexin A5 is a member of the annexin family, a group of highly-conserved Ca2+ dependent 
proteins that bind to negatively-charged phospholipid surfaces. Annexin A5 is primarily an 
intracellular protein that is released upon injury and binds specifically and with high affinity 
to phosphatidylserine (PS) [28]. PS becomes externalized and presented upon the outer 
cellular membrane during the process of apoptosis, but also during platelet activation and 
erythrocyte aging[29]. For this reason annexin A5, alone and bound to contrast agents, has 
been used world-wide for the detection of apoptosis in vitro and in pilot experiments in vivo 
in patients [28]. 
PS serves as an ‘eat-me’ signal on apoptotic cells for circulating phagocytes. Annexin A5 
than binds PS leading to the formation two-dimensional crystals. Annexin A5 thereby may 
act as a lattice shielding PS from phagocytes and from interacting in phospholipid-dependent 
coagulation reactions[30, 31]. In addition to its anti-thrombogenic properties, annexin 
A5 binds with high affinity to oxLDL cholesterol which together with apoptotic cells is 
present in native atherosclerotic and restenotic lesions in high concentrations[32]. For this 
reason, annexin A5 is also detectable in high concentrations in (accelerated) atherosclerotic 
lesions[33]. 
Next to its presence in the vascular wall, annexin A5 has been suggested in the prevention 
of pro-inflammatory microparticle formation. Stimulated platelets and apoptotic cells 
expressing PS on their membrane have been shown to shed PS-containing membrane-derived 
microparticles. Annexin A5 is able to inhibit the formation of microparticles by binding to PS 
on these cells[30].
Annexin A5 is partially removed from the circulation by binding to specific components 
of atherosclerotic tissues, such as oxLDL and activated or damaged cells. Measurement 
of plasma annexin A5 concentration requires only limited amounts of venous blood and 
is therefore an easy-to-perform diagnostic test. Although this information does not allow 
discrimination between a restenotic and a de novo atherosclerotic lesion, it could certainly be 
of much additive value to current diagnostic strategies and screening purposes. In addition, it 
was found that the prognostic value of the oxLDL / annexin A5 ratio is even more sensitive 
than annexin A5 alone, stressing the importance of combined biomarkers for disease 
screening[34]. 
The presence of high concentrations of annexin A5 in atherosclerotic lesions leads to annexin 
A5 release in the circulation following myocardial infarction[35]. Increased annexin A5 
levels are therefore indicative of the extent of myocardial tissue damage. Since annexin A5 
levels provide both information on plaque severity in the stable period of atherosclerosis 
and on infarction severity during acute episodes of plaque rupture, annexin A5 is a highly 
potential future biomarker of cardiovascular disease progress.  
Damage Associated Molecular Patterns (DAMPs)
Restenosis is a late process, although it is believed that events that take place within 72 hours 
after intervention are already triggering the restenosis process. The intervention will cause 
severe damage to the vessel wall leading to a release op DAMPs. DAMPs can be seen as 
endogenous fragments that are recognized by the immune system by toll-like receptors (TLR) 
[26].  During the whole process of restenosis a continuous process of cell stress, lipid influx, 
inflammation and matrix degradation, the release of DAMPs will continue. The last decade 
much focus has been towards the involvement of TLR in cardiovascular disease where the 
TLRs were predominantly found on circulating cells and in vascular lesions[36-38]. TLRs are 
 48
membrane-bound receptors located on a variety of immune and non-immune cells including 
macrophages, endothelium, SMCs and platelets. Release of the DAMPS as endogenous TLR 
ligands may have serious consequences due to the activation of the TLR signalling pathway 
on variety of cells carrying TLRs.  These cells may than initiate a severe inflammatory 
response with direct activation of the vessel wall but also platelet activation and infiltration 
of inflammatory cells[26, 39, 40]. A causal role for TLR4 in post-interventional vascular 
remodeling was previously demonstrated. Neointima formation, arterial outward remodeling 
as well as vein graft remodelling were decreased by in TLR4 deficient mice, and TLR4 
ligands and TLR4 silencing tools could modify these processes[41-43]. Furthermore TLR4 
is importantly involved in the sterile inflammatory response upon CD36 activation by oxLDL 
particles[44]. Two very important DAMPs that can be linked to multiple TLRs are high 
mobility group box 1 (HMGB1) and fibronectin-EDA (FN-EDA) that also come available in 
the circulation upon their release. These DAMPS may potentially serve as ideal biomarkers 
since they are only upregulated in response to tissue damage, have direct inflammatory 
effects via multiple TLRs and can also be detected in the plasma[27, 49-51] . 
Nuclear HMGB1 may become present in the cytoplasm or even outside the cell where it 
is known to act as TLR2 and TLR4 ligand[45, 49]. Not only can this release be initiated 
upon cell stress but also activated macrophages are capable of releasing HMGB1[26, 49-
51]. Previously our group was able to detect intra- and extra-nuclear HMGB1 in remodeled 
vein grafts[42]. Furthermore presence of HMGB1 was detected in atherosclerotic plaques. 
Although the number of macrophages increased markedly in fatty streaks and fibrofatty 
lesions, the proportion that expressed HMGB1 did not alter significantly. However, the 
proportion of macrophages containing HMGB1 in both cytoplasm and nuclei increased 
markedly[52]. Others showed that elevation of serum HMGB1 level is associated with severe 
cardiac remodeling complications such as pump failure, cardiac rupture, and eventually in-
hospital cardiac death. This was in association with an increased serum C-reactive protein 
level in these patients. However, in an animal model for myocardial infarction blockade 
of HMGB1 caused impaired infarct healing and marked scar thinning thereby worsening 
left ventricular remodelling[53]. Furthermore, HMGB1 serum levels are markedly increased 
upon surgical thoracic aortic aneurysm repair[54]. HMGB1 is also of interest in other 
inflammatory disease processes like SLE and kidney ischemia reperfusion[55, 56]. HMGB1 
also has pro-thrombogenic features by increasing tissue factor expression on monocytes and 
inhibiting anti-coagulant protein C pathway in vitro. In vivo the combined administration of 
thrombin and HMGB1 caused prolonged plasma clotting times[57]. The effect of HMBG1 
on platelets via direct TLR4 activation is still unknown. 
Fibronectin is a part of the extracellular matrix that undergoes severe stress during 
interventional procedures. Fibronectin-EDA (FN-EDA) is an adhesive glycoprotein spliced 
from fibronectin and is important in wound healing and can be produced by activated 
endothelium and fibroblasts. FN-EDA has been implicated in fibroblast differentiation, 
proliferation and migration and is capable of monocytes activation and induction of 
inflammation through upregulation of cytokines like interleukin-1α and β and matrix 
metalloproteinases. Interestingly, FN-EDA is the only spliced variant of FN that binds and 
activates TLR4[58, 59]. FN-EDA targets antigen to TLR4-expressing cells and induces 
cytotoxic T cell responses[60]. FN-EDA is also considered to be a TLR2 ligand and therefore 
has the potential to activate the two most important TLRs in vascular disease. We showed 
that lack of FN-EDA prevents myocardial remodeling and preserves pump function after 




atherosclerosis and in the myocardium in the early phase of the remodeling process following 
infarction[61]. Additionally absence of FN-EDA reduced atherosclerosis formation. In 
normal aortas the spliced FN-EDA could not be found, although FN-EDA was found in 
atherosclerotic plaques and in plasma of atherosclerotic mice. FN-EDA was shown to have 
effects in both plasma lipoprotein metabolism and in macrophage foam cell formation[59, 62]. 
Studies with atherosclerotic mice that lack FN-EDA indeed showed that cholesterol levels 
were lowered[59, 62]. In addition, FN-EDA may influence post-interventional remodeling 
directly via inducing an inflammatory reaction but also via effects on lipid metabolism. 
Cytokines and chemokines
Cytokines and chemokines are important mediators of inflammatory responses and can be easily 
measured in serum. Both lowered and elevated concentrations of cytokines and chemokines 
are associated with cardiovascular risk profiles and specifically post-interventional vascular 
remodeling due to accelerated atherosclerosis development. Nevertheless their levels can 
strongly differ due to different pathophysiological processes initiated by different treatment 
strategies. The treatment strategy (BMS vs. DES) therefore may have strong influence on the 
reliability of a selected cytokine or chemokine as biomarker[1, 22]. Interestingly conditions 
after acute myocardial infarction could exacerbate post-angioplasty restenosis by stimulating 
signaling via TNFα[63]. This may cause differences for patients that undergo scheduled 
PCI versus patients that had an acute myocardial infarction before PCI. It may therefore 
be important to look for combinations of specific cytokines besides a selected biomarker. 
Activation of innate immune response via TLRs will lead to nuclear factor kappa B (NFκB) 
activation followed by upregulation of cytokines and chemokines[26, 39]. Many different 
cytokines have been studied in relation to post-interventional remodeling and may be used 
in combination with specific biomarkers to correlate DAMP presence with remodeling 
related cytokines. Additionally this may provide better insight in the underlying mechanism 
of the pathophysiological process and thereby indications for proper treatment strategies. 
Cytokines could also be interesting to measure the effect of these treatment strategies by 
checking ratios of pro- and anti-inflammatory cytokines. Here we discuss a few cytokines/
chemokines that have been intensively researched in relation to cardiovascular disease and 
have showed biomarker potential
Tumor necrosis factor α
Tumor necrosis factor (TNF) α is a pro-inflammatory cytokine that is importantly involved in 
inflammatory responses. Multiple cells including endothelial cells, vascular smooth muscle 
cells and monocytes-derived macrophages can secrete it. Several studies have shown that 
blockade of TNF α caused a reduction in neointimal formation via acceleration of endothelium 
repair, found increased mRNA expression of TNF α in the neointima of damaged vessels 
which may be upregulated 4000 times compared to resting levels. These kinds of studies also 
showed a relation with accelerated atherosclerosis[64, 65].
Interestingly, the local delivery of thalidomide as a potent TNF α biosynthesis inhibitor 
demonstrated a powerful reduction of the neointima formation in mice. In humans single 
nucleotide polymorphisms in the TNF α gene were found and showed associations with 
an increased clinical and angiographic risk for restenosis[66]. Angioplasty in peripheral 
arterial segments gave increased levels of TNF α within 1 hour, although no statistically 
significant correlation was found between failed angioplasty and the following inflammatory 
response[67]. Kubica et al stated that the combined analysis of CRP and TNF α might be an 
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effective approach to the clinical restenosis prediction and long-term outcome is markedly 
influenced by the periprocedural activation of inflammation[68]. 
Monocyte chemoattractant protein 1
Monocyte chemoattractant protein (MCP)-1 binds to its receptor CC chemokine receptor 2 
(CCR2) that belongs to the family of G-coupled receptors and is a chemokine that is capable 
of attracting immune cells like monocytes. Upon vascular injury MCP-1 recruits monocytes, 
memory T cells and dendritic cells to the injured site. Attracted monocytes infiltrate the vessel 
and contribute importantly to neointima formation[69]. MCP-1 is strongly expressed locally 
in different stages of the remodeling process. Furthermore, it has strong influence on SMC 
proliferation. Both mouse models for arterial restenosis as for vein graft remodeling showed 
a MCP-1 inhibitor showed sufficient reduction in neointima formation. Furthermore studies 
in which the receptor for MCP-1 was targeted gave similar results[70-72]. No differences in 
MCP-1 concentrations between patients with acute MI, patients with stable coronary artery 
disease and healthy individuals were found[73]. However, an inverse correlation was found 
between MCP-1 concentration at baseline and the time to reperfusion, and a significant 
decrease in MCP-1 concentration immediately after PCI and lower MCP-1 concentrations 
over time in patients who developed restenosis within 6 months were found[73]. Elevated 
baseline level of MCP-1 was associated both with traditional risk factors for atherosclerosis as 
well as an increased risk for death or myocardial infarction, independent of baseline variables. 
Interestingly MCP-1 levels are not associated with CRP levels indicating the importance of 
selecting specific inflammatory markers in stead of general markers like CRP[74]. MCP-1 
levels are different amongst patients that received a BMS versus a DES[75]. Furthermore 
in the same study they found increased monocyte CCR-2 expression 24 hr and 48 hr after 
stenting in the BMS but not the DES group and changes in plasma MCP-1 after stenting 
correlated significantly with in-stent lumen loss. Previously another Japanese study already 
showed a correlation between MCP-1 and the risk for restenosis after stenting[76].
Interleukin 10
Interleukin 10 (IL-10) is one of the most prominent anti-inflammatory cytokines. It may 
suppress antigen presentation and is capable of inhibiting pro-inflammatory cytokine 
production. Different animal models for restenosis and atherosclerosis showed protective 
effects of IL-10 by the use of recombinant human IL-10 or using animals deficient in IL-10. 
In humans three polymorphisms significantly increased the risk of restenosis in patients and 
demonstrate that IL-10 is associated with restenosis[77-79]. IL-10 is however upregulated 
together with pro-inflammatory cytokines to maintain a balance between pro- and anti-
inflammatory cytokines. Most of the time upregulation of pro-inflammatory cytokines exerts 
the upregulation of IL-10. Peripheral therapeutic angioplasty gave no difference in IL-10 
levels compared to patients that underwent only angiography[67]. In a study using BMS 
after PCI a significant low IL-10 levels was associated with an increase in restenosis after 
6 months[80]. The use of undergoing zotarolimus-eluting (Zotarolimus is a semi-synthetic 
derivative of rapamycin that works as immunosupressant) stent implantation combined 
with pioglitazone significantly reduced neointimal hyperplasia within the stented lesion 
and attenuated total plaque burden in the in-segment regions of the stent at the 8-month 






CCL5 (RANTES) deposition was involved in wire-induced intimal hyperplasia and blocking 
of RANTES receptors attenuates neointima formation and macrophage infiltration in animal 
studies[82]. Two clinical studies focused on the relation of RANTES levels and restenosis. 
While one of these studies found a decrease of RANTES in time in the non-restenosis group 
another found a significant time-dependent increase in the restenosis group[83, 84]. No 
association was found between RANTES promoter genotype and restenosis[85]. 
Plasma antibodies
Recent results from murine interventional studies indicate that inflammation and (auto)
immune mechanisms are both strong contributors to the development of post-interventional 
restenosis development have led to the hypothesis that (auto)antibodies are both causally 
related to restenosis development, and titers could serve as biological biomarkers for the 
identification of restenosis risk or lesion severity. Longitudinal studies will be required to 
determine both the diagnostic and predictive values of antibody profiles, but promising 
candidates have emerged over the past decade, which will be discussed below. 
The immune system can be divided into the innate and adaptive systems, which are closely 
linked and regulated. The innate immunity forms the first line of defense and offers a quick 
but unspecific response to invading microorganisms, whilst adaptive immunity takes longer to 
develop, but targets highly specific antigen-bearing foreign intruders. To this end, the former 
system is comprised of various toll-like receptors, the complement system and cytokines 
and chemokines, whilst the latter depends on the vast variety of B and T cell receptors and 
antigen-specific immunoglobulines.  
Anti-oxidized LDL and phosphorylcholine antibodies
Immune responses against oxidized forms of cholesterol-containing LDL particles play 
a critical role in activation and regulation of the inflammatory process that characterizes 
all stages of atherosclerosisp[86]. LDL cholesterol is the most important risk factor for 
cardiovascular disease and cholesterol-lowering therapy (statins) alone can reduce CVD-
risk by 30-40%. LDL has been found to play a key role in lesion development and LDL 
oxidation by enzymes such as lipoxygenases primarily occurs in the extracellular matrix in 
the arterial wall. Oxidative modification of phospholipid fatty acids, degradation of apoB-
100 into peptide fragments and modification of these structures by aldehydes derived from 
oxidized fatty acids leads to the development of immunogenic neo-antigens[87, 88]. These 
contain pathogen-associated molecular patterns (PAMPs) that are recognized by the pathogen 
recognition receptors (PRRs) from the immune system, of which TLRs and scavenger 
receptors are considered to be the most important. TLRs occur both intra- and extracellular 
and are activated by lipopolysaccharide (LPS) and various other (viral) micro-biological 
antigens, but also by endogenous ligands such as heat shock proteins and fibronectin extra-
domain A[89].Their activation stimulates MyD88-dependent and independent intracellular 
cascades that eventually all lead to increased NFκB transcription and inflammation.
In both mouse and man, natural anti-oxLDL IgM and IgG antibodies occur, whilst in vitro, 
antibodies are directed towards malondialdehyde (MDA) and copper-oxidized LDL[87]. 
These antibodies proved to be exactly similar to those produced by natural occurring T15 
B-1 cell clones and all recognize the phosphorylcholine (PC) antigen on oxLDL[90], but also 
on apoptotic cells and Streptococcus pneumoniae, which share molecular mimicry[91, 92]. 
These antibodies are suggested to block the oxLDL-uptake by scavenger receptor-
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bearing macrophages and block foam cell and atherosclerotic lesion formation, but could 
also serve as risk markers for atherosclerotic and restenotic lesion development. Several 
studies have reported increased plasma titers of IgG anti-oxLDL antibodies in patients with 
angiographically verified coronary artery disease and with acute myocardial infarction[93-95]. 
Many studies found that low levels of IgM anti-oxLDL antibodies are associated with 
increased atherosclerosis in hypertensive patients and low levels of IgM anti-PC antibodies 
with acute myocardial infarction, ischemic stroke and cardiovascular disease in general in 
both the general population and patients with either hypertension or SLE[93-96]. Therefore, 
this could also hold true for restenosis due to accelerated atherosclerosis development and 
the severity of lesion development. In general, these studies have identified anti-oxLDL and 
specifically anti-PC antibodies as biomarkers for cardiovascular disease monitoring with 
potentially high additive value to current diagnostic strategies.
Microparticles
Thrombocytes, monocytes and those cellular types lining the arterial wall including 
endothelial cells and SMCs have been shown to vesiculate and release membrane-shed 
microparticles in response to cellular activation and apoptosis such as occur during the 
development of atherosclerotic and restenotic lesions[97, 98]. Membrane integrity is 
largely controlled by intracellular calcium and caspase homeostasis[99]. Disorganization of 
the cytoskeleton enables blebbing to occur and disruption of the membrane phospholipid 
symmetry supports PS externalization[99]. These PS-containing microparticles have been 
implicated in the development, progression and complications of atherosclerotic lesions and 
patients suffering from atherosclerotic or restenotic cardiovascular disease display high levels 
of circulating microparticles and since these microparticles are absent in healthy individuals, 
their circulating levels prove to allow excellent follow-up of lesion progression and serve as 
surrogate markers for vascular function[99]. 
Specifically endothelium-derived microparticles, but not those originating from other cellular 
types, have been shown to bear high prognostic value in the risk assessment of mortality 
and major adverse cardiovascular events in patients with coronary artery disease, but also 
pulmonary hypertension and end-stage renal failure[98]. 
What can we learn from the lesion itself for selecting novel biomarkers?  
In an ideal situation we would like to extract our biomarkers directly out of the lesion since 
this area previously gave problems and here postinterventional remodeling will start again.
Previously detectable CRP levels in the arterial intima were found preceding the appearance 
of monocytes. Furthermore, CRP had actually chemotactic capacities by direct influence 
on monocyte recruitment both in vitro as in vivo[100]. Another study showed that 
immunoreactivity to CRP was localized to macrophages, SMCs and necrotic areas. Moreover, 
the immunoreactivity to CRP in coronary atheromatous plaque increases in culprit lesions 
of unstable angina and it affects restenosis[101]. This may indicate that local CRP levels 
are much more specific to study while the role of circulating CRP and the relation with 
post-interventional remodeling may still be difficult to assess since it may be upregulated in 
multiple ways even independently of the interventional procedure. Another factor of which its 
plaque levels were more than 70 times higher in plaques than in plasma is oxLDL in patients 
undergoing carotid endarterectomy[102]. The same authors also found differences in the 
oxLDL amount in macrophages rich plaques versus macrophage poor plaques. Interestingly 




with macrophage-rich plaques which may indicate that when studying only oxLDL on the 
plasma level will not discriminate patients without or patients with a macrophage-poor 
plaque and may be more helpful in determination of plaque vulnerability than just plaque 
formation or progression[102] Bamberg and co-workers showed that different biomarkers 
of inflammation, vascular remodeling, oxidation, and lipoprotein metabolism maybe 
associated with different patterns of coronary atherosclerosis as quantified by coronary CT 
angiography[103]. So lesion phenotype may be very important for the selection of proper 
novel biomarkers. Only recently a novel study was conducted that uses the knowledge of 
specific lesions to study the disease process and use it as a predictor of future restenosis and 
or atherosclerosis occurrence even at other sites than the initial lesion. This Athero-Express 
study was the first study to provide prospective evidence that plaque composition may predict 
the risk of restenosis after endarterectomy. Here they found associations for non-vulnerable 
plaque phenotype to be more prone to develop restenosis[104]. The Athero-Express biobank 
was also used for a proteomics search approach to identify local biomarkers (selected 
proteins that have been identified earlier in experimental set-ups with any cardiovascular 
phenotype but not necessarily with atherosclerosis, osteopontin (OPN) and Macrophage 
migration inhibitory factor (MIF))  in the atherosclerotic plaque to predict atherosclerotic 
plaque development in other vascular beds. The authors collected plaques from carotids as 
well as plaques from femoral arteries and in both cases they found plaque osteopontin (OPN) 
levels highly predictive for secondary atherosclerotic development. Furthermore, plaque 
MIF levels were strongly associated with secondary cardiovascular events and showed that 
the concept not only applies for OPN[105]. Although beyond the scope of this review, the 
field of proteomic research is evolving and could contribute substantially to the discovery of 
new biomarkers in post-interventional restenosis and accelerated atherosclerosis. 
Most studies are of limited value for the risk stratification of individual patients with the 
current available biomarkers[25] and are therefore playing a very little role in the prediction 
of restenosis and decision-making for its exploration and treatment. Furthermore, in many 
clinical centers it is not possible yet to sample and extract tissue to select for biomarkers patient 
specifically however combining results of these kind of studies on plaque development and 
progression together with increased specific knowledge on the complex pathways extracted 
from experimental research may help us in understanding not only the pathophysiological 
process but also to select novel biomarkers. They probably will contribute largely to our 
knowledge and selection of novel biomarkers and may find new correlations between local 
and circulating levels of biomarkers and post-interventional remodeling and accelerated 
atherosclerosis. In addition these local studies may even come up with novel biomarkers 
inside the plaque that can not be detected in plasma due to their low plasma levels, incapacity 
of being released outside the plaque or just being plaque specific. 
Conclusion
Recently published studies have demonstrated that both lowered and elevated concentrations 
of local arterial and circulating biomarkers are associated with cardiovascular risk profiles 
and specifically post-interventional vascular remodeling due to accelerated atherosclerosis 
development. These associations are independent of traditional risk factors and could serve as 
helpful tools for risk stratification or diagnostic assessment of patients eligible for intensified 
treatment for clinicians performing target lesion revascularization interventions. Improved 
assays have identified not only circulating biomarkers, but also cellular-expressed receptors, 
co-factors and microparticles that all directly causally involved in disease progress, but 
also indirectly as biomarkers of inflammatory status and vascular function. Provided these 
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findings are replicated in other studies, the combined power of current diagnostic strategies 
with the latest tools and multiple biological risk markers could contribute significantly to the 
optimization of patient selection and future individual tailor-made treatment.
Future perspective
The insight into the development of atherosclerosis and post-PCI restenosis has developed 
very quickly over the past decade. Ever since, atherosclerosis is primarily viewed as a chronic 
inflammatory disease due to a dysfunctional immune response towards the arterial wall. To 
this end, the focus on atherosclerotic biomarkers has shifted from traditional markers that 
serve as risk factors, such as hypercholesterolemia, towards markers of systemic inflammation 
(e.g. C-reactive protein) and arterial dysfunction. The important notion remains that causal 
factors are additionally powerful predictors of disease progression and the same would apply 
for inflammatory markers. The field of diagnostic and treatment-evaluation markers will shift 
in the same direction, guided by new insights, and rely heavily on the additional value of 
new biomarkers to the current diagnostic strategies. Epidemiologic assessment of additional 
value from combining biomarkers is a powerful tool to discover new biomarkers entities 
for the development of highly specific assays, specifically for genetic biomarkers such as 
polymorphisms that are associated with disease risk. 
The field of biomarkers for accelerated atherosclerosis and post-interventional vascular 
remodeling has changed due to the introduction of drug-eluting stents. These stents have 
rendered various markers of little use, since they closely followed the inflammatory reaction 
towards BMS placement and are currently prevented by adequate local drug release. Their 
usefulness could be further compromised in future due to the ever-increasing application 
of drug-eluting balloons. Nevertheless, new inflammatory factors such as intraplaque and 
circulating proteins, natural antibodies, microparticles and cellular receptor expression 
could prove to be of highly-specific and diagnostic value. Furthermore, application of such 
screening assays would allow for optimal treatment evaluation such as occurred in the past 
with the introduction of cholesterol-lowering statin therapy. 
Development and application of future biomarkers requires clinical validation, which remains 
a time-consuming and expansive entity, and this uncertainty is inherently (most notably 




development. In spite of this, investigations continue to proceed and will improve diagnostic 
and treatment accuracy of post-interventional atherosclerotic vascular remodeling.
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Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing 
reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. 
Karper JC, de Vries MR, van den Brand BT, Hoefer IE, Fischer JW, Jukema JW, Niessen HW, Quax PH  
Arteriocler Thromb Vasc Biol. 2011;31(5):1033-40.
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Abstract:
Objective Explore the role of TLR4 in vein graft remodeling and disease.
Methods and Results First, expression of TLR4 was analyzed in human Saphenous Veins 
(huSV), either freshly isolated, or freshly isolated huSV ex vivo perfused in an extracorporeal 
circulation or in huSV used as coronary vein grafts. Marked induction of focal TLR4 expression 
was observed in perfused fresh huSV. Moreover, TLR4 was abundantly present in lesions in 
fresh huSV or in intimal hyperplasia in coronary vein grafts. Secondly mouse venous bypass 
grafting was performed. In grafts of hypercholesterolemic APOE*3Leiden mice increased 
TLR4 mRNA and protein was detected over time by RT-PCR and immunohistochemistry. 
Furthermore local presence of the endogenous TLR4-ligands HSP60, HMGB1, Tenascin-C 
and biglycan in the grafts was demonstrated. 
TLR4 deficiency in C3H-Tlr4LPS-d mice resulted in 48±12% less vein graft wall thickening 
(p=0.04) than in Balb/c controls. Moreover, local TLR4 gene silencing in hypercholesterolemic 
APOE*3Leiden mice using lentiviral-shRNA against TLR4 administered perivascularly 
around vein grafts led to a 44±13% reduction of vessel wall thickening compared to controls 
(p=0.0059). 
Conclusion: These results indicate that TLR4 is involved in vein graft remodeling and can 





Vein grafts are important conduits for revascularization during both coronary and peripheral 
bypass surgery although vein grafts sometimes have poor long term patency. Early graft 
failure is usually due to thrombosis but long term graft failure is caused by vein graft disease 
(VGD) induced by wall thickening due intimal hyperplasia that is triggered by inflammation. 
Vein graft wall thickening is in part characterized by smooth muscle cell (SMC) proliferation, 
matrix turnover and influx of lipids and inflammatory cells1, 2.
The innate immune system contains multiple receptors that recognize a broad variety of 
molecular structures. Toll Like Receptors (TLRs) have a key role in driving inflammation 
regulating the innate response after binding pathogen associated molecular patterns 
(PAMPs) or damage associated molecular patterns (DAMPs), respectively3-7. TLR4 is a 
membrane bound receptor located on a variety of immune and non-immune cells including 
macrophages, endothelial and SMCs. Cell stress and tissue damage may cause a release of 
DAMPS that function as endogenous TLR4 ligands and lead to activation and up-regulation 
of the expression of TLR4 resulting in a pro-inflammatory response6, 8-10. The role of TLR4 
in vascular remodeling, especially arterial remodeling has previously been demonstrated in 
various studies either directed at atherogenesis and plaque (de)stabilization or directed at 
the role of TLR4 in postinterventional arterial remodeling after angioplasty11-16. However 
the role of TLR4 and its endogenous ligands in remodeling of venous segments e.g. in vein 
graft remodeling is still unknown. Furthermore it is sugested that unactivated arterial VSMC 
do not express TLR4 and that TLRs may have a vessel specific profile which may also vary 
due to changes in cellular activation, differentiation and other local processes.17 Interestingly 
non-activated VSMC from huSV do express TLR418. 
To modulate atherosclerotic plaque formation by interfering in the TLR4 pathway, systemic 
therapeutic interventions would be required. However, due to its important role in the host 
defense mechanism, such a systemic approach would be undesirable. In contrast, venous 
bypass grafts do permit local therapeutic interventions. From the point of therapeutic 
interventions in the TLR4 pathway to reduce vascular remodeling VGD is of more interest and 
potential. Local therapy against VGD can be done easily e.g. by topical inhibitor application 
to the adventitial layer since adventitial cells contribute extensively to proliferation and 
migration of SMC and subsequent vein graft remodeling.19-23. Therefore local gene transfer 
in order to silence TLR4 expression would be an interesting approach for therapy to improve 
graft survival, once the role of TLR4 in VGD is established. 
In the current study we focus on the role for TLR4 in vein graft remodeling by illustrating the 
presence and upregulation of TLR4 and its endogenous ligands in both human and murine 
venous segments used for vein grafting. Moreover, a causal role of TLR4 was studied by 
performing vein grafting in TLR4 deficient mice (C3H-Tlr4LPS-d mice) or by local TLR4 gene 
silencing in murine vein graft using a lentiviral shRNA construct against TLR4. The latter 
study was performed in hypercholesterolemic APOE*3Leiden mice in order to mimic the 
situation vein grafting in hypercholesterolemic patients as close as possible.
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Material and methods:
For a detailed description of all materials and methods used see the online supplement 
(available online at http://atvb.ahajournals.org
In brief, immunohistochemistry for TLR4 was performed on paraffin embedded sections 
of human saphenous vein (huSV) segments, either freshly isolated, or freshly isolated and 
ex vivo perfused in an extracorporeal circulation for 4h or huSV used for at least 5 years as 
coronary vein grafts. Also murine vein graft segments were analyzed for TLR4 expression, 
but also its endogenous ligands HPS60, HMGB1, Tenascin-C and biglycan.
Lentiviral shRNA vectors against murine TLR4 were established based on the “Mission” 
library (Sigma Aldrich, the Netherlands).
Vein grafting in mice was performed by placing a venous interposition (vena cava) in the carotid 
artery of either Balb/c mice, TLR4 deficient (C3H-Tlr4LPS-d) mice or hypercholesterolemic 
APOE*3Leiden mice. In the APOE*3Leiden mice grafts were treated locally with the 
lentiviral shTLR4 construct. 
Results
TLR4 presence in human saphenous veins and coronary vein grafts.
Human vein graft obtained in the operating room during coronary artery bypass grafting 
procedures one segment directly taken for histologic and immunohistochemical examination 
and the remaining segment was placed in a perfusion circuit that was connected to the heart 
lung machine. Samples were perfused with autologous whole blood, with a pressure of 60 mm 
Hg (nonpulsatile flow). After 4 hours of perfusion, segments were taken for histologic and 
immunohistochemical examination. Furthermore vein grafts that served as coronary arterial 
bypass grafts for more than 6 years were derived at autopsy. To study the presence of TLR4 
during remodeling in huSV TLR4 expression was analyzed in the freshly isolated huSV, in 
pre-existing intimal lesions within these segments and the coronary vein grafts. In the fresh 
huSVs TLR4 expression could be detected especially in the circular smooth muscle cell layer 
(Figure 1A). Also the endothelial layer and adventitial vessels stained positive for TLR4 (not 
shown). Some of the venous segments contained spontaneous lesions, indicated by intimal 
hyperplasia formation. These lesions represent a focal area of spontaneous remodeling 
and demonstrated a marked presence of TLR4 (Figure 1B). Additionally a profound TLR4 
expression was observed in severely remodeled coronary vein grafts with a saphenous vein 
origin (Figure 1C). These grafts were obtained at autopsy, had been in situ for more than 5yrs 
and are representative sections of remodeled vein grafts. 
Focal TLR4 expression after graft perfusion. 
In vein grafting, early damage to the vessel wall is initiated immediately by surgical 
manipulation and after transplantation due to increased shear stress and wall tension initiated 
by increased perfusion pressure. Non-perfused fresh huSV showed only little TLR4-positive 
cells in sub-endothelial longitudinal muscle layer (Figure 2A). Parallel sections of the same 
fresh huSV were subjected to 4hrs perfusion with autologous blood on arterial pressure. These 
sections showed an impressive focal increase of TLR4 expression within the longitudinal 
layer (Figure 2B). 
TLR4 expression in murine vein grafts during remodeling                    
As the above presented findings indicate an increase of TLR4 presence during huSV 
remodeling, TLR4 presence on protein and mRNA level was analyzed during remodeling in 




Figure 2: Freshly isolated huSV was divided into two parts. 
One part was directly fixated (and paraffin embedded) 
while the other part was placed into an extra-corporeal 
circulation system for 4h with arterial pressure before 
fixation. Cross sections of both huSV parts were stained for 
TLR4. The longitudinal muscle layer of directly fixated huSV 
showed a few TLR4 positive spots (A). A rapid increase of 
TLR4 expression was seen in the longitudinal muscle layer 
of huSV after 4h perfusion with arterial pressure (B). LML= 
longitudinal muscle layer.
Figure 1: TLR4 expression on cross-sections of 
huSV. Freshly harvested huSV stained positive 
for TLR4 on the circular muscle layer (A). Pre-
existent intimal lesions in freshly harvested huSV 
showed several TLR4 positive spots (B) and 
coronary huSV grafts derived at autopsy showed 
a profound expression of TLR4 in the thickened 
vein graft wall (C). CML= circular muscle layer, 
LML= longitudinal muscle layer, PIL= pre-existent 














thickening and accelerated atherosclerosis. TLR4 protein presence was studied by IHC during 
progression of remodeling over time in hypercholesterolemic APOE*3Leiden mice. A marked 
expression of TLR4 was detectable in these vein grafts. In the early remodeling phase, when 
the graft is only a single to a couple of cell layers thick, TLR4 positive spots were observed 
(Figure 3AB). At t=7 and t=14d vessel wall thickness has increased markedly. Within these 
segments focal areas of intense TLR4 protein expression could be detected (Figure 3CD). 
Rabbit IgG isotype control showed no staining (Figure 3E). Expression of TLR4 mRNA 
during remodeling was detected by RT-PCR in hypercholesterolemic APOE*3Leiden mice 
over time at t=0, 6hours, 1, 3, 7 and 28d after graft placement. A rapid increase in TLR4 
mRNA could be detected in the early remodeling phase. During intermediate and late phase 
remodeling TLR4 mRNA remained up regulated (Figure 3F) (t=0 vs 6h p=0.03, t=0 vs 1d 
p=0.0039, t=0 vs 3d p=0.02, t=0 vs 7d p=0.1, t=0 vs 28d p=0.09. Increase of TLR4 expression 
may be partly related to an influx of cd68+ cells (t=0 vs 6h p=0.6, t=0 vs 1d p=0.0037, t=0 vs 
3d p=0.0026, t=0 vs 7d p=0.0032, t=0 vs 28d p=0.0003 during remodeling and proliferation/
migration of SMC (t=0 vs 6h p=0.07, t=0 vs 1d p=0.0007, t=0 vs 3d p=0.17, t=0 vs 7d 
p=0.02, t=0 vs 28d p=0.006, Figure 3GH).   
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Presence of endogenous TLR4 ligands in murine vein grafts                                    
Remodeled grafts have been subjected to proliferation, migration and turnover of cells 
and matrix components. These processes may cause an upregulation of DAMPs that 
can be recognized by TLR4.  We localized several of these DAMPS in vein grafts of 
hypercholesterolemic APOE3*Leiden mice harvested at t=14d. Proteins in response to 
cellular stress like Heat Shock Protein 60 (HSP60) and High Mobility Group Box 1 (HMGB1) 
are known TLR4 ligands. Presence of HSP60 was detected especially in the sub-endothelial 
layer of the thickened vessel wall (Figure 4A). HMGB1, normally at rest located inside the 
nucleus, was now detected in the cytoplasm were it is known to act in a cytokine-like way 
(Figure 4B)24. In addition, matrix components that are expressed during matrix turnover were 
studied. Glycoprotein Tenascin-C was demonstrated especially at the matrix rich adventitial 
site of the graft but also near the luminal site in matrix containing areas (Figure 4C). These 
endogenous ligands could potentially colocalize with TLR4 since they were present in the 
lesions site and in areas that also express TLR4 at the same time point (Figure 3D and 4ABC). 
Figure 3: TLR4 expression on murine vein grafts of hypercholesterolemic APOE*3Leiden mice was detected by IHC 
and RT-PCR. Over time analysis was done at grafts harvested t=1 (A), 3 (B), 7 (C) and 14d (D) after surgery. Rabbit 
IgG isotype control (E). Arrows indicate  positive TLR4 staining. RT-PCR of TLR4 (F) CD68 (G) and αSMactin 
(H) mRNA at t= 0h, 6h, 1, 3, 7 and 28d after surgery. A students t-test was used for statistical analysis, * = P<0.05 





















Furthermore mRNA expression of matrix component Biglycan (BGN), that may function as 
TLR4 ligand, was studied in time and a more than 10-fold increase of mRNA was detectable 
after 7d. This increase in Biglycan expression remained up regulated during the remodeling 
process (t=0 vs 6h p=0.25, t=0 vs 1d p=0.017, t=0 vs 3d p=0.21, t=0 vs 7d p=0.004, t=0 vs 
28d p=0.021, Figure 4D).
Figure 4: Endogenous TLR4 ligands were detected in vein grafts of hypercholesterolemic APOE*3Leiden mice. 
Presence of HSP60 (A), HMGB1 (B)  and Tenascin-C (C) was detected by IHC in vein grafts 14 days after surgery. 
RT-PCR on matrix component Biglycan mRNA was performed at t= 0h, 6h, 1, 3, 7 and 28d after surgery (n= 3-4 per 
timepoint) (D). A students t-test was used for statistical analysis, * = P<0.05 compared to t=0.
Functional role of TLR4 in murine vein graft remodeling
To explore whether TLR4 has a functional role in vein graft thickening, an essential step in 
vein graft disease leading to vein graft failure, a venous interposition was placed in the carotid 
artery of Balb/c (n=8) and TLR4 deficient (C3H-Tlr4LPS-d) mice (n=7). C3H-Tlr4LPS-d mice 
showed 48±12% (0.264±0.06mm2 vs. 0.136±0.02mm2, p=0.04) less wall thickening than 
Balb/c controls (Figure 5A). Graft patency was kept by compensatory outward remodeling 
in the Balb/c mice indicated by a significantly larger total vessel wall area (0.60±0.03mm2vs. 
0.42±0.05mm2, P=0.01) (figure 5B) and thereby only a small difference in ratio lumen/
total vessel wall area (online supplement figure I). Furthermore the reduced vessel wall 
thickening correlated with a reduced alpha-SMC-actin positive area in the C3H-Tlr4LPS-d 
mice. (0.022±0.003mm2 vs 0.047±0.009mm2, p=0.035) (Figure 5C). 
TLR4 silencing in vitro
To create a tool for local TLR4 gene silencing five lentiviral based shRNAs were produced 
and validated by measurement of murine TLR4/MD2 expression on CHO cells by FACS 
analysis and the best vector was selected (not shown). The selected vector showed a dose 
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dependent down regulation of TLR4 protein expression (online supplement figure II). Murine 
3T3 fibroblasts were then transduced by selected lenti-shTLR4 (TRCN0000065787), lenti-
control or PBS and subsequently stimulated with different pro-inflammatory stimuli to obtain 
insight on its specificity in reducing TLR4 induced NFκB activation. Lenti-shTLR4 gave a 
significant reduction in NFκB activation after administration of TLR4 ligand LPS (P<0.01). 
Application of Pam3Cys, TNFa or IL1beta gave no different effects on NFκB activation 
when compared to the controls (online supplement figure III). 
Local TLR4 silencing in hypercholesterolemic APOE*3Leiden mice
To validate the potential of TLR4 as a local therapeutic in vein graft disease, a study was 
pursued using local TLR4 gene silencing to diminish vein graft disease in APOE*3Leiden 
mice. These mice, when fed a high cholesterolemic diet, are well known to develop massive 
vein graft disease due to neointima formation and accelerated atherosclerosis. After graft 
placement in APOE*3Leiden mice pluronic gel (pg) with PBS (n=8), lenti-control (n=9) or 
lenti-shTLR4 (n=7) was lubricated around the graft. Mice were fed a western type diet for 
total duration of the experiment, starting 3 weeks before surgery. No significant differences 
between groups in cholesterol levels (PBS 9.6±0.9 mmol/L, lenti-control 9.7±1.0 mmol/L 
and lenti-shTLR4 10.2±0.6 mmol/L) and body weights were observed (not shown). 
Local gene silencing of TLR4 led to a 44±13% reduction of vessel wall thickening in the graft 
segment (PBS 0.40±0.04mm2, lenti-control 0.42±0.04mm2, lenti-shTLR4 0.23±0.03mm2) 
Figure 5: 
Vein graft remodeling in Balb/c and C3H-Tlr4LPS-d mice (balb/c 
n=8, C3H-Tlr4LPS-d n=7). Areas of vein graft sections were 
quantified by using 6 sequential sections per vein graft of each 
mouse. A mean of these 6 sections was used as the outcome 
of vein graft remodeling per mouse. Outcomes of analysis are 
expressed in millimeters squared (mean ± SEM). C3H-Tlr4LPS-d 
mice showed a significant reduction in vein graft wall thickening 
compared to Balb/c controls (A). C3H-Tlr4LPS-d mice showed a 







alpha SMC actin area was significantly smaller in C3H-Tlr4LPS-d mice (C) Representative HPS stained sections of 





(PBS vs. lenti-shTLR4 p=0.0059, lenti-control vs. lenti-shTLR4 p=0.0052, PBS vs. lenti-
control p=0.96). A difference in total vessel wall area was only found between lenti-control 
vs lenti-shTLR4. Additionally a beneficial lumen/total cross sectional ratio showed a 
beneficial outcome for the lenti-shTLR4 treated group (PBS 0.45±0.05mm2, lenti-control 
0.54±0.04mm2, lenti-shTLR4 0.70±0.03mm2) (PBS vs. lenti-shTLR4 p=0.0012, lenti-control 
vs. lenti-shTLR4 p=0.0079, PBS vs. lenti-control p=0.14) (Figure 6A-D). Furthermore 
although quantitative interpretation of immunohistochemistry has to be done with extreme 
caution, treatment with lenti-shTLR4 gave a reduction in focal TLR4 expression in the 
graft (Figure 6E). After TLR4 silencing in the vein grafts of APOE*3Leiden mice the area 
positive for macrophages (MAC3 positive area) and SMC (alpha-SMC-actin positive area) 
was reduced by 54% and 61% respectively when compared to the PBS group. (details: Table 








Figure 6: Vein graft remodeling after local TLR4 
silencing in hypercholesterolemic APOE*3Leiden 
mice (PBS n=8, lenti-control n=9, lenti-shTLR4 
n=7). Areas of vein graft sections were quantified 
by using 6 sequential sections per vein graft vein 
graft of each mouse. A mean of these 6 sections 
was used as the outcome of vein graft remodeling 
per mouse. Outcomes of analysis are expressed in 
millimeters squared (mean±SEM). Vein graft wall 
thickening was reduced in the lenti-shTLR4 treated 
group compared to the controls (A). Total vessel 
wall area was smaller in the lenti-shTLR4 group 
compared to the lenti-control (B). A beneficial 
lumen/total cross-sectional area ratio was 
observed in the lenti-shTLR4 treated group (C). 
Representative HPS stained sections of focal vein 
graft wall thickening (D). Focal TLR4 expression 
in vein grafts locally treated with PBS (1), lenti-
control (2) and lenti-shTLR4 (3) (E), *= P<0.01. 




The present study describes the role of TLR4 in vein graft remodeling in human and mice with 
a profound presence TLR4, endogenous TLR4 ligands during remodeling and the therapeutic 
potential for local TLR4 silencing. Abundant TLR4 presence was noticed in freshly isolated 
huSV. Additionally in remodeled areas of fresh huSV, in fresh huSV after reperfusion and in 
coronary vein grafts derived at autopsy an up regulation of TLR4 protein was observed. In 
murine vein grafts of hypercholesterolemic APOE*3Leiden mice TLR4 expression is present 
over time at protein and mRNA level and a series of endogenous TLR4 ligands, HSP60, 
HMGB1, Tenascin C and Biglycan was expressed. Furthermore TLR4 deficient mice show a 
significant reduction in vein graft thickening and less outward remodeling after vein grafting. 
Moreover, local gene silencing of TLR4 gives a clear reduction in vein graft thickening and 
a beneficial lumen/total cross sectional area ratio.
Nowadays TLR4 is considered to be an important factor in inflammatory mediated 
diseases. VGD is strongly mediated by remodeling initiated by wall stress, cell damage and 
inflammation. The level of TLR4 expression may vary amongst different vessel specimens 
and is dependent on activation and local environmental changes like wall stress, cell damage 
and inflammation. 17. Furthermore these differences may also be relevant for the presence 
and levels of endogenous TLR4 ligands. Therefore it is of major importance to evaluate 
TLR4 expression, function and therapeutic potential in a VGD related setting. Here we report 
presence of TLR4 on the circular muscle layer of fresh huSV and a rapid increase of focal 
TLR4 expression within 4 hours of reperfusion in an extracorporeal circulation set up with 
arterial pressure on sections of fresh huSV.  Increased TLR4 expression may be initiated by 
damage inducing processes like ischemia/reperfusion and increased wall tension/shear stress 
due to pressure and flow disturbances25, 26. Additionally, the initiated damage to the vessel 
contributes, most likely by inducing the release of endogenous ligands, to proliferation and 
migration of VSMC and influx of inflammatory cells like macrophages resulting in thickening 
of the vessel wall. These cells playing an important role in vascular remodeling have been 
shown to express TLR413, 18, 27, 28. In support we notice abundant TLR4 presence within the 
thickened vessel wall of severely remodeled areas in vein grafts of human and mouse origin. 
Previously, localization of TLR4 has been shown in remodeled arteries during atherogenesis 
and after angioplasty and that presence of TLR4 ligands may alter its expression13, 14, 16.
The discovery that these TLR4 ligands can be of endogenous origin further emphasize 
the importance of TLR4 in inflammatory mediated diseases3. The endogenous ligands, 
most often referred as DAMPs, are most often danger signals or degradation products of 
matrix component that become available in response to injury. Bypass surgery itself and 
the subjection of the transplanted vessel to hypoxia and increased blood pressure can cause 
a release of powerful inducers of cellular stress and tissue damage. The observed presence 
of Heat Shock Protein 60 (HSP60), extracellular High Mobility Group Box 1 (HMGB1), 
Tenascin-C and up regulation of Biglycan mRNA during remodeling are nice examples of 
this. Previously Hochleitner et al. described the release of HSP60 after shear stress29 and 
others showed the capability of HSP60 to bind directly to TLR4 thereby initiating proliferation 
of VSMC30. Cellular stress may also cause passive release of HMGB1 by a variety of cell 
types including endothelium and monocytes/macrophages and acts like a cytokine capable 
of binding to TLR4 thereby initiating a pro-inflammatory response8, 31, 32. Matrix turnover 
importantly mediates vein graft remodeling. Extracellular matrix glycoprotein Tenascin-C 
is related to tissue repair and injury. Normally Tenascin-C is not present in huSV but after 




capable of promoting SMC migration35, growth36 and effecting important genes in vascular 
remodeling. Recently Tenascin-C was found to be an endogenous TLR4 ligand without 
the need for CD14 or MD-2 as accessory molecules for signal transduction and therefore 
Tenascin-C may act in vein grafts also via TLR4 signaling37. The matrix component Biglycan 
is co-immunoprecipitated with TLR4 and by signaling via TLR4 on macrophages it has a 
pro-inflammatory effect. Moreover it enhances SMC proliferation36, 38. The observed increase 
in Biglycan expression over time in the vein graft point towards an increased TLR4 signaling 
in murine vein grafts with Biglycan as ligand. 
The reduced vein graft wall thickening in the C3H-Tlr4LPS-d mice by reducing total SMC 
amount demonstrates that TLR4 and its endogenous ligands are not just only expressed in the 
remodeling vein graft segments, but TLR4 is also causally involved in vein graft remodeling. 
As the current results indicate presence and even causal involvement of TLR4 and up 
regulation of multiple endogenous ligands in VGD, several new targets can be proposed 
for therapeutic interference. Long-term systemic anti-inflammatory treatment against TLR4 
would be difficult and undesirable due to expected adverse side effects. Furthermore targeting 
of a single DAMP would be not a good option since multiple DAMPS are up regulated and 
are able to trigger TLR4 signalling involved in vascular remodeling making it difficult to 
select them as therapeutic targets individually. Local RNA interference (RNAi) for TLR4 
may overcome this problem. Short hairpin RNA constructs are able to inhibit gene translation 
into protein thereby initiating effective gene silencing39, 40. Previously our group showed that 
local graft transduction using a lentivirus can be performed efficiently in vivo41. In support, 
others have shown encouraging results for the applicability of local gene therapy42, 43.
Therefore local lentiviral infection with the selected TLR4 shRNA was performed in on 
vein grafts positioned in the carotid artery of hypercholesterolemic APOE*3Leiden mice. 
The specificity of the shRNA construct used was demonstrated by its capacity to decrease 
murine TLR4 expression on transformed CHO cells and to reduce NFkB activation in murine 
fibroblasts after LPS activation.  NFkB activation after challenging the cells with other stimuli 
than the TLR4-ligand LPS, such as Pam3Cys, TNFa or IL1b, was not affected demonstrating 
the specificity of the construct.
Morphometric analysis after silencing TLR4 demonstrates a reduction in vessel wall 
thickening which is supported by a focal decrease in TLR4 expression and a reduction in 
total amount of macrophages in the lesions. Like in the TLR4 deficient mice reduction of 
total SMC in the lenti-shTLR4 treated group correlated with the decrease in vessel wall 
thickening. Furthermore local TLR4 silencing increases the ratio of lumen versus total 
cross sectional area. This indicates a beneficial effect of local TLR4 silencing on vein graft 
remodeling with effects on graft patency on long term.
This also might have impact for the treatment of patients since vein grafts can readily be 
treated locally ex vivo during surgery thus presenting a unique opportunity for gene transfer 
or gene inhibition to alter the remodeling response. 
In summary, upregulation of TLR4 expression (both in human and mouse) as well as its 
endogenous ligands in vein grafts during graft remodeling and the reduced vein graft 
thickening in TLR4 deficient C3H-Tlr4LPS-d mice point out important involvement of TLR4 
and its endogenous ligands in vein graft disease. Furthermore the reduction of vein graft 
vessel wall thickening in hypercholesterolemic APOE*3Leiden mice after local lentiviral 
shRNA mediated interference in the TLR4 pathway indicate the potential of TLR4 as a local 
therapeutic target to improve vein graft survival. 
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All animal experiments were approved by the animal welfare committee of our institute.
10 week old male Balb/c, C3H-Tlr4LPS-d and APOE*3Leiden mice, bred in our laboratory, 
were used. C3H-Tlr4LPS-d mice have a Balb/c background but carry a mutation that causes 
a deficiency in TLR4 signaling.
APOE*3Leiden were fed a western-type diet (Arie Blok, The Netherlands), starting 3 
weeks before surgery and continued during the experiment to develop a diet dependent 
hypercholesterolemia.
All mice received water and food ad libitum. One week before surgery cholesterol levels in 
serum were determined (Roche Diagnostics, The Netherlands).
Production of lentiviral shRNA against TLR4
Out of the “Mission Library” (Sigma Aldrich, The Netherlands) 5 sequence-verified short 
hairpin RNA (shRNA) lentiviral-plasmids against TLR4 were isolated and produced. 
Lentiviral packaging vectors (pCMV-VSVG, pMDLg-RREgag/pol, pRSV-REV) and 
transfer vector (pLKO.1-puro Vector) were co-transfected in HEK293T cells using calcium-
phosphate precipitation method. Lentiviral particles were concentrated using sucrose cushion 
centrifugation (30.000rpm, 2h). Quantification of lentiviral titer was
done by p24 ELISA (ZeptoMetrix, USA).






* Selected and in vivo applied lenti-shTLR4
In vitro targeting of murine TLR4 expression
CHO cells expressing murine TLR4/MD2 and control cells (kindly provided by Dr. A. 
Garritsen, Merck Sharp Dome, The Netherlands) were transduced with the 5 different 
lentiviral based shRNAs in a 0.1:1, 0.5:1, 1:1 and 2:1 ratio (lentiviral particles/cells) in 
DMEM (Invitrogen, The Netherlands) containing 0.8ug/ml polybrene (Sigma Aldrich, The 
Netherlands) with 5% Fetal Calf Serum. After overnight transduction medium was replaced 
by fresh medium. Subsequent TLR4 expression was measured by FACS analysis with a 
TLR4-MD2 FITC antibody (HyCult biotechnology, The Netherlands) after 5d.
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Transduction of murine 3T3 fibroblasts:
NIH 3T3 mouse fibroblasts stably transfected with a 5xNFκB-Luciferase vector as described 
1. After overnight adherence, cells were transduced with, lenti-control (lentivirus-GFP) or 
lenti-shTLR4 (TRCN0000065787) per well (MOI of 7.5) or PBS. Medium was discarded 
after 4h transduction and replaced by fresh medium. Cells were cultured for 5d followed by 
stimulation with LPS, TNFα, Pam3Cys, or IL1β. After 6h stimulation, cells were washed 
with 0.9% NaCl and lysed for 15min on ice. Bright-Glo was added and luminescence was 
measured on the Lumistar Optima.
 
Murine vein graft model
In the mouse carotid artery a venous interposition was placed as described previously2. Caval 
veins of donor mice were placed as vein grafts in the right carotid artery of recipient mice.
Lentiviral transduction of the vein graft in situ
Before wound closure , in the APOE*3Leiden mice, 150μl 20% pluronic gel (Sigma Aldrich, 
The Netherlands) containing 1.5*106 lentiviral particles (P24 Elisa, ZeptoMetrix, USA) and 
0.8μg/ml DEAE (Sigma Aldrich, The Netherlands) was lubricated around the graft.
Vein graft thickening quantification
Mice were sacrificed 28d (or as stated otherwise) after surgery for histological analysis. 
Vein graft segments were harvested after perfusion fixation with 4% formaldehyde, fixated 
overnight and paraffin-embedded using an automated tissue processor (Leica, Germany). 
Cross-sections were made throughout the embedded vein grafts. Six representative sections 
per vessel segment were stained with Haematoxylin-Phloxine- Saffron (HPS) for histological 
and morphometric analysis (Leica, Germany). Vein graft thickening was defined as the area 
between lumen and adventitia and determined by subtracting the luminal area from the total 
vessel wall area.
Human vein graft tissue
Veins were surplus segments of huSVs that were collected in the operating room from patients 
undergoing coronary artery bypass grafting (CABG). Vessel specimens were freshly collected 
under sterile conditions. One part of the segment was directly fixated for histopathological 
examination and another part was perfused on an extracorporeal perfusion circuit connected 
to the heart-lung machine during the CABG procedure with autologous blood and under 
arterial pressure (60mmHg) as described by Stooker3. The study was approved by the local 
ethics committee. Patients were included in the study after providing informed consent. Non-
perfused fresh huSV segments (n=6 patients) and parallel fresh huSV segments that were 
perfused for 4h respectively (n=6 patients) were analyzed huSV segments that have served 
as coronary bypass for more than 5yrs (n=5 patients) were derived at autopsy. Use of patient 
material after completion of the





Paraffin embedded sections (5µm) were deparaffinized in xylene. Peroxidase activity was 
blocked by incubation in 0.3% (v/v) H2O2 in methanol for 20min. Antigen retrieval was 
performed and tissue sections were pre-incubated with 5% bovine serum albumin (BSA), 
followed by incubation with detecting antibody.
TLR4 presence was stained with TLR4 antibody (sc-10741 rabbit anti-human, Santa Cruz, 
United States)4, HSP60 (rabbit anti-mouse, Abcam, UK), HMGB1 (rabbit anti- mouse Abcam, 
UK), Tenascin C (rabbit anti-mouse, Millipore, USA), SMCs with α- smooth muscle cell 
actin staining (Roche Applied Biosciences, Germany) and macrophages with MAC3ab (BD 
Pharmigen, USA). After washing in PBS, sections were incubated for 1h with a secondary 
antibody (Donkey anti-Rabbit, GE Healthcare, USA), washed in PBS, incubated for 1h with 
AB complex (Vector laboratories, The Netherlands) and visualized with Novared (Vector 
laboratories) or DAB (Dako, Denmark). Slides were counterstained with haematoxylin. 
Immunopositive areas of SMC and macrophages were calculated as percentage of total 
vein graft area in cross-sections by morphometry (Leica, Germany). To increase the TLR4 
detection after AB complex slides were incubated for 10 minutes with biotinylated thyramids 
and again 1h with ABcomplex prior to visualization with Novared. As control parallel 
sections were incubated with 1% PBS/BSA alone or with Rabbit IgG isotype without adding 
detecting antibodies. Controls were all negative (not shown).
RT-PCR
Total RNA was isolated using Tri-Reagent (Sigma-Aldrich) according to the manufacturer’s 
protocol. The expression levels of TLR4 and Biglycan were analyzed by RT-PCR (real time 
polymerase chain reaction). The relative mRNA expression levels were determined by using 
GAPDH as house keeping gene and the 2[−ΔΔC(T)] method. Values were expressed as fold 
of respective controls.
Statistical analysis
Values are presented as mean±standard error of the mean (SEM). Statistical significance was 
calculated in SPSS for Windows-17.0. Differences between groups were determined using 
a non parametric Mann-Whitney and One-way ANOVA (Kruskal-Wallis, non- parametric 
Dunn’s Multiple Comparison Test) tests. A Student’s t-test was used for statistical analysis of 
in vitro assays. Probability values of less than 0.05 were considered statistically significant.
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Figure III: Murine 3T3 fibroblast were transduced with PBS, lenti-control or lenti-shTLR4 and subsequently 
stimulated with LPS, 100ng/ml; Pam3Cys, 10µg/ml; TNF-α, 10ng/ml; IL-1β, 10ng/ml; Non Stimulated. NFkB 
activation due to LPS stimulation was significantly reduced in the lenti-shTLR4 transduced fibroblasts (F), A 
students t-test was used for statistical analysis * = P<0.01.
Figure I: Ratio lumen/total vessel wall area of vein 
grafts of balb/c (n=8) and TLR4 deficient C3H-
Tlr4LPS-d) mice (n=7) Figure II In vitro analysis 
of lenti-shTLR4 silencing. 
Murine TLR4 expression 
on CHO cells was analyzed 
after a dose dependent 
transduction with lenti-shTLR4. Positive control (A). Dose dependent transduction of lenti-shTLR4 in a 1:0.1 (B) 






  PBS  Lenti-control Lenti-shTLR4
Macrophages 406±53μm2  * 446±87μm2 187±64μm2
SMC  1289±120μm2  * 515±169μm2 511±63μm2
Macrophages: PBS vs. lenti-shTLR4 p=0.037, lenti-control vs. lenti-shTLR4 p=0.054, PBS 
vs. lenti-control p=1.00. SMC: PBS vs. lenti-shTLR4 p=0.00006, lenti-control vs. lenti-
shTLR4 p=0.53, PBS vs. lenti-control p=0.0059.
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 Blocking Toll-Like Receptors 7 and 9 Reduces Postinterventional Remodeling via    
 Reduced Macrophage Activation, Foam Cell Formation, and Migration.
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Objective The role of Toll-like Receptors in vascular remodeling is well established. 
However, the involvement of the endosomal TLRs is unknown. Here we study the effect of 
combined blocking of TLR7 and TLR9 on post-interventional remodeling and accelerated 
atherosclerosis. 
Methods and Results In hypercholesterolemic APOE*3Leiden mice femoral artery 
cuff placement led to strong increase of TLR7 and 9 presence, demonstrated by 
immunohistochemistry (IHC). Blocking TLR7/9 with a dual antagonist in vivo reduced 
neointimal thickening and foam cell accumulation 14d after surgery by 65.6% (p=0.0079). 
Intima/media ratio was reduced by 64.5%, and luminal stenosis by 62.8%. The TLR7/9 
antagonist reduced the arterial wall inflammation, with reduced macrophage infiltration, 
decreased cytoplasmic High Mobility Group Box1 expression and altered serum IL10 
levels. Stimulation of cultured macrophages with TLR7 and TLR9 ligands enhanced TNFa 
expression, which is decreased by TLR7/9 antagonist co-administration. Additionally, the 
antagonist abolished the TLR7/9 enhanced LDL uptake. The antagonist also reduced oxLDL 
induced foam cell formation, most likely not via decreased influx but via increased efflux, 
since CD36 expression was unchanged whereas IL-10 levels were higher (36.1±22.3pg/ml 
vs. 128.9±6.6pg/ml; p=0.008).
Conclusion, blocking TLR7 and TLR9 reduced post-interventional vascular remodeling and 





Post-interventional remodeling is a critical determinant of long-term efficacy of Percutaneous 
Coronary Interventions (PCI). Restenosis is characterized by acute elastic recoil and intimal 
hyperplasia due to inflammation, smooth muscle cell proliferation and extracellular matrix 
turnover.1 Under hypercholesterolemic conditions this is accompanied by influx and 
accumulation of low-density lipoprotein (LDL) cholesterol in the vessel wall that becomes 
oxidized and taken up by macrophages. Thereby these macrophages become foam cells 
and initiate a process of accelerated atherosclerosis.2 Previously, we and others described 
an important causal role for extracellular Toll-like Receptors (TLRs) in post-interventional 
remodeling. It has been shown that TLR4 and the Myd88-dependent pathway play an 
important role in restenosis and postinterventional accelerated atherosclerosis3-6. Similarly a 
crucial role for TLR 2 has been described7 
TLRs as part of the innate immune system are pattern recognition receptors (PRR) known to 
recognize exogenous ligands that originate from bacteria or viruses as well as endogenous 
ligands. These endogenous ligands may be released after tissue damage or cell stress, processes 
that may be initiated by PCI. Myd88-dependent signaling is the dominant activation pathway 
of TLR signaling leading to NFkB activation and upregulation of several pro-inflammatory 
cytokines. Since TLR2 and TLR4 are known to be expressed on the cell surface of vascular 
cells and activated in vascular disease processes via Damage-Associated Molecular Patterns 
(DAMPs) as endogenous ligands, such as Heat Shock Proteins, Fibronectin-EDA, Tenascin 
C and High Mobility Group Box1 (HMGB1) 8-11, research in the cardiovascular field mainly 
focused on TLR2 and TLR4.
Little is known about the role of endosomal TLRs that are mostly studied for their recognition 
of viral/bacterial DNA and RNA fragments and were originally considered absent in the 
healthy arterial vessel wall.12 Activation of endosomal TLRs like TLR7 and TLR9 may lead 
to up regulation of IFNa, IL-6, IL-12 or TNFa by innate immune cells, e.g. macrophages. 
Recently, increased TLR7 mRNA was found in atheroma of human carotids.13 Moreover 
TLR9 was also found in human atherosclerotic plaques14 and arterial cells were responsive 
to TLR9 ligand.15 Interestingly, it has been suggested that these receptors may also recognize 
self DNA/RNA that is exposed after cell stress and damage causing a sterile inflammatory 
reaction.16-19 TLR7 and TLR9 have also been shown to recognize immune complexes 
containing self nucleic acids in autoimmune diseases.16, 20 PCI is considered to cause severe 
damage to the endothelium allowing influx of lipids and inflammatory cells into the vessel 
wall. Concurrently, deeper layers in the vessel wall experience severe stress and cellular 
death at the place of intervention may cause a release of self RNA/DNA or proteins that 
enhance the direct recognition of nucleic acids by intracellular TLRs or binding of these 
nucleic acids to intracellular TLR signaling regulators such as HMGB1.21 Most interestingly, 
activation of TLR9 is also reported to increase the secretion of HMGB1, the endogenous 
ligand for TLR422 
Recently, we have identified a novel class of oligonucleotide-based compounds that act as 
dual antagonists of TLR7 and TLR9 and inhibit immune responses mediated through these 
receptors.23, 24 In the current study we focus on the therapeutic potential of targeting TLR7 
and TLR9 to reduce post-interventional remodeling by preventing neointimal formation and 
accelerated atherosclerosis. We illustrate the presence and upregulation of TLR7 and TLR9 
and their co-localization with macrophages/foam cells in a murine model for neointimal 
formation and accelerated atherosclerosis. A causal role of the TLR7/9 was studied in a murine 
model for postinterventional vascular remodeling in hypercholesterolemic APOE*3Leiden 
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mice by the use of the TLR7/9 antagonist. Furthermore, we studied activation and antagonism 
of TLR7 and TLR9 on cultured macrophages and on foam cell formation using a novel 
TLR7/9 dual antagonist. 
Material and methods:
For a detailed description of all materials and methods used see the online supplement 
(available online at http://atvb.ahajournals.org).
In brief, non-constricted polyethelene cuffs were placed around the femoral arteries as 
a well-established model for neointima formation and accelerated atherosclerosis in 
hypercholesterolemic ApoE3Leiden mice. Immunohistochemistry for TLR7 and TLR9 
was performed on paraffin embedded sections of cuffed arteries of hypercholesterolemic 
ApoE3Leiden mice at t=0 and t=14. A TLR7/TLR9 dual antagonist was synthesized and 
specificity was determined. We studied its effect on neointima formation and accelerated 
atherosclerosis in hypercholesterolemic APOE*3Leiden mice after femoral arterial cuff 
placement by injecting the antagonist biweekly to get sufficient TLR7/9 blockade. Intimal 
lesions were analysed for CD45, MAC3 and HMGB1 by immunohistochemistry. The 
antagonist was used to study the effect of blocking of TLR7/9 on macrophage activation and 
lipid accumulation in macrophages. Cytokine levels of TNFa, IP-10, IL6, IL12 and IL10 





Arterial injury leads to TLR7 and TLR9 presence in the vessel wall
Little is known about the presence of TLR7 and TLR9 in the vessel wall after surgical 
intervention. Using immunohistochemical analysis, we explored whether TLR7 and TLR9 
are expressed in cuffed remodeled arteries with neointimal lesions after 14d and in non-
cuffed arteries of hypercholesterolemic APOE*3Leiden mice, since TLR expression may 
differ amongst different arterial segments and also in response to vessel damage12, 13 Cuff 
placement for 14d provoked severe neointimal thickening and showed presence of TLR7/9 
profoundly in the tunica media of these arterial segments. Presence of either TLR7 or TLR9 
could not be observed in non-cuffed femoral arteries (Figure 1A-D). Lesions in cuffed 
arteries of wild type mice on a chow diet that consist dominantly of vascular smooth muscle 
cells were also negative for TLR7 and TLR9 (Supplemental figure I AB).  Negative controls 
showed no staining (Supplemental Figure I C). The area with positive staining for both TLRs 
contained many macrophages while in mice with a normal cholesterol these lesions do hardly 
show any of these cells. (Supplemental figure I DE)
Figure 1: TLR expression in injured femoral artery lesions of hypercholesterolemic APOE3*Leiden mice. TLR7 
expression (A) and TLR9 expression on femoral arteries with neoinitma 14 days after cuff placement (B). Non-cuffed 
femoral arteries stained for TLR7 (C) and TLR9 (D). IEL= Internal Elastic Lamina. EEL= External Elastic Lamina. 
Inhibition of TLR7- and TLR9-mediated immune responses by antagonist
Splenocytes cultured with 0.01 to 10µg/ml of the dual TLR7/9 antagonist in combination 
with TLR3, TLR4, TLR7 or TLR9 agonist. The antagonist showed a dose dependent reduced 
production of TNF, IL6 and IP-10 upon either TLR7 or TLR9 activation. Activation of TLR4, 
the most robust signaling TLR, was not affected. Also cytokine production via activation of 
intracellular TLR3, that recognizes double-stranded RNA, was not affected by the antagonist. 
(Supplemental figure II A-D) Culturing of splenocytes with the antagonist alone did not 
induce cytokine production (not shown). Administration of either TLR7 or TLR9 agonists 
alone to mice resulted in elevated inflammation indicated by increased levels of serum IL-12. 
Mice administered with antagonist prior to TLR7 or TLR9 agonist administration displayed 
lower levels of serum IL-12. TLR7/9 antagonist alone did not induce IL-12 expression, 
suggesting it does not induce immune responses. At the dose used, antagonist showed about 














































(Supplemental figure III). Control oligo showed no inhibition of either TLR7- or TLR9-
mediated immune response in mice (Figure 2).
TLR7/9 antagonist reduced neointima formation and accelerated atherosclerosis
After detecting TLR7 and TLR9 presence in remodeled arteries we focused on vascular 
remodeling. By in vivo administration of the antagonist the causal involvement of 
TLR7/9 activation in intimal hyperplasia and accelerated atherosclerosis was assessed in 
hypercholesterolemic APOE*3Leiden mice that underwent femoral arterial cuff placement, 
a widely applied model for restenosis. These mice were fed a Western-type diet, starting 3 
weeks before surgery to induce hypercholesterolemia and are well known to develop intimal 
lesions due to neointima formation and accelerated atherosclerosis. No significant difference 
in plasma total cholesterol levels was detected before surgery (control 9.3±0.60mmol/L, 
TLR7/9 antagonist 9.0±0.46 mmol/L), nor had antagonist-treated mice significant altered 
cholesterol levels compared to control mice after 14 days at sacrifice (control 8.4±0.4 
mmol/L, TLR7/9 antagonist 7.7±0.8 mmol/L). HPS stained sections were used to study vessel 
wall composition and showed a profound neointima formation with foam cell formation, 
which was clearly reduced in the antagonist treated group. After quantification, we observed 
reduction in neointima formation of 66% (n=9 vs. n=7) (5838±1158µm2 vs. 2008±223µm2, 
p=0.0079) a beneficial intima/media ratio (0.473±0.09µm2 vs. 0.168±0.018µm2, p=0.0021) 
and a reduction in percentage of lumen stenosis of 64% (33.9±6.6% vs. 12.5±2.9%, p=0.0021) 
after administration of antagonist biweekly. No differences in total vessel wall area or media 
area were found (Figure 3A-G). In addition we found a difference in IL10 serum levels that 
were significantly higher in the antagonist treated mice 14 days after cuff placement (0.43 
vs 15.46 pg/ml, p=0.0003) (supplemental figure IV). At sacrifice the antagonist treated mice 
had a higher number of circulating Ly6Clow monocytes compared to PBS treated controls 
(supplemental figure V). In the lesions of the antagonist treated mice, a reduced number of 
macrophages (MAC-3 positive cells) was observed (figure 3). This difference may be due to 
reduced infiltration of the vessel wall by the circulating monocytes since the expression of 
adhesion molecule CD11b was decreased on the cells of the antagonist treated mice (Figure 
3H). Non-specific oligonucleotide administration not only had no effect on the number of 
circulating (Ly6Clow) monocytes or CD11b expression compared to PBS treatment, it also did 
not affect neointima formation (Figure 3IJ).
Figure 2: Antagonist or control oligo was 
injected at 5 mg/kg, s.c. in the left flank of 
6-8 week old female C57BL/6 mice 
(n=2/group).  RNA-based TLR7 agonist at
 10 mg/kg, s.c. or TLR9 agonist at 0.25 
mg/kg, s.c. was injected 48 hr later in the
 right flank.  Two hours post TLR agonist 
administration, blood was collected and 
serum IL-12 level was determined by ELISA.
 TLR7 or TLR9 agonist alone was used as a 
positive control. Data shown are 





      
Figure 3: Restenosis with accelerated atherosclerosis 
was initiated via cuff placement around the femoral 
artery in hypercholesterolemic APOE*3Leiden mice. 
Areas of femoral arteries were quantified by using 6 
sections per vessel of each mouse. A mean of these 6 
sections was used as the outcome of arterial remodeling 
per mouse. Outcomes of analysis are expressed in 
µm2 (mean ± SEM). Mice treated with the antagonist 
showed a significant reduction in neointima formation 


























































































TLR7/9 blockade reduced macrophage/foam cell positive area
As stated above we observed a significant reduced MAC-3 positive area. This was the case in 
both media (2445±327µm2 vs. 661±199µm2, p=0.002) as well as neointima (268±59µm2 vs. 
26±9µm2, p=0.003) indicating less infiltration of macrophages that are importantly involved 





















































































showed a decrease in percentage of lumen stenosis (B) and a beneficial intima/media ratio (C). Neither total vessel 
wall area, nor media area was altered (D-E). Representative Hematoxylin-Phloxine-Saffron (HPS) (F) and Weigert’s 
Elastin (G) stained cross-sections of control mice and antagonist-treated mice 14d after cuff placement. Number 
of circulating Ly6cLow monocytes (corrected for total white blood cell count) (H). Expression of adhesion molecule 
CD11b on Ly6cLow monocytes (I) Neointima formation of cuffed mice treated with PBS, control-oligo and TLR7/9 




The percentage of positive area was also significantly reduced indicating a reduction of 
positive cells per µm2 in both media as well as in the formed neointima.  We also checked 
whether the effects observed in vivo could be related to the accumulation of total leukocytes 
in the lesions. Therefore, we quantified the area of the vessel segments that was positive 
of CD45, a pan-leukocyte marker. Vessels of the antagonist-treated mice showed a trend 
towards a reduced CD45 positive area which was significant in the neointima (Figure 4A-J).
TLR7/9 blockade reduced cytoplasmic High Mobility Group Box 1 
Layers in the vessel wall undergo severe stress upon intervention. Together with our finding 
of a significant decrease in macrophages we searched for presence of cytoplasmic or extra-
cellular HMGB1 that is a marker of cell stress and macrophage activation. HMGB1 can be 
directly up regulated by TLR9 activation and is an important TLR7/9 signaling regulator 
and an endogenous TLR2/4 ligand. Kalinina et al previously showed that HMGB1 could 
be detected in atherosclerotic plaques. Furthermore the showed that this was dominant in 
macrophages and that in these macrophages there was a markedly increase of HMGB1 in 
the cytoplasm25. Therefore we performed analysis for the presence of cytoplasmic HMGB1 
in the arterial wall. Since TLR7/9 was predominately expressed in the tunica media, were 
most macrophages/foam cells were present, the media area of the vessel segments that was 
positive for HMGB1 outside the nucleus was quantified. We found a significant decrease in 
percentage of positive cytoplasmic HMGB1 in the media area of mice treated with antagonist 
(12.97±1.03% vs. 7.80±1.28%, p=0.011) (Figure 5A-C). This is of special interest, since 
HMGB1 release is increased upon TLR7/9 activation, regulates TLR7/9 signaling and is 
known to function as an endogenous ligand for TLR2 and TLR4 (Figure 5A-C)
TLR7/9 blockade reduced macrophage pro-inflammatory cytokine production upon 
TLR7/9 activation 
Macrophage activation and foam cell accumulation play a crucial role in lesion formation and 
accelerated atherosclerosis development after cuff placement. As we found less macrophages 
and HMGB1 after blocking TLR7/9 we studied the effects of modulation of the TLR7/9 
signaling in cultured Bone Marrow Derived (BMD) macrophages. BMD macrophages were 
cultured for 7d and then stimulated with either TLR7 ligand imiquimod, TLR9 ligand CpG-
ODN or a combination of both for 24hours. Activation was monitored by analysis of TNFa 
expression, a key pro-inflammatory cytokine also known to be regulated in vivo after cuff 
placement.26 Co-administration of TLR7/9 ligands with the antagonist caused a significant 
reduction in production of TNFa while LPS induced production of TNFa was not altered by 
the antagonist (Figure 6A)
Figure 4 (previous page): Lesion composition after treatment with TLR7/9 antagonist in hypercholesterolemic 
APOE*3Leiden mice. Sections were stained for Mac3 and CD45. Positive staining in areas of femoral arteries 
was quantified by using 6 sequential sections per artery of each mouse. A mean of positive staining of these 6 
sections was used as the outcome of positive immuno staining per mouse. Outcomes of analysis are expressed in μm2 
(mean±SEM) and percentage of area of either media or neointima. Macrophage infiltration was significantly reduced 
in the antagonist treated group compared to the controls in both neointima (A) as well as media (B). Percentage of 
positive staining for Mac3 was reduced in this group in both media (C) and neointima (D). Representative pictures 
of control mice and antagonist treated mice (E). Leukocyte infiltration in the antagonist treated group compared to 
the controls in media (F) as well as neointima (G). Percentage of positive staining for CD45 in the media (H) and 
neointima (I). Representative pictures of CD45 stained sections of control mice and antagonist treated mice (J). 

































Figure 6: Bone marrow-derived macrophages cultured with imiquimod (IQ) as a ligand for TLR7, CpG-ODN as a 
ligand for TLR9 or TLR7/9 antagonist for 24hours. IQ and CpG induced macrophage activation. Use of the TLR7/9 
antagonist caused a decrease in TNFα production. TLR4 (LPS) induced activation was not altered by the antagonist. 
(A) Foam cell formation was studied on cultured macrophages in the presence of either empty medium, native LDL, 
imiquimod (IQ), IQ + LDL, IQ + LDL + antagonist. All wells were screened for positive Oil-Red-O (ORO) staining 
and representative pictures are shown. Macrophages with native LDL showed no lipid uptake after staining with 
ORO (B). Positive staining in the presence IQ with native LDL (C). IQ + LDL + antagonist (D). IQ (E).  Foam cell 
formation independent of direct TLR activation was studied on cultured macrophages in the presence of oxLDL or 
oxLDL + antagonist. All wells were screened for positive Oil-Red-O (ORO) staining and representative pictures 
are shown. Macrophages with oxLDL showed lipid uptake after staining with Oil Red O (ORO) (F) but only a few 
positive spots in the presence of TLR7/9 antagonist (G). Analysis by ELISA showed a significant difference in IL10 






















Figure 5: Presence of cytoplasmic 
HMGB1 in the injured vessel wall of 
hypercholesterolemic ApoE3*Leiden mice, 
14d after surgery. Sections were stained 
for HMGB1. Positive staining in areas of 
femoral arteries was quantified by using 
6 sequential sections per artery of each 
mouse. A mean of positive staining of 
these 6 sections was used as the outcome 
of positive immuno staining per mouse. 
Outcome of cytoplasmic HMGB1 analysis 
in percentage (mean±SEM) of area of media 
(A). Representative pictures of HMGB1 
staining in control mice (B) and antagonist-
treated mice (C). Statistical analysis was 
performed with a non-parametric Mann 




TLR7/9 blockade reduced foam cell formation by macrophages
Additionally to the direct effect of pro-inflammatory cytokine excretion by macrophages we 
looked to effect on lipid accumulation by macrophages since both processes are very important 
in post-interventional remodeling. Since macrophage-induced cytokine production and foam 
cell formation are major contributors to neointima formation and accelerated atherosclerosis, 
we studied whether TLR7 activation in combination with native LDL could induce lipid 
uptake by macrophages as was shown previously for TLR9. Reduced TLR9 activation was 
previously described to be important in foam cell formation via oxidation of native LDL 
cholesterol that normally is not capable of causing foam cell formation.27 Furthermore we 
were interested in whether our antagonist could block this process efficiently like it did on 
inflammation with only the agonists. Presence of native LDL with TLR7 stimulation alone 
caused lipid accumulation shown by positive Oil-Red-O (ORO) staining in the macrophages 
while native LDL cholesterol alone showed no staining at all (figure 6A+B). The use of 
antagonist showed a clear reduction in lipid uptake and thus foam cell formation indicated 
by less intracellular ORO staining in the fixed macrophages (Figure 6B-E). TLR9 activation 
and blockade in the presence of LDL gave the same results and was described previously27, 
28 (data not shown). 
Foam cells, formed by oxLDL uptake of macrophages, die releasing lipids, intracellular 
molecules and necrotic debris which can further activate the remaining macrophages 
via endosomal receptors like TLR7/TLR929. Therefore we cultured macrophages in the 
presence of oxLDL cholesterol (Figure 6F) and to check whether the antagonist also could 
influence this lipid accumulation if we combined oxLDL administration with the antagonist. 
ORO staining was found in the oxLDL treated macrophages while combination with the 
antagonist showed only a few slightly positive cells (figure 6F+G). To see if this effect was 
dependent on influx or efflux of lipids we analyzed expression of scavenger receptor CD36 
and IL10 production. CD36 scavenger receptor expression was not different (positive CD36 
macrophages; control 41.48% vs antagonist 41.32%) (supplemental figure V) however we 
noticed significant change in IL10 levels (figure 6G) indicating effects on lipid efflux while 
IL-10 enhances lipid efflux via the PPARgamma-LXR-ABCA1/ABCG1 pathway30.
Discussion 
The present study describes the role of a novel TLR7/9 dual antagonist in restenosis and 
accelerated atherosclerosis in mice. Individual presence of both TLR7 and TLR9 was noticed 
in femoral arteries of hypercholesterolemic APOE*3Leiden mice with neointimal lesions 
and accelerated atherosclerosis after 14d. These have to be infiltrating cells e.g macrophages 
while normal arteries or arterial lesion from normal mice that consist dominantly of VSMC 
stained negative for both TLRs and macrophages. In vivo administration of antagonist 
showed a significant reduction in neointima formation with a beneficial intima/media ratio in 
hypercholesterolemic APOE*3Leiden mice. Moreover, blockade of TLR7/9 signaling led to 
a reduction in CD45 and Mac3 positive cells in both media as well as in the neointimal lesions 
and we notice a decrease in cytoplasmic HMGB1 indicating a decrease in cellular stress and 
a difference in serum IL10.  In vitro, macrophages showed a significant increase in TNFa 
production upon TLR7 or TLR9 activation that was reduced after receiving TLR7/9 dual 
antagonist. Administration with TLR7 ligand imiquimod or TLR9 agonist CpG caused lipid 
accumulation in macrophages that could be sufficiently blocked by the antagonist. Moreover 
oxLDL induced foam cell formation was inhibited by antagonist possibly via upregulation 
of IL-10. 
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Previously, we and others described involvement of TLR2 and TLR4 in post interventional 
neointima formation.3, 6, 7 Recently, a protective role for intracellular receptor TLR3, important 
in recognition of double stranded RNA, was found in vascular remodeling.31 Neointima 
formation due to post interventional remodeling is strongly mediated by local activation and 
physiological changes, such as increased wall stress, cell damage and inflammation. In the 
present study, we were able to notice presence of TLR7 and TLR9 in post interventional 
remodeled arteries whereas non-cuffed vessels show no presence of these TLRs at all. This 
can probably be related to leukocytes that express these TLRs and infiltrate the vessel wall 
due to the damage of the intervention such as macrophages and start to clear apoptotic cells 
and infiltrated lipids. The level of TLR expression may vary among different vessel specimens 
and may be influenced by these changes.12 Other studies in addition to the present showed 
TLR7 expression in atheroma of carotids13 and TLR9 presence in human atherosclerotic 
plaques14 that may be activated via unmethylated CpG motifs from bacteria.32 Furthermore, 
DNA from 17 different bacterial genera that can activate TLR9 were found in atherosclerotic 
carotids15, together indicating a possibly important contribution of these PRRs to vascular 
remodeling. 
Blocking TLR7/9 signaling by antagonist strongly inhibited neointima formation thereby 
reducing the percentage of lumen stenosis. Neointima formation is strongly mediated by 
smooth muscle cell (SMC) proliferation/migration and macrophage activation and lipid 
uptake. Since TLR7/9 presence could not be detected in undamaged arteries it is unlikely that 
there is a direct activation of SMC. However, indirect activation of SMC is still possible via 
cytokines produced by leukocytes which express these TLRs. Our results may be explained, 
at least in part, by the difference in IL-10 production. On the other hand TLR7 and TLR9 
stimulation by their ligands cause a strong increase in the upregulation of TNFa, which 
is important in post-interventional vascular remodeling, indicating a direct influence of 
TLR7/9 activation on inflammation. This response was nicely blocked by the antagonist in 
macrophages. Furthermore, we observed lower levels of HMGB1 in the cytoplasm after cuff 
placement in the antagonist treated mice, thereby reducing its effect via direct activation of 
TLR2/4 and activation of intracellular TLRs via its binding to their nucleic acid ligands.21, 33 
Moreover, there were significantly less numbers of macrophages/foam cells present in media 
as well as neointima. 
Activation of TLR7/9 leads to NFkB-mediated upregulation of pro-inflammatory cytokines. 
Furthermore, it is known that TLR9 activation causes release of nuclear HMGB1 that may 
become available in the cytoplasm or even outside the cell where it is known to act as TLR2 
and TLR4 ligand and was seen in macrophages in atherosclerotic plaques.22, 25, 33, 34 Not only 
can this release be initiated upon cell stress but also activated macrophages are capable of 
releasing HMGB1.34, 35 Previously we were able to detect HMGB1 in remodeled vein grafts 
in and outside the nucleus.4 Upon cuff placement we noticed presence of HMGB1 in the 
cytoplasm as well. Others previously showed that CpG-ODN stimulates macrophages to 
secrete HMGB1 and extracellular HMGB1 is known to accelerate the delivery of CpG-
ODNs to its receptor, leading to a TLR9-dependent enhancement of IL-6, IL-12, and 
TNFa.22 Interestingly, HMGB1 is also known as a regulator of TLR7/9 signaling itself since 
the absence of HMGBs also severely impairs the activation of TLR3, TLR7 and TLR9 by 
their cognate nucleic acids.21 Therefore these intracellular TLRs are thought to play a very 
important role in autoimmune and other inflammatory diseases.20, 21 Our data confirm causal 
involvement of TLR7 and TLR9 in vascular-related diseases and development of a novel 




of exacerbation periods of other inflammatory diseases such as rheumatoid arthritis and after 
vascular interventions that cause direct vessel damage.
Blocking TLR7/9 signaling leads to a reduction in inflammation and reduced lipid 
accumulation. The role for TLR7/9 may therefore indicate regulation of cell stress and thereby 
providing activation of e.g. macrophages to start scavenging lipids, dying cells and attracting 
more leukocytes to the inflammatory hazard. Our results confirm macrophage activation via 
TLR7/9 ligands and show a decrease of the presence of macrophages in the vessel wall after 
cuff placement in the TLR7/9 antagonist-treated mice. 
Several studies have demonstrated the effect of intracellular TLR activation on lipid uptake27, 
28, 36, 37. Both TLR7 and TLR9 agonists cause up regulation of adipocyte differentiation-
related protein that is involved in lipid droplet formation in macrophages.38 TLR9 was 
previously described to be involved in foam cell formation via up regulation of NOX1, 
LOX1 and Perilipin 3.27 28 This foam cell formation was NFkB and IRF7 dependent and can 
be countered via LXR activation.37 Both NFkB and IRF7 are also very important mediators 
of TLR7 signaling and additionally we show that TLR7 stimulation in the presence of LDL 
leads to lipid uptake in macrophages. Our data show that blocking of TLR7 receptor results 
in no lipid uptake in macrophages that receive only LDL. Interestingly, the antagonist 
was capable of decreasing lipid accumulation of oxLDL in macrophages probably via IL-
10. This might be due to altered efflux of lipids rather then decreased influx since CD36 
expression is not altered whereas IL10, like in vivo, is upregulated. Macrophage IL-10 is 
known to enhance the efflux of cholesterol.30 Different mechanisms, directly related to TLR 
signaling, can be involved in changes IL10 levels. Martin et al. showed that GSK3 can 
differentially regulate TLR mediated cytokine production39. In the normal TLR activation 
situation there is little PI(3)K stimulation and GSK3 primarily remains constitutively active 
promoting the expression of IL12. Alternative situations, with different pathogenic stimuli 
or blocking antagonists (small molecule inhibitors, RNA inhibitors), can lead to TLR 
dependent activation of PI(3)K and thereby inhibition of GSK3 that causes a decrease in Il-
12 production and an increase in IL10 production. Woodgett and Ohashi have provided a nice 
overview about this GSK3 in TLR signaling.40 Alternatively it was previously described that 
TLR4 activation can cause an increase of HMGB1 in macrophages and that this HMGB1 is 
capable of reducing IL10 levels41. Oxidized LDL triggers inflammatory signaling through a 
heterodimer of TLR 4 and TLR6. Assembly of this newly identified heterodimer is regulated 
by signals from the scavenger receptor CD3642. Foam cells die releasing lipids, intracellular 
molecules and necrotic debris which can further activate the remaining macrophages via 
endosomal receptors like TLR7/TLR929. While HMGB1 can also be upregulated via TLR9 
activation and it further enhances TLR7/9 activation this might be a mechanism that cause 
the differences seen in IL10 levels. Previously it was already shown on regulatory T cells 
that additional TLR9 activation could inhibit IL10 synthesis43.  Further studies are needed 
to fully elucidate the mechanisms causing differences in IL10 levels in the relation to TLR 
signaling and blockade. In summary, we observed upregulation of TLR7/9 expression during 
arterial restenosis and reduced macrophage activation and foam cell formation after TLR7/9 
blockade which was accompanied with increase in IL-10 production. Additional blocking 
of TLR7/9 leads to a reduction in neointima formation, increased IL10 production, reduced 
macrophage presence in the lesions as well as less HMGB1 release, indicating the important 
role of TLR7 and TLR9 in post-interventional remodeling via reducing inflammation as well 
as lipid accumulation thereby making it an interesting therapeutic target to reduce restenosis 
and accelerated atherosclerosis after vascular intervention. 
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Supplemental Material and Methods
Animals
All animal experiments were approved by the animal welfare committee of our institute and 
are performed according to the regulatory guidelines. Ten week old male hypercholesterolemic 
APOE*3Leiden mice bred in our laboratory were used as previously described elsewhere.1 
Mice were fed a Western-type diet starting three weeks before surgery that was continued 
throughout the entire experiment. Mice were allocated randomly to different treatment 
groups. Cholesterol levels were measured one day before surgery and at sacrifice. All mice 
received water and food ad libitum.
Murine model for neointima formation
Non-constricted polyethelene cuffs were placed around the femoral arteries as a well- 
established model for neointima formation and accelerated atherosclerosis.1 Mice were 
sacrificed 14 days after cuff placement. All mice received a subcutaneous (s.c) injection with 
either 200µl sterile water (n=9) or 200µl TLR7/9 antagonist (n=7) (15mg/kg dissolved in sterile 
water) for sufficient blocking of TLR7/9 continuously without infectious complications. The 
first injection was administrated directly after cuff placement and injections were repeated 
4 times (schedule of two injection per week) until sacrifice of the mice. Antagonist activity 
for TLR7 and TLR9 was assessed in six-to-eight-week-old female C57BL/6 mice obtained 
from Charles River Labs, (Wilmington, MA). Experimental procedures were performed 
according to the approved protocols and guidelines of the Institutional Animal Care and Use 
Committee of Idera Pharmaceuticals. Mice (N=2) were injected subcutaneously (s.c.) with 5 
mg/kg antagonist. This was followed twenty- four hours later by 0.25 mg/kg TLR9 agonist 2 
or 10 mg/kg of an RNA-based TLR7 agonist.3 Two hours post agonist administration, blood 
was collected by retro-orbital bleeding.
Morphological Quantification
At sacrifice blood was taken for cholesterol measurement and perfusion/fixation was done at 
100mmHg with 4% formaldehyde via the left ventricle. Paraffin-embedded cross- sections 
were stained with either Weigert’s Elastin stain or Hematoxilin-Phloxine- Saphrane (HPS) to 
visualize overall morphology. Six sections (5 µm thick) equally
spaced throughout the cuffed segment were used to quantify intimal lesions, media and total 
vessel size using image analysis software for morphometric analysis (Qwin, Leica, Germany).
Cell cultures and reagents
Macrophages were derived from bone marrow from tibia and femur and seeded at a density 
of 250.000 cells/well in 6-wells plates and cultured for 7 days in RPMI GlutaMax (Gibco) 
supplemented with 100U/ml penicillin/streptavidin, 25% Fetal Calf Serum (FCS) and 20mcg/
ml M-CSF (Myltec Biotechnologies) as described previously.4 Cells were cultured in the 
presence of the TLR7 agonist imiquimod (5µg/ml, Invivogen), the TLR9 agonist ODN-CpG 
(10µg/ml, Invivogen), oxLDL 50 mcg/ml or native LDL 50 mcg/ml
(Myltec Biotechnologies) and TLR7/9 antagonist (10mcg/ml antagonist, Idera 
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Pharmaceuticals). All analysis was done on triplicate wells each in three independent 
experiments. C57BL/6 spleen cells (1x106 cells/ml) were cultured with 0.01 to 10 µg/ml 
of a TLR7/9 antagonist in combination with 1 µg/ml of a TLR9 agonist (DNA), 200µg/ml 
of a TLR7 (sRNA) agonist or 50 µg/ml of a TLR4 agonist (LPS) or 1µg/ml TLR3 agonist 
(Poly I:C). As controls, spleen cells were cultured with medium alone, TLR9, 7, 4 or 3 
agonist alone, or highest dose (10 µg/ml) of the TLR7/9 antagonist alone.  After 24 hours, 
culture supernatants were collected and induction of selected cytokines and chemokines was 
assessed. All analysis was done on triplicate wells each in three independent experiments.
FACS analysis
Circulating monocytes were stained with anti-mouse CD11b (Biolegend 101224) and Ly6C 
(Bioconnect MCA2389A488). BMD Macrophages (non-stimulated, antagonist, oxLDL or 
oxLDL+antagonist, 24h) were stained anti-mouse CD36-PE, clone 72-1, isotype Rat IgG2a 
(Ebioscience) and analyzed by FACS (BDcalibur).
TLR7/9 antagonist
TLR7 and TLR9 antagonist (5’-TGUCG*TTCT-X-TCTTG*CUGT-5’; wherein, G/U are 
2’-O-methyl-ribonucleotides, G* is 7-deaza-dG, and X is glycerol linker) was synthesized 
at Idera Pharmaceuticals on solid support on an automated DNA/RNA synthesizer with 
phosphorothioate backbone, purified by HPLC, and analyzed. The purity of full-length 
antagonist was over 93% with the material balance comprised of oligonucleotides shorter 
than the full-length product (n-1 and n-2) as determined by
anion-exchange HPLC, capillary gel electrophoresis and/or denaturing polyacrylamide 
gel electrophoresis. Sequence integrity was confirmed by MALDI-TOF mass spectral 
analysis. Antagonist contained less than 0.2 EU/ml of endotoxin, as determined by the 
Limulus assay (Bio-Whittaker). A novel control oligo was created with similar chemical 
modulations in the backbone as in our antagonist since these modifications are crucial to the 
functional activities of the antagonist. The following sequence was used as a control oligo=: 
5’-CACCCAAGACAGCAGAAAG-3’; It is a phosphorothioate oligodeoxynucleotide with 
2’-O-methyl-ribonucleotides at each end (nucleotides shown in bold).
Assessment of foam cell formation
Foam cell formation was assessed in macrophages that were either stimulated with native 
LDL 50 mcg/ml or oxLDL 50mcg/ml (Myltec Biotechnologies). Incubation with native 
LDL was used to study the effect of TLR7 and TLR9 agonists (IQ, and ODN CpG) on lipid 
accumulation in macrophages, whereas oxLDL was used under conditions where effects the 
antagonist are studied. Oil-red-O staining of macrophages was used to identify foam cells. 
Cells were washed with PBS, fixed in 4%formaldehyde and pretreated with 60% isopropanol 
followed by staining with 1% Oil-Red-O solution (Sigma Aldrich). Cells were washed 
with 60% isopropanol followed by three times washing with PBS and examined by light 






ELISA assays were performed with cell free supernatant using commercial available kits 




Paraffin-embedded sections (5 µm thick) were stained with antibodies against TLR7 (AbD 
serotec), TLR9 (AbD serotec), CD45 (BD Biosciences), Mac3 (BD Biosciences), HMGB1 
(Abcam, Cambridge, United Kingdom) followed by the appropriate secondary antibody 
(Donkey anti Rabbit, GE Healthcare) (Goat anti Rat, Jackson labs) and incubated with AB 
complex (Vector laboratories) and were visualized with Novared (Vector laboratories). Slides 
were counterstained with haematoxylin.
To confirm the specificity of the IHC staining, parallel sections were incubated with 1% PBS/
BSA alone without adding the primary antibody or with Rabbit IgG or Rat IgG controls or 
staining without 1e antibody or staining without the 2nd antibody. Sections were incubated 
with the secondary antibody, AB complex and were visualized with Novared. Controls were 
all negative.
Statistics
For to the animal experiments, values are presented as mean ± standard error of the mean 
(SEM). Statistical significance was calculated in SPSS for Windows 17.0. Differences 
between groups were determined using a non-parametric Mann-Whitney test. In vitro assays 
are presented as mean ± standard error of the mean (SEM) and were statistically analyzed 
with a students T test.
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Supplemental figure I: TLR7 staining on arterial lesion of wild type mice (A). TLR9 staining on arterial lesion of 
wild type mice (B). Example of negative control (C), Macrophage staining in lesions of hypercholesterolemic mice 
(D) and in wild type mice (E).  N= 4 mice per staining; at least 6 sections per mouse were stained for either TLR7 
or TLR9.
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Karper et al
 at Rijksuniversiteit Leiden on May 27, 2013http://atvb.ahajournals.org/Downloaded from Supplemental figure II: Effect of antagonist on different TLR stimuli. Cytokine production of TNFα, IL6 and IP-
10 upon TLR activation in the presence of 0.01 to 10 µg/ml of the TLR7/9 antagonist. TLR7 agonist IQ+ TLR7/9 
antagonist (A), TLR9 agonist ODN-CpG + TLR7/9 antagonist (B), TLR3 agonist PolyI:C + TLR7/9 antagonist 
(C), TLR4 agonist LPS + TLR7/9 antagonist (D). Data shown is 1 representative experiment out of 3 independent 
experiments.
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Supplemental figure III:
Inhibition of TLR9 and TLR7 agonist induced IL-12 by dual antagonist of TLR7/9 in C57BL/6 mice.  Mice (n=2/
group) were injected s.c. with 5 mg/kg of antagonist in the left flank and 24 hr later 0.25 mg/kg of TLR9 agonist or 
10 mg/kg of TLR7 agonist s.c. in the right flank.  Two hours after agonist administration, blood was collected and 
serum IL-12 levels were measured by ELISA
Supplemental figure IV
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Supplemental figure IV:
Plasma IL10 levels in hypercholesterolemic ApoE3Leiden 
mice treated with or without TLR7/9 antagonist 14days 
after cuff placement. Statistical analysis was performed by 
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Supplemental figure V (right panel):
FACS analysis of CD36 expression on oxLDL stimulated 
macrophages. CD36 expression on macrophages 
stimulated for 24h with either oxLDL (A) and or with 











Toll like receptors in vein graft remodeling: protective effects of TLR3 and
downstream Interferon regulating factors.
de Vries M.R*, Karper J.C*, van der Pouw Kraan T.C, Peters H.A.B, de Jong R.C.M, Hamming J.F,
Jukema J.W, Horrevoets A, Quax P.H. 




As a part of the innate immunity, Toll like receptors (TLRs) are thought to be important in 
the inflammatory process of vein graft remodeling. TLR3 activates the MyD88 independent 
pathway via  activation  of  TRIF  and  key  interferon  regulating  factors,  IRF3  and  IRF7, 
resulting in induction of type I interferons. The aim of this study was to investigate the role 
of TLR3 pathway constituents on vein graft remodeling.
Methods and Results
Vein grafting was performed by interpositioning the caval vein of a donor mouse in the 
carotid artery of a receiver mouse and subsequently the vein grafts were harvested at 
specific time point for further analysis. Pathway analysis by gene set enrichment analysis 
revealed that in 14 and 28 days old vein grafts of hypercholesterolemic ApoE3Leiden mice 
the TLR pathway and the type I Interferon pathway belonged to the top 15 of significant 
regulated pathways.  The importance of the type I Interferon pathway is further illustrated 
by the 2-fold increase in vein graft wall thickening in Tlr3-/- mice compared to control 
mice (p<0.001). Also Irf3-/- and Irf7-/- mice showed increased  vein  graft  wall  thickening 
(Irf3-/-;  39%,  p=0.185,  Irf7-/-;  68%  p=0.003).  Also  the outward remodeling increased 
compared to control mice, resulting in (Tlr3-/-; 52%, p<0.001, Irf3-/-; 26%, p=0.081, Irf7-/-; 
42%, p=0.049). Morphologic analysis revealed that Tlr3-/-, Irf3-/- and Irf7-/-  mice showed 
significant more influx of macrophages than the control mice.   Expression of typical Type I 
interferons inducible genes were found decreased in all three strains. In contrast, TNFα and 
CCL2 were only significantly increased in the Tlr3-/- mice.
Conclusions
The TLR3 pathway regulates vein graft remodeling in a protective way since Tlr3-/-, as well 
as the key downstream factors  Irf3-/- and Irf7-/-  vein grafts show increased vessel wall 
thickening and outward remodeling. This increased remodeling in the knockout mice is the 
result of a pro-inflammatory  response  as  reflected  by  the  increase  in  macrophages  and 





Autologous (saphenous) veins are commonly used as conduits to bypass occlusive 
atherosclerotic lesions  in  both  coronary  and  femoral  arteries.  Unfortunately  vein  graft 
failure  is  a  major drawback since, within 10 years, almost half of the patients may again 
require a form of revascularization. In the patho-physiological processes of vein graft failure, 
inflammation is considered to be an important accelerating factor 1-5. Toll like receptors 
(TLRs), part of the innate immune system, are important in inflammatory reactions via their 
recognition of exogenous pathogen associated molecular patterns (PAMPs) and endogenous 
damage associated molecular patterns (DAMPs). DAMPs are up regulated by cell death and 
tissue injury. Previously, we showed that cell death and tissue injury is part of the process of 
vein graft remodeling in murine vein grafts6. In agreement, DAMPs for TLR2 and TLR4, such 
as the extracellular matrix component EDA (alternatively spliced domain A of Fibronectin), 
Heat shock protein 60 (HSP60), extracellular matrix protein Biglycan and chromatin protein, 
high-mobility group protein B1 (HMGB1), are abundantly present in remodeled vein grafts7. 
Furthermore, TLR4 is functionally
involved in intimal hyperplasia formation, accelerated atherosclerosis and vein graft 
remodeling7.
The role of other TLRs in vein graft development is currently unknown. Since TLRs 
have vessel- specific profiles that further vary due to changes in cellular activation and 
differentiation, and other local processes8, it is of particular interest to investigate their 
role in vein graft remodeling. The Toll like receptor (TLR) family consists of at least 13 
members. All TLRs, except TLR3, signal via the myeloid differentiation primary response 
gene 88 (MyD88 pathway), which drives the induction of the transcription factor nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFĸB) resulting in induction of 
pro-inflammatory cytokines9. TLR3 signals via a MyD88- independent pathway with a 
central role for the adapter TIR-domain-containing adapter-inducing interferon-β (TRIF) 
and interferon regulatory factor (IRF)3 and IRF7 resulting in induction of type I interferons 
(IFNs) (Figure 1).
Interestingly, an unexpected protective role for TLR3 was found on neointima and 
atherosclerosis formation by Cole et al.10. Others however, found that TLR3 augments the 
inflammatory response to nucleic acids. TLR3 ligation also impaired endothelial function 
and specific deletion of TLR3 in immune cells resulted in reduced aortic inflammation and 
atherosclerotic burden11-14. One should appreciate that the response to TLR3 stimulation is 
not uniform, and differs in specific tissue microenvironments8. TLR3 responsive genes,  Type 
I  IFNs  and  IFN-inducible  genes  are  involved  in  bridging  innate  and  adaptive immunity 
and induction of co-stimulation15. In viral infections, downstream TLR3 transcription 
factors IRF3 and IRF7 are the most important factors that control the expression of type I 
IFNs. IRF3 signaling results in early induction of the Ifnb gene, whereas IRF7 has a pivotal 
role in the induction of all type I IFN genes16. The role of Type I interferon (inducible) 
genes in vascular remodeling however, is unclear. Like most TLRs, TLR4 activation leads 
to an inflammatory profile resulting in augmentation of lesion formation and remodeling17, 
18.  TLR4 signaling however depend on both the MyD88 and TRIF pathways for proper 
functioning9, 19. Upon activation, TLR4 can be internalized into the endosome after which 
activation of the TRIF pathway follows. This indicates that not only different effects of TLRs 
are critical in vascular disease but also the importance of the underlying pathways as well as 
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the presence and/or quantity of endogenous ligands. Therefore it would be important to see if 
and how TLR3 influences vein graft remodeling.  In this study we explored the role the TLR3 
pathway by performing vein graft surgery in mice that are deficient in TLR3 and downstream 
factors IRF3 and IRF7 in comparison with TLR4 and TLR2 deficient mice without further 
exogenous ligand stimulation.
 
Figure 1.TLR signaling pathways. TLRs signal via specific pathways using transcription factors nuclear factor 
NFĸB in the myeloid differentiation factor 88 (MyD88) route and interferon regulating factors IRF3 and IRF7 in the 
TIR-domain containing adaptor inducing interferon-β (TRIF) signaling route. MyD88 activation occurs upon cell 
surface signaling (TLR1, TLR2, TLR4, TLR6) using MyD88 adaptor-like (MAL) as an adaptor or via endosomal 
(TLR7, TLR9) signaling via Il1 receptor-associated kinases, IRAK4, IRAK-M, IRAK1, IRAK2 in interaction with 
TNF receptor associated factor-6 (TRAF-6). This complex activates an inhibitor of κB kinase (IKK) complex that 
upon phosphorylation activates nuclear NFĸB activation resulting in transcription of pro-inflammatory cytokines. 
TRIF signaling occurs via IRF3, specifically upon TLR3 activation also via IRF7, resulting in activation of Type I 




MATERIALS AND METHODS 
Mice
This study was performed in compliance with Dutch government guidelines and the Directive
2010/63/EU of the European Parliament.  All animal experiments were approved by the 
animal welfare committee of the Leiden University Medical Center. For the experiments 
10-16 weeks old male mice were used. ApoE3Leiden mice (fed a high cholesterol diet (AB 
diets)) were bred in the local animal facility. As did the Tlr2-/-  and Tlr4-/-  that were kindly 
provided by Dr. Akira (Osaka University, Japan) and the Irf3-/-  and Irf7-/-  that were kindly 
provided by Dr. Taniguchi (University of Tokyo, Japan). Control C57BL/6 mice and Tlr3-/- 
were purchased from Charles River Laboratories.
Vein graft surgery
Vein graft surgery was performed by donor caval vein interpositioning (caval vein of 
approximately 2 mm length) in the carotid artery of recipient mice as reported previously5. 
Before surgery, mice were anesthetized with midazolam (5 mg/kg, Roche Diagnostics), 
medetomidine (0.5 mg/kg, Orion) and fentanyl (0.05 mg/kg, Janssen Pharmaceutical). After 
the procedure the mice  were  antagonized  with  atipamezol  (2.5  mg/kg,  Orion)  and 
fluminasenil  (0.5  mg/kg Fresenius Kabi). Buprenorphine (0.1 mg/kg, MSD Animal Health) 
was given after surgery to relieve pain.
Whole-genome expression
In ApoE3L mice vein graft surgery was performed and mice were sacrificed at time point 
3, 7, 14 and 28 days after surgery. From 3-4 mice per time point vein grafts were collected 
and total RNA was extracted using RNeasy fibrous tissue minikit (Qiagen). RNA integrity 
was checked by NanoDrop 1000 Spectrophotometer (NanoDrop Technologies) and 2100 
Bioanalyzer (Agilent Technologies).  For  whole-genome  expression  profiling,  amplified 
biotinylated  RNA  was generated using the Illumina TotalPrep RNA Amplification Kit. For 
array analysis, MouseWG-6 v2.0 Expression Beadchips (Illumina) were used. Expression 
levels were Log2-transformed and after quantile normalization, transcripts showing 
background intensity were removed from the analysis. Gene expression levels at the different 
time points were expressed relative to average t0 levels generating ratios for 23.067 regulated 
genes.
RNA isolation, cDNA synthesis and RT-PCR
Total RNA was isolated from 10 (20µm thick) paraffin sections of vein grafts 28d after surgery 
(n=6/strain). RNA was isolated according manufacturers protocol (FFPE RNA isolation kit, 
Qiagen). Quantitative PCR (Q-PCR) analysis of 84 type I Interferon response-related genes 
was performed using a RT2 ProfilerPCRArray (SA Biosciences) as per the manufacturer’s 
protocol. The complete list of the genes analyzed is available at http://www.sabiosciences.
com/ rt_pcr_product/HTML/PAMM-016Z.html. Prior to RT2 profiler array FPPE RNA was 
reverse transcribed using the RT² First Strand Kit (SA Biosciences). RNA for single Q-PCR 
was reverse transcribed using a High Capacity RNA-to-cDNA kit (Applied Biosystems). 
Commercially available TaqMan gene expression assays for hypoxanthine phosphoribosyl 
transferase (HPRT1), and selected genes were used (Applied Biosystems). All Q-PCRs were 
performed on the ABI




Gene set enrichment analysis (GSEA) was performed with the curated gene sets from Kegg, 
Biocarta, the Reactome and published studies, resulting in a total of 1564 gene sets. For each 
gene set (pathway) an enrichment score (ES) is calculated20  representing the difference 
between expected and observed ranking which correlates with the phenotype of the vein 
grafts at the different time points.
 
Histological and immunohistochemical assessment of vein grafts
Vein grafts were harvested after perfusion fixation with 4% formaldehyde, fixated for 4 
hours and paraffin-embedded. Six consecutive sections (with 150 µm interspace) per vein 
graft were routinely stained with hematoxylin-phloxine-saffron (HPS) for histological and 
morphometric analysis (Qwin, Leica). Vein graft thickening or vessel wall area was defined 
as the area between lumen and adventitia and determined by subtracting the luminal area 
from the total vessel wall area. Picrosirius red  staining was  used to  visualize collagen 
content.  Antibodies directed at smooth muscle cell actin, TLR3 (Sigma), CD45 (BD 
Pharmingen) TLR2, IRF3, IRF7 (Abcam), Mac-3 and TLR4 (Santa Cruz) were used for 
immunohistochemical stainings. For each antibody, isotype-matched antibodies were used 
as negative controls and staining was absent these sections (data not shown). SMC actin 
and Sirius red stained sections were quantified by computer assisted analysis (Qwin, Leica). 
The immuno-positive area measured is expressed as a percentage of the vessel wall area5. 
Vein graft segments were analyzed for influx of leukocytes (CD45) or macrophages (Mac-3) 
by scoring cells in 6 consecutive sections per mouse in a semi-quantitative manner. 1: < 25 
positive cells / section, 2: 25-50 positive cells / section, 3: >50 positive cells.
Statistical analysis
Results are expressed as mean±SEM. Data, except for the GSEA, were analyzed by the non- 
parametric  Kruskal-Wallis  or  Mann-Whitney  test  using  GraphPad  Prism.  Probability-
values <0.05  were  regarded  significant.  GSEA;  by  permuting  the  phenotype  labels  for 
the  ES,  a statistical significance (nominal P value) for the ES is provided. An adjustment for 
the gene set size generated the normalized enrichment score (NES). To correct for multiple 
testing the proportion of false positives is calculated to provide the false discovery rate 




TLR pathway and type I Interferon pathway are strongly regulated during vein graft 
development
To obtain an overview on how TLRs are regulated during vein graft remodeling we analyzed 
expression of TLRs in hypercholesterolemic ApoE3Leiden mice with help of mRNA array 
analysis. Most TLRs showed significant up regulation at most time points compared to 
untreated caval veins (t0) (Figure 2A). Interestingly, TLR3 did not show any regulation in 
time whereas TLR4 was only significantly up regulated at t3. TLR5 was the only down 
regulated TLR.  We further analyzed whether IRFs were regulated since these are the 
most prominent transcription factors downstream TLR3. Most IRFs showed regulation as 
illustrated by Figure 2B; especially IRF 7 was strongly up regulated. To better understand 
the biologic role of genes regulated in time during vein graft development, we performed 




regulated curated gene sets at t14 compared to uninjured caval veins (t0) whereas 52 gene 
sets were down regulated at t14. At t28 120 gene sets were significant up regulated and 108 
gene sets were down regulated compared to t0. Within the top 15 of significant curated gene 
sets on both time points besides the expected extracellular matrix organization gene sets, 
TLR and Type I IFN gene sets can be found in Table 1 illustrating that both pathways are 
involved in vein graft development.
TLR3 deficiency results in enhanced vein graft thickening and outward remodeling
Since TLRs have vessel-specific profiles we first evaluated the expression of TLR3 in native 
caval veins and 28 day old vein grafts of C57BL/6 mice.  Immunohistochemical staining of 
TLR3 (Figure 3A) revealed that most native caval vein SMCs as well as endothelial cells 
stained negative for TLR3 (in contrast to the surrounding adipose tissue). In 28 day old 
C57BL/6 vein graft segments (n=6) almost all inflammatory cells, adventitial fibroblasts 
and endothelium were found positive whereas SMCs showed diverse staining (Figure 3A). 
To investigate whether TLR3 might be involved in vein graft remodeling Tlr3-/- (n=9) and 
control mice (n=10) underwent vein graft surgery. No differences in weight were found 
between the groups pre- and post-surgery (data not shown). Interestingly, 28 days after 
surgery Tlr3-/- mice had developed a 2-fold increase in vein graft wall thickness compared 
to the control mice (figure 3B, E).  This was accompanied by a significant increase in total 
vessel area (figure 3C). Do to this compensatory outward remodeling the lumen area did not 
deviate between the two groups (figure 3D). Next, we focused on the cellular composition 
Figure 2. Regulation of TLRs and 
IRFs during vein graft remodeling. 
Array analysis of vein grafts in 
hypercholesterolemic ApoE3Leiden 
mice was performed on t3, t7, t14 and 
t28 in comparison  to  non-injured 
caval  veins  (t0).  A.  Most  TLRs  show 
up  regulation  at  all  the timepoints. 
TLR3 is not regulated in time. TLR4 is 
only significantly regulated at t3 and 
TLR5 is significantly down regulated 
at t28. B. IRFs show a diverse pattern 
in regulation; especially IRF7 is 
significantly up regulated, whereas IRF3 
shows little regulation.
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of the vein grafts. Analyzing the influx of inflammatory cells we detected significant more 
leukocytes in the Tlr3-/- mice compared to the control group (Figure 3F). Since  macrophages 
are  a  well-known  source  of  TLRs  we  also  looked  at  the  influx  of macrophages. 
Macrophage numbers were increased in the vein graft wall of the Tlr3-/-  mice (Figure 3G). 
A non-significant increase in SMC positive area was found in the knockout mice. When 
corrected for the vessel wall thickness (expressed as percentage SMCs in the vessel wall) 
there  was  no  difference  anymore  between  the  Tlr3-/-   and  control  mice  (figure  3H, 
I).  A comparable effect was seen with the collagen content; a significant increase in collagen 
area was measured but corrected for vessel wall area the difference between the groups did 
not hold (Figure 3J, K).
Table 1. Top 40 of significantly regulated gene sets in vein grafts of hypercholesterolemic ApoE3Leiden mice 28 days 
after surgery as analyzed by gene set enrichment analysis (GSEA) with curated gene sets from Kegg, Biocarta, the 
Reactome and published studies. In red, relevant pathways regarding TLR signaling are shown.
Deficiency of downstream TLR3 factors IRF3 and IRF7 results in aggravated vein graft 
remodeling.
IRF3 and IRF7 are key regulators of type I IFNs gene expression elicited by virus activated 
TLR3 signaling. Here we explored the role of these IRFs in vein graft remodeling. To see 
whether IRF3 and IRF7 are expressed by vascular tissues, we stained caval veins and vein 
grafts of C57BL/6 mice for both factors. Both cytoplasmic as well as nuclear staining was 
seen indicating that latent and active forms of IRF3 and IRF7 are available. IRF3 and IRF7 
are constitutively expressed by SMC and endothelial cells in caval veins (left panels) and 
mature vein grafts (right panels). In the vein grafts inflammatory cells also stained positive 
for both factors. SMCs of remodeled vein grafts showed more intense staining of IRF7 than 




vein graft wall thickening compared to control mice (n=7) although non-significant 
(p=0.185).  Interestingly, IRF7-/- mice (n=8) showed a significant (p=0.003), 68% increase in 
size compared to controls (Figure 4C, F). Total vessel wall area, as an indicator for outward 
remodeling, was increased in the IRF7-/- mice (p=0.049) whereas the IRF3-/- showed a non-
significant trend (p=0.081) in figure 2D. The lumen in all three groups was not significantly 
different  (Figure  4E).  Analysis  of  the  inflammatory  aspects  of  the  vein  grafts revealed 
that,  in  contrast  to  the  Tlr3-/-  mice,  both  the  IRF3-/-  and  IRF7-/-   mice  showed  no 
significant differences in number of leukocytes compared to the control group (Figure 4G). 
The macrophage  score  however  was  in  both  the  IRF3-/-  (p=  0.059)  and  IRF7-/- 
(p=0.038)  mice increased compared to the control group (Figure 4H). Again as seen in the 
Tlr3-/- mice no differences in absolute area of SMCs and collagen between the three groups, 
except for the percentage collagen in the vessel wall which was significantly decreased in 
IRF7-/- mice (Figure 4I-L).
Figure 3. Deficiency of TLR3 
ameliorates vein graft remodeling. 
A. TLR3 staining is absent in the 
vessel wall of native caval veins 
in C57BL/6 mice except for the 
surrounding fat tissue (left panel). 
28 days after surgery intense TLR3 
staining could be observed in the 
adventitia of vein grafts (C57BL/6) 
in fibroblasts and inflammatory 
cells, whereas SMCs in the vessel 
wall showed a patchy distribution 
(right panel), inset; overview of vein 
graft. B. Vein graft surgeries were 
performed in Tlr3-/- mice (n=9) and 
control mice (n=10). Tlr3-/- mice 
showed a 2-fold increase in vessel 
wall area, 28 days after surgery, 
compared to the control mice. C. 
Outward remodeling as scored by 
the total vessel wall area (D) graph 
representing the luminal area. E. 
shows representative photographs 
of control C57BL/6 and Tlr3-/- mice 
indicating the differences in vein 
graft  size  between  the  strains. 
F.  The  number  of  infiltrating 
leukocytes  were  significantly increased in Tlr3-/- mice (semi-quantitative scored in arbitrary units, 1; <25 cells, 
2; 50-100 cells, 3>100 cells). This also accounts for the number of infiltrating macrophages (G) semi-quantitative 
scored in arbitrary units, 1; <25 cells, 2; 50-100 cells, 3>100 cells.  H. Quantative analysis of the SMCs content 
(expressed in mm2) did not reveal significant differences between the groups. I. The relative percentage SMCs in the 
vein graft segments was also not significantly different between the control and Tlr3-/- mice J. Quantative analysis 
of the Sirius red staining revealed an increased collagen content in the Tlr3-/- vein grafts. However, when expressed 
as the relative percentage collagen in the vein grafts, no differences were observed between the groups (K).
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Figure 4. IRF 3 and IRF7 deficiency 
result in enhanced vein graft remodeling. 
Expression of IRFs in caval veins and 
vein grafts stained for IRF3 (A) and 
IRF7 (B). C. vein graft thickening in 
Irf3-/-  mice  (n=9)  and  Irf7-/-  mice 
(n=8)  compared  to  controls  (n=7). 
Irf7-/-  mice  showed  a significant 68% 
increase in vein graft size. D. Irf3-/- 
and Irf7-/- mice showed an increase 
in total vessel wall area representing 
outward remodeling whereas all three 
groups showed comparable luminal 
areas (E). F. Represents photographs 
of control C57BL/6, Irf3-/- and Irf7-
/- Hematoxillin Phloxine and Saffron 
(HPS) stained sections. G. The number 
of infiltrating leukocytes was not significantly different in all groups (semi-quantitative scored in arbitrary units, 
1; <25 cells, 2;50-100 cells, 3>100 cells). H. The number of infiltrating macrophages was significantly increased 
in Irf3-/- and Irf7-/- vein grafts (semi-quantitative scored in arbitrary units, 1; <25 cells, 2; 50-100 cells, 3>100 
cells).  I. Quantification of the SMC content expressed in absolute numbers (mm2) or percentage (J) did not deviate 
between the groups. J. Quantative analysis of the collagen content as measured by Sirius red staining, did not deviate 




Deficiency of TLR4 deteriorates vein graft thickening
Besides the well-known MyD88-dependent signaling pathway resulting in activated (pro- 
inflammatory) genes9, TLR4 can signal via downstream pathway factors such as TRIF and 
IRF3 similar to TLR3, resulting in activation of the Ifnb gene  To investigate how the TLR4 
pathway is involved in vein graft remodeling we included TLR4 deficient mice in our study. 
Although we previously showed the inhibiting effects of TLR4 deficiency on vein graft 
remodeling, that was studied in congenic BALB/c C3H-Tlr4LPS-d mice7. It is known that 
BALB/c mice show a T helper
2-like  immune  response  whereas  the  C57BL/6  mice  express  a  pro-inflammatory  Th1-
like profile21.  To enable a fair comparison of the effects of TLR4 deficiency with those of the 
other TLR and IRF deficient strains and not to linger in Th1/Th2 differences, we performed 
vein graft surgeries in C57BL/6 mice deficient for TLR4 (n=7) and littermate control mice 
(n=10).  Both groups showed no differences in weight pre- and 28 days post-surgery (data not 
shown). TLR4 expression was first examined in caval veins and vein grafts in C57Bl/6 mice 
(Figure 5A). Vein graft SMCs as well as endothelial cells and fibroblasts in the adventitia 
showed pronounced expression of TLR4 whereas native caval veins showed hardly any 
TLR4 staining. TLR4 deficiency on a C57BL/6 background resulted, in agreement with the 
C3H-Tlr4LPS-d  mice7, in a significant 40% decrease in vessel wall area. No significant 
differences in outward remodeling and lumen area were detected between the groups (Figure 
5B-E). The number of CD45 positive cells was significantly decreased in the Tlr4-/-  mice 
whereas no significant difference in macrophage counts could be detected (Figure 5F, G). 
Additional morphologic quantification revealed that the absolute area and percentage SMCs 
in the vessel wall did not differ between the Tlr4-/- and control mice (figure 5H, I) nor did the 
collagen area and percentage collagen (Figure5J, K)
TLR2 does not seems to be crucial in vein graft development
Since  the  Tlr4-/-   mice  demonstrated  complete  opposing  remodeling  to  the  Tlr3-/-   mice, 
we wondered if signaling via the MyD88 pathway was primarily responsible for the decrease 
in vein graft remodeling. Therefore we performed vein graft surgeries in mice that solely 
signal via the MyD88 pathway: the Tlr2-/- mice. First, we examined the expression of TLR2 
in the vein graft segments. Hardly any TLR2 was detectable in caval veins, whereas clear 
staining of TLR2 was found in infiltrating inflammatory cells, SMCs and endothelial cells in 
the vein grafts (figure 6A). Next, we performed vein graft surgery on Tlr2-/- and C57BL/6 
littermate control mice (n=7). No differences in weight were found pre- and 28 days post-
surgery between the two groups (data not shown). Surprisingly, no difference in vessel wall 
area could be detected between the two groups (Figure 6B, E). Also total vessel area/outward 
remodeling and lumen area did not deviate either between  the  groups  (Figure  6C  and  5D). 
Leukocyte  and  macrophage  numbers  were  equal between the groups (Figure 6F, G) while 
quantification of the smooth muscle cells (SMCs) area as well as percentage in the vessel 
wall revealed no significant differences between the Tlr2-/- and control mice (figure 6H, I) 
nor did the area or percentage collagen (Figure 6J, K) deviated between the groups.
Figure 5 (next page). TLR4 deficiency results in decreased vein graft thickening and vascular inflammation. A. 
In caval veins TLR4 staining was restricted to a few cells, mainly SMCs (left panel). The majority of the SMCs in 
the vein grafts stained positive as did the inflammatory cells (right panel). B. A significant increase in vein graft 
thickening was seen in the Tlr4-/- mice. In contrast both total vessel area and lumen area did not deviate between the 
Tlr4-/- and control mice (C, D). E. representative photographs of vein grafts in Tlr4-/- mice (n=7) and control mice 
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(n=10), HPS staining. The number of leukocytes was significantly increased in Tlr4-/-mice whereas the macrophage 
score was not different from that of the control mice (F, G). Analysis of the area and percentage SMCs and collagen 
revealed no significant differences between the groups (H-K).
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C
hapter  6Figure 6. TLR2 deficiency does 
not affect vein graft remodeling 
A.TLR2 staining is almost absent in 
the caval veins (left panel) whereas 
most cell types in the vein graft wall 
(SMCs, fibroblasts, endothelial 
cells and invading inflammatory 
cells express TLR2 (right panel). 
Vein graft interpositioning in 
Tlr2-/- mice did not result in 
differences compared to control 
mice in vein graft thickening, total 
vessel area and lumen area (B-E). 
Leukocyte score and macrophage 
score did not deviate between 
Tlr2-/- and control mice (F-G).
Quantification of the SMC content 
expressed in absolute numbers 
(H) or percentage (I) showed no 
significant differences between 
the groups also the collagen area 
as well as the percentage collagen 
were comparable between the 
groups (J-K).
 118
Type I interferon response genes involved in outward vein graft remodeling
We hypothesized that the outward vein graft remodeling in the TLR3, IRF3 and IRF7 
deficient mice were the result of type I interferon (inducible) gene expression profiles. To test 
this hypothesis we performed a specific RT2 profiler array with 84 type I interferon response 
genes on pools of Tlr2-/-, Tlr3-/-, Tlr4-/-, Irf3-/-, Irf7-/- and control C57BL/6 vein grafts.  A 
low number of genes were found up regulated in the various knockout mice (Figure 7A). 
Deficiency of TLR3, IRF3 and IRF7, but unexpectedly also TLR2 deficiency, resulted in a 
(non-significant) decrease in specific IFN inducible genes such as Ifit1, Ifit3 and Isg15. Also 
IRF7 and Il6 were decreased expressed  in  these  knockout  mice  as  shown  in  figure  7B. 
Remarkably,  Tlr4-/-   mice  hardly expressed regulation of any of these genes.
To assess the effect of TLR and IRF deficiency on inflammatory cytokine expression we 
explored the gene expression of CCL2, TNFα and Il10 in the various knockout mice. RNA 
levels of CCL2 (Figure 7C) and TNFα (Figure 7D) were significantly increased in the Tlr3-
/-  mice. Il10 was up regulated to a lesser extent although non-significant in the Tlr3-/-  mice 





Figure 7 (previous page). Deficiencies of TLR and IRF differentially regulate type I interferon (inducible) genes and 
inflammatory  cytokines.  mRNA  of  vein  graft  of  TLR2,  TLR3,  TLR4,  IRF3  and  IRF7 deficient   mice   were 
analyzed   with   reverse-transcription   real-time   PCR   normalized   to housekeeping genes A. RT2 profiler array 
of Type I IFNs on pools of TLR and IRF deficient vein grafts; genes are shown that are up regulated more than 2-fold 
in one of the strains. B. Type I IFNs  RT2    profiler  array;  genes  are  shown  that  are  down  regulated  more  than 
2-fold. Inflammatory cytokines CCL2 (C), TNFα (D) and Il10 (E), data are expressed as fold induction.
*p<0.05.
Discussion
Although there is evidence of exogenous pathogens in vascular lesions22, it seems unlikely 
that these account for the complete repertoire of TLR activation. DAMP mediated activation 
of TLRs is  thought  to  be  an  important  process  that  drives  immune-activated  diseases 
such  as cardiovascular diseases, rheumatoid arthritis and lupus23-25. We previously 
demonstrated the presence of several TLR DAMPS in remodeled vein grafts7.  Cavasanni et 
al. showed that RNA
from necrotic cells could serve as ligand for TLR3 independent of viral stimuli26. Here we
focused on the effects of TLR activation upon tissue damage and activation as a result of the 
engraftment procedure, flow disturbances and subsequent arterialization phase. mRNA array 
analysis revealed that both TLRs and IRFs are highly regulated during vein graft remodeling 
indicating that both pathways are substantially   involved in vein graft development. This is 
further fueled by GSEA pathway analysis which showed that TLR and Type I IFN gene sets 
belonged to the top 15 of significantly regulated gene sets.
A prominent role for type I IFN genes in vein graft remodeling is suggested by the increased 
vein graft thickening and outward remodeling as seen in the Tlr3-/-   mice and the Irf7-
/- mice whereas, the  Irf3-/- mice showed near significant outward remodeling. This was 
accompanied by down regulation of typical type I IFN inducible genes in the vein grafts 
and pro-inflammatory responses in the vein grafts of Tlr3-/-  mice. Type I IFNs contribute to 
disease progression in auto-immune diseases by increased pro-inflammatory responses27-29. 
In animal models of cardiovascular  diseases,  inhibition  of  IFNβ  results  in  pro-
inflammatory  responses  in  the monocytic lineage30, 31. This is in line with the increased 
influx of macrophages in these knockout strains suggesting that pro-inflammatory responses 
are responsible for the observed outward
remodeling.
 
In contrast to the Tlr3-/- mice, gene expression of pro-inflammatory cytokines in the Irf3-/- 
and Irf7-/- mice were not affected. Compensatory mechanisms by other TLRs in the Tlr3-/- 
mice are a possible explanation for the increased expression of CCL2 and TNFα, especially 
since MyD88 gene transcription was found to be increased in Tlr3-/-  vein grafts. The main 
function of IRF3 and IRF7 is transcription of type I IFNs, therefore limited effect of IRFs 
on other genes such as pro-inflammatory cytokines are expected9. IRF7 is an inducer of  a 
positive feedback loop of enhanced activation of type I IFNs-(TLR3)-IRF716, 32, this may 
explain the stronger reduction of type I Interferon (inducible) genes in the Irf7-/- mice and 
subsequent effects on vein graft thickening and outward remodeling in comparison to the 
Irf3-/- mice. Vein  graft  thickening  was  found  impaired  in  the  Tlr4-/-   mice.  This  was 
accompanied  by  a reduction in leukocytes but not the macrophages in the vessel wall. 
Reduced inflammatory responses and reduced vascular burden match the findings observed 
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in other TLR4 deficient murine models7, 33, 34. TLR4 signaling to induce pro-inflammatory 
cytokines occurs initially via the MyD88 signaling pathway19. TLR4 was only significant up 
regulated at t3 in the array analysis. These results match the findings observed in the 28 day 
old Tlr4-/-  vein grafts that regulation of Type I IFN (inducible) genes was not detectable, 
nor regulation of MyD88 or pro- inflammatory cytokines suggesting that TLR4 is an early 
effector in vein graft remodeling. The fact that the remodeling was reduced after 28 days in 
Tlr4-/- mice and no effects on type I IFN gene expression is observed suggests that in vein 
graft remodeling TLR4 signaling is rather an early response and associated with MyD88 
signaling as described previously19 and not linked to the TRIF mediated , IRF3 associated 
type I IFN inducible genes. The latter pathway is linked to a late activation response that is 
observed after internalization of TLR4. TLR4  and  TLR2  share  common  features  such 
as  the  MyD88  signaling  route  as  well  as endogenous ligands such as HMGB1, Biglycan 
and HSP60 that were found to be expressed in remodeled vein grafts7. In contrast to the 
Tlr4-/- mice, vein graft remodeling was not affected in Tlr2-/- mice. Neither the cellular 
composition nor inflammatory cytokine expression was affected. This effect of limited 
responses without exogenous stimulation was also observed by Schoneveld et al. in a model 
of arterial remodeling, although stimulation of TLR2 with PAM3Cys clearly increased 
vascular burden35. Remarkably, Tlr2-/- vein grafts showed down regulation of some typical 
type I IFN inducible genes e.g. IFIT 1-3, Isg15 and Oas1a whereas IFNa2 and IFNa4 were
up regulated. To our knowledge no direct links between TLR2 and Type I IFNs are reported, 
however,  Liu  et  al.  showed  an  indirect  link:  they  showed  that  TLR2  can  inhibit 
TLR7/9- dependent  induction  of  type  I  IFNs  via  IRAK1  depletion36,  demonstrating  that 
indirect effectuation of Type I IFNs by TLR2 is possible. Whether this particular pathway is 
applicable to our experiments seems unlikely since we did not observed regulation of TLR7, 
TLR9 or MyD88 in the Tlr2-/- vein grafts at the 28 day time point. 
Collectively,  we  here  demonstrate  that  besides  the  MyD88  dependent  pathways, 
the  TRIF dependent pathway and downstream type I IFNs are of importance in vein graft 
remodeling. In particular our finding of increased vein graft thickening and remodeling in 
the Irf7-/- mice gives food for thought to the discussion on the role of TLR pathways in 
vascular diseases. These data confirms once more that depending of the microenvironment 
and especially the contribution of immune cells to the vessel wall, TLRs exert different sets 
of pro-inflammatory mediators that ultimately determine the extent of vascular remodeling.
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TLR accessory molecule RP105 (CD180) is involved in post-interventional vascular remodeling and 
soluble RP105 modulates neointima formation
Karper JC, Ewing MM, de Vries MR, de Jager SC, Peters EA, de Boer HC, van Zonneveld AJ, 




Background: RP105 (CD180) is TLR4 homologue lacking the intracellular TLR4 signaling 
domain and acts a TLR accessory molecule and physiological inhibitor of TLR4-signaling. 
The role of RP105 in vascular remodeling, in particular post-interventional remodeling is 
unknown.
Methods and Results TLR4 and RP105 are expressed on vascular smooth muscle cells 
(VSMC) as well as in the media of murine femoral artery segments as detected by qPCR and 
immunohistochemistry. Furthermore, the response to the TLR4 ligand LPS was stronger in 
VSMC from RP105-/- mice resulting in a higher proliferation rate. In RP105-/- mice femoral 
artery cuff placement resulted in an increase in neointima formation as compared to WT mice 
(4982±974µm2 vs.1947±278µm2,p=0.0014). Local LPS application augmented neointima
formation in both groups, but in RP105-/- mice this effect was more pronounced 
(10316±1243µm2 vs.4208±555µm2,p=0.0002), suggesting a functional role for RP105. For 
additional functional studies, the extracellular domain of murine RP105 was expressed with
or without its adaptor protein MD1 and purified. SEC-MALSanalysis showed a functional 
2:2 homodimer formation of the RP105-MD1 complex. This protein complex was able to 
block the TLR4 response in whole blood ex-vivo. In vivo gene transfer of plasmid vectors 
encoding the extracellular part of RP105 and its adaptor protein MD1 were performed to 
initiate a
stable endogenous soluble protein production. Expression of soluble RP105-MD1 resulted 
in a significant reduction in neointima formation in hypercholesterolemic mice (2500±573 
vs.6581±1894 µm2,p<0.05), whereas expression of the single factors RP105 or MD1 had no 
effect .





In interventional cardiology restenosis remains a critical determinant of long-term efficacy 
of Percutaneous Coronary Interventions (PCI). Neointima formation is a common feature of 
restenosis and atherosclerosis and is characterized by proliferation and migration of vascular 
smooth muscle cells (VSMC) and extracellular matrix formation1, 2. These processes are 
strongly mediated by inflammation and influx of inflammatory cells in the affected vessel 
wall3. Under hypercholesterolemic conditions this is accompanied by lipid accumulation 
in the vessel wall, thereby initiating a process of accelerated atherosclerosis. Previously, we 
and others described an important causal role for Toll Like Receptor 4 (TLR4) in neointima 
formation. Furthermore, TLR4 activation by local application of LPS had a stimulatory effect 
on neointima formation and accelerated atherosclerosis development4-6. LPS initiates TLR4
activation and the resulting inflammatory reaction causes a release of many pro -inflammatory
cytokines that will affect the pathophysiological process of neointima formation strongly7, 8. 
TLR4 is expressed on VSMC and is involved in their proliferation9. Previously, we were able 
to detect co-localization between endogenous TLR4 ligands (HSP60 and fibronectin-EDA) 
and TLR4 during vascular remodeling 4, 6.
TLR4 is a pattern recognition receptor (PRR) of the innate immune system and is expressed 
by both immune and non-immune cells. It is the most robust and complex signaling TLR 
and can be activated by an array of ligands, including damage associated molecular patterns 
(DAMPs), which can for instance be degradation products of endogenous matrix molecules, 
necrotic cells, oxidized molecules and inflammation-specific molecules10. Activation of 
TLR4 by binding of LPS and or other ligands that become available after cell stress or tissue 
damage11, 12 is dependent on the presence of MD2, a TLR accessory molecule.
It is becoming more and more clear that accessory molecules play a key role in the complex 
TLR-signaling. Accessory molecules can be divided into molecules that reside in the 
endoplasmic reticulum, molecules that directly interact with TLR ligands or regulatory 
molecules present on the cell surface such as RP105 (CD180)13. RP105 is reported to be a 
physiological TLR4 inhibitor on myeloid cells.
In the presence of RP105 on myeloid cells activation of the TLR4 signaling pathway is 
directly reduced making RP105 one of the most important accessory molecules acting as a 
regulator of TLR4 signaling. Structurally, RP105 is highly homologous to TLR4, but lacks 
the intracellular Toll Interleukin Receptor (TIR) domain. TLR4 activation in cellular
immunity, induced by e.g. its ligand LPS, is negatively regulated by RP10514-16. RP105 forms 
a complex with MD1, a MD2 homolog, in an unusual 2:2 homodimer17, 18. This orientation 
is opposite to that of known ligand-induced TLR-homodimers. The functional consequence 
of this unusual dimer configuration is still under debate17, 18. RP105/MD1 is thought to bind 
LPS and other TLR4 ligands, therefore RP105 is linked to several inflammatory processes 
including autoimmune diseases16, 19, 20. So far, the involvement and possible causal role of 
RP105 in vascular remodeling and other cardiovascular related events is unknown.
In the current study we demonstrate a functional role for RP105 in vascular remodeling 
during neointimal formation by the use knockout mice, cultured VSMC, purified proteins 
and by in vivo gene transfer mediated overexpression of soluble RP105 (solRP105) protein 
combined with the MD1 accessory protein.
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Material and methods:
Cell culture and cell culture immunostaining
Murine VSMCs explanted from aortas were cultured and incubated overnight with either PBS 
or LPS (1ng/ml or 10ng/ml). Cells were either cultured for RNA isolation or were cultured on 
glass coverslips and fixed. The latter was followed by blocking with PBS, 3% BSA, 2% FCS 
for one hour at room temperature. After blocking, primary antibodies and isotype controls 
were incubated for one hour followed by washing and incubation with labeled secondary 
antibodies for one hour in the dark. TLR4 presence was demonstrated using TLR4 antibody 
(rabbit anti-human, Santa Cruz). RP105 was stained with RP105 antibody (rat anti-mouse, 
Abcam, United Kindom). A ZEISS 510 microscope was used for analysis and confocal 
microscopy.
Macrophages
Macrophages were derived from bone marrow from tibia and femur and seeded at a density 
of 500.000 cells/well in 6-wells plates and cultured for 7 days in RPMI GlutaMax (Gibco)
supplemented with 100U/ml penicillin/streptavidin, 25% Fetal Calf Serum (FCS) and
20mcg/ml M-CSF (Myltec Biotechnologies) as described previously21 .
Dendritic cells
Dendritic cells were derived from bone marrow from tibia and femur and seeded at a density 
of 1.500.000 cells/well in 6-wells plates and cultured for 10 days in RPMI Glutamin (Gibco) 
supplemented with 100U/ml penicillin/streptavidin, 10% Fetal Calf Serum (FCS) and
20mcg/ml GM-CSF (Myltec Biotechnologies). as described previously22 . Cells were 
cultured in the presence of 1ng/ml LPS.
RT-PCR
From VSMCs, total RNA was isolated using Tri-Reagent (Sigma-Aldrich) according to the
manufacturer’s protocol. The expression levels of TLR4 and RP105 were analyzed by real 
time polymerase chain reaction (RT-PCR) (Taqman, Applied Bioscience) on non-stimulated 
VSMCs and VSMCs stimulated with LPS overnight. The relative mRNA expression levels 
were determined using GAPDH as housekeeping gene and the 2[−ΔΔC(T)] method. Values 
were expressed as fold of unstimulated controls.
SMC Proliferation Assay
Murine SMCs, explanted from aortas, were subsequently cultured, characterized, and 
proliferation was measured using the 3H-Thymidine incorporation method as described 
previously21. Briefly, cells were seeded in a 24 well disk at a density of at least 100.000 cells
per cm2. Next, cells were made quiescent for 48 hours in serum free medium followed by
stimulation with LPS in full medium containing 10% FCS. Methyl-3H-thymidine incorporation 
(Amersham, 0.25μCu per well) over a 16 hours period was measured by liquid- scintillation 
counting and compared to non stimulated control cells of WT and RP105-/- VSMC in serum 
free medium. All experiments were done in triplicates.
Animals
Animal experiments were approved by the Institutional Committee for Animal Welfare of 




guidelines. 10 week old male wild type (WT, C57/B6) and 10 week old male RP105-/- animals 
(C57/B6 background, backcrossed for more than 10 generations) bred in our laboratory, were 
used. RP105-/- mice were provided by K.Miyake, Tokyo University, Japan and described
previously22. 10 week old male hypercholesteremic ApoE3Leiden mice were used to study
the effect of soluble RP105 overexpression. ApoE3Leiden mice received a western-type diet 
that started 3 weeks before surgery and continued during the experiment. One week before
surgery cholesterol levels in serum were determined (Roche Diagnostics, The Netherlands). 
All mice received water and food ad libitum.
Murine model for neointima formation
Non-constricted polyethylene cuffs were placed around the femoral arteries as described 
previously23 Mice were killed 3 weeks after cuff placement. The hypercholesterolemic 
mice were sacrificed after two weeks , since at this time point first signs of accelerated 
atherosclerosis and foam cells formation becomes detectable.. For local TLR4 stimulation, 
TLR4 ligand LPS (1 µg/µL) (from Escherichia coli 055:B5, Sigma Aldrich, The Netherlands) 
was dissolved in pluronic gel (F-127, Sigma Aldrich, The Netherlands) and administered 
inside the cuff4.
Purification of solRP105 and solRP105-MD1
Plasmid Constructs
The extracellular domain of mouse RP105 comprising residues Thr21-Ala630 was inserted 
into a pUPE expression vector (U-Protein Express BV, Utrecht) that includes an N-terminal 
(His)6-(StrepII)3-TEV-tag. Mouse MD1 without its native signal sequence; residues Asp20- 
Ser162, was cloned into a pUPE expression vector that includes an N-terminal (His)6-
tag. Both vectors include the human cystatin-S signal peptide for efficient secretion and 
expression is controlled by the CMV-promoter. The cloning procedure introduces a triple- 
alanine sequence at the C-terminus of both proteins.
Protein expression and purification
Expression vectors encoding solRP105 and MD1 were transfected transiently, either 
individually or in combination, in HEK293-EBNA1-S cells. Culture supernatant was 
harvested 6 days post-transfection. Supernatant was concentrated 10-fold using a Quixstand 
hollow fiber system (GE Healthcare) prior to diafiltration into 50 mM Tris-Cl, pH8.0, 300
mM NaCl. RP105 and RP105-MD1 complex were purified using Ni-Sepharose/Streptactin- 
Sepharose tandem-affinity-purification and eluted in 50 mM Tris-Cl, pH8.0, 300 mM 
NaCl supplemented with 5 mM desthiobiotin. MD1 was purified by Ni-Sepharose affinity 
purification in 50 mM Tris-Cl pH8.0, 300 mM NaCl supplemented with 250 mM imidazole 
followed by dialysis to buffer without imidazole. N-glycosylation of SDS-denatured MD1 
was analysed by cleavage with PNGase (Roche) according to the manufacturer’s protocol. 
Protein quality was further assessed by size-exclusion chromatography on a Superdex 200
PC3.2/30 column (GE Healthcare) using 50 mM Tris-Cl, pH8.0, 300 mM NaCl as the running 
buffer at 0.05 ml/min. The molecular weight of the solRP105-MD1 complex was determined 
by size exclusion chromatography with multi-angle light scattering (SEC-MALS) using a 
WTC-030S5 column (Wyatt technologies) and 50 mM Tris-Cl, pH8.0, 300 mM NaCl as the 
running buffer at 0.5 ml/min. Molecular weight was calculated by ASTRA software  version
5.3.4.18 Wyatt technologies).
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In vivo overexpression of soluble RP105
In vivo overexpression of soluble RP105 (solRP105) was achieved by gene-transfer of the 
expression plasmids encoding the extracellular domain of RP105, MD1 or both plasmids 
together. A Luciferase encoding plasmid was used as control. Electroporation mediated gene 
transfer was performed 3 days before cuff placement by injecting 50 μg of each plasmid per 
leg, either Luciferase, solRP105, MD1 or MD1 plus solRP105, into the calf muscles of both 
legs, followed by electroporation (8 pulses of 10 ms, field strength of 200 V/cm [Sq Wave 
Electroporator ECM 830, BTX] using Caliper Electrodes). Calf muscles were primed with 
an intramuscular injection containing 30 μL of hyaluronidase (0.45 U/μL, Sigma) one hour
before electroporation as described previously24.
Whole blood assay
Blood from three C57/B6 mice was collected (180µl blood with 20µl heparin) and incubated 
with either solRP105 purified protein (7.5µg/ml, MW=74706), solRP105-MD1 purified 
protein complex (9µg/ml, MW=90975) or PBS. Blood was stimulated overnight with
100ng/ml LPS and subsequently the cytokine TNFα was measured by ELISA (BD
biosciences).
Morphological Quantification
Mice were sacrificed 21d (or as stated otherwise) after surgery for histological analysis. 
Arterial segments were harvested after perfusion fixation (100 mm Hg) with 4% 
formaldehyde, fixed overnight and paraffin-embedded using an automated tissue processor 
(Leica, Germany). Cross-sections were made throughout the embedded cuffed arteries. 
Six representative sections per vessel segment were stained with Elastin von Giesson and 
Haematoxylin-Phloxine- Saffron (HPS) for histological and morphometric analysis (QWin, 
Leica, Germany). Neointima formation was defined as the area between lumen and the 
internal elastic lamina.
Immunohistochemisty on vessels
Paraffin embedded sections (5μm) were de-paraffinized in xylene. Peroxidase activity was 
blocked by incubation in 0.3% (v/v) H2O2 in methanol for 20 min. Antigen retrieval was 
performed and tissue sections were pre-incubated with 5% bovine serum albumin (BSA), 
followed by overnight incubation with detecting antibody for either RP105 antibody (rat anti 
mouse, Abcam, United Kingdom) or CD45 (rat-anti mouse). After washing in PBS, sections
were incubated for 1h with a secondary antibody, washed in PBS, incubated for 1h with 
AB complex (Vector laboratories, The Netherlands) and visualized with Novared (Vector 
laboratories) or DAB (Dako, Denmark). Slides were counterstained with haematoxylin. 
Immunopositive areas of leukocytes were calculated as percentage of total either media or 
neointima area in cross-sections by morphometry (Qwin, Leica, Germany).To confirm the 
specificity of the IHC staining, parallel sections were incubated with 1% PBS/BSA alone 
without adding the primary antibody or with IgG isotype control or without first antibody. 
Sections were incubated with the secondary antibody, AB complex and were visualized with 
Novared. Controls were all negative.
Statistics
For the animal experiments, values are presented as mean ± standard error of the mean 




between groups were determined using a non-parametric Mann-Whitney test or One-Way 
ANOVA. In vitro data was statistically analyzed with a Student’s-T-test.
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Results
RP105 and TLR4 are both expressed by VSMC
Both TLR4 and RP105 mRNA are expressed in VSMC and as expected overnight 
incubation with LPS decreased mRNA expression for both TLR4 as described previously 
on leukocytes25,26 as well as RP105 (Figure 1A-B). TLR4 and RP105 protein was detected 
by immunohistochemistry (IHC) and was also decreased after overnight LPS incubation 
(Figure1C-D). In non-stimulated cells co-localization between TLR4 and RP105 was 
sporadically detected (Figure 1E and Supplementary Figure 1). To detect RP105 expression 
in the vessel wall IHC was performed on cross sections of murine femoral arteries. RP105 
was expressed particularly in the media that consists of VSMC (Figure 1F). Furthermore, 
RP105-/- VSMC showed an increase in proliferation-index (fold of proliferation increase 
compared to unstimulated controls) compared to wild type controls upon LPS stimulation 







Figure 1: RT-PCR of TLR4 (A) or RP105 (B) on wild 
type VSMC that were incubated with PBS, 1ng/ml LPS 
or 10ng/ml LPS. Immunostaining of TLR4 (green) 
or RP105 (red) or both (overlay) on wild type VSMC 
that were incubated with PBS (C) or 1ng/ml LPS. (D) 
Colocalized TLR4 and RP105 staining on VSMC (E). 
RP105 staining in media area of a murine femoral 
artery (F). Proliferation of VSMC of WT  and 
RP105-/- (G) 
Liquid-scintillation counting after 16 hours of WT 
and RP105-/- VSMC. VSMC of show a RP105-/-an 
increased proliferative response to LPS. VSMC were 
cultured in medium containing 10%FCS or 10%FCS 
with1ng/ml LPS. Starved WT and RP105-/- VSMC were 
used as controls. White bars represent WT VSMC, black 




RP105 is present in the arterial wall and is protective in neointima formation
Cuff placement induces a mild vascular injury that is driven by a damage induced inflammatory 
response and can be detected as intimal thickening. Studies to determine the functional role 
of RP105 in restenosis were initiated. Femoral cuff placement to induce neointima formation 
was performed in RP105-/- and control wild type (WT) mice. The neointima consists 
dominantly of VSMC as can be appreciated in (Figure 2AB). Quantification of the neointima 
revealed that RP105 deficiency resulted in enhanced neointima formation compared to WT 
mice (4982±974µm2 (n=8) vs 1947±278µm2 (n=10), p=0.0014) (figure 2B). The stronger 
neointima formation in the RP105-/- caused a difference in intima/media ratio (0.62±0.13 vs. 









Figure 2: Neointima formation after femoral artery cuff placement in RP105-/- and wild type mice. Areas of femoral 
arterial sections were quantified by using 6 sequential sections per segment and are expressed in micrometers 
squared (mean±SEM). Increased neointima formation in RP105-/- mice compared to WT (wild type) controls (A). 
Increased intima/media ratio inRP105-/- mice compared to WT controls (B). Representative pictures of Elastin von 
Giesson(C) HPS (D) and alpha-smooth muscle cell actin (F) of RP105-/- and WT controls. * = P<0.05 Arrows 














LPS induced increased neoinitma formation and caused outward remodeling in RP105 
deficient mice.
To initiate a stronger TLR4-driven vascular remodeling, the experiment presented above was 
repeated with local application of the TLR4 ligand LPS (1 µg/µL in pluronic gel) around the 
cuffed artery. Local LPS application caused augmented neointima formation in both groups 
(RP105-/- (n=9) vs WT (n=8)) and again significantly stronger neointima formation in RP105-
/- mice (10316±1243µm2 vs. 4208±555µm2, p=0.0002) (figure 3A). Intima/media ratio after
LPS application increased in both groups (1.05±0.12 vs. 0.52±0.07 p= 0.0037) (figure3B). 
Previously, we showed that TLR4 induced neointima formation via local LPS application 
caused outward remodeling4, 18. Therefore, we compared the total vessel wall areas of both
groups to study the outward remodeling response. Outward remodeling in the RP105-/- mice 
(33315±3945µm2 vs. 21401±1140µm2, p=0.027) (figure 3C) was significantly stronger 
compared to the controls.
Previously, RP105-mediated suppression of TLR4 signaling by plasmid overexpression in 
HEK-293 cells was shown in vitro15. So far we found negative effects of RP105 deficiency on 
vascular remodeling and therefore we hypothesized that RP105, by regulating TLR signaling, 
might have therapeutic potential in post-interventional vascular remodeling. Therefore we 
produced soluble RP105 protein, characterized it and tested its therapeutic potential.
Figure 3 Neointima formation 
after femoral artery cuff 
placement with LPS in RP105-
/- and wild type mice. Areas of 
femoral arterial sections were 
quantified by using 6 sequential 
sections per segment and are 
expressed in micrometers 
squared (mean±SEM). 
Increased neointima formation 
in RP105-/- mice compared to 
WT controls after local LPS 
application (A). Increased 
intima/media ratio in RP105-/- 
mice compared to WT controls 
after local LPS application (B). 
Increased outward remodeling 
in RP105-/- mice compared to 
WT controls after local LPS 
application (C) Representative 
pictures of Elastin von Giesson 
(D), HPS (E) and alpha-smooth 
muscle cell actin (F) of RP105-
/- and WT controls. * = P<0.05. 
Arrows indicate the Internal 
Elastic Lamina (IEL) and the 
















Soluble RP105 protein – characterization SDS-PAGE analysis of the purified proteins, 
shows that the solRP105-MD1 complex and MD1 preparations are >95% pure, whereas 
the solRP105 preparation shows some impurities (Figure 4A). solRP105 has the expected 
molecular weight of ~90 kD whereas MD1 shows as a double band at approximately 23 and 
26 kD (Figure 4A). Deglycosylation of denatured MD1 shows that the two bands in the MD1 
preparation are due to differential glycosylation of the two N-glycosylation sites at positions 
Asn96 and Asn156 (Figure 4B). During size-exclusion chromatography, the solRP105-MD1
complex shows a single peak with an elution volume that is consistent with a hetero- tetrameric 
RP1052MD12 complex, as was observed in the recently published crystal structures of the 
RP105-MD1 complex (16, 18). solRP105 shows a broad peak that is indicative of aggregation 
with a peak maximum at an elution volume that is consistent with monomeric RP105 (Figure 
4C). The molecular weight of the complex was determined more accurately using SEC-
MALS and yielding a value of 208±11 kD, which is in good agreement with the expected 
molecular weight of 214 kD for fully glycosylated RP1052MD12 complex.
Figure 4: Purification and analysis of RP105, MD1 and RP105-MD1 complex. RP105 (lane 1) and RP105-MD1 
complex (lane 2) purified by nickel- and streptactin- tandem affinity purification and analysed by SDS-PAGE (10%) 
and subsequent silverstaining. Lane 3 shows MD1 purified by nickel-affinity purification and analysed by SDS-PAGE 
(12%) and subsequent Coomassie staining (A). SDS-PAGE analysis of PNGase deglycosylation of SDS denatured 
MD1 (B). Size exclusion chromatography (Superdex200 PC3.2/30) of the purified RP105 (dashed line) and RP105-
MD1 complex (solid line).  Molecular weight determination of the RP105-MD1 complex  using SEC-MALS (inset). 
The dashed horizontal lines indicate a molecular weight of 180 kD and 220 kD, respectively (C).
Soluble RP105 protein – functionality
We were able to show the increased TLR4 mediated inflammatory response in RP105 
deficient myeloid cells (Supplementary Figure 2). To see whether solRP105 or solRP105- 
MD1 could have effects on cytokine production by these circulating cells we performed an 
ex vivo whole blood stimulation assay in the presence of these proteins. Blood was incubated 
RP105
RP105-MD1




















































with LPS in the presence of solRP105, solRP105-MD1 complex or PBS and TNF was after 
measured after overnight LPS stimulation. solRP105-MD1 showed a marked decrease in 
TNFalpha production compared to controls (Figure 5).
solRP105-MD1 reduced neointima formation.
To see whether solRP105 could be a functional inhibitor of neointima formation in a more 
humanized model with mild foam cell formation in the neointima we applied our cuff model 
in ApoE3Leiden mice. Since RP105 also had strong effects on macrophages15 important in
foam cell formation23 and the above described effects on VSMC proliferation we hypothesized 
that overexpression of the soluble form of the RP105 receptor, either alone or in complex 
with MD1, could have potential therapeutic benefits to reduce restenosis. Plasmids encoding 
solRP105, MD1 or luciferase (control) were injected in calf muscles followed by
electroporation into the muscle cells 3 days before cuff placement in transgenic ApoE3Leiden 
mice that develop a diet induced hypercholesterolemia. This resulted in systemic 
overexpression of the recombinant proteins, as we have demonstrated previously 8, 27, 28. 
Overexpression of both solRP105 and MD1 proteins combined caused a significant reduction 
in neointima formation compared to luciferase control (2500±573 vs. 6581±1894 µm2, 
P<0.05) and a more beneficial intima media ratio (Figure 6A-D), whereas overexpression of 
either solRP105 or MD1 did not affect neointima formation
Discussion
To our knowledge, the present study is the first to describe a role of RP105 in vascular disease. 
RP105 is expressed in cultured VSMC, as well as in the media. Furthermore, RP105 deficient 
mice develop less neointima after vascular injury and in these mice lacking the inhibitor 
TLR4 inhibitor R105, TLR4 activation via LPS clearly enhanced vascular remodeling more 
profoundly. Finally we demonstrated that overexpression of a soluble RP105/MD1 protein 
complex strongly reduced neointima formation.
RP105 can be distinguished from other endogenous TLR regulators by being an extracellular 
TLR4 structural homolog with contrasting capabilities like the inhibitory effects on myeloid 
cells and activation of B cells 13. Our study shows that RP105 protein is also expressed 
by vascular smooth muscle cells (VSMC). Others have shown RP105 presence on smooth 
muscle cells of the airway29. Additionally, we found via immunostaining as well as via RT- 
Figure 5 Whole blood stimulation. Blood stimulated with LPS and PBS or combined with purified solRP105 protein 





Figure 6: Neointima formation after femoral artery cuff placement with LPS in hypercholesterolemic APOE3Leiden 
mice. Areas of femoral arterial sections were quantified by using 6 sequential sections per segment and are expressed 
in micrometers squared (mean±SEM). Decreased neointima formation in mice that had overexpression of solRP105-
MD1 (A). Intima Media ratio (B) Pictures of Elastin von Giesson (C) HPS (D) alpha-smooth muscle cell actin (E) 







Elastin HPS SMC CD45 
PCR that the expression of both receptors is down regulated upon overnight incubation with 
LPS as can be appreciated in figure 1. This is in line with previous observations in monocytes/
macrophages exposed to LPS, which show reduced responses to second stimulation with LPS. 
Furthermore, after an initial LPS stimulation, TLR4 mRNA expression was significantly 
decreased within a few hours and remained suppressed over 24h. TLR4
presence at the cells surface rapidly decreased within 1hour, with a gradual decrease after that
26. In patients a similar situation can be observed where a reduction in TLR4 expression can 
be appreciated on monocytes at the end of cardiopulmonary bypass procedures 25. While 
TLR4 might be down-regulated as a protective response, RP105 may just follow TLR4 
expression as RP105 expression mimics that of TLR4 in human and mouse myeloid cells15.
RP105 deficiency on VSMC caused an increase in proliferation upon incubation with TLR4 
ligand LPS. A stimulating effect of TLR4 on VSMC proliferat ion was published previously 9.
This points towards a functional role of RP105 in vascular remodeling via its TLR4 inhibitory 
function, via its effects on VSMC in the pathophysiological process of neointima formation,
as a common feature of restenosis. Femoral cuff placement in mice allows employing of a 
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mild mechanically-induced inflammatory-based neointima formation. Lesions in mice consist 
primarily of VSMC and application of this model to RP105-/- and WT control mice leads to 
an increase in neointima formation in the RP105-/- mice. This underscores the suggestion that
RP105 is also functionally involved in the inhibition of post-interventional neointima 
formation, a process known to be regulated by TLR4 activation and may play a role in the 
pathophysiological process of restenosis.
The influence of inflammation on restenosis is most prominent in the early phase after 
intervention. Interestingly, TLR4 was previously described to be involved in cardiovascular 
remodeling 5, 6, 30 and local application of LPS causes a strong increase in neointima
formation after cuff placement 4. RP105 deficient mice have a stronger pro-inflammatory 
response upon systemically delivered TLR4 ligand LPS 14. In figure 3 we show that short 
term activation of TLR4 directly after cuff placement via local application of LPS causes 
a strong increase in neointima formation. As a result, the vessel seems to respond by 
compensatory outward remodeling to secure the vessel patency 31. In TLR4-deficient mice 
this response is inhibited upon local LPS application 4. Due to a more prominent TLR4 
activation in RP105-/- mice we see that these mice have an increase in outward remodeling.
So far a protective role for RP105 on post-interventional remodeling is appreciated. This 
indicates potential for new strategies to use RP105 in a therapeutic approach. Therefore we 
focused on the development of recombinant protein expression. Divanovic et al showed that 
the extracellular region of RP105 is functional only when co-expressed with MD115. Similar 
to TLR4 surface expression that is dependent on MD2, RP105 surface expression was shown 
to be dependent on MD1 32. While we could express the soluble ectodomain of RP105 in the
absence of MD1, we find that MD1 is necessary to prevent its aggregation. Monomeric 
RP105 protein is not capable of inhibiting the LPS response on whole blood while the RP105- 
MD1 complex did inhibit LPS induced TNFα production, a factor known to be important in 
neointima formation7. The exact mechanism of how RP105-MD1 regulates TLR4 signaling
is still under discussion. However, it is suggested that the complex formation is crucial, since
monomeric RP105 is highly unstable. It has been shown that RP105-MD1 interacts directly 
with TLR4-MD2 15. The unusual 2:2 homodimer of the RP105-MD1 complex suggests two 
possible mechanisms for inhibition of TLR4-MD218; either (i) a lateral binding of TLR4-
MD2 to the RP105-MD1 complex which would involve direct MD1-MD2 interactions or, 
(ii) the formation of quasi-symmetrical TLR4-MD2/RP105-MD1 complexes reminiscent 
of the usual ligand-induced TLR homodimers. In both scenarios RP105-MD1 could block 
TLR4 homodimer formation and possibly prevent/destabilize LPS binding to MD218. 
However, the second mechanism was considered to be more plausible since it explains the 
regulation of the LPS response by RP105–MD1 regardless of LPS binding 18.To set more 
focus on the therapeutic potential we initiated experiments to study the therapeutic potential 
of RP105 in a more humanized model having vessel damage combined with a diet induced 
hypercholesterolemia, i.e. cuff induced neointimal formation in hypercholesterolemic 
ApoE3*Leiden mice. No effect was seen of gene transfer of vectors expressing MD1 as a 
single factor. The absence of an effect of MD1 expression, as was also previously shown in 
vitro15, demonstrates that the mechanism that leads to reduction in TLR4
signaling does not rely on MD1-MD2 interactions, thus the above-discussed scenario 1 is 
unlikely. Overexpression of solRP105 alone as a single factor did not alter neointima formation 
suggesting that the endogenously produced MD1 is not sufficient to stabilize RP105 by 
formation of complexes as is required in vitro (Figure 4). Combined overexpression of both




decrease in neointima formation. The soluble RP105/MD1 complex may act as a decoy 
receptor and as such have a therapeutic potential.
Apparently, overexpression in vivo of solRP105 with MD1 at the site of production is essential 
to form a stable and effective RP105-MD1 complex for functional inhibition of neointimal 
formation. These results are also supportive for the quasi-symmetrical working mechanism 
of RP105-MD1, the above-discussed second scenario of RP105 mediated TLR4 inhibition.
In summary, we demonstrate the presence of RP105 on cultured VSMC and in VSMC in vivo 
in media and neointima and the increased restenosis in RP105-/- mice indicate RP105 as a 
mediator of restenosis, probably as an inhibitor of TLR4. Furthermore, solRP105 significantly 
modulates the strong TLR4 driven vascular remodeling. Thus RP105 is an interesting new 
factor involved in the complex regulation of vascular remodeling and can be used to develop 
novel therapeutic strategies to inhibit neointima formation.
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Supplementary Figure 2 TNFα levels produced 
upon LPS stimulation by dendritic cells (A) and 
macrophages (B) from WT and RP105-/- mice. 
* = P<0.05
Supplementary Figure  1. Colocalized TLR4 and RP105 
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Background: Toll-like receptor-4 (TLR4), a receptor of the innate immune system, is 
suggested to have detrimental effects on cardiac function after myocardial infarction 
(MI). RP105 (CD180) is a TLR4 homolog lacking the intracellular signalling domain that 
competitively inhibits TLR4-signalling. Thus, we hypothesized that RP105 deficiency, by 
amplifying TLR4 signalling, would lead to aggravated cardiac dysfunction after MI.
Methods and Results: First, whole blood from RP105-/- and wild-type (WT) male C57Bl/6N 
mice was stimulated with LPS, which induced a strong inflammatory TNFα response in 
RP105-/- mice. Then, baseline heart function was assessed by left ventricular pressure-
volume relationships which were not different between RP105-/- and WT mice. Permanent 
ligation of the left anterior descending coronary artery was performed to induce MI. Infarct 
sizes were analysed by (immuno)histology and did not differ. Fifteen days post MI heart 
function was assessed and RP105-/- mice had significantly higher heart rate (+21%,P<0.01), 
end systolic volume index (+57%,P<0.05), end systolic pressure (+22%,P<0.05) and lower 
relaxation time constant tau (-12%,P<0.05), and a tendency for increased end diastolic 
volume index (+42%,P<0.06), compared to WT mice. In the area adjacent to the infarct zone, 
compared to the healthy myocardium, levels of RP105, TLR4 and the endogenous TLR4 
ligand fibronectin-EDA were increased as well as the number of macrophages, however this 
was not different between both groups.
Conclusion: Deficiency of the endogenous TLR4 inhibitor RP105 leads to an enhanced 
inflammatory status and more pronounced cardiac dilatation after induction of MI, 





Cardiovascular diseases remain the leading cause of death in the western countries, which is 
mainly accounted for by the high incidence of myocardial infarction (MI). Although survival 
after MI has improved significantly due to novel medical strategies and interventions, the 
incidence and prevalence of MI related morbidity is increasing which is mainly due to 
development of congestive heart failure (CHF) [1, 2]. CHF is the result of a remodelling 
response of the ventricle upon reduced contraction capacity after cardiac damage such as 
MI [2]. During the last decades the immune system was demonstrated to play a major role 
in myocardial repair and remodelling. Evidence accumulates that prolongation of the post-
infarction inflammatory response leads to increased remodelling and thereby CHF progression 
[3-5]. Therefore, new strategies to intervene in the pathogenesis of CHF may be worthwhile, 
which can be achieved by immediate anticipation and tackling of the inflammatory- and 
matrix degeneration processes that have been initiated by the immune system [6].
Toll like receptors (TLR) are part of the innate immune system and are capable of recognizing 
Pathogen Associated Molecular Patterns (PAMPS) as well as Damage Associated Molecular 
Patterns (DAMPs). PAMPs are parts of exogenous pathogens such as bacteria while DAMPs, 
like fibronectin-EDA or Heat Shock Protein, may become available after cell stress or 
tissue damage/injury without the involvement of exogenous pathogens [7]. They have been 
widely associated with atherosclerotic plaque formation, restenosis and vein graft failure; all 
processes that may initiate ischemia or MI, resulting in cardiac remodelling [8-10]. One of 
the most studied TLRs is TLR4, which is present on circulating cells and cardiomyocytes. 
Cardiac expression of TLR4 was shown to be upregulated in cardiomyopathy [11]. In 
preclinical studies TLR4 was shown to play an important role in myocardial infarct healing, 
LV remodelling and functional impairment following MI [12]. Additionally, intervention with 
a specific TLR4 antagonist Eritoran was demonstrated to be protective against remodelling 
[13].
TLR-signalling is mainly regulated by accessory molecules [14], and no role for these 
accessory molecules in cardiac remodelling has been defined yet. RadioProtective105 
(RP105), one of these molecules, resides on the cell surface and has a high extracellular 
structural similarity to TLR4 (Fig. 1) [15]. In addition, like TLR4, whose signalling depends 
on association with the extracellular accessory protein MD-2, RP105 surface expression 
depends on co-expression of the MD2 homolog: MD1. However, in contrast to TLR4, RP105 
lacks the intracellular Toll Interleukin Receptor (TIR) domain that is essential to initiate 
cellular activation. As such RP105 is an inhibitor of the TLR4 signaling pathway [16, 17]. 
Whereas no direct ligands have been found for RP105, strong indications exist that it can 
bind TLR4 ligands, thereby influencing TLR4 signalling and dampening the inflammatory 
responses induced by TLR4 activation.
As TLR4 activation has been shown to enhance cardiac remodelling after MI, we hypothesized 
that RP105 deficiency would aggravate these effects, through reduced inhibition (thus by 
stimulation) of TLR4 signalling. In this study we demonstrate that RP105 deficiency indeed 
has a functional role in cardiac remodeling, since systolic and diastolic cardiac function 





2.1 Animals and experimental design
Studies were performed with 10-12 week old, male RP105-deficient (RP105-/-) mice bred in 
our animal facility and wild-type (WT) mice (Charles River, Maastricht, The Netherlands), 
both on a C57Bl/6N background. Animals were housed in a temperature and humidity-
controlled room on a 12:12-h light-dark cycle with ad libitum access to water and normal 
chow diet. Body weights were measured weekly (RP105-/- day 0: 28.6±1.6, day 15: 27.3±1.8 
g; WT day 0: 24.4±1.4 g, day 15: 23.6±1.5 g). MI was induced by coronary ligation (see 
below) at day 0 in RP105-/- (n=12) and WT (n=12) mice. Subsequently, cardiac function 
assessments by pressure-volume loops (PV-loops) were performed at day 15. To obtain 
baseline cardiac function, additional PV-loop measurements were performed in a separate 
group of animals (RP105-/-, n=4; WT, n=4) without MI. After PV-loop measurements the 
mice were sacrificed and hearts were isolated for further examination. The protocol was 
approved by the Animal Ethics Committee from the Leiden University Medical Center and 
conformed to the Guide for Care and Use of Laboratory Animals (NIH publication No.85-23, 
Revised 1996).
2.2 Whole blood TNFα stimulation assay
In order to investigate the inflammatory response at baseline of the different groups, venous 
blood via a tail vein cut was collected in a separate batch of mice and suspended 1:25 with 
RPMI 1640 (Gibco 52400-025) supplemented with non-essential amino acids (PAA M11-
003) and glutamax (Gibco 35050). Blood from both WT en RP105-/- mice was incubated 
overnight at 37ºC in absence and presence of LPS in the concentrations 25 ng/mL and 50 ng/
mL. Subsequently, TNFα levels were measured by ELISA (BD Biosciences, Erembodegem, 
Belgium).
2.3 Induction of myocardial infarctions
Mice were anesthetized by an intraperitoneal injection of a mixture of dormicum (0.7 mg/
kg BW), dexdomitor (7.2 mg/kg BW) and fentanyl (0.07 mg/kg BW). Body temperature 
was maintained at 37°C using a temperature-controlled, automatic heating pad. Mice were 
artificially ventilated using a dedicated mouse ventilator (model 845, Harvard Apparatus, 
Holliston, MA). The left anterior descending coronary artery (LAD) was ligated with a 
7-0 ethilon suture (Johnson and Johnson, New Brunswick, NJ), just distal to the left atrial 
appendage. Ischemia was visually confirmed by bleaching of the LV. The thorax was closed 
and the mice received an intraperitoneal injection of anexate (0.5 mg/kg BW), antisedan (2.5 
mg/kg BW), naloxon (1.2 mg/kg BW) to antagonize the anesthesia. Analgesic temgesic (1.5 
µg in 50 µL PBS) was administered subcutaneously. Thereafter, the mice were allowed to 
recover on a temperature-controlled heating pad.
2.4 Hemodynamic measurements 
Thirteen days after induction of the MI, transthoracic, cardiac echocardiography was performed 
using a VisualSonics Vevo 770 with a 30 MHz ultrasound transducer (VisualSonics, Toronto, 
Canada) as described earlier [18]. The following parameters were obtained: heart rate (HR), 
stroke volume (SV), cardiac output (CO), end-diastolic volume (EDV) end-systolic volume 
(ESV), ejection fraction (EF), fractional area change (FAC) and area change. Briefly, mice 




platform. Parasternal long axis and short axis images were recorded in all animals. Analysis 
of the data was performed with software provided by VisualSonics. Subsequently, 2 days 
later (at day 15 post MI), LV function was assessed by invasive PV-loops as described earlier 
[18]. Mice were anesthetized with a starting dose of 4% isoflurane and a maintenance dose of 
1.5% isoflurane. After intubation mice were ventilated and the jugular vein was cannulated 
for infusion of hypertonic saline to determine parallel conductance. Via the right carotid 
artery a 1.2F PV catheter (FTS-1212B-4518, Scisense Inc., London, Ontario, Canada) 
was placed into the LV. The catheter was connected to a Scisense ADV signal processor 
(Scisense Inc) to generate high-fidelity pressure and volume signals. Positioning of the 
catheter was guided by online pressure and volume signals. On-line display and acquisition 
of the signals (2000 samples/s) was performed with a PowerLab 8/30 data acquisition system 
and LabChart Pro software (AD Instruments GmbH, Spechbach, Germany). Off-line data 
analysis was performed with custom-made software (CircLab, P. Steendijk). Conversion of 
conductance data to absolute volumes was based on matching conductance derived volumes 
with echocardiographically determined EDV and ESV the same mouse two days earlier. The 
following parameters were measured: heart rate (HR), stroke volume (SV), cardiac output 
(CO), end-diastolic volume (EDV) end-systolic volume (ESV), ejection fraction (EF), end-
diastolic pressure (EDP) and end-systolic pressure (ESP). Stroke work (SW) was determined 
as the area of the PV-loop and the maximal and minimal rate of LV pressure change, dP/
dtMAX and dP/dtMIN, were obtained. Effective arterial elastance (EA) was calculated 
as ESP/SV. Relaxation time tau was calculated as the time-constant of mono-exponential 
pressure decay during isovolumic relaxation. The end-systolic pressure-volume relationship 
(ESPVR) was determined by a single-beat method as previously described and validated 
[19]. Subsequently, the ESPVR was quantified by its slope, end-systolic elastance Ees, and 
the volume intercept at 70 mmHg ESV70.. The end-diastolic pressure-volume relationship 
(EDPVR) was estimated using a single-beat approach as described previously [20]. Briefly, 
the filling phase pressure-volume data (from the point with minimal pressure to the point with 
maximal volume) were fitted with an exponential relation to determine the stiffness constant 
KED (P = A.exp (KED.V). Alternatively, we applied a linear fit to determine end-diastolic 
elastance Eed (P = Po + Eed.V) and the pressure-intercept at 2 µL/g, EDV2
2.5 Myocardial (immuno)histochemistry
Hearts were fixed overnight in para-formaldehyde and cut into five 1 mm-thick slices, 
perpendicular to the long axis of the heart. These slices were flat-embedded in paraffin 
and 5 µm-thick sections were prepared. To delineate LV area and infarct area the lower 3 
sections were stained for collagen with Sirius Red. Total LV wall area (including septum, but 
excluding lumen) and infarct area were measured with cell^D imaging software (Olympus 
Soft Imaging Solutions). The infarct area was expressed as percentage (vol/vol) of the LV 
wall volume. Additionally, sections were immunohistochemically stained for macrophages 
(rat anti-mouse MAC-3, 1:200; BD Biosciences, Erembodegem, Belgium) to count the 
infiltrating macrophages into the myocardium, TLR4 (rabbit anti-human TLR4, 1:150 
SantaCruz, Heidelberg, Germany) to observe presence of TLR4 in the different areas of the 
myocardium, RP105 (rabbit anti-human, 1:250 SantaCruz, Heidelberg, Germany) to verify 
the presence of the accessory molecule in WT mice, and fibronectin-EDA (mouse anti-human 
1:800, Abcam, Cambridge, United Kingdom) whose presence precedes that of collagen and 
serves as an endogenous ligand for TLR4 and is frequently induced upon tissue injury and 
is know to play a role in cardiac remodeling. Images were scored by an observer blinded for 
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the study groups. Per image three specific areas of the myocardium were distinguished: the 
infarcted area, the border zone and the remote, undamaged, healthy myocardium. MAC-3 
staining was analyzed by counting the number of macrophages in three consecutive fields 
of view per specific area. For TLR4, RP105 and fibronectin-EDA stainings were scored in a 
semi-quantitative manner, using zero staining as grade 0, mild to moderate staining as grade 
1 and a profound staining as grade 2. 
2.6 Statistical methods
Significance of differences between the groups was calculated non-parametrically using a 
Mann-Whitney U-test. Difference in survival rate after MI was calculated using a chi-squared 
test. P-values <0.05 were considered statistically significant. SPSS 17.0 for Windows (SPSS, 
Chicago, USA) was used for statistical analysis. Values are presented as means ± SD. 
 
Fig. 1. Schematic model of the TLR4-MD2 and RP105-MD1 complex. Activation of the TLR4-MD2 heterodimer by 
ligand binding results in activation of the intracellular signaling domain thereby initiating a downstream signaling 
cascade (left panel). The formation of the unusual 2:2 homodimer by TLR4-MD2 and RP105-MD1 alters the TLR4 
signaling cascade, whereas RP105 dimerization by itself has no signaling capacity at all as it lacks the intracellular 
Toll Interleukin Receptor (TIR) domain (right panel). Adapted from Otho et al. [27]
Blood samples of WT and RP105-/- mice were diluted 1:25 with RPMI 1640, and incubated overnight with 25 or 50 
ng/mL LPS. Subsequently TNFα levels were measured and expressed as ng/mL. Values represent means ± SD; n=5 




Table 1. Effect of RP105 deficiency TLR4 mediated inflammatory response.  




25 20.0±4.1 ng/mL 108±24 ng/mL* 
50 28.7±7.0 ng/mL 128±25 ng/mL* 
 
Blood samples of WT and RP105-/- mice were diluted 1:25 with RPMI 1640, and incubated 
overnight with 25 or 50 ng/mL LPS. Subsequently TNFα levels were measured and expressed as 






















3.1 Increased inflammatory response in RP105-/- mice after TLR4 stimulation by LPS
To demonstrate whether an increased TLR4 mediated inflammatory response is present in 
RP105-/- mice as compared to WT mice, an ex vivo whole blood stimulation assay was 
performed in the presence and absence of LPS. After an overnight LPS stimulation with 25 
ng/mL and 50 ng/mL LPS, TNFα levels were markedly increased in RP105-/- mice compared 
to WT mice for both concentrations, whereas no significant difference was observed under 
non-stimulated conditions (Table 1). 
3.2 RP105 deficiency does not affect baseline cardiac function 
To determine possible differences in baseline cardiac function between WT and RP105-/- 
mice, echocardiography and pressure-volume loops were measured in animals without MI. 
Since body weight differed between the groups (25.7 ± 0.7 g in WT vs. 28.9 ± 2.7 g in 
RP105-/-, P=0.036) all volumetric parameters were corrected for body weight. Results for 
the main PV loop-derived parameters show no significant differences between the WT and 
the RP105-/- mice (see online data supplement table). These findings indicate that RP105 
deficiency per se does not influence basal cardiac function.
3.3 RP105 deficiency promotes cardiac dilatation after myocardial infarction
To investigate whether RP105 deficiency influences cardiac function after MI, the LAD was 
permanently ligated in 12 WT and 12 RP105-/- mice. No significant difference in survival 
rates was observed (92% in WT vs. 75% in RP105-/-, P=0.273), suggesting that both strains 
were equally able to cope with the severe cardiac damage.
Fifteen days after induction of the MI, functional parameters were obtained by intraventricular 
PV-loop measurements. The results of these analyses are summarized in Table 2. Based on 
mean values for end-diastolic and end-systolic pressures and volumes, average PV-loops 
were created for both groups (Fig. 2). 
Fig. 2. Pressure-volume loops after myocardial infarction. WT and RP105-/- mice underwent ligation of the LAD, 
and 15 days post myocardial infarction pressure-volume loops were recorded in each mouse. Average pressure-







Corresponding end-diastolic and end-systolic PV-relations were added, based on mean EES 
and EED values. These measurements revealed that RP105 deficiency significantly affected 
heart function after MI. Compared with WT mice, RP105-/- mice showed significantly 
higher heart rate (+21% P=0.003), end-systolic volume index (+42%, P=0.038), end-systolic 
pressure (+22%, P=0.021) and lower Tau (-12%, P=0.046). Furthermore a clear tendency for 
a higher end-diastolic volume (+35%, P=0.058) and higher –dP/dtMIN (+24%, P=0.093) was 
observed. Taken together, RP105-/- mice showed more prominent cardiac dilatation after MI, 
but general hemodynamics appeared to be relatively unaffected at this stage.
3.4 RP105 deficiency does not influence infarct size
Then it was investigated whether the enhanced dilatation of the RP105-/- mice could be 
secondary to an increased myocardial infarct size. Directly after the PV-loop measurements, 
15 days after MI, mice were sacrificed and hearts were isolated. Fig. 3 shows representative 
Sirius Red stained cross sections of the infarcted heart. No differences in total LV area were 
observed (27*106 ± 4*106 цM in WT vs 31*106 ± 3*106 цM in RP105-/-, P=0.11) whereas 
the infarct area comprised 12 ± 5% of the total LV in the WT animals versus 16 ± 10% in the 
RP105-/- mice (P=0.53). 
Fig. 3. Left ventricular area and myocardial infarct size in WT and RP105-/- mice. Infarct size was measured by 
Sirius red staining in the two groups of mice and quantified as the area occupied by collagen. Representative cross 
sections, after Sirius Red staining, are shown above the corresponding bars for myocardial infarct size. Each bar 
represent mean ± SD; n= 8-10 per group.
3.5 Structural analysis of the myocardium and infarct area
To investigate potential underlying mechanisms causing the observed differences in cardiac 
function after MI, (immune)histochemical analyses on the myocardium of both groups were 
performed. We focused on inflammatory components in specific areas of the myocardium: 
the infarcted area, the border zone and the remote ‘undamaged/healthy’ myocardium. Fig. 4 
shows representative images of the different stainings for Sirius Red, TLR4, EDA, MAC-3 
and RP105. All stainings showed little to no response in the undamaged myocardium remote 
from the infarct area. An upregulation of TLR4, fibronectin-EDA staining and the number of 
macrophages (Fig. 5) were observed in the area adjacent to the infarcted zone. As expected 
the infarcted area consisted mainly of collagen (scar tissue) and macrophages. No differences 





Table 2. Effect of RP105 deficiency on cardiac function after a myocardial infarction.  
 WT RP105-/- P value 
General    
HR (beats/min) 446±19 538±44 0.003 
SV (µL/g) 0.8±0.3 0.9±0.4 0.490 
CO ((mL/g)/min) 0.4±0.1 0.5±0.2 0.300 
SW (mmHg.(µL/g)) 42±14 57±44 0.916 
Ea (mmHg/(µL/g)) 0.2±0.1 0.1±0.1 0.223 
Ees/Ea 0.7±0.3 0.6±0.3 0.395 
    
Systolic    
ESP (mmHg) 58±9 70±9 0.021 
ESV (µL/g) 1.1±0.7 1.8±0.7 0.038 
EF (%) 43±16 35±10 0.372 
dP/dtMax (mmHg/ms) 5±2 6±2 0.462 
Ees (mmHg/(µL/g)) 48±10 49±27 0.955 
    
Diastolic    
EDP (mmHg) 1±2 2±2 0.293 
EDV (µL/g) 1.9±0.6 2.7±0.9 0.058 
Tau (ms) 11.9±0.9 10.4±1.5 0.046 
-dP/dtMin (mmHg/ms) 4±0.8 5±2 0.093 
Eed (mmHg/(µL/g)) 6±4 5±3 0.721 
Ked (1/(µL/g)) 0.2±0.1 0.1±0.0 0.114 
 
HR, heart rate; SV, stroke volume; CO, cardiac output; SW, stroke work; Ea, arterial elastance 
(afterload); Ees/Ea, ventricular arterial coupling; ESP, end systolic pressure; ESV, end systolic 
HR, heart rate; SV, stroke volume; CO, cardiac output; SW, stroke work; Ea, arterial elastance (afterload); Ees/Ea, 
ventricular arterial coupling; ESP, end systolic pressure; ESV, end systolic volume; EF, ejection fraction; dP/dtMax, 
maximal rate of pressure increase; es, end systolic elastance (slope of ESPVR); EDP, end diastolic p ssure; EDV, 
end diastolic volume; Tau, relaxation time constant; -dP/dtMin, maximal rate op pressure decline; Eed, diastolic 
stiffness (slope of EDPVR); KED, diastolic stiffness constant. Values represent means ± SD; n=8 per group.
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Fig. 4. Typical examples of (immuno)histological stainings for WT mouse (left panel) and RP105-/- mouse (right 
panel), 200x magnification. Images are shown of (A) Sirius Red staining indicating the collagen in the tissue adjacent 
to the MI area (*), (B) TLR4 staining in tissue adjacent to the MI area (*), (C) EDA staining in tissue adjacent to 
the MI area (*), (D) MAC-3 (macrophages) and (E) RP105 staining in tissue adjacent to the MI area (*). All images 
were photographed in sections adjacent to the infarcted area. No differences were observed for Sirius Red, TLR4, 






Fig. 5. Amount of macrophages per specific area of the myocardium in WT and RP105-/- mice.  the infarcted area, 
the border zone and the remote ‘undamaged/healthy’ myocardium Per image three specific areas of the myocardium 
were distinguished per image; the infarcted area, the border zone and the remote, undamaged, healthy myocardium. 
The number of macrophages was in three consecutive fields of view per specific area. Each bar represent mean ± 
SD; n= 8-10 per group.
4. Discussion
The innate immune system, and especially TLRs, plays a pivotal role in the remodeling 
process that is initiated after an MI. Since the role of TLR accessory molecules and especially 
the negative regulator of TLR4, RP105, in cardiovascular disease is still largely unknown, 
we investigated its role in post MI cardiac function and remodeling. Our results show, for the 
first time, that deficiency of the TLR accessory molecule RP105, results in hampered post 
MI repair and subsequently increased cardiac volumes indicated by the right shifted pv-loop 
that corresponds to pv loops found in dilated cardiomyopathy. This causal involvement of 
RP105 in the post MI inflammatory processes provides new opportunities for therapeutic 
approaches to reduce cardiac remodeling and thereby improving cardiac function after a 
myocardial event. 
RP105 was originally identified as a B-cell specific molecule, but turned out to be also present 
on myeloid cells including macrophages and dendritic cells [16, 21]. Since the expression 
of RP105 mirrors that of TLR4, and TLR4 is an important player in the pathophysiology of 
cardiovascular disease processes, we hypothesized that RP105 might be an essential regulator 
in cardiovascular diseases.  In this study we demonstrate that after an MI, RP105 deficiency 
results in an increased ESV and EDV which is associated with a more dilated left ventricle. 
Since infarct size was similar in both groups, this effect suggests that the unaffected healthy 
myocardium of RP105-/- mice is less able to preserve cardiac function after MI as compared 
to WT mice. 
After MI, loss of function in the infarct zone may be compensated by the unaffected 
myocardium, for example by hypertrophy, or by invoking the Frank-Starling mechanism 
via cardiac dilatation. In addition, cardiac output may be maintained by increased heart rate. 
No significant differences in cardiac output were observed between the two groups, but the 
RP105-/- mice showed a more pronounced dilatation and higher heart rate. This suggests 
that the intrinsic myocardial function in the undamaged myocardium was less in these mice, 































This conclusion is supported by the results regarding the ESPVR as shown in Fig. 2. The 
figure illustrates that the differences between the groups do not merely reflect altered loading 
conditions, but changes in intrinsic LV function as well, reflected by a rightward shift of 
the ESPRV. Interestingly, in contrast to the ESPVR which indicates a depressed systolic LV 
function, the downward shift of the EDPVR points towards an improved diastolic function in 
line with the positive effects on Tau, dP/dtMIN and Ked. 
Although macrophages in the infarcted zone are essential for the removal of necrotic tissue 
[22] they may also contribute to cardiac dysfunction by adherence to cardiomyocytes [23]. 
However, as both WT and RP105-/- animals show a comparable density of macrophages in 
the border and infarcted areas, this cannot explain the differences in cardiac function. 
Another factor that may contribute to the observed LV dilatation could be the availability of 
ligands for TLR4. Previously we showed presence of TLR4 and the endogenous TLR4 ligand 
fibronectin-EDA after myocardial infarction resulting in deteriorating effects on cardiac 
remodeling [12, 24]. Similarly, in this study we observed an upregulation of fibronectin-EDA 
in WT mice when the damaged myocardium is compared to the undamaged myocardium. 
This was similar in the RP105 deficient animals showing equal fibronectin-EDA expression. 
We thereby demonstrated that RP105 does not influence local endogenous TLR ligand 
fibronectin-EDA expression. 
In the current study we did not observe any effects of RP105 deficiency on histologic 
parameters. This could be explained by the lack of RP105 expression in the myocardium, 
since RP105 is known to be present on antigen presenting cells (APC) [16] but not on 
cardiomyocytes. APCs are well known to be involved in the cardiac remodeling process
Alternatively it could be that RP105 has no direct signaling capacities. Since RP105 has 
no direct signaling function, but rather acts as a potent inhibitor of TLR4 signaling, it is 
more likely that the effects of RP105 deficiency are due to enhanced TLR4 signaling. In line 
with previously published results of Divanovic et al. [16, 25] we were able to demonstrate 
an enhanced inflammatory response in whole blood in RP105-/- mice. Ex vivo stimulation 
of whole blood samples of RP105-/- mice by the TLR4 ligand LPS resulted in strong 
upregulation of TNFα levels compared to the controls (Table 1), a difference in TNFα levels 
that was not observed under unstimulated conditions. This supports the hypothesis that the 
TLR4 mediated inflammatory response is enhanced by RP105 deficiency. 
RP105 alters TLR4 signaling via the RP105-MD1 complex which forms an unusual 2:2 
homodimer. Two possible mechanisms for signaling inhibition effects on TLR4-MD2 were 
suggested previously; a lateral binding of TLR4-MD2 to the RP105-MD1 complex or the 
formation of TLR4-MD2/RP105-MD1 complexes reminiscent of the usual ligand-induced 
TLR homodimers [26]. Therefore the final effects of same amount of endogenous ligands 
activating TLR signaling, and thereby initiating cardiac remodeling, may have been increased 
due to the lack of RP105. While TLR4 expression in the myocardium was also comparable in 
both groups, this supports the hypothesis that RP105 does not cause its effects in remodeling 
directly via endogenous ligand or modulation of TLR4 receptor expression but probably via 
its previously described alternation of TLR4 signalling. By demonstrating that deficiency 
of the TLR accessory molecule RP105 affects the remodelling process, we reveal that a 
non-signalling extracellular receptor may be a potential target in the prevention of cardiac 
remodelling. 




underlying the TLR4 pathway induced post-infarction healing process. We show that RP105 
deficiency has deleterious effects on cardiac function after a MI compared to WT mice with 
similar infarct size. These results underscore the role of the TLR4-pathway in post-infarction 
remodelling and as a result modulating RP105 may be an interesting new therapeutic strategy. 
To elucidate the exact mechanism further investigations are necessary. 
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Online data supplement table 
Table 1. Baseline cardiac function of WT and RP105-/- mice.  
 WT RP105-/- P value 
General    
HR (beats/min) 587 ± 51 545 ± 79 1.000 
SV (µL/g) 0.7±0.3 0.8±0.3 1.000 
CO ((mL/g)/min) 0.4 ± 0.1 0.4 ± 0.2 0.886 
SW (mmHg.(µL/g)) 69±20 71±19 1.000 
Ea (mmHg/(µL/g)) 0.2±0.1 0.2±0.1 0.486 
Ees/Ea 1.0±0.1 0.9±0.1 0.343 
    
Systolic    
ESP (mmHg) 96 ± 14 90 ± 17 0.686 
ESV (µL/g) 1.0 ± 0.3 0.9 ± 02 0.686 
EF (%) 42.3 ± 5.7  45 ± 10.4  0.686 
dP/dtMax (mmHg/ms) 8.9±1.8 8.0±1.4 0.686 
Ees (mmHg/(µL/g)) 138±57 116±66 0.686 
    
Diastolic    
EDP (mmHg) 6 ± 5 3 ± 3 0.686 
EDV (µL/g) 1.7 ± 0.6 1.7 ± 0.4 1.000 
Tau (ms) 10±3 9±1 1.000 
-dP/dtMin (mmHg/ms) 8±2 7±1 1.000 
Eed (mmHg/(µL/g)) 6±1 8±4 1.000 
Ked (1/(µL/g)) 0.16±0.03 0.09±0.0 0.500 
 
HR, heart rate; SV, stroke volume; CO, cardiac output; SW, stroke work; Ea, arterial elastance (afterload); Ees/Ea, 
ventricular arterial coupling; ESP, end systolic pressure; ESV, end systolic volume; EF, ejection fraction; dP/dtMax, 
maximal rate of pressure increase; Ees, end systolic elastance (slope of ESPVR); EDP, end diastolic pressure; EDV, 
end diastolic volume; Tau, relaxation time constant; -dP/dtMin, maximal rate op pressure decline; Eed, diastolic 
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Abstract
Objective In atherosclerosis Toll like Receptors are traditionally linked to effects on tissue 
macrophages or foam cells. RP105, a structural TLR4 homolog, is an important regulator of 
TLR signaling. The effects of RP105 on TLR signaling vary for different leukocyte subsets 
known to be involved in atherosclerosis making it unique in its role of either suppressing 
(in myeloid cells) or enhancing (in B cells) TLR regulated inflammation in different cell 
types. We aimed to identify a role of TLR accessory molecule RP105 on circulating cells in 
atherosclerotic plaque formation.
Approach and results Irradiated LDLr-/- mice received RP105-/- or wild-type bone mar-
row. RP105-/- chimeras displayed a 57% reduced plaque burden. Interestingly, total and 
activated B-cell numbers were significantly reduced in RP105-/- chimeras. Activation of B1 
B-cells was unaltered, suggesting that RP105 deficiency only affected inflammatory B2 B-
cells. IgM levels were unaltered but anti-oxLDL and anti-MDA-LDL IgG2c antibody levels 
were significantly lower in RP105-/- chimeras, confirming effects on B2 B-cells rather than 
B1 B-cells. Moreover BAFF expression was reduced in spleens of RP105-/- chimeras.
Conclusion RP105 deficiency on circulating cells results in an intriguing unexpected TLR-
associated mechanisms that decrease atherosclerotic lesion formation with alterations on 





Atherosclerosis is characterized by infiltration of circulating leukocytes into the intimal 
area that initiate a local inflammatory response and subsequent atherosclerotic lesion 
formation1. Currently, different subtypes of leukocytes are linked to atherosclerotic lesion 
formation and progression. Both macrophages and T cells are well known contributors to 
atherosclerosis, but also dendritic cells (DCs), mast cells and B cells were more recently 
shown to be involved2, 3. 
Toll Like Receptors (TLR) are major contributors to cardiovascular disease development4-8, 
as they initiate inflammatory responses in both immune and non-immune cells by recog-
nizing pathogen and damage associated molecular patterns (PAMPs and DAMPs respecti-
vely) that can be up regulated upon e.g. tissue damage or cell stress9-11. In atherosclerosis 
TLR function is traditionally linked to its effect on tissue macrophages or foam cells. This 
mechanism is however not fully elucidated12, 13. Mice deficient for TLR4 or its downstream 
adaptor protein Myd88 have reduced atherosclerosis formation14, 15. TLR activation and 
signaling is strongly regulated by a number of accessory molecules16. Activation of TLR4 is 
dependent on the presence of MD2 which is capable of binding LPS and a variety of other 
known endogenous ligands17, 18. Next to MD2, RP105 (CD180) is an important accessory 
molecules acting as a regulator of TLR signalling19-21. RP105 consists of the same extracel-
lular domain as TLR4, but lacks the Toll like Interleukin Receptor (TIR) domain that regu-
lates downstream signaling and has an, for TLR family members, atypical dimeric struc-
ture22. Interestingly the role of RP105 in modulating inflammatory responses depends on 
the cell type making it unique in its role of either enhancing or suppressing TLR regulated 
inflammation in different cell types23. While it functions as an inhibitor of TLR4 signaling 
in myeloid cells such as DCs and macrophages, it enhances TLR4-induced activation in B 
cells24, 25. Both myeloid cells as well as B and T cells are considered to play a major role 
in atherosclerosis and these cell types can all be influenced directly or indirectly via TLR 
signaling and regulation2. Unlike myeloid cells, B cells do not express MD2, representing a 
major difference between their respective TLR4 pathways25-27. In MD2 deficient B cells, the 
RP105/MD1 complex was shown to function as MD2 on these cells25. RP105 cell surface 
expression is strongly influenced by MD1, a structural homolog of MD2 and capable of 
binding lipids in its cavity28, 29. A recent paper by Allen et al. suggested a mechanistic role 
for BAFF expression in B cell proliferation of RP105-/- mice30. Direct and indirect ef-
fects of TLR signaling on adaptive immunity players such as T- and B cells could play an 
important role in enhanced stimulation atherosclerosis development besides their traditional 
role on myeloid cells31. The TLR regulator RP105 may play a very important role in the 
complex TLR pathway mediated atherosclerosis formation by its unique function on dif-
ferent cell types23.
In this study, we investigated the contribution of RP105 deficiency in atherosclerosis by re-
populating lethally irradiated LDLr-/- mice with either wild-type or RP105-/- bone marrow 
and observed that RP105 deficiency led to an unexpected decrease in atherosclerotic plaque 
formation indicating a novel route via which the TLR signaling pathway affects atheroscle-
rosis. 
Material and Methods
For a detailed description of all materials and methods used, see the supplemental material, 
available online at http://atvb.ahajournals.org.
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Results: 
RP105 deficiency ameliorates atherosclerosis
To assess the role of RP105 in atherosclerosis, we generated bone marrow chimeras by 
transplantation of RP105-/- or wild type (WT) bone marrow cells in LDLr-/- mice. Animals 
were allowed to recover for 6 weeks and were subsequently fed a high fat, high cholesterol 
diet (Western Type Diet (WTD), 0.25% cholesterol and 15% cacao butter (SDS, Sussex, 
UK)). RP105 deficiency was assessed by flow cytometry on CD19+ B cells, CD11c+ Den-
dritic cells and CD11b+ monocytes isolated from spleen (Supplemental figure 1) Suscepti-
bility to atherosclerosis in the proximal aortic root of LDLr-/- mice reconstituted with either 
WT or RP105-/- bone marrow was analyzed after 9 weeks WTD feeding. Cryostat sections 
of the proximal aortic root showed reduced Oil-red O staining in the RP105-/- chimera 
transplanted group as compared to the WT transplanted controls. (Figure 1AB). Lesion 
burden in the proximal aortic root was significantly decreased in the RP105-/- chimeras 
(230±26x103μm2 vs 131±15x103μm2, p=0.004) indicating decreased atherosclerosis for-
mation in these mice (Figure 1C). No differences in bodyweight (supplemental figure 2) or 
cholesterol levels (supplemental figure 2) were observed between the WT and the RP105-
/- chimeras. 
Plaque composition 
Next to the observed effects on lesion size we also assessed plaque composition. Intimal 
macrophage area was significantly decreased in RP105-/- chimeras (57.2±8.8x103μm2 vs 




















































































































Figure 1. Atherosclerotic lesion formation is attenuated in RP105-/- chimeras. Hematopoietic deficiency of 
RP105 in atherosclerosis and atherosclerotic plaque composition. LDLr-/- mice were irradiated and subsequently 
received bone marrow from either RP105-/- or wild type (WT) control mice. After recovery LDLr-/- mice received 
a high-fat diet for 9 weeks. A, Atherosclerotic plaques were quantified in the aortic root after Oil Red O staining. 
Representative pictures of Oil Red O-stained plaques from WT (A) and RP105-/- chimeras (B). Initmal lesion area 
was significantly decreased in RP105-/- chimeras (C). Macrophages, collagen content and T cells were visualized 
by MoMa, Trichrome or CD3 respectively. Macrophage content (MoMa+ intimal area (D) and relative macrophage 
content (E). Collagen content (F) and T cell infiltration (intimal (G) and adventitial (H)). Image acquisition was 
performed on a Leica DMRE microscope with Leica DC 500 camera at 50x magnification (5x/0.15 objective). T cells 
were counted manually at 1000x magnification (110x/1.30 oil objective). Black bars represent WT chimeras, white 
bars represent RP105-/- chimeras, n=16, *p<0.05, **p<0.01, ***p<0.001.
Even when correcting the macrophage area for total intimal area we still observed a signi-
ficant 33% decrease (27.6±3.2 vs 18.5±0.9%, p=0.039, Figure 1E and supplemental figure 
2). Collagen content in the plaque was not affected (WT vs RP105-/-; 4.6±0.4 vs. 5.1±0.04 
%, p=0.39, Figure 1F and supplemental figure 2). Immunohistochemical analysis of CD3 
expression as a T-cell marker revealed that T-cell numbers were significantly reduced in 
the intimal (13.6±1.9 cells vs 4.4±0.8 cells, p<0.0001, Figure 1G and supplemental figure 
2) and perivascular area (48.9±15.9 cells vs 32.0±12.4 cells, p=0.0037, Figure 1H) of the 
proximal aortic root in the RP105-/- chimeras.
Decreased B-cell activation in RP105-/- chimeras 
RP105 deficiency is known to result in an increase of pro-inflammatory cytokine production 
by cultured myeloid cells upon LPS administration. Myeloid cells are known to be impor-
tant in atherosclerosis development and contain multiple TLRs. Therefore we analyzed the 
activation status of splenic DC and macrophages in both chimera groups. No difference in 
activation status of DC, (MHC-II and CD40 expression)(Figure 2A), macrophages (CD40 
expression) (figure 2B) or CD4 and CD8 T cells (Figure 2C-D) was found between the 
chimera groups. Since RP105 was originally described to be highly expressed on B cells, 
we also investigated B cells activation. Less IgM+ B cells were detected in the RP105-/- 
chimeras. Concomitantly, a decreased percentage of CD86+ B cells was found, indicative 
of a decreased number of activated B2-cells in the RP105-/- chimeras (Figure 2E). Subtype 
analysis showed no difference in B1-cell number or activation status (Figure 2F).  
Proliferation of splenocytes by LPS is reduced in RP105-/- chimeras
Splenocytes from both chimera groups were stimulated ex vivo with 10 or 100ng/ml LPS 
and proliferation was assessed by [3H]-Thymidine incorporation. Splenocytes from the 
RP105-/- chimeras showed a lower degree of proliferation to LPS (proliferation index 
1.9±0.5 vs. 3.0±1.6 to 10ng/ml LPS and 2.2±0.6 vs. 6.6±3.0 to 100ng/ml LPS, p<0.05) 
(figure 3A). 
RP105 deficient B cells have reduced proliferation and are less activated upon TLR4 
stimulation 
In order to establish if the observed effect on splenocyte proliferation could be B-cell rela-
ted, we isolated CD19+ B cells from WT and RP105-/- mice and exposed these cells to LPS 
and anti-CD40mAb to stimulate B-cell surface receptors. In agreement with earlier obser-
vations, RP105 deficient cells were less responsive to LPS (proliferation index: 22.6±3.7 
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vs. 58.2±7.2 to 100ng LPS, p=0.0001 and 85.7±4.7 vs. 129.7±12.8 to 1µg LPS, p=0.0007), 
but not to anti-CD40mAb stimulation (135.0±0.6 vs. 114.7±18.0, p=0.12, figure 3B). 
The observed decrease in proliferation may reflect altered cell survival, cell cycle progres-
sion or both. Cell cycle progression was then assessed by monitoring CFSE dilution. Loss 
of CFSE fluorescence, indicative of cell division, was measured by flow cytometry on day 
3 and was strongly reduced in the RP105-/- B cells upon LPS stimulation, but not upon 
anti-CD40mAb, indicating a TLR4-specific induction of cell cycle arrest (Figure 3C). B 
cells from RP105-/- mice also produced less IL-6 (supplemental figure 1) and showed less 



























































































































































Figure 2. Decreased B Cell activation in the spleen of RP105-/- chimeras. Splenocytes from LDLr-/- chimeras 
were harvested and analyzed for cell subtype and activation status by flowcytometry. Activation status of CD11c+ 
DCs (identified by high MHCII expression or CD40 expression) (A) and F4/80+ macrophages (identified by CD40 
expression) (B). No difference in CD4 or CD8 T cell activation was observed. Activated CD4+ (C) and CD8+ T 
(D) cell subsets identified by low CD62L or high CD69 expression. B cells were selected as CD19 positive cells. 
Percentage of IgM/CD19 and CD86/CD19 positive cells (E). Percentage of B1-cells expressing IgM or CD86 (F). 




Together, these results indicate that RP105 modulates B-cell function through cell surface 
receptor TLR4 but not CD40.
Altered levels of IgG but not IgM specific antibodies
Plasma IgM and IgG antibody titers against oxLDL and MDA-LDL were determined at 











































Figure 3. Reduced proliferative response to LPS by RP105-/- splenocytes of chimeras. 
Splenocytes derived from LDLr-/- chimeras at sacrifice were with LPS (10 and 100ng/ml) incorperated with 
3H-thymidine stimulated. Proliferative response of splenocytes from chimeras to LPS (A) Black bars represent WT 
chimeras, white bars represent RP105-/- chimeras,  n=6, average of 4 experiments, **p<0.01. 
Reduced proliferative response to LPS by RP105-/- B cells.
CD19+ cells from WT or RP105-/- were stimulated with 100ng/ml LPS, 1µg/ml LPS or αCD40mAb. Proliferative 
response to LPS, and to αCD40mAb (B). Black bars represent WT B cells, white bars represent RP105-/- B cells, 
average of 3 experiments n=4 mice per experiment, ***p<0.001. To count the amount of cell divisions and the 
amount of cells dividing, B cells were incorporated with CFSE. Loss of CFSE fluorescence (indicating cell division 
progression) by B cells from RP105-/- (green line) and WT (filled histogram) mice (C). 
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Figure 4. Reduced oxLDL and MDA-LDL IgG(2c) titers in RP105-/- chimeras.
Antibody titers were measured in plasma by chemiluminescent ELISA. Blood was harvested at sacrifice of the 
chimera hypercholesterolemic LDLr-/- mice. Total IgG against cu-oxLDL (A), IgG2c against cu-oxLDL (B), IgG2c 
against MDA-LDL (C), Total IgM against cu-oxLDL (D), total IgM against MDA-LDL (E) and PC-specific IgM 
T15/EO6 (F). Black bars represent WT chimeras, white bars represent RP105-/- chimeras and data is presented as 































































































































significantly reduced in the RP105-/- chimeras (Figure 4A/C/E). The exact role of IgG 
isotype antibodies is however still under debate32 Interestingly we did not observe dif-
ferences in oxLDL or malondialdehyde-modified LDL (MDA-LDL) specific IgM produc-
tion, indicating effects of RP105 predominately on B2 but not B1a cells. (Figure 4B/D). 
Phosphocholine (PC)-specific IgM T15/EO6, which is a B1a-cell derived natural antibody 
was also not different between the chimera groups, supporting the hypothesis that B1a IgM 
production was not altered and in line with the finding that B1-cell number and activation 
was not affected (figure F). 
Decreased cytokine expression in spleens of RP105-/- chimeras. 
In atherosclerosis increased expression of cytokines in the plaque usually parallels that in 
splenocytes33. mRNA levels of IL6, IP-10, IL12 and IL10 were significantly reduced in 
spleens of the RP105-/- compared to WT chimeras (Figure 5A-D). Even more interesting 
we found a reduced expression of B-cell activating factor (BAFF) in the spleens of the 
RP105-/- chimeras (Figure 5E). These reductions were representative since total numbers 









































































































E Figure 5. Reduced cytokine expression in the spleens of 
RP105-/- chimeras. 
mRNA expression of the cytokines IL6, IP10, IL10, 
p35 and p40 (subunits of IL12) in spleens. Relative 
expression of IL6 (A) IP-10 (B) IL-12 subunits p35 and 
p40 (C), IL10 (D) and BAFF (E) in WT and RP105-/- 
chimeras at time of sacrifice. Black bars represent WT 
chimeras, white bars represent RP105-/- chimeras, WT 
n=10, RP105-/- n=11, *p<0.05, **p<0.01, ***p<0.001.
the groups (supplemental table 1). Interestingly basal BAFF expression in splenocytes of 
normal WT or RP105-/- mice is much lower compared to the chimera groups receiving a 
western type diet. Moreover full body RP105 knockout mice on a normal diet show a trend 
towards higher instead of lower BAFF expression in the splenocytes (P=0.08) compared to 
WT mice (supplemental figure 4).
 
Discussion
In the present study we show that deficiency of the TLR regulator RP105 on circulating 
cells in LDLr-/- mice results in an unexpected 57% reduction in atherosclerotic lesion 
formation. This finding is quite intriguing since the hypothesis thus far was that TLR4 
activation on macrophages stimulates atherosclerotic lesion development, and consequently 
that in the absence of the TLR4 inhibitor RP105 atherosclerotic lesion development would 
be enhanced. Here we show for the first time an unexpected regulation of atherosclerosis 
formation via TLR regulator RP105 with effects on inflammatory B2 B cells and BAFF 
expression but not on myeloid cells. Hereby it shows a novel manner of TLR pathway 
mediated atherosclerosis formation via B cell activation that was stronger than the TLR4 
modulation by RP105 on macrophages. 
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In atherosclerosis TLR function is traditionally linked to its effect on tissue macrophages 
or foam cells. This mechanism is however not fully elucidated. The modulating capacities 
of RP105 on inflammatory responses depend on the cell type making it unique in its role of 
either enhancing or suppressing TLR regulated inflammation in different cell types. In our 
experiments we could notice effects on inflammatory B2 B cells and BAFF expression but 
not on myeloid cells. Although currently the role of B cells in atherosclerosis receives much 
attention, several issues of controversy exist32. Interestingly the crosstalk between TLR 
and B cell receptor signals plays a crucial role in B cell responses to pathogens13. B cells 
are considered to play a major role in the pathophysiology of autoimmune diseases34 and 
during the last decade a number of studies have also indicated an important role for TLRs 
in autoimmunity35. Interestingly, patients with autoimmune-like diseases such as systemic 
lupus erythematosus (SLE) or rheumatoid arthritis (RA) have an increased risk of athero-
sclerotic plaque development36. B cells can affect atherosclerosis development via antibody 
production to modified LDL37. Besides their important role in antibody production, B cells 
are also capable of producing cytokines and thereby can have an additional effector role 
to their regulating role in inflammation. The cytokine producing effector B cells are most 
likely derived from B2 subtype mature follicular B cells, while B1 cells are IgM antibody 
producing cells38. 
We now demonstrate that RP105 deficiency on hematopoietic cells reduced atherosclerotic 
plaque formation with reduced B cell numbers and considerably less activated B cells in 
the RP105-/- mice, as indicated by less CD19+ IgM+ CD86+ cells. CD86 is a B7 family 
member and important for co-stimulation of other cells like T cells39. The effect of RP105 
deficiency on cell number and activation was not observed on B cell subtype B1 cells 
(CD4-, CD5+) and we did consequently not observe effects on the levels of IgM antibodies, 
which are mainly produced by these cells. Our in vitro studies confirmed that RP105 affects 
B2 B cells via modulation of the TLR4 response. LPS, as a TLR4 cell surface stimulator, 
but not anti-CD40, as a CD40 cell surface stimulator, caused multiple effects on B cells. 
The function of RP105 is complex since it has a divergent role on myeloid and B cells16. 
The differential effects of RP105 on myeloid and B cells may be related to the lack of MD2 
in B cells25, 27 and the capability of RP105 to directly cause B-cell activation40. 
Previously, Ait-Oufella and co-workers showed that the atheroprotective effect of CD20+ B 
cell depletion may be due to effects on T cell activation. They showed this mainly depended 
on reduction in IgG-type antibodies and not in IgM-isotype antibody titers 41. In addition 
Kyaw and co-authors showed that B2 B cells may enhance atherosclerosis without presence 
of other inflammatory cells and independent of antibody levels 42. Both depletion studies 
noticed a decrease in macrophages in the plaque while Ait-Oufella et al, also observed a 
reduction in T-cell accumulation41. Our data is in agreement with both studies showing a 
decrease in both T cells and macrophages in the plaque. More recent studies on the mecha-
nism of B cell mediated atherosclerotic plaque formation demonstrated a role for B cell 
activating factor (BAFF) receptor. BAFF is required for B cell maturation and supports the 
survival of self reactive B cells43. BAFF receptor deficiency in bone marrow cells resulted 
in reduced B2 B cells and attenuated atherosclerotic lesion development44. Depletion of 
B2 B cells in BAFF receptor knockout mice inhibited lesion development by ameliorating 
vascular inflammation45. In agreement with these observations, we now found reduced 
expression of BAFF and B2 B cell responses in the RP105-/- chimeras that had less plaque 
formation. Recently modulation of B cell proliferation by RP105 was mechanistically 




splenocytes of full body WT and full body RP105-/- mice on a normal diet. Interestingly 
both chimera groups on a western type diet showed actually much higher BAFF expression. 
In the chimeras however BAFF expression in splenocytes of RP105-/- chimeras was signifi-
cantly lower to WT chimera mice. in splenocytesThis data suggests an association of BAFF 
expression with RP105 which may play an important role in effects seen on atherosclerosis 
in the RP105-/- chimeric LDRr-/-.
Additionally we found a decrease in mRNA expression of cytokines/chemokines such as 
IP-10 in the spleens of the RP105-/- chimeras. In atherosclerosis increased expression of 
cytokines in the plaque usually parallels that in splenocytes and since IP-10 is an important 
T-cell attractant this may partly explain differences in T-cell numbers in the plaque of the 
RP105-/- chimeras33, 46. In contrast hypercholesterolemic mice lacking B cells showed an 
increase in atherosclerosis, an effect attributed to the loss of protective natural IgM antibo-
dies33, 46-49, the opposite effect of the discussed studies that depleted B cells via anti-CD20 
administration41, 42. Lifelong deficiency in B cells will certainly influence (long lived) 
plasma cell formation and antibody production by these cells, and may very well explain 
the different findings in these studies. Specific depletion by anti-CD20 will spare CD20 
deficient long-lived plasma cells. Interestingly autoimmune disease patients treated with 
anti-CD20 humanized antibody (Rituximab) show extended periods of clinical remission 
without reductions in antibody titers50. Particularly in autoimmune settings B cells can 
actively promote atherosclerosis51. Using Rituximab would however be a difficult therapy 
for CVD patients since statins may impair its effect by inducing conformational changes 
on CD2052. This would make new therapeutic targets on B cells such as RP105 even more 
interesting. In addition SLE patients with a history of CVD showed elevated titers of ox-
LDL and malondialdehyde-modified LDL (MDA-LDL) specific IgG antibodies compared 
with other SLE patients without CVD or population controls53. In the RP105-/- chimeras 
we also found a reduction in IgG2c titers against oxLDL and MDA-LDL while IgM levels 
against oxLDL or MDA-LDA were not altered. IgM titers specifically derived from B1a B 
cells were also not altered, thus confirming our results on B1 B cell number and activation 
and thereby indicating the cell specific effects of RP105 via TLR signaling on inflammatory 
type B2 B cells. 
Recently new data suggests that RP105 is expressed in epididymal white adipose tissue 
on stromal vascular fractions and has an important role in the induction of adipose tissue 
inflammation. High fat diet induced obesity, adipose tissue inflammation and insulin resis-
tance are hampered in RP105-/- mice. On long term these processes are associated with hy-
pertension, diabetes and coronary disease54. In our study we did not use full body knockout 
mice but performed bone marrow transfer to LDLR-/- mice. At sacrifice we did not observe 
any difference in body mass of LDLR-/- on a high fat diet that received RP105-/- bone mar-
row cells compared to mice that received WT bone marrow. Therefore effects of insuline 
resistance are not likely to be involved in the effects on atherosclerotic lesion formation we 
observed here. Nevertheless, the protective effects of RP105 deficiency on atherosclerosis 
in our study combined with previously published attenuation of obesity and insulin resis-
tance by RP105 deficiency definitely point out the potential of RP105 as therapeutic target 
for disease processes that are considered to be responsible for the highest morbidity and 
mortality numbers in the western world. 
In conclusion RP105 is an important TLR regulator that influences atherosclerotic plaque 
formation with strong effects on B2 B cells and BAFF expression without directly affecting 
myeloid subsets. This may have strong implications for the role of TLR signaling in athero-
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sclerosis and development of novel therapeutic approaches.
 
Acknowledgements
The authors thank K. Miyake for kindly providing the RP105-/- mice. The authors have no 
conflicting financial interests. This work was performed within the framework of the Dutch 




1. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am 
Coll Cardiol 2009;54:2129-38.
2. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204-12.
3. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. Perivascular mast cells 
promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice Circulation 
2007;115:2516-25.
4. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic 
lesions: a possible pathway for plaque activation. Circulation 2002;105:1158-61.
5. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ, 
Pasterkamp G, Quax PH, de Kleijn DP. Toll-like receptor 4 is involved in outward arterial remodeling. 
Circulation 2004;109:393-8.
6. Karper JC, De Vries MR, van den Brand BT, Hoefer IE, Fischer JW, Jukema JW, Niessen HW, Quax 
PH. Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing 
reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Arterioscler Thromb Vasc Biol 
2011;31:1033-40.
7. Karper JC, Ewing MM, Habets KL, De Vries MR, Peters EA, van Oeveren-Rietdijk AM, de Boer HC, 
Hamming JF, Kuiper J, Kandimalla ER, La MN, Jukema JW, Quax PH. Blocking toll-like receptors 7 
and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and 
migration. Arterioscler Thromb Vasc Biol 2012;32:e72-e80.
8. Vink A, Schoneveld AH, van der Meer JJ, Van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, 
Borst C, Pasterkamp G, de Kleijn DP. In vivo evidence for a role of toll-like receptor 4 in the development 
of intimal lesions. Circulation 2002;106:1985-90.
9. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. 
Nat Immunol 2001;2:675-80.
10. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like 
receptors. Nat Immunol 2010;11:373-84.
11. Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG, Peters JH, Hoefer IE, Doevendans 
PA, Pasterkamp G, de Kleijn DP. Lack of fibronectin-EDA promotes survival and prevents adverse 
remodeling and heart function deterioration after myocardial infarction Circ Res 2011;108:582-92.
12. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in 
atherosclerosis. Clin Chim Acta 2012;413:3-14.
13. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through Toll-
like receptors and antigen receptors. Nat Rev Immunol 2012;12:282-94.
14. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. 
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque 




15. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster 
AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum 
cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004;10:416-21.
16. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008;20:420-5.
17. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, 
Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, Verrier ED. Inhibition of Toll-like receptor 4 with eritoran 
attenuates myocardial ischemia-reperfusion injury. Circulation 2006;114:I270-I274.
18. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO. 
Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007;130:906-
17.
19. Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, Belkaid Y, Madan R, Haky JJ, Karp CL. 
Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J 
Leukoc Biol 2007;82:265-71.
20. Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M. RP105, a novel B cell surface molecule implicated 
in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol 1995;154:3333-40.
21. Miyake K, Ogata H, Nagai Y, Akashi S, Kimoto M. Innate recognition of lipopolysaccharide by Toll-like 
receptor 4/MD-2 and RP105/MD-1. J Endotoxin Res 2000;6:389-91.
22. Yoon SI, Hong M, Wilson IA. An unusual dimeric structure and assembly for TLR4 regulator RP105-MD-1. 
Nat Struct Mol Biol 2011;18:1028-35.
23. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. Nat Rev 
Immunol 2012;12:168-79.
24. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, 
Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Negative regulation of Toll-like receptor 4 signaling by the 
Toll-like receptor homolog RP105. Nat Immunol 2005;6:571-8.
25. Ogata H, Su I, Miyake K, Nagai Y, Akashi S, Mecklenbrauker I, Rajewsky K, Kimoto M, Tarakhovsky 
A. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med 
2000;192:23-9.
26. Nagai Y, Shimazu R, Ogata H, Akashi S, Sudo K, Yamasaki H, Hayashi S, Iwakura Y, Kimoto M, Miyake 
K. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to 
lipopolysaccharide. Blood 2002;99:1699-705.
27. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K. Cutting edge: cell surface 
expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal 
macrophages. J Immunol 2000;164:3471-5.
28. Harada H, Ohto U, Satow Y. Crystal structure of mouse MD-1 with endogenous phospholipid bound in its 
cavity. J Mol Biol 2010;400:838-46.
29. Miyake K, Shimazu R, Kondo J, Niki T, Akashi S, Ogata H, Yamashita Y, Miura Y, Kimoto M. Mouse MD-
1, a molecule that is physically associated with RP105 and positively regulates its expression. J Immunol 
1998;161:1348-53.
30. Allen JL, Flick LM, Divanovic S, Jackson SW, Bram R, Rawlings DJ, Finkelman FD, Karp CL. Cutting 
edge: regulation of TLR4-driven B cell proliferation by RP105 is not B cell autonomous J Immunol 
2012;188:2065-9.
31. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of 
adaptive immune responses. Nat Immunol 2001;2:947-50.
32. Nilsson J, Fredrikson GN. The B cell in atherosclerosis: teaming up with the bad guys? Clin Chem 
2010;56:1789-91.
33. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 
2006;86:515-81.
 172
34. Pillai S, Mattoo H, Cariappa A. B cells and autoimmunity. Curr Opin Immunol 2011;23:721-31.
35. Midwood KS, Piccinini AM, Sacre S. Targeting Toll-like receptors in autoimmunity. Curr Drug Targets 
2009;10:1139-55.
36. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, 
Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon 
G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy 
H, McCarthy T, St PY, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis 
Rheum 2006;54:2550-7.
37. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, Bobik A, Toh BH. B1a B lymphocytes 
are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in 
atherosclerotic lesions. Circ Res 2011;109:830-40.
38. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008;20:332-
8.
39. Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 1999;77:304-
11.
40. Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira 
S, Tedder TF, Tamaki K. CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B 
lymphocytes. Blood 2003;102:1374-80.
41. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van VE, Esposito 
B, Vilar J, Sirvent J, Van SJ, Tedgui A, Tedder TF, Mallat Z. B cell depletion reduces the development of 
atherosclerosis in mice. J Exp Med 2010;207:1579-87.
42. Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, Kehry M, Dunn R, Agrotis A, Tipping P, Bobik A, Toh 
BH. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. 
J Immunol 2010;185:4410-9.
43. MacKay F, Schneider P. Cracking the BAFF code Nat Rev Immunol 2009;9:491-502.
44. Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, Loinard C, Binder CJ, Mallat Z. BAFF 
receptor deficiency reduces the development of atherosclerosis in mice--brief report Arterioscler Thromb 
Vasc Biol 2012;32:1573-6.
45. Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, Tipping P, Bobik A, Toh BH. Depletion 
of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently 
ameliorating arterial inflammation PLoS One 2012;7:e29371.
46. van Wanrooij EJ, de Jager SC, van ET, de VP, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, 
van Berkel TJ, Kuiper J. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL 
receptor-deficient mice. Arterioscler Thromb Vasc Biol 2008;28:251-7.
47. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null 
mice. Arterioscler Thromb Vasc Biol 2002;22:1892-8.
48. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B 
cells of hypercholesterolemic mice. J Clin Invest 2002;109:745-53.
49. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required 
for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 
2009;120:417-26.
50. Sanz I, Anolik JH, Looney RJ. B cell depletion therapy in autoimmune diseases. Front Biosci 2007;12:2546-
67.
51. Zhao M, Wigren M, Duner P, Kolbus D, Olofsson KE, Bjorkbacka H, Nilsson J, Fredrikson GN. 
FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient 
mice. J Immunol 2010;184:2253-60.




L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-
Iwanicka A, Basak GW, Wasik M, Warzocha K, Sinski M, Gaciong Z, Jakobisiak M, Parren PW, Golab 
J. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 
2008;5:e64. 
53. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de FU, Witztum JL, Frostegard 
J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93.
54. Nagai, Y., Y. Watanabe, and K. Takatsu, The TLR family protein RP105/MD-1 complex: A new player in 
obesity and adipose tissue inflammation. Adipocyte, 2013. 2(2): p. 61-6.
Significance 
This is the first paper to provide evidence of RP105 involvement in atherosclerotic plaque 
formation with effects on B2-cells and BAFF expression. We show a previously unknown 
involvement of TLR signaling in B-cell regulation in atherosclerosis indicating a novel 
route via which the TLR signaling pathway affects atherosclerosis. These effects seem to 
be more pronounced than effects of RP105 deficiency on TLR signaling on monocytes/ma-
crophages, a process thought to enhance atherosclerosis. This makes RP105 an interesting 
new therapeutic target and our findings not only identify a novel mediator of atherosclerotic 
plaque formation but may have strong implications for the understanding the underlying 
mechanism of TLR signaling in atherosclerosis and consequently the development of novel 
therapeutic approaches. This might even contribute to the explanation why patients with 
autoimmune diseases are prone to develop more atherosclerosis as in autoimmune settings 
B cells can actively promote atherosclerosis
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Online supplement: Material and methods
Animals
LDLreceptor (LDLr)−/− and RP105−/− mice (on C57BL/6 background) were obtained 
from the local animal breeding facility. WT controls were obtained from Charles River. All 
experimental protocols were approved by the ethics committee for animal experiments of 
Leiden University Medical Center. 
Bone marrow transplantation
To induce bone marrow aplasia, male LDLr−/− recipient mice were exposed to a single 
dose of 9 Gy (0.19 Gy/min, 200 kV, 4 mA) total body irradiation using an Andrex Smart 
225 Röntgen source (YXLON International) with a 6-mm aluminum filter 1 day before the 
transplantation. Bone marrow was isolated by flushing the femurs and tibias of RP105−/− 
and WT mice with PBS. Subsequently, the cell suspension was gently filtered through a 
70µm cell strainer to obtain a single cell suspension (70μm pores, BD Bioscience). Ir-
radiated recipients received 0.5×107 bone marrow cells by tail vein injection. Drinking 
water was supplied with antibiotics (83 mg/liter ciprofloxacin and 67 mg/liter polymyxin B 
sulfate) and 6.5 g/liter sucrose for the first three weeks after irradiation. Thereafter animals 
received normal drinking water ad libitum. After a six week recovery period, animals were 
placed on a Western-type diet containing 0.25% cholesterol and 15% cacao butter (SDS) 
diet for 9 wk and subsequently sacrificed. N=17 WT, N=18 RP105-/-, male mice, 12 weeks 
of age at start of the experiment. 
Flow Cytometry
Spleens were harvested and single-cell suspensions of splenocytes were prepared by 
gently mincing the spleen through a cell strainer (70μm pores, BD Bioscience). Spleno-
cytes were incubated at 4°C with erythrocyte lysis buffer (155mM NH4CL in 10mM Tris/
HCL, pH 7.2) for 5 minutes. Cells were centrifuged for 5 minutes at 1500 rpm, resus-
pended in lysis buffer to remove residual erythrocytes. Cells were washed twice with 
PBS. Cell suspensions were incubated with 1% normal mouse serum in PBS and stained 
for the surface markers CD4, CD5, CD8, CD19, CD11c, CD40, CD62L, CD69, F4/80, 
IgM, MHCII(eBioscience, Vienna, Austria), at a concentration of 0.25 µg Ab/200,000 
cells.1,2,3,4 Subsequently cells were subjected to flow cytometric analysis (FACSCANTO, 
BD Biosciences). FACS data were analyzed with CELLQuest software (BD Biosciences). 
RT-PCR
Total RNA was isolated from the spleens of the WT and RP105-/- chimeras using Tri-
Reagent (Sigma-Aldrich) according to the manufacturer’s protocol. The expression levels 
of IL6, IP10, IL10, p35 and p40 (subunits of IL12) and BAFF were analyzed by real time 
polymerase chain reaction (RT-PCR) (Taqman, Applied Bioscience). The relative mRNA 
expression levels were determined using HPRT and RPL27 as housekeeping gene and the 
2[−ΔΔC(T)] method.
Splenocyte proliferation
Splenocytes were isolated by gently squeezing the spleen over a cell strainer (70μm pores, 
BD Bioscience). Cells were resuspended in RPMI 1640 (supplemented with 10% FCS, 




density of 2x105 cells/well in a 96 wells plate. Cells were stimulated with 10 or 100 ng/ml 
LPS. Cells were incubated with 0.5 μCi [3H]Thymidine during the last 16 hours of 3 days 
in culture. To quantify thymidine incorporation the cells was washed with PBS and lysed 
with 0.1M NaOH and and cell-associated radioactivity was determined by liquid scintilla-
tion counting.
B-cell proliferation
Single-cell suspensions of splenocytes were obtained by mincing through cell strainers, and 
erythrocytes were lysed with ammonium chloride solution. B cells were positively enriched 
by using CD19 MACS microbeads and the MACS system, according to the manufacturer’s 
guidelines (Miltenyi Biotec, Germany). The purity of the isolated cells was verified by 
flow cytometric analysis (>95% CD19). Purified B cells were cultured in IMDM medium 
(Invitrogen Life Technologies, Gaithersburg, MD) supplemented with 10% heat-inactivated 
FCS, L-glutamine, gentamicin, and 5 x 105 M 2-ME. B cells were seeded at 2 x 105 cells/
well in a final volume of 200 µl in 96-well flat-bottom plates and incubated for the indi-
cated time periods at 37°C in a humidified atmosphere containing 5% CO2. Cells were 
stimulated with various concentrations of either LPS (Sigma-Aldrich, St. Louis, MO) or 
anti-CD40 mAb (BD Pharmingen, USA).
Cell cycle analysis
Cell cycle progression was analyzed by flow cytometry using CFSE. B cells (1 × 107) were 
washed three times with PBS, and subsequently CFSE was added to a final concentration of 
5 μM in PBS. After 10 min at 37°C, labeling was stopped by adding 10% FCS-containing 
IMDM and cells were washed twice. CFSE-labeled cells were cultured, as described above, 
with 1 μg/ml LPS or anti-CD40 for 3 days. 
ELISA assays
ELISA assays were performed with cell free supernatant using commercial available kits 
following the instructions of the manufacturer (BD Biosciences). Specific antibody titers 
to given antigens in plasma were determined by chemiluminescent ELISA, as previously 
described32, 33
Histological analysis
Cryostat sections of the aortic root (10 μm) were collected and stained with Oil-red-O 
to determine lesion size. Macrophages were visualized immunohistochemically with an 
antibody directed against a macrophage specific antigen (MOMA-2, monoclonal rat IgG2b, 
dilution 1:50; Serotec, Oxford, UK). Goat anti-rat IgG-AP (dilution 1:100; Sigma, St. 
Louis, MO) was used as secondary antibody and NBT-BCIP (Dako, Glostrup, Denmark) 
as enzyme substrates. Masson’s trichrome staining (Sigma) was used to visualize collagen 
(blue staining). T cells were visualized immunohistochemically with an antibody directed 
against CD3 (CD3). Goat anti–rabbit (dilution 1:100; Sigma-Aldrich) was used as seconda-
ry antibody and Novared (Dako) as enzyme substrates. Histological analysis was performed 
at room temperature, by an independent operator (blinded to specimen identity) using Leica 
DMRE Microscope equipped with a Leica DC 500 camera and with Qwin quantification 
software (Leica, Rijswijk, the Netherlands).
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Statistics
Data are expressed as mean±SEM. A two-tailed Student’s T-test was used to compare indi-
vidual groups. Nonparametric data were analyzed using a Mann-Whitney U test. A level of 
P<0.05 was considered significant. 
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RP105 expression levels on total splenocytes (A), CD19+ B Cells (B), CD11c+ Dendritic Cells (C) and F4/80+ 
macrophages (D) in WT and RP105-/- LDLR-/- chimeras (A). Black bars represent WT chimeras, white bars 
represent RP105-/- chimeras. *p<0.05, **p<0.01, ***p<0.001. n=6 mice per group.
Supplemental table 1: Cellular composition of the spleens of WT and RP105-/- chimeras
 178
Supplemental figure 2 Cholesterol levels (A) and bodyweight (B) for the WT and the RP105-/- LDLR-/- chimeras. 
IL6 production by B cells from RP105-/- and WT mice stimulated with LPS (B). Representative pictures of MoMa2 
macrophage, collagen and CD3 T Cell staining in 5 WT and RP105-/- chimeras (D). Black bars represent WT 




Number of activated B cells from RP105-/- and WT mice stimulated with either LPS or anti-CD40. B cell activation 
measured by the number of CD19/CD86 and CD19/CD25 positive cells. After LPS stimulation; CD19/CD86 cells: 
87.6% (WT) vs 73.6% (RP105-/-) positive cells. CD19/CD25 cells: 71.8% (WT) vs. 55.7% (RP105-/-) positive cells 
after LPS stimulation. After anti-CD40 stimulation; CD19/CD86: 71.3% (WT) vs 68.2% (RP105-/-) positive cells. 
CD19/CD25: 56.5% (WT) vs 54.4% (RP105-/-) positive cells.
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Summary and general discussion:
Background
Atherosclerosis, restenosis and cardiac remodeling after myocardial infarction can cause 
serious clinical problems that greatly contribute to both high morbidity and mortality. In 
all these processes, the inflammatory responses caused by activation of the immune system 
play a very prominent role. This thesis elaborates on the role of specific components of 
the immune system and the therapeutic possibilities that lay hidden therein. This was done 
by focussing on the pathophysiological process in which Damage Associated Molecular 
Patterns (DAMPs) are released upon cell stress and cell death or other tissue damage, and 
may play an important role via different mechanisms. The data in this thesis illustrates 
specific involvement of DAMPs recognizing factors such as Toll-like Receptors in vascular 
remodeling and the therapeutic potential that lies within these findings. 
This thesis
Overall, the aim of this thesis was to investigate the non-pathogenic-induced inflammatory 
response in cardiovascular remodeling with a specific focus on DAMPs and Toll Like 
Receptors. Chapter 1 provides a general introduction on vascular remodeling, involvement 
of the immune system and Toll Like Receptor signalling. 
In this thesis we investigate the pathophysiological processes of vascular remodeling in a pre-
clinical setting. Explorations of these processes require good models that allow involvement 
of e.g. hypercholesterolemia and damage caused by intervention, to mimic the clinical 
setting. This is discussed in Chapter 2 that focus on the various available animal models that 
can be used to study the process of restenosis. Furthermore, it examines the potential of local 
therapy to reduce adverse systemic side effects. These models can also be used to discover 
and study potential biomarkers.
Chapter 3 zooms in on these potential future biomarkers for restenosis. Biomarkers may 
provide tools to monitor disease initiation or progression. The fact that the problems of vascular 
remodeling and restenosis continue to exist, emphasizes the need for specific biomarkers 
to detect pathogenic vascular remodeling, upon which adequate treatment can be initiated. 
The immunogenic reactions leading to cardiovascular remodeling and atherosclerosis 
development are rather complex and therefore require more specific biomarkers to 
adequately evaluate these processes. We discuss a number of possible biomarkers selected 
due to their involvement in the pathophysiological process of restenosis. In this process 
DAMPs, released after cell stress or death or by other forms of tissue damage, seem to play 
an important role and may be recognized by various components of the immune system. 
Examples of DAMPs that can serve as potential biomarkers are Annexin A5, HMGB1, 
HSP60, Tenasin C and Fibronectin-EDA. These DAMPs can be found locally in the damaged 
vessel wall and are known to trigger the immune response directly e.g. via TLR signalling. 
In particular intervention procedures such as PCI may cause cell and tissue damage that will 
lead to enhanced expression of a wide variety of these DAMPs. A distinction in potential 
biomarkers was made between circulating, local and circulating cell-bound markers. Via 
better understanding of the underlying pathophysiological process a more specific biomarker 
selection can take place, which will increase the reliability and applicability of these markers. 
TLR 4 is considered to be an important DAMP recognizer. In Chapter 4 we have in addition 
to previous studies, focused on the possible involvement of Toll-like receptor 4 (TLR4) on 




as Pattern Recognition Receptors (PRR) are important receptors of a large variety of DAMPs. 
We showed that reperfusion of venous segments, of both murine and human origin, gives an 
increase in the expression of TLR4. This was studied ex vivo (in case of the human segments) 
and in vivo using a mouse vein grafting model. Furthermore, the functional involvement of 
TLR4 on intimal hyperplasia and remodeling in vein grafts was demonstrated in mice. In 
addition, it was shown that a fair number of DAMPs, known to act as endogenous ligands 
for TLR4, are present during the remodeling process in the vessel wall of the vein grafts.  It 
is thought that their presence is caused by the vascular injury induced by the intervention 
and vascular distension of the venous segment positioned in the arterial circuit, for they 
are not detected in healthy undamaged vessels. These ligands can activate TLR4, and so 
further enhance the inflammatory response. Finally we provided evidence, via application 
of local gene silencing in hypercholesterolemic mice, that TLR4 can be a local therapeutic 
target to reduce vein graft thickening and remodeling. Other TLRs may also be involved in 
these processes and thereby interesting local therapeutic targets. Some however are located 
intracellular and it unknown if and how they are involved.  
In Chapter 5, we showed validation of a new TLR7 and TLR9 antagonist that did not affect 
other TLRs. TLR7 and 9 were unknown to be involved in vascular remodeling and are 
traditionally linked to inflammation initiated by viral components such as CpG. Our TLR7/9 
blocking compound was capable of inhibiting restenosis and accelerated atherosclerosis in 
hypercholesterolemic mice. Intracellular TLRs such as TLR7 and TLR9 recognize DAMPs 
in the form of self DNA and / or RNA fragments that are frequently released from cells that 
underwent increased cell stress or damage. In this way, these TLRs cause an inflammatory 
reaction in response to released endogenous ligands. The antagonist reduced restenosis by 
minimalizing the infiltration of macrophages, reduced foam cell formation and increased 
production of anti-inflammatory cytokine IL10. Furthermore HMGB1, which can be up 
regulated via TLR9 activation and serves as an enhancer of TLR7 and TLR9 activation was 
reduced in the vessel wall of mice treated with the antagonist. These data suggests that this 
could be a potential future therapy used for the inhibition of post-interventional restenosis. 
Another intracellular and nucleic acid recognizing TLR is TLR3. Chapter 6 focused on the 
effects of TLR3 and downstream signalling mediators on vein graft remodeling. Pathway 
analysis showed that the TLR and type 1 Interferon pathway belonged to the top 15 of 
regulated pathways in vein graft remodeling. TLR3 is the only TLR that solely signals through 
the myd88-independent pathway that causes up regulation of type 1 interferons. Therefore 
TLR3 and important downstream Interferon Regulating Factors (IRF) were studied using 
the same vein graft model. Here TLR3 showed protective effects on vein graft remodeling 
with a decrease of inflammatory cell influx into the vessel wall compared to TLR3-/- mice. 
Interestingly TLRs that are traditionally linked to vascular inflammation such as TLR2 or 
TLR4 do not have these protective effects and TLR4 even enhances the vascular remodeling 
process, which was also previously shown in Chapter 5. Furthermore IRF7 also showed 
strong protective effects on remodeling by decreasing inflammatory cell influx. Since no 
exogenous ligands were used in these studies the data shown in this chapter provides evidence 
that the TLR3 pathway is involved in damage-associated vascular remodeling with effects 
that are uncommon for TLR signalling in vascular remodeling. Recently we know that TLR 
signalling is strongly influenced by co-factors that function as accessory molecules.
Chapter 7 examined the role of the TLR accessory molecule RP105 in the arterial restenosis 
process. RP105 is a receptor homologous to TLR4, but lacks the intracellular portion of the 
protein and is therefore unable to instigate an intracellular signalling cascade by itself. This 
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chapter described the presence of RP105 on smooth muscle cells and functional effects on 
restenosis for the first time. Analysis of the crystal structure showed that RP105 only forms a 
stable protein in the presence of MD1 and that compared to other TLRs, this complex thereby 
formed an unusual protein structure. In addition, we were able by means of ex-vivo whole 
blood stimulation to demonstrate that a soluble form of RP105 combined with the accessory 
molecule MD1 is able to inhibit the TLR4-induced inflammation, and that over-expression of 
this complex in vivo can inhibit restenosis. 
Chapter 8 described the effects of RP105 absence on cardiac function after myocardial 
infarction. Here we showed that RP105 deficiency had no effect on infarct size and no 
significant differences in cardiac output 15 days post-infarction. RP105-/ - mice however 
had a marked left ventricular dilatation and showed an elevated heart rate. This suggests 
that the intrinsic myocardial function of the intact heart muscle was decreased in these 
mice, and therefore a more pronounced need for a post-infarction compensatory response. 
This conclusion was supported by the results with respect to the pressure-volume curves. 
Interestingly, in contrast to indications of a depressed systolic function, the diastolic function 
seemed to be improved. Therefore RP105-/ - mice have a more prominent cardiac dilation 
after MI, but displayed relatively good hemodynamic parameters by adequate compensation.
In chapter 9, we studied the effects of RP105 on atherosclerotic plaque formation in order 
to understand the role of RP105 in the development of atherosclerosis without the strong 
cellular damage induced by PCI or infarction. This chapter described an effect of TLR-
regulator RP105 on atherosclerosis formation. Previously we described a strong increase in 
remodeling in post-interventional remodeling processes such as restenosis and myocardial 
remodeling after infarction in RP105-deficient mice. In this chapter however we noticed 
an intriguing unexpected effect since atherosclerosis formation was hampered in irradiated 
hypercholesterolemic mice that had received RP105 deficient bone marrow. These effects 
could be partly explained by effects noticed on B cell activation and antibody production. For 
the first time, a direct link between TLR involvement in atherosclerosis and B cell activation 
was shown that was not caused by the traditional affiliated TLR cells of the innate immune 
system such as the monocytes/macrophages. Moreover, these results may be important for 
patients with autoimmune disorders such as SLE and Rheumatoid Arthritis (RA), in which 
B cells play an important pathological role in disease progression. These patients also have 
an increased risk of developing heart and vascular disease, thus further emphasizing the 
important role of the immune system in atherosclerosis. 
Supplemental material to chapter 2
Rheumatoid Arthritis (RA) is considered an autoimmune disease for which a variety of 
new drugs have been developed such as Abatacept. Abatacept is a soluble CTLA4 Ig fusion 
protein that acts by blocking T-cell activation via interfering with CD28-CD80/86 the co-
stimulation complex of T cells. This paper offers a closer look at the involvement of T cells 
in the restenosis process and in particular the role of co-stimulation. Reduced neointima 
formation was observed in mice that have no T cells (CD4-/- mice), or that have a disturbed 
T cell co-stimulation pathway (CD80-/-CD86-/- mice). In hypercholesterolemic animals, 
administration of Abatacept led to a reduced neointima formation and inhibition of accelerated 
atherosclerosis. This shows that inhibition of the T cell co-stimulation had a protective effect 
on vascular remodeling even after vascular interventions and could be a potentially beneficial 
side effect for RA patients. During these kind of inflammatory processes many cells are 




or cells that are activated by an inflammatory reaction all express phosphatidylserine (PS) 
on their outer cell surface. Annexin A5 binds to PS and can also be used to demonstrate 
the presence of PS in atherosclerotic plaques. The paper describes the possibilities to use 
Annexin A5 as a therapeutic and as a risk marker of arterial restenosis. In physiological 
conditions, PS remains on the inside of the cellular membrane. When PS appears at the 
outer cell surface it supports platelet binding and activation. This makes PS an interesting 
functional DAMP and therefore a potential therapeutic target. We show that single nucleotide 
polymorphisms of Annexin A5 could be related to an increased risk of restenosis in patients. 
Administration of Annexin A5 to hypercholesterolemic mice has demonstrated that there 
is a reduced leukocyte adhesion, less inflammatory activity, and also less atherosclerosis 
formation in the Annexin A5 treated mice after femoral artery cuff placement. Blocking 
of a DAMP such as PS thus gives promising results in reducing vascular remodelling by 
interfering in the DAMP-induced inflammatory response.
Discussion
The aim of this thesis was to gain insight into the involvement of the immune system in the 
pathophysiological mechanism of vascular remodeling in order to be able to point out new 
potential therapeutic targets. The focus was in particular on the involvement of Damage 
Associated Molecular Patterns (DAMPs), Toll Like Receptors and final application of 
immunomodulation to inhibit adverse remodeling. The results presented in this thesis allow 
us to better understand how vascular remodeling is mediated by inflammation and how 
targeted immunemodulation may have beneficial effects. However, it will take some time 
before this pre-clinical work will be effectively applicable to daily clinical practice, partly 
because immunomodulation may have downside effects such as a decreased resistance to 
pathogens. Therefore it is necessary to apply immunomodulation that is specifically directed 
against a target, which is only possible if there is a proper understanding of the underlying 
pathophysiological mechanism. The discoveries from pre-clinical studies unravel these 
mechanisms and thereby allow us to design novel safe and effective therapies. Nevertheless 
one can only speculate on the future success of these findings for clinical application. However 
the involvement of TLRs and presence of DAMPs as demonstrated in this thesis offer a 
huge therapeutic potential that may even go beyond the process of vascular remodeling. 
Interestingly DAMPs and TLRs are considered to be involved in other diseases as well such 
as cancer and autoimmune diseases. Recently a phase 2 study was successfully completed 
with our TLR7/9 antagonist for the treatment of psoriasis. On the other hand, one should 
consider that apart from beneficial effects on vascular remodeling it is still possible that these 
therapies will initiate or worsen other diseases. Furthermore one should take into account 
that individual TLRs may have different effects. Our finding that TLR3 has an opposite effect 
on vein graft remodeling compared to TLR4, although they share an important signalling 
pathway, is a nice example. Additionally the discovery of various co-factors involved in TLR 
signalling, such as RP105, have made the understanding and interpretation of TLR signalling 
even more complex. Yet these cofactors offer interesting possibilities for therapeutic 
intervention since they regulate TLR signalling. Modulation of the co-factors may therefore 
keep a proper immune balance instead of shutting down a full TLR signalling route. Once 
again, as we show for RP105, the specific underlying disease mechanism should be taken 
into account to understand the results in different models of vascular remodeling. Future 
experiments have to be performed to understand and clarify these intriguing but complex 
findings. Finally it is interesting to focus on DAMPs. If DAMPs present in the plaque, will 
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also be released in the circulation and can be detected in plasma, their levels may be related 
to a particular risk profile and thereby not only function as therapeutic target but as biomarker 
as well. Especially DAMPs are excellent candidates for both indications since they are only 
released in response to tissue or cellular damage. 
Before the results presented in this thesis will lead to adequate therapies to counteract adverse 
vascular remodelling, additional research has to be performed focused on effectiveness and 
safety.
Conclusion:
Endogenous activation of the immune system plays an important role in the post-
interventional vascular remodeling process. The release of DAMPs after vascular damage 
cause activation of Toll-like receptors leading to an inflammatory response that contributes 
significantly to the remodeling process. Multiple DAMPs such as HMGB1 are absent before 
the intervention however they were found highly up regulated locally in the vessel wall after 
intervention indicating a specific relation with the intervention procedure. The presence and 
involvement of a variety of Toll Like Receptors in different models of vascular remodeling 
is interesting since these receptors are considered to be important recognizers of the DAMPs 
locally found in the vessel wall. Different intracellular signalling pathways and TLR 
accessory molecules seem to mediate the outcome of the specific DAMP-TLR interactions 
on vascular remodeling majorly. Protective effects of TLR3 and different outcomes of RP105 
deficiency on vascular remodeling processes indicate the complexity of the underlying 
pathophysiological processes. These results can be partly explained by downstream TLR 
signalling and involvement of specific cell subtypes. The exploration of these underlying 
mechanisms offers new opportunities for biomarker selection and therapy development. A 
good biomarker predicts the amount of damage by the intervention, restenosis risk, disease 
progression or can monitor therapy efficacy. Especially for therapies targeted against TLRs 
one should weigh the risks and benefits since these receptors are considered to be involved 
in many other disease processes and important for host defence against exogenous derived 
pathogens. Nevertheless specifically targeted immunomodulation has the potential of 
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Atherosclerose, restenose en remodeling na myocardinfarct veroorzaken ernstige klinische 
problemen die sterk bijdragen aan zowel een hoge morbiditeit als mortaliteit. In al deze 
processen spelen ontstekingsreacties, veroorzaakt door activering van het immuunsysteem, 
een zeer belangrijke rol. Dit proefschrift gaat in op de rol van specifieke onderdelen van 
het immuunsysteem en de therapeutische mogelijkheden die hierin verborgen liggen. Er 
is gefocust op de pathofysiologische processen waarin Schade Geassocieerde Moleculaire 
Patronen (DAMPs=damage associated molecular pattern) vrijkomen bij cel-stress en celdood 
of andere weefselschade, waardoor ze via verschillende mechanismen een belangrijke rol 
kunnen spelen. De studies in dit proefschrift illustreren ook specifieke betrokkenheid van 
DAMPs herkennende factoren zoals Toll-like Receptoren in vasculaire remodeling en hun 
therapeutisch potentieel.
Dit proefschrift
In het algemeen is het doel van dit proefschrift om de niet-pathogene-geïnduceerde 
ontstekingsreactie in cardiovasculaire remodeling te onderzoeken met een specifieke focus 
op DAMPs en Toll like Receptoren. Hoofdstuk 1 geeft een algemene inleiding op vasculaire 
remodeling, betrokkenheid van het immuunsysteem en Toll Like Receptor signalering.
In dit proefschrift onderzoeken we de pathofysiologische processen van vasculaire remodeling 
in een preklinische setting. Verkenningen van deze processen vereisen goede modellen die 
betrokkenheid toestaan van bijvoorbeeld hypercholesterolemie en schade als gevolg van de 
interventie procedure, om de klinische setting adequaat na te bootsen.
In hoofdstuk 2 wordt ingegaan op de verschillende beschikbare diermodellen die gebruikt 
kunnen worden om het proces van restenose na te bootsen. Bovendien wordt het potentieel 
van lokale therapie besproken waarmee nadelige bijwerkingen van systemische therapie 
verminderd kunnen worden. Deze modellen kunnen ook gebruikt worden om potentiele 
biomarkers te ontdekken en te bestuderen
Hoofdstuk 3 richt zich op deze mogelijk toekomstige biomarkers voor restenose. Biomarkers 
kunnen tools bieden om de ziekte initiatie of progressie te volgen. Het feit dat de problemen 
van vasculaire remodeling en restenose nog steeds bestaan benadrukt de noodzaak van 
specifieke biomarker-selectie om zo pathogene vasculaire remodeling tijdig te detecteren 
zodat adequate behandeling kan worden ingezet. De immunogene reacties die leiden 
tot cardiale-remodeling en tot het ontwikkelen van atherosclerose, zijn tamelijk complex 
en vragen om meer specifieke biomarkers waarmee deze processen adequaat geëvalueerd 
kunnen worden. Een aantal mogelijke biomarkers, geselecteerd vanwege hun betrokkenheid 
bij het pathofysiologische proces van restenose, zijn uitgelicht en besproken. Daarbij lijken 
DAMPs, vrijgegeven na celspanning, celdood of andere vormen van weefselbeschadiging 
een belangrijke rol te spelen en worden ze herkend door verschillende componenten van het 
immuunsysteem. Voorbeelden van DAMPs die kunnen dienen als potentiële biomarkers zijn 
annexine A5, HMGB1, HSP60, Tenasin C en fibronectine-EDA. Deze DAMPs kunnen lokaal 
worden gevonden in de beschadigde vaatwand en staan bekend de immuunrespons direct aan 
te kunnen zwengelen, bijvoorbeeld via TLR-signalering. Vooral interventieprocedures zoals 
Percutane Coronaire Interventie (PCI) kunnen cel en weefselschade geven die leiden tot 
expressie van een groot aantal van deze DAMPs. In potentiële biomarkers werd onderscheid 




beter begrijpen van het onderliggende pathofysiologische proces kan een meer specifieke 
biomarkerselectie plaatsvinden, die de betrouwbaarheid en toepasbaarheid van deze markers 
doet toenemen. TLR4 wordt gezien als een belangrijke DAMP herkenner. 
In hoofdstuk 4 hebben we ons, in aanvulling op eerdere studies, gericht op de mogelijke 
betrokkenheid van Toll-like receptor 4 (TLR4) op intima hyperplasie vorming, remodeling 
en atherosclerose vorming in veneuze bypasses. TLRs als Pattern Recognition Receptors 
(PRR) zijn belangrijke receptoren van een zeer uiteenlopend aantal DAMPs. We tonen aan 
dat reperfusie van veneuze segmenten, van zowel muis als humane oorsprong, een verhoging 
geeft van de expressie van TLR4. Dit is onderzocht ex vivo in humane veneuze vaatsegmenten 
en in vivo in een veneuze bypass muis model. Bovendien is de functionele betrokkenheid van 
TLR4 aangetoond op intimale hyperplasie en remodeling in bypasses in muizen. Tevens is 
aangetoond dat een behoorlijk aantal DAMPs, bekend als endogene liganden voor TLR4, 
aanwezig zijn in de vaatwand van de veneuze grafts gedurende het remodelingsproces. 
De gedachte is dat de aanwezigheid van deze DAMPs wordt veroorzaakt door vasculaire 
schade geïnitieerd door chirurgische interventie en vaatstress door de hogere bloeddruk van 
het arteriële circuit. Dit wordt ondersteund doordat zij niet in gezonde onbeschadigde vaten 
worden gedetecteerd. Deze liganden kunnen TLR4 activeren en dus verdere versterking van 
de ontstekingsreactie initiëren. Tot slot hebben we het bewijs geleverd, via de toepassing 
van lokale gen uitschakeling in hypercholesterolemische muizen, dat TLR4 een lokaal 
therapeutisch doel kan zijn waarmee vaatwandverdikking en remodeling zijn te verminderen. 
Andere TLRs zijn mogelijk ook bij deze processen betrokken en daarmee interessante 
therapeutisch targets. Sommige zitten echter in de cel en het is onduidelijk of en hoe ze 
hierbij betrokken te zijn.
In hoofdstuk 5, tonen we de validatie van een nieuwe TLR7/TLR9 antagonist aan, die 
geen invloed heeft op andere TLRs. TLR7 en 9 zijn niet bekend betrokken te hebben bij 
vasculaire remodeling maar zijn traditioneel verbonden met ontstekingen, geïnitieerd door 
virale componenten zoals CpG. In hypercholesterolemische muizen zien we dat de TLR7/9 
blokkerende verbinding restenose en versnelde atherosclerose kan remmen. Intracellulaire 
TLRs, zoals TLR7 en TLR9, herkennen DAMPs in de vorm van eigen DNA en / of RNA-
fragmenten, die vaak worden vrijgemaakt uit cellen die onder verhoogde celstress staan 
of schade hebben opgelopen. Deze TLRs veroorzaken een ontsteking in reactie op deze 
vrijgegeven endogene liganden. De antagonist verminderd restenose via het minimaliseren 
van de infiltratie van macrofagen, verminderde vorming van schuimcellen en een verhoogde 
productie van het anti-inflammatoire cytokine IL10. Bovendien is de hoeveelheid van HMGB1, 
die als een versterker van TLR7 en TLR9 activatie kan dienen, verminderd in de vaatwand 
van muizen behandeld met de antagonist. Deze hoeveelheid kan tevens worden geregeld via 
TLR9 activatie. De resultaten suggereren dat dit een potentiële toekomstige therapie voor 
de remming van restenose na interventie zou kunnen worden. Een andere  intracellulaire en 
nucleine zuur herkennende TLR is TLR3. Hoofdstuk 6 richt zich op de effecten van TLR3 en 
lager gelegen signalerings mediatoren op veneuze graft remodeling. Pathway-analyse toont 
aan dat de TLR en type 1 interferon pathway tot de top 15 van gereguleerde pathways in 
veneuze graft remodeling behoren. TLR3 is de enige TLR die uitsluitend signaleert via de 
MyD88-onafhankelijke pathway, die regulering van type 1 interferonen veroorzaakt. Om 
deze reden zijn TLR3 en belangrijke downstream Interferon Regulerende Factoren (IRF) 
onderzocht met behulp van hetzelfde bypass model. TLR3 toont aan een beschermend effect 
te hebben op bypass remodeling met afname van de instroom van inflammatoire cellen in de 
vaatwand ten opzichte van TLR3-/- muizen. Interessant genoeg laten TLRs die traditioneel 
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verbonden zijn met vasculaire ontsteking, zoals TLR2 of TLR4, zien niet deze beschermende 
effecten te hebben. TLR4 verbetert zelfs het vasculaire remodeling proces, zoals in hoofdstuk 
4 ook is aangetoond. Verder heeft IRF7 ook sterke beschermende effecten op de remodeling 
door het verlagen van inflammatoire cel instroom. Aangezien er geen exogene liganden zijn 
gebruikt in deze studies, levert dit onderzoek bewijs dat het TLR3 pathway betrokken is bij 
schade-geassocieerde vasculaire remodeling, met effecten die ongewoon zijn voor de eerder 
bekende TLR signalering in vasculaire remodeling. 
Sinds kort weten we dat TLR signalering sterk wordt beinvloed door co-factoren die 
werken als hulpmolecuul in de TLR signalering. In hoofdstuk 7 wordt de rol van het TLR 
hulpmolecuul RP105 beschreven in het arteriële restenose proces. RP105 is een receptor 
homoloog aan TLR4, maar mist het intracellulaire gedeelte van het eiwit en is daarom niet in 
staat om een  intracellulaire signalering cascade uit zichzelf aan te zetten. Voor de eerste keer 
wordt de aanwezigheid van RP105 op gladde spiercellen beschreven en zijn de functionele 
effecten op restenose aangetoond. Uit analyse van de kristalstructuur blijkt dat RP105 slechts 
een stabiel eiwit vormt in aanwezigheid van MD1. Dit is in vergelijking met andere TLRs 
een ongewoon complex. Bovendien hebben we door middel van ex-vivo volbloed stimulatie 
kunnen aantonen dat een oplosbare vorm van RP105 in combinatie met het accessoire 
molecuul MD1 de TLR4-geïnduceerde ontstekingsreactie kan remmen en overexpressie van 
dit eiwit in vivo restenose kan doen verminderen.
In hoofdstuk 8 wordt gekeken naar het effect van RP105 deficiëntie op de hartfunctie na een 
myocard infarct. Hier tonen we aan dat RP105 deficiëntie geen effect heeft op infarctgrootte 
en geen significante verschillen laat zien in hartminuutvolume 15 dagen na het infarct. 
RP105-/- muizen tonen echter een duidelijke linker ventriculaire dilatatie en een verhoogde 
hartslag. Dit suggereert dat de intrinsieke myocardiale functie van de intacte hartspier 
verminderd is bij deze muizen en er derhalve een meer uitgesproken behoefte is aan een 
compenserende respons post-infarct. Deze conclusie wordt ondersteund door de resultaten 
van de druk-volume curven. Interessant is dat in tegenstelling tot vermeldingen van een 
verminderde systolische functie de diastolische functie lijkt te verbeteren. RP105-/- muizen 
hebben derhalve een prominentere cardiale dilatatie na myocard infarct, maar relatief goede 
hemodynamische parameters door adequate compensatie mechanismen.
In hoofdstuk 9 hebben we de effecten van RP105 onderzocht op atherosclerotische 
plaquevorming om inzicht te krijgen in de ontwikkeling van atherosclerose onder invloed 
van RP105 zonder de aanwezigheid van sterke cellulaire schade veroorzaakt door 
bijvoorbeeld een PCI of infarct. Eerder hebben we een sterke toename in remodeling in post-
interventionele remodeling processen beschreven zoals restenose en myocard remodeling na 
infarct in RP105-deficiënte muizen. Echter, we hebben hier een intrigerend onverwacht effect 
bemerkt waarbij atherosclerose vorming wordt geremd in bestraalde hypercholesterolemische 
muizen, die RP105 deficiënt beenmerg hebben ontvangen. Deze resultaten kunnen deels 
worden verklaard door de effecten op B cel activatie en antilichaam productie. Voor het 
eerst is een direct verband aangetoond tussen TLR betrokkenheid bij atherosclerose en B 
cel activatie, die niet werd veroorzaakt door de traditionele gelieerde TLR cellen van het 
aangeboren immuunsysteem, zoals monocyten / macrofagen. Bovendien kunnen deze 
resultaten belangrijk zijn voor patiënten met auto-immuunziekten zoals SLE en reumatoïde 
artritis (RA), waarbij B-cellen een belangrijke pathologische rol spelen in de ziekteprogressie. 
Deze patiënten hebben ook een verhoogd risico op hart-en vaatziekten, waarbij meer nadruk 




Aanvullend materiaal bij hoofstuk 2
Reumatoïde artritis (RA) wordt beschouwd als een auto-immuunziekte waarvoor een 
verscheidenheid van nieuwe geneesmiddelen wordt ontwikkeld, zoals Abatacept. Abatacept 
is een oplosbaar CTLA4-Ig fusie-eiwit dat werkt door het blokkeren van T-celactivering via 
inmenging in de CD28-CD80/86 co-stimulatie van T-cellen. Dit artikel geeft inzicht in de 
betrokkenheid van T-cellen binnen het restenose-proces en in het bijzonder de rol van co-
stimulatie. Verminderde neointima vorming is waargenomen bij muizen die geen T-cellen 
(CD4-/- muizen) hebben en- of  een verstoorde T-cel co-stimulatie aanwezig is (CD80-/-
CD86-/- muizen). In hypercholesterolemische dieren leidt toediening van Abatacept tot 
een verminderde neointimavorming en remming van versnelde atherosclerose. Dit toont 
aan dat de remming van de T-cel co-stimulatie een beschermend effect heeft op vasculaire 
remodeling, zelfs na vasculaire interventies en dit kan potentieel gunstig bijeffect hebben 
voor RA patiënten. 
Tijdens dergelijke ontstekingsprocessen worden er veel cellen geactiveerd of gaan cellen 
dood via apoptose of necrose. Cellen die apoptose of necrose ondergaan of cellen die 
worden geactiveerd door een ontstekingsreactie laten allen expliciete aanwezigheid van 
fosfatidylserine (PS) op hun celoppervlak zien. Annexine A5 bindt aan PS en kan ook worden 
gebruikt om de aanwezigheid van PS aan te tonen in atherosclerotische plaques. In dit artikel 
worden de mogelijkheden beschreven om annexine A5 te gebruiken als therapeutische- en 
als een risicofactor van arteriële restenose. In fysiologische omstandigheden blijft PS aan de 
binnenkant van het celmembraan zitten. Indien PS verschijnt aan het buitenoppervlak van 
de cel dan ondersteunt het de binding en activering van bloedplaatjes. Dit maakt PS tot een 
interessante functionele DAMP en daarmee een potentieel therapeutisch doelwit. We laten 
zien dat bepaalde single nucleotide polymorfismen (SNPs) van annexine A5 kunnen worden 
gerelateerd aan een verhoogd risico op restenose bij patiënten. Toediening van Annexine A5 
aan hypercholesterolemische muizen heeft aangetoond dat er een verlaagde leukocyt adhesie 
is, er een verminderde ontstekingsactiviteit is en ook minder atherosclerose vorming optreedt 
in de annexine A5 behandelde muizen na plaatsing een femorale arteriële cuff. Het blokkeren 
van een DAMP, zoals PS, geeft dus veelbelovende resultaten in het verminderen van 
vasculaire remodeling door zich te mengen in de DAMP-geïnduceerde ontstekingsreactie.
Discussie
Doel van dit proefschrift was om beter inzicht te krijgen in de betrokkenheid van het 
immuunsysteem in het pathofysiologisch  mechanisme van vasculaire remodelling om 
zo nieuwe potentiële therapeutisch targets aan te kunnen wijzen. De focus lag hierbij met 
name op de betrokkenheid van DAMPs, Toll Like Receptoren en de uiteindelijke toepassing 
van immunomodulatie om de ongunstige remodeling te remmen. Met de resultaten in dit 
proefschrift begrijpen we beter hoe vasculaire remodeling door ontsteking wordt beïnvloed 
en hoe hierop gerichte behandelingen gunstige effecten kunnen hebben. Diverse voorbeelden 
zijn hiervan in dit proefschrift terug te vinden. Het zal echter nog wel enige tijd duren voordat 
dit pre-klinische werk daadwerkelijk toegepast zal kunnen worden in de dagelijkse praktijk, 
mede omdat immunomodulatie ook zijn keerzijde kent in de vorm van een afgenomen 
weerstand tegen pathogenen. Daarom zal men zeer specifieke immunomodulatie moeten toe 
passen wat alleen kan indien er goed begrip bestaat van het onderliggende pathofysiologisch 
mechanisme. Het pre-klinisch ontrafelen hiervan is dus van wezenlijk belang om nieuwe 
therapieën veilig en effectief te laten zijn. Over toekomstig succes in de kliniek kan op 
basis van dit proefschrift echter alleen worden gespeculeerd.  De betrokkenheid van TLRs 
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en aanwezigheid van DAMPs zoals aangetoond in dit proefschrift bieden wel een enorm 
therapeutisch potentieel dat mogelijk verder reikt dan alleen vasculaire remodeling. In andere 
ziekteprocessen waarin het immuunsysteem belangrijk is zoals kanker en autoimmuun 
ziekten, lijken TLRs en DAMPs ook van groot belang. Zo is er recent een succesvolle fase 
2 studie afgerond met de door ons gebruikte TLR7/9 antagonist voor de behandeling van 
psoriasis. Aan de andere kant is het mogelijk dat een gunstig effect op bijvoorbeeld vasculaire 
remodeling juist negatieve effecten heeft voor een andere ziekte door deze te initiëren of 
te verergeren. Ook zal men rekening moeten houden met de verschillende effecten van 
individuele TLRs. Zo is onze bevinding dat TLR3 een tegengesteld effect heeft op vein 
graft remodeling in vergelijking met TLR4. Daarnaast heeft de ontdekking van diverse co-
factoren, zoals RP105, die de TLR signalering beïnvloeden, het begrip en interpretatie van 
TLR signalering een stuk complexer gemaakt. Toch bieden deze cofactoren juist interessante 
mogelijkheden voor therapie omdat hiermee niet een heel TLR systeem volledig wordt 
plat gelegd. Immunomodulatie via deze cofactoren kunnen er mogelijk voor zorgen dat 
ontstekingsprocessen via TLR signalering niet doorslaan en in balans blijven. Ook hier zal 
weer rekening gehouden moeten worden met het specifieke onderliggende proces zoals wij 
bijvoorbeeld voor RP105 laten zien. Hoe dit precies werkt is nog niet helemaal duidelijk en 
zal met toekomstige experimenten verder opgehelderd moeten worden. Verder is het voor 
de toekomst interessant om therapie juist op DAMPs te richten. Indien DAMPs, aanwezig 
in de plaque, ook circulerend vrijkomen en in plasma kunnen worden aangetoond kunnen ze 
mogelijk gerelateerd worden aan een bepaald risico en zouden ze naast therapeutisch target 
ook als biomarker kunnen gaan fungeren. Juist DAMPs zijn hiervoor interessant omdat ze 
alleen vrijkomen bij schade geïnduceerde processen. 
Voordat de in dit proefschrift gevonden resultaten tot een adequate therapie leiden om 
ongunstige vasculaire remodeling tegen te gaan, dient er echter nog veel onderzoek naar 
effectiviteit en veilige toepassing te worden gedaan.
Conclusie:
Endogene activering van het immuunsysteem speelt een belangrijke rol in post-interventionele 
vasculaire remodeling. De afgifte van DAMPs na vasculaire schade veroorzaakt activering 
van Toll-like Receptoren hetgeen leidt tot een ontstekingsreactie die sterk bijdraagt  aan het 
remodeling proces. Meerdere DAMPs, zoals HMGB1, zijn afwezig voor een vasculaire 
interventie procedure maar blijken lokaal verhoogd aanwezig te zijn in de vaatwand na een 
ingreep, wat wijst op een specifieke relatie met de interventie procedure. De aanwezigheid 
en betrokkenheid van diverse Toll Like Receptoren in verschillende modellen van vasculaire 
remodeling is interessant omdat deze receptoren belangrijk herkenners zijn van lokale 
DAMPs in de vaatwand. Verschillende intracellulaire signalen en TLR accessoire moleculen 
lijken de uitkomst van de specifieke DAMP-TLR interacties op vasculaire remodeling in 
belangrijke mate te bepalen. Beschermende effecten van TLR3 en verschillende uitkomsten 
van RP105 deficiëntie op vasculaire remodeling geven de complexiteit van de onderliggende 
pathofysiologische processen weer. Deze resultaten kunnen deels worden verklaard door 
downstream TLR signalering en betrokkenheid van specifieke cel subtypes. De verkenning 
van deze onderliggende mechanismen biedt nieuwe kansen voor biomarker selectie en 
ontwikkeling van behandelingen. Een goede biomarker voorspelt de mate van schade door de 
interventie, restenose risico, ziekteprogressie en/of kan de effectiviteit van de therapie volgen. 
Met name bij therapieën, gericht tegen TLRs, moeten de risico’s en voordelen goed worden 




en belangrijk zijn voor afweermechanismen tegen exogene afgeleide pathogenen. Niettemin 
heeft specifieke immunomodulatie het potentieel het pathofysiologische remodelingsproces 
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Abstract
Objective T-cells are central to the immune response responsible for native atherosclerosis. 
The objective of this study is to investigate T-cell contribution to post-interventional 
accelerated atherosclerosis development, as well as the role of the CD28-CD80/86 co-
stimulatory and Cytotoxic T-Lymphocyte Antigen (CTLA)-4 co-inhibitory pathways 
controlling T-cell activation status in this process.
Methods and Results The role of T-cells and the CD28-CD80/86 co-stimulatory and 
CTLA-4 co-inhibitory pathways were investigated in a femoral artery cuff mouse model 
for post-interventional remodeling, with notable intravascular CTLA-4+ T-cell infiltration. 
Reduced intimal lesions developed in CD4-/- and CD80-/-CD86-/- mice compared to normal 
C57Bl/6J controls. Systemic abatacept-treatment, a soluble CTLA-4Ig fusion protein that 
prevents CD28-CD80/86 co-stimulatory T-cell activation, prevented intimal thickening by 
58.5% (p=0.029).
Next, hypercholesterolemic ApoE3*Leiden mice received abatacept-treatment which 
reduced accelerated atherosclerosis development by 78.1% (p=0.040) and prevented CD4 
T-cell activation, indicated by reduced splenic fractions of activated KLRG1+, PD1+, 
CD69+ and CTLA-4+ T-cells. This correlated with reduced plasma interferon-γ and elevated 
interleukin-10 levels. The role of CTLA-4 was confirmed using CTLA-4 blocking antibodies, 
which strongly increased vascular lesion size by 66.7% (p=0.008), compared to isotype-
treated controls.
Conclusions T-cell CD28-CD80/86 co-stimulation is vital for post-interventional accelerated 
atherosclerosis development and is regulated by CTLA-4 co-inhibition, indicating promising 
clinical potential for prevention of post-interventional remodeling by abatacept.
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Introduction
Atherosclerosis is a chronic inflammatory disease in which endothelial dysfunction leads 
to retention of oxidized low-density lipoprotein (oxLDL) cholesterol particles, attracting 
leukocytes and leading to a local inflammatory response[1-3]. T-cell subsets have been shown 
to play a vital role in this process[4, 5]. Unlike native atherosclerosis, their contribution 
to post-interventional remodeling and accelerated atherosclerosis development remains 
uninvestigated. Although local intimal hyperplasia consist predominately of smooth muscle 
cells (SMCs) and connective tissue[6], platelet and leukocyte (e.g. T-cells) adherence and 
activation have been shown to be driving factors behind this overshooting inflammatory 
healing response, leading to re-occlusion[7].
T-cell responses to immunogenic (neo) antigens such as oxLDL cholesterol are regulated 
by antigen recognition signals provided by peptide-MHC antigen complexes on antigen-
presenting cells (APCs) that bind to the T-cell antigen receptor (TCR), which operates 
in concert with co-stimulatory signals. The dominant co-stimulatory receptor CD28 is 
constitutively expressed on resting T-cells, whereas Cytotoxic T-lymphocyte antigen (CTLA)-
4 is a co-inhibitory receptor expressed on activated T-cells[8, 9]. Their ligands CD80 and 
CD86 are upregulated upon activation and predominantly expressed on dendritic cells, B 
cells, and monocytes/macrophages. CTLA-4 is homologous to CD28 and binds CD80-CD86 
with much higher affinity than CD28[10]. During an ongoing immune response, CTLA-4 is 
upregulated and outcompetes CD28 leading to inhibition of T-cell proliferation and reduction 
of interleukin (IL)-2 production[11]. The importance of the CD28/CTLA-4 pathways has 
become evident by generating mice genetically deficient in CTLA-4, which develop fatal 
lymphoproliferative disease with progressive T-cell accumulation in peripheral lymphoid and 
solid organs[12, 13].
Upon stimulation, CD4+ T helper 1 (Th1) effector cells upregulate CD40 ligand and produce 
interferon (IFN)-γ, responsible for pro-atherogenic cellular chemotaxis and macrophage 
activation [3], leading to inflammation. Blocking of CD28-CD80/86 mediated co-stimulation 
by CTLA-4 domain-containing Ig fusion proteins (abatacept), capable of binding CD80/86 
with high-affinity can downregulate T-cell proliferation[14] and production of tumor necrosis 
factor (TNF)-α, IL-2 and IFN-γ in vitro[15]. Abatacept displays little immunogenicity, with 
<3% of patients developing an antibody response towards abatacept[16] and is used to treat 
rheumatoid arthritis (RA) patients[17-19]. Although the T-cell[20, 21] and CD28-CD80/
CD86 co-stimulation[5, 22] roles have been demonstrated in native atherosclerosis, their 
contribution to post-interventional remodeling and accelerated atherosclerosis development 
is unknown, as is the role of CTLA-4. We hypothesized that the CD28-CD80/86 pathway 
is instrumental in post-interventional T-cell-regulated arterial inflammation and that the co-
inhibitory CTLA-4 pathway downregulates these T-cell responses limiting inflammatory-
induced intimal thickening.
In the present study, we studied the role of CD4 T-cells and co-stimulatory cellular activation 
in post-interventional remodeling in both CD4-/- and CD80-/-CD86-/- mice using a well-
established mouse model[7, 23]. CTLA-4 contribution to this process is investigated by 
treating operated C57Bl/6 mice with abatacept. Next, CTLA-4 co-inhibition effects are 
investigated by studying post-interventional accelerated atherosclerosis development in 
hypercholesterolemic ApoE3*Leiden mice after both abatacept treatment and systemic 
CTLA-4 antibody blockade. Our results demonstrate that CD4 T-cells promote post-
interventional atherosclerosis in a CD28-CD80/CD86-dependent fashion and that CD4 
T-cell CTLA-4 co-inhibition regulates accelerated atherosclerosis development and bears 
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high potential for prevention of post-revascularization vascular remodeling.
Methods
The authors of this manuscript have certified that they comply with the Principles of Ethical 
Publishing in the International Journal of Cardiology[24].
Femoral arterial cuff mouse model
All experiments were approved by the Institutional Committee for Animal Welfare of the 
Leiden University Medical Center and the investigations are in conformation with the Guide 
for the Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996). We performed multiple in vivo studies in which 
wildtype (C57Bl/6) control, CD4-/- and CD80-/-CD86-/- mice were subjected to femoral 
artery cuff placement to induce vascular injury and remodeling[7, 23]. Both during surgery 
and sacrifice, mice were anesthetized with a combination of IP injected Midazolam (5 mg/kg, 
Roche), Medetomidine (0.5 mg/kg, Orion) and Fentanyl (0.05 mg/kg, Janssen). This surgery 
produces concentric intimal lesions that affect vessel patency and consist predominately of 
SMCs and connective tissue and is strongly inflammation-dependent[6]. 
Abatacept treatment
Treatment with 10 mg/kg abatacept at the time of surgery through intraperitoneal injection, 
similarly to that used in clinical treatment of RA and in earlier murine studies was given to 
evaluate the role of the CD28-CD80/CD86 co-stimulatory pathway in this process. 
Vascular wall lesion analysis
In these vascular segments, inflammatory cell adhesion, infiltration, intimal thickening and 
lesion composition were assessed using histology, morphometry and immunohistochemistry 
(IHC), as described previously[23]. Samples were stained with hematoxylin-phloxine-
saffron and specific vessel wall composition was visualized for elastin, collagen and with 
antibodies against leukocytes, macrophages, vascular SMCs, CD3 and CD4 T-cells, matrix 
metalloproteinase-9 and CTLA-4. This analysis was repeated in operated hypercholesterolemic 
ApoE3*Leiden mice to assess accelerated atherosclerotic lesion phenotype. 
Flow cytometry 
Leukocyte subsets were characterized using flow cytometry in spleen and draining inguinal 
lymph nodes[25]. These were harvested and single-cell suspensions were prepared by mincing 
the tissue through a 70-µm cell strainer. For cell surface staining, cells were resuspended 
in staining buffer and incubated with fluorescent conjugated antibodies. After washing and 
resuspension in staining buffer, cells were acquired using a BD LSRII flow cytometer and 
data was analyzed using FlowJo software. Cells were stained with fluorochrome-conjugated 
monoclonal antibodies specific for CD3, CD4, CD44, CD25, CD62L CD69, CD127, CTLA-
4, and KLRG1 and staining for intracellular FoxP3 was performed using the FoxP3 staining 
set. 7-AAD was used to exclude dead cells.
Biochemical analysis 
Plasma IFN-γ and IL-10 levels were determined using ELISA were performed according to 
the manufacturer’s instructions and total plasma cholesterol was measured enzymatically. 
Functional CTLA-blockade
CTLA-4 co-inhibition effects on accelerated atherosclerosis development was confirmed 
using anti-CTLA-4 blocking antibodies[11]. Anti-murine CTLA-4 IgG antibodies used 
in this study were isolated from supernatants from the 9H10 hybridoma line. Antibody 
concentration was performed using an artificial kidney and the concentrated antibodies were 
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protein G-purified. CTLA-4 blockade in ApoE3*Leiden mice was induced by injecting 
animals IP with 200 μg of anti-mouse CTLA-4 or control IgG once every 2 days, starting at 
the time of surgery. 
All materials and methods are described in detail in the supplemental material.
 
Results
CD4 T-cells and CD80/86 mediated-co-stimulation are critically involved in post-
interventional vascular remodeling 
To investigate the contribution of CD4 T-cells and the CD28/CTLA-4-CD80/86 pathways 
to vascular remodeling, we placed femoral artery cuffs in control, CD4-/- and CD80-/-
CD86-/- mice and animals receiving abatacept-treatment. Murine body weights were similar 
at surgery and sacrifice (table 1). 21d after surgery lesions were stained with hematoxylin-
phloxine-saffron (HPS) to visualize overall vascular wall morphology (fig 1A), and revealed 
that untreated animals, compared to CD4-/-, CD80-/-CD86-/- and abatacept-treated mice, 
developed concentric intimal thickening leading to luminal stenosis. Weigert’s elastin staining 
was performed to allow morphometric analysis using the elastic laminae to assess vessel 
layer surface area and remodeling. Analysis showed that intimal thickening was reduced by 
72.1% (p=0.006) in CD4-/- ¬¬mice, by 64.2% (p=0.015) in CD80-/-CD86-/- mice and by 
58.5% (p=0.029) in abatacept-treated animals compared to controls (fig 1B). 
Since the total surface area (μm2) of the media was similar in all groups (fig IB), absence 
of CD4 T-cells and CD80/86 co-stimulatory molecules and abatacept-treatment led to 
reduced intima / media ratio with respectively 70.0% (p=0.011), 66.4% (p=0.005) and 
55.3% (p=0.047, fig 1C). Additionally, the percentage luminal stenosis was reduced in these 
groups by 48.7% (p=0.042), 47.7% (p=0.031) and 49.9% (p=0.036) respectively (fig 1D). 
These results indicate a reduced inflammatory-driven remodeling process the injured arterial 
segments. The total vessel and luminal areas (μm2) were not different between all groups (fig 
IA,C). These data indicate an important role of CD4 T-cells and the CD28/CTLA-4-CD80/
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Figure 1. Reduced vascular remodeling in CD4-/- and CD80-/-CD86-/- and abatacept-treated mice. Representative 
cross-sections of cuffed-femoral arteries of CD4-/-CD80-/-CD86-/- and abatacept-treated mice (A) after 21d 
(hematoxylin-phloxine-saffron (HPS) and Weigert’s elastin staining, 80x, arrows indicate internal elastic laminae). 
Quantification of intimal thickening (µm2) (B), intima / media ratio (C) and luminal stenosis (%) (D). Representative 
cross-sections of cuffed-femoral arteries of CD4-/-CD80-/-CD86-/- and abatacept-treated mice (E) after 21d 
(α-SMC actin and Sirius Red collagen staining, 80x). Quantification of relative medial SMC (F) and collagen (G) 
areas (%) and intimal SMC (H) and collagen (I) areas (%). Horizontal bars indicate median values, n=10. * p<0.05, 
** p<0.01.
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CD4-/-, CD80-/-CD86-/- and abatacept-treated mice display an altered lesion composition 
during post-interventional vascular remodeling 
Lesion composition was analyzed using IHC, which showed larger relative areas (to the total 
vessel layer surface area) of α-SMC actin in the media by 15.8% (p=0.028) in CD4-/- and 
16.1% (p=0.028) in abatacept-treated mice (fig 1E), whilst α-SMC actin+ relative area in 
the intima was significantly decreased compared to controls by 31.6% (p=0.001) and 29.3% 
(p=0.019) respectively (fig 1G). Both medial (fig 1H) and intimal (fig 1I) relative collagen 
areas (%) were similar between groups, reflecting absolute α-SMC actin+ and collagen 
areas (μm2) in the media (fig IIA,C). Total α-actin+ SMC area (μm2) in the intima was only 
reduced in CD4-/- mice by 59.7% (p=0.008) whilst collagen area (μm2) remained unchanged 
(fig IIB,D) with limited CD45 leukocyte and CD4 T-cell infiltration in the vascular layers in 
control sections (fig IIE), indicating an indirect but clear effect of CD4 T-cells upon vascular 
SMC proliferation and migration.
legend figure 2; next page
Abatacept prevents accelerated atherosclerosis 
The contribution of the CD28-CD80/CD86 co-stimulatory pathway to accelerated 
atherosclerosis development was tested in a preclinical model of accelerated atherosclerosis 
development in Western-type diet-fed hypercholesterolemic ApoE3*Leiden mice using 
abatacept as therapeutic intervention strategy. Plasma cholesterol concentrations (12.1±3.1 
mmol/L) were similar in all groups throughout this study (table 2). Vehicle and abatacept-
treated ApoE3*Leiden mice were sacrificed 14d after arterial cuff placement and accelerated 
atherosclerotic lesions were stained with HPS to visualize overall vascular morphology (fig 
2A). This revealed that vehicle-treated animals developed concentric intimal thickening and 
luminal stenosis, consisting of connective tissue with profound cellular infiltration which 
was absent in abatacept-treated mice. Quantitative analysis of cuffed arteries stained with 
Weigert’s elastin identified reduced intimal thickening after abatacept treatment with 78.1% 
(p=0.040, fig 2B). Abatacept also decreased absolute medial surface area (μm2) by 22.9% 
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Figure 2. Abatacept prevents accelerated atherosclerosis in hypercholesterolemic mice. Representative cross-
sections of cuffed-femoral arteries of hypercholesterolemic ApoE3*Leiden mice following vehicle or abatacept-
treatment (A) after 14d (HPS and Weigert’s elastin staining, 80x, arrows in inserts indicate internal elastic laminae). 
Quantification of intimal thickening (µm2) (B), medial area (µm2) (C), intima / media ratio (D) and luminal stenosis 
(%) (E). Horizontal bars indicate median values, n=10. * p<0.05.
(p=0.040, fig 2C), and intima / media ratio by 69.5% (p=0.037, fig 2D). Furthermore, luminal 
stenosis percentage was reduced by 48.2% (p=0.021, fig 2E), identifying a potent role for 
CTLA-4 co-inhibition controlling inflammatory post-interventional vascular remodeling. 
The total vessel and luminal areas (μm2) were similar in the abatacept-treated group, although 
a trend towards reduced total vessel area by 34.6% was observed (p=0.094) (fig IIIA, B). 
Abatacept positively affects accelerated atherosclerotic lesion composition
Lesion composition was analyzed using IHC to allow arterial wall inflammatory phenotype 
assessment (fig 3A). Abatacept-treatment produced an altered lesion composition with a 
reduced inflammatory phenotype. Abatacept reduced leukocyte and macrophage/foam cell 
fractions (% of all cells) in the media by 64.0% (p=0.043, fig 3B) and 72.1% respectively 
(p=0.003, fig 3D) and intima by 73.9% (p=0.009, fig 3C) and 30.5% (p=0.048, fig 3E), 
respectively. Abatacept-treatment also led to a comparable medial (p=0.602, fig 3F) and 
29.8% (p=0.042, fig 3G) increased intimal α-SMC actin surface area (%), although absolute 
intimal SMC area (µm2) was not increased (p=0.743, fig IVA), similarly to the tunica media 
(p=0.888, fig IVB). Whereas limited CD3 T-cells and matrix metalloproteinase-9 expressing 
cells could be detected in the tunica intima (fig 3H, I), corresponding with a similar collagen 
quantity in the intima, abatacept reduced these cells in the tunica adventitia by 65.9% 
(p<0.0001, fig 3J) and 64.7% (p<0.0001, fig 3K) respectively. T-cell CTLA-4 and CD4 co-
localized expression was identified using IHC in the injured arterial segments of vehicle-
treated ApoE3*Leiden mice and was absent in uninjured arteries, but occurred 3d after 
surgery and could still be observed 14d after injury, indicating continuing local arterial T-cell 
activation throughout the remodeling process and accelerated atherosclerosis development 
(fig 3L).
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Figure 3 (next page). Abatacept positively affects accelerated atherosclerotic lesion composition.
Representative cross-sections of cuffed-femoral arteries of ApoE3*Leiden mice following vehicle or abatacept-
treatment (A) after 14d (leukocyte, macrophage and α-SMC actin staining, 80x). Quantification of relative medial 
leukocyte (B), macrophage (D) and SMC (F) areas (%) and intimal leukocyte (C), macrophage (E) and SMC (G) 
areas (%) and intimal CD3 (n) (H) and MMP-9 (n) (I), as well as adventitial CD3 (n) (J) and MMP-9 cells (n) 
(K). Horizontal bars indicate median values, n=10. * p<0.05, ** p<0.01. (L) T-cell CTLA-4 and CD4 expression 
throughout the vessel wall of ApoE3*Leiden mice in time before and 3d and 14d after surgery (CTLA-4 and CD4 




















































































































































































































































Abatacept prevents systemic CD4 T-cell activation during accelerated atherosclerosis 
To examine the role of CTLA-4 co-inhibition upon T-cell activation involved in accelerated 
atherosclerosis development, CD4 T-cell numbers and T-cell activation status were assessed. 
The markers Killer cell lectin-like receptor subfamily G member (KLRG)-1, Programmed 
Death (PD)-1, CD69 and CTLA-4 were used to analyze T-cell activation in the splenic 
reservoir and draining inguinal lymph nodes of mice 14d after surgery. 
Absolute CD4 (p=0.557, fig 4A) splenic T-cell numbers were similar in vehicle and 
abatacept-treated mice, as were total splenic cell contents (absolute cells) and percentages 
CD4 T-cell fractions (fig VA,B). Abatacept reduced splenic CD4 T-cells fractions expressing 
CD69 by 61.9% (p=0.008, fig 4B), PD1 by 49.4% (p=0.041, fig 4C), KLRG1 by 47.4% 
(p=0.032, fig 4E), and CTLA-4 by 47.0% (p=0.016, fig 4F). These data indicate that 
abatacept strongly and consistently prevented systemic CD4 T-cell activation, thereby 
reducing accelerated atherosclerotic lesion formation. In contrast to the reduced severity 
of inflammatory vascular remodeling, co-inhibition with abatacept treatment also reduced 
fractions of CD4+CD25+FoxP3+ regulatory T-cells by 33.3% (p=0.016, fig 4H) in the 






































































































memory (CD62L+ CD44+) or effector-memory (CD62L- CD44+) CD4 T-cell populations 
were observed (p>0.05, fig VC-F).
Contrary to significant reduction of activated CD4 T-cells in the spleen after abatacept-
treatment, no evidence of T-cell activation in draining inguinal lymph nodes could be found 
(fig VIA-G), despite adequate cell number isolation for analysis. 
Figure 4. Abatacept prevents systemic CD4 T-cell activation in ApoE3*Leiden mice. Abatacept did not affect total 
CD4 splenic T-cell count (absolute cells) 14d after surgery (A). T-cells were analyzed using multiparametric flow 
cytometry and gated for 7AAD-, CD3+ and CD4+ markers and subsequently for either KLRG1+, PD1+, CD69+, 
CTLA-4+ or CD25+ and FoxP3+ expression and are displayed in dot plots (D and G). Abatacept reduced CD69+ 
(B), PD1+ (C), KLRG1+ (E) and CTLA-4+ (F) activated CD4 T-cell fractions (%), together with CD25+FoxP3+ 




























































































































































































































































































Abatacept affects systemic cytokine levels during accelerated atherosclerosis 
Contribution of activated T-cell fractions to vascular remodeling severity is supported by the 
positive correlation (R2=0.61, p=0.002) between KLRG1+ CD4+ T-cells (%) and intimal 
thickening (μm2) (fig 5A). Interestingly, the ratio between regulatory and effector helper 
T-cells remained unchanged in treated animals (fig 5B). Affected systemic CD4 T-cell 
activation in abatacept-treated mice was investigated by IFN-γ and IL-10 measurements 
in plasma at 14d. Hypercholesterolemic control animals contained an elevated plasma 
concentration IFN-γ of 43.2±12.1 pg/ml, while abatacept-treatment reduced the IFN-γ 
concentration to non-detectable levels (p=0.00023, fig 5C) after vascular injury. In contrast, 
plasma IL-10 was significantly elevated from 4.5±2.0 pg/ml in controls to 23.7±7.1 pg/ml 
(p=0.012, fig 5D) in abatacept-treated mice. Together, these cytokines indicate that abatacept 
reduced systemic inflammation.
Figure 5. Profound CD4 T-cell contribution to post-interventional accelerated atherosclerosis development. (A) 
Positive correlation between KLRG1+ CD4 T-cell fractions (%) and intimal thickening (µm2) (n=6). Abatacept did 
not affect CD4 regulatory T-cell: effector T-cell ratio (B). Plasma IFNγ (pg/ml) was reduced after 14d following 
abatacept-treatment (C), whilst plasma IL-10 (pg/ml) was upregulated (D). Horizontal bars indicate median values, 
n=10. n.d. non-detectable. * p<0.05, ** p<0.01.
CTLA-4 blockade exacerbates accelerated atherosclerosis development. 
To confirm the anti-inflammatory role of CTLA-4 co-inhibition in accelerated atherosclerotic 
lesion development, we analyzed injured femoral lesions of mice undergoing CTLA-4 
blockade using antibodies. HPS staining (fig 6A) revealed that CTLA-4 blocking provoked 
increased accelerated atherosclerosis development and decreased luminal patency. Weigert’s 
elastin staining and morphometric vessel wall analysis confirmed increased intimal thickening 
by 66.7% compared to control mice receiving non-specific anti-β gal IgG (p=0.008, fig 6B). 
Due to a comparable medial area between groups, the intima / media ratio was increased by 
69.3% (p=0.010, fig 6C). Finally, CTLA-4 blockade increased relative luminal stenosis by 





































































































































































































Total vessel and medial areas (μm2) were both not different between groups (fig VIIA,B). 
Together, these results indicate a strong increase of inflammatory induced post-interventional 
vascular remodeling during functional blockade of CTLA-4 function.
Accelerated atherosclerotic lesion phenotype is preserved during CTLA-4 blockade
Lesion composition was analyzed using IHC to assess arterial wall inflammatory phenotype 
(fig VIIIA). Although CTLA-4 blockade enhanced accelerated atherosclerosis development, 
no lesion composition differences were observed compared to controls. There were similar 
leukocyte and macrophage/foam cell fractions (% of all cells) in the media (p=0.414, fig 
VIIIB; p=0.097, fig VIIID, respectively) and intima (p=0.142, fig VIIIC; p=0.769, fig VIIIE, 
respectively). CTLA-4 blockade also led to a comparable medial (p=0.728, fig VIIIF) and 
intimal (p=0.258, fig VIIIG) α-SMC actin surface areas (%). IHC revealed that functional 
CTLA-4 blockade led to a significant increase of CD3+ T-cells (n) in both the tunica intima 
by 200.0% (p=0.0001, fig 6F) and in the tunica adventitia by 241.4% (p=0.0003, fig 6G) 
compared to controls.
 
Figure 6. CTLA-4 blockade exacerbates accelerated atherosclerosis development. Representative cross-sections 
of cuffed-femoral arteries of hypercholesterolemic ApoE3*Leiden mice following isotype antibody or anti-CTLA-4 
IgG-treatment (A) after 14d (HPS, Weigert’s elastin and CD3 staining, 80-160x, arrows in inserts indicate internal 
elastic laminae and CD3+ T-cells). Quantification of intimal thickening (µm2) (B), intima / media ratio (C), luminal 
stenosis (%) (D) and luminal area (µm2) (E). Quantification of intimal CD3 (n) (F) and adventitial CD3 (n) (G) 
cells. Horizontal bars indicate median values, n=10. * p<0.05, ** p<0.01.
Figure 6






















































































































This study demonstrates an important role for T-cell co-stimulation by CD28-CD80/
CD86 and the negative regulator CTLA-4 in post-interventional intimal hyperplasia and 
accelerated atherosclerosis development. We show that CD4-/- and CD80-/-CD86-/- mice 
develop significantly smaller SMC-rich lesions following vascular injury and that infiltrated 
T-cells express CTLA-4 early after surgery. Therapeutic inhibition of CD28-CD80/86 
function by abatacept significantly prevented accelerated atherosclerosis development in 
hypercholesterolemic ApoE3*Leiden mice together with reduced IFN-γ plasma concentration 
(fig 5C), probably due to reduced CD4 T-cell activation. The role of CTLA-4 co-inhibition 
was confirmed using blocking antibodies which led to profound increased vascular lesion 
size. 
The role of CD4 T-cells and CD80/86-mediated co-stimulation during native atherosclerosis 
development[26, 27] has been investigated, but their contribution to post-interventional 
vascular remodeling remained until this study unknown. In ApoE-/- mice, T-cells have 
been shown to be important in early native atherosclerotic lesion progression, but not its 
initiation[27, 28]. We provide evidence for activated CD4 T-cell involvement in the early 
stage of vascular remodeling following intervention. As of yet, it remains to be investigated 
towards which antigen the T-cell response is raised. Nevertheless, this form of accelerated 
atherosclerosis develops within months and in a localized area, opening the perspective for 
(local) T-cell-directed treatment directly after percutaneous coronary interventions. 
CTLA-4 is expressed on activated effector T-cells and constitutively on regulatory T-cells, 
while both CD80 and CD86 are primarily expressed on activated dendritic cells, B cells, 
monocytes/macrophages, which play an important role in native atherosclerosis development 
[4]. T-cell-mediated immune responses are initiated in lymphoid tissues where they are 
activated by APCs presenting two concomitant signals: an antigenic signal provoked by 
specific MHC-antigen peptide complexes that bind to the TCR and a co-stimulatory signal 
induced by CD80 and CD86 molecules that interact with CD28 expressed on all T-cells. 
Together, TCR and CD28 signals lead to an inflammatory and pro-atherogenic response. 
We show that abatacept-treatment was able to prevent this systemic activation by reducing 
the number of activated CD4 T-cells fractions in the spleen as evidenced by the activation 
markers KLRG1, PD1, CD69 and CTLA-4. Since vascular injury occurs locally, profound 
T-cell activation was expected to occur in draining lymph nodes. However, only low fractions 
of activated T-cells were identified in these lymph nodes (fig VIA-G) whilst analysis of 
splenic T-cell fractions revealed significant activation (fig 4A-F). We cannot exclude effects 
of abatacept in other lymph nodes, but these are unlikely to supersede the effects in the 
analyzed primary draining lymph nodes. 
Although abatacept effects on accelerated atherosclerosis are mediated through systemically 
reduced T-cell activation, it is not clear to which extent effects on specific T-cell subsets 
contributed to the lesion development. Buono et al.[22] showed that CD80-/-CD86-/-LDL-
receptor (r)-/- mice developed decreased atherosclerotic lesions compared to LDL-r-/- mice 
through reduced CD4 Th1 cell activation by CD80/86 on APCs. Unlike activated effector 
T-cells, regulatory CD25+ FoxP3+ T-cells constitutively express CTLA-4[29] and this is 
essential for their suppressive function[30, 31]. Ait-Oufella et al.[5] demonstrated the vital 
role of regulatory T-cells in native atherosclerosis development , using irradiated LDL-r-/- 
mice receiving reconstituted bone-marrow from CD80-/-CD86-/- mice which developed 
increased atherosclerotic lesions through strongly reduced splenic fractions of regulatory 
CD25+FoxP3+ T-cells. Therefore, it is possible that abatacept, may have inhibitory effects 
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on accelerated atherosclerosis development through regulatory T-cell activation status 
modulation. However, Platt et al. showed that abatacept prevented effector T-cell activation, 
although effects on regulatory T-cell status in this murine arthritis model were not studied[14]. 
This study shows reduced fractions of both activated Th1 and regulatory T-cells in 
hypercholesterolemic ApoE3*Leiden mice receiving abatacept. Since the Th1: regulatory 
T-cell ratio remained unchanged (fig 5B), this strongly suggests that therapeutic effects of 
abatacept can primarily be attributed to directly reduced activation of Th1 T-cells and not to 
Th1 suppression through regulatory T-cells, reflected by an elevated concentration of IL-10 
(fig 5D) in plasma (baseline 14.4±2.3 pg/ml)[23] and reduced concentration of IFN-γ (fig 
5C) (baseline 9.8±4.6 pg/ml)[23], similarly to that observed following IL-12 vaccination by 
Hauer et al. which downregulated the Th1 immune response and led to attenuation of native 
atherosclerosis development[32]. 
These findings are based upon results from animal studies and cannot be automatically 
extrapolated to the clinical situation. However, they do provide further insight into the role of 
T-cell co-stimulatory pathways when viewed in the light of recent exiting data by Dumitriu 
et al.[33] concerning the role of CD28-/- activated T-cells and regulatory T-cells during acute 
coronary syndromes (ACS) in humans, as well as carotid stenosis[34], unstable angina[35, 
36] and atherosclerosis development in both humans[37] and animals in general[38]. The 
function relevance of CTLA-4 expression for human peripheral T-cell has previously been 
shown by Hoff et al.[39] and Yi-qun et al.[40], in which CTLA-4 blockade was found to 
both determine CD28null T-cell and memory T-cell longevity and responsiveness (e.g. IL-2 
production). The potential of co-stimulatory-based T-cell-directed intervention strategies 
in the clinical situation is further enhanced by the findings of Bluestone et al.[41] and 
Körmendy et al.[42], in which functional CTLA-4 blockade functionally affected circulating 
regulatory T-cells in patients undergoing kidney transplantation and peripheral Th cells in 
rheumatoid arthritis patients. This study demonstrated the effectiveness of modulation of 
co-stimulatory receptors against post-interventional atherosclerotic vascular remodeling in 
mice, thus greatly enhancing the potential of a similar therapeutic approach to improve the 
survival of ACS patients.
In conclusion, this study shows that T-cell co-stimulation through the CD28-CD80/86 
pathway plays a vital role in post-interventional accelerated atherosclerosis development and 
is strongly negatively regulated by CTLA-4 co-inhibition. These results may have important 
clinical implications. Immune-mediated interventions directed towards therapeutically 
controlling the inflammatory T-cell response such as abatacept are widely applied in other 
immune (e.g. rheumatoid) disorders and could now be used in an early phase following 
interventions such as revascularization or bypass grafting procedures in patients to prevent 
subsequent vascular remodeling. This application could be accelerated by the availability of 
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T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influ-
ence accelerated atherosclerosis development
Materials and Methods
Mice
All experiments were approved by the Institutional Committee for Animal Welfare of the 
Leiden University Medical Center (LUMC). Male C57Bl/6J controls, CD4-/- and CD80-/-
CD86-/- mice on a C57Bl/6J background were purchased from the Jackson Laboratory (Bar 
Harbor) and transgenic male ApoE*3-Leiden mice, backcrossed for more than 20 genera-
tions on a C57BL/6J background, were bred in our own laboratory. All animals used for 
this experiment were 10-12 weeks at the start of a dietary run-in period or surgery and were 
weighed before and at the end of the experimental period.
Diets
C57Bl/6J controls, CD4-/- and CD80-/-CD86-/- mice received chow diet and transgenic 
male ApoE*3-Leiden mice were fed a Western-type diet containing 1% cholesterol and 
0.05% cholate to induce hypercholesterolemia to desired levels in male ApoE3*Leiden 
mice (AB Diets). The Western-type diet was given three weeks prior to surgery and was 
continued throughout the experiment. All animals received food and water ad libitum 
during the entire experiment.
Treatment protocol
To investigate the role of CTLA-4 co-inhibition, C57Bl/6J control and ApoE3*Leiden 
animals were injected intraperitoneally (IP) with abatacept (Bristol-Myers Squibb B.V.) in a 
concentration of 10 mg/kg twice monthly (200 μl) or vehicle, starting at the time of surgery. 
CTLA-4 blockade in ApoE3*Leiden mice was induced by injecting animals IP with 200 
μg of anti-mouse CTLA-4 IgG (clone 9H10[1]) or control IgG diluted in 200 μl sterile 
phosphate-buffered saline (PBS) once every 2 days, starting at the time of surgery. 
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Blocking CTLA-4 IgG antibody generation
Anti-murine CTLA-4 IgG antibodies used in this study were isolated from supernatants 
from the 9H10 hybridoma line[1], first using Iscove’s Modified Dulbecco’s Medium 
(IMDM) (Invitrogen) with 8% FCS and 1% glutamine, followed by GIBCO™ protein-free 
hybridoma medium (PFHM)-II (Invitrogen) throughout T75, T175 and roller bottle culture 
systems (Sigma-Aldrich Chemie B.V), maintained at 37°C with 5% CO2. Antibody con-
centration was performed using an artificial kidney (Fresenius Medical Care). The concen-
trated antibodies were protein G-purified (GE Healthcare Bio-Sciences AB) and antibody 
concentrations were determined using a Nanodrop spectrophotometer and stored at 2 mg/ml 
in sterile PBS at -20°C for further use.
Femoral artery cuff mouse model
To investigate the role of CD4 T lymphocytes, CD28-CD80/CD86 co-stimulation and 
CTLA-4 co-inhibition, mice were subjected to arterial femoral arterial cuff placement to 
induce intimal thickening and accelerated atherosclerosis development[2-4]. In brief, mice 
were anesthetized before surgery with a combination of IP injected Midazolam (5 mg/
kg, Roche), Medetomidine (0.5 mg/kg, Orion) and Fentanyl (0.05 mg/kg, Janssen). The 
right femoral artery was isolated and sheathed with a rigid non-constrictive polyethylene 
cuff (Portex, 0.40mm inner diameter, 0.80mm outer diameter and an approximate length 
of 2.0mm). Using two ligatures, the polyethylene cuff was held in place, after which the 
wound was closed using continuous sutures.
Either 14 days (ApoE3*Leiden mice) or 21 days (normocholesterolemic mice) after cuff 
placement, mice were anesthetized as before and euthanized. At sacrifice, venous blood 
was drawn in EDTA collection tubes (Sarstedt B.V.) and subjected to centrifugation (6000 
r.p.m. for 10 min at 4°C) to obtain plasma, which was stored at -20°C for further research. 
The spleen and draining inguinal lymph nodes were isolated and either snap frozen in liquid 
nitrogen for further analysis (stored at -80°C) or minced through a 70-mm cell strainer 
(BD Biosciences) to create single-cell suspensions and stored in 3% fetal calf serum-rich 
GIBCO™ RMPI 1640 medium (Invitrogen) on ice. 
Next, the thorax was opened and mild pressure-perfusion (100mm Hg) with PBS for 4min 
by cardiac puncture in the left ventricle. After perfusion, the cuffed femoral artery was har-
vested, fixed overnight in 3.7% formaldehyde in water (w/v) and paraffin-embedded. Serial 
cross-sections (5 μm thick) were made from the entire length of the artery for analysis.
Biochemical analysis
Total plasma cholesterol (Roche Diagnostics, kit 1489437) concentration was measured 
enzymatically before randomization and at sacrifice. Plasma cholesterol concentrations 
(12.1±3.1 mmol/L) were similar in all groups throughout this study (p>0.15, table 2). To 
investigate effects of abatacept on systemic CD4 T-cell specific activation after surgery, in-
terferon (IFN)-γ and interleukin-10 enzyme-linked immuno sorbent assays (ELISAs) were 
performed (BD Biosciences) according to the manufacturer’s instructions. 
Quantification of cuffed femoral artery lesions
Immunohistochemical (IHC) staining was performed using positive and negative tissue-
specific controls as indicated by the antibody manufacturer. Samples were stained with 
hematoxylin-phloxine-saffron (HPS) and specific vessel wall composition was visualized 
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for elastin (Weigert’s elastin staining), collagen (Sirius Red staining) and with antibodies 
against leukocytes (anti-CD45 antibodies 1:200, Pharmingen), macrophages (MAC3, 1:200, 
BD Biosciences), vascular SMCs (α-SMC actin 1:800, Dako), T-cells (anti-CD3, 1:100, 
AbD Serotec and anti-CD4, 1:250, Abcam), matrix metalloproteinase-9 (anti-MMP-9, 
1:100, Santa Cruz), and CTLA-4 (anti-mouse CTLA-4, 1:200, Abbiotec), using hematoxy-
lin for counterstaining to visualize all cells. The anti-CD4 antibody specificity for CD4 was 
confirmed on cuffed sections of CD4 knock-out mice (21d) (fig IIF).
Sections were deparaffinized by placement in xylene for 5 minutes, followed by ethanol 
100% for 2 minutes, ethanol 70% for 2 minutes and ethanol 50% for 2 minutes and distilled 
water for 2 minutes. Sections underwent citrate buffer antigen retrieval (10mM sodium ci-
trate, pH 6.0) for 10 minutes at 100°C, followed by 30 minutes cooling. PBS (1%) was used 
as a wash solution and for diluting antibodies. Novared (Vector laboratories) was used as 
staining vector according to the manufacturer’s instructions. Sections were dehydrated by 
placement in ethanol 50% for 2 minutes, ethanol 70% for 2 minutes and ethanol 100% for 
2 minutes, followed by xylene for 5 minutes. The slides were mounted with xylene-based 
pertex and 24x60 mm coverslips.
 The number of leukocytes, macrophages and cells expressing CTLA-4 attached to the en-
dothelium, within the neointimal tissue or infiltrated in the medial layer of the femoral arte-
ries was quantified and is displayed as a percentage of the total number of present cells. The 
area containing vascular SMCs, collagen or macrophages was quantified using computer-
assisted morphometric analysis (Qwin, Leica) and is expressed as a percentage of the total 
cross-sectional arterial wall layer area. All quantification in this study was performed on six 
equally spaced (150µm distance) serial stained perpendicular cross-sections throughout the 
entire length of the vessel and was performed by blinded observers.
Flow cytometry 
Spleens and draining inguinal lymph nodes were harvested and single-cell suspensions 
were prepared by mincing the tissue through a 70-µm cell strainer (BD Biosciences). Ery-
throcytes were lysed using hypotonic (0.82%) ammonium chloride buffer. For cell surface 
staining, cells were resuspended in staining buffer (PBS + 3%P PFCS + 0.05% sodium 
azide) and incubated with fluorescent conjugated antibodies at 4C° for 30 minutes in 96-
well plates. After washing and resuspension in staining buffer, cells were acquired using 
a BD LSRII flow cytometer and data was analyzed using FlowJo software (version 7.4.6., 
Tree Star). 
Cells were stained with fluorochrome-conjugated monoclonal antibodies specific for CD3, 
CD4, CD44, CD25, CD62L CD69, CD127, CTLA-4, and KLRG1. All antibodies were 
purchased from eBioscience or BD Biosciences. Staining for intracellular FoxP3 was per-
formed using the FoxP3 staining set from eBioscience (1:200, APC). 7-AAD was used to 
exclude dead cells. 
Statistical analysis
All data are presented as mean± standard error of the mean (SEM). Groups were compa-
red using a Mann-Whitney sum test for non-parametric data. All statistical analyses were 
performed with SPSS 17.0 software for Windows or using Prism software. P-values <0.05 
were regarded as statistically significant and are indicated with an asterisk (*).
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Body weight (gram) of control, CD4-/-, CD80-/-CD86-/- and abatacept-treated (10 mg/kg/twice monthly) C57Bl/6J 
mice at surgery and sacrifice at day 21 (mean±SEM, n=10). No significant differences were observed. 
Body weight (gram) and plasma total cholesterol (mmol/L) of vehicle, abatacept (10 mg/kg/twice monthly), isotype 
control antibody (anti-β gal IgG 200 μg every 2 days) or anti-mouse CTLA-4 IgG (200 μg every 2 days)-treated 
ApoE3*Leiden mice measured at surgery and sacrifice (14 days) (mean±SEM, n=10). No significant differences 
were observed.  
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Figure I. Reduced vascular remodeling in CD4-/- and CD80-/-CD86-/- and abatacept-treated mice. Quantification 
of total vessel area (µm2) (A), medial area (µm2) (B) and luminal area (µm2) (C) after 21 days. Horizontal bars 
indicate median values, n=10.
Figure I
T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 





























































































Figure II. CD4-/-, CD80-/-CD86-/- and abatacept-treated mice display an 
altered lesion composition. Quantification of medial (A) and intimal (B) 
vascular α-SMC actin area (µm2) and medial (C) and intimal (D) collagen 
area (µm2) after 21 days. Representative cross-sections of cuffed-femoral 
arteries of vehicle-treated C57Bl/6J mice (E) after 21d (CD45 leukocyte 
and CD4 T-cell staining, 80-160x). (F) Representative cross-sections of 
cuffed-femoral arteries of CD4 knock-out mice after 21d (HPS and CD4 
















































































































































Figure III. Abatacept prevents accelerated atherosclerosis in hypercholesterolemic ApoE3*Leiden mice. 
Quantification of total vessel area (µm2) (A) and luminal area (µm2) (B) after day 14. Horizontal bars indicate 
median values, n=10.
Figure IV. Abatacept positively affects accelerated atherosclerotic lesion composition. Quantification of total intimal 







































































Figure V. Abatacept prevents systemic CD4 T-cell activation in ApoE3*Leiden mice. Quantification of splenic total 
cell count (*106 cells) (A), CD4 T-cell fractions (%) (B), splenic naïve (CD62L+CD44-) (C) and activated central-
memory (CD62L+CD44+) (D) and effector-memory (CD62L-CD44+) (E) CD3+CD4+ T-cells (%) 14 days after 





























































































































































Figure VI. Abatacept does not affect draining inguinal lymph node T-cell activation status in hypercholesterolemic 
ApoE3*Leiden mice. Quantification of total cell count (*106 cells) (A), total CD4 T-cells (*106 cells) (B), CD4 
T-cell fraction (%) (C), regulatory CD4+CD25+FoxP3+ T-cells (%) (D), activated PD1+ (E), CD69+ (F) and 












































































































































































































Figure VII. CTLA-4 blockade exacerbates accelerated atherosclerosis development in hypercholesterolemic 
ApoE3*Leiden mice. Quantification of total vessel area (µm2) (A) and medial area (µm2) (B), 14 days after surgery. 
Horizontal bars indicate median values, n=10. 
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Figure VIII. Accelerated atherosclerotic lesion phenotype is preserved during CTLA-4 blockade. Representative 
cross-sections of cuffed-femoral arteries of ApoE3*Leiden mice following isotype antibody or anti-CTL A-4 IgG-
treatment (A) after 14d (leukocyte, macrophage and α-SMC actin staining, 80x). Quantification of relative medial 
leukocyte (B), macrophage (D) and SMC (F) areas (%) and intimal leukocyte (C), macrophage (E) and SMC (G) 















































































































































Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent 
fashion. 
Ewing MM, Karper JC, Sampietro ML, de Vries MR, Pettersson K, Jukema JW, Quax PH




Background Activated cells in atherosclerotic lesions expose phosphatidylserine (PS) on 
their surface. Annexin A5 (AnxA5) binds to PS and is used for imaging atherosclerotic lesions. 
Recently, AnxA5 was shown to inhibit vascular inflammatory processes after vein grafting. 
Here, we report a therapeutic role for AnxA5 in post-interventional vascular remodeling in a 
mouse model mimicking percutaneous coronary intervention (PCI).
Methods and Results Associations between the rs4833229 (OR=1.29 (CI 95%), pallelic=0.011) 
and rs6830321 (OR=1.35 (CI 95%), pallelic=0.003) SNPs in the AnxA5 gene and increased 
restenosis-risk in patients undergoing PCI were found in the GENDER study. To evaluate 
AnxA5 effects on post-interventional vascular remodeling and accelerated atherosclerosis 
development in vivo, hypercholesterolemic ApoE-/- mice underwent femoral arterial cuff 
placement to induce intimal thickening. Dose-dependent effects were investigated after 3 
days (effects on inflammation and leukocyte recruitment) or 14 days (effects on remodeling) 
after cuff placement. Systemically administered AnxA5 in doses of 0.1, 0.3 and 1.0 mg/
kg compared to vehicle reduced early leukocyte and macrophage adherence up to 48.3% 
(p=0.001) and diminished atherosclerosis development by 71.2% (p=0.012) with a reduction 
in macrophage/foam cell presence. Moreover, it reduced the expression of the endoplasmic 
reticulum stress marker GRP78/BiP, indicating lower inflammatory activity of the cells 
present. 
Conclusions AnxA5 SNPs could serve as markers for restenosis after PCI and AnxA5 
therapeutically prevents vascular remodeling in a dose-dependent fashion, together indicating 
clinical potential for AnxA5 against post-interventional remodeling.
Keywords
Atherosclerosis, restenosis, inflammation, annexin A5, genetics
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Introduction 
Post-interventional vascular remodeling and accelerated atherosclerosis development are 
important complications of revascularization strategies and limit treatment success rate 
(1). These features are elicited by endothelial and atherosclerotic plaque injury, triggering 
inflammatory activation and leukocyte recruitment to the injured arterial segment. These 
cells are the driving factors behind smooth muscle cell (SMC) proliferation and extracellular 
matrix deposition leading to intimal hyperplasia. Subendothelial retention and oxidation 
of low-density lipoprotein (LDL) cholesterol is central to the initial lesion formation in 
both native atherosclerosis and restenosis development (2,3). Recently, it was postulated 
that endoplasmic reticulum (ER) stress, leading to the unfolded protein response (UPR), 
is involved in the regulation of inflammation in activated vascular cells and the link 
between UPR and arterial inflammation is emerging as an important factor in (accelerated) 
atherosclerosis development (4-7). 
AnxA5 is a member of the annexin family of proteins that calcium-dependently bind to 
negatively-charged phospholipid surfaces and was originally discovered as an anticoagulant 
and antithrombotic protein (8-11) and has been shown to inhibit the prothrombinase complex 
(12) and to down-regulate the surface expression of tissue factor (13). It is now known to 
have anti-inflammatory and anti-atherosclerotic properties (14,15) and to regulate interferon γ 
signalling (16). Viable cells express phosphatidylserine (PS) on their inner cellular membrane 
leaflet. When PS is externalized, it serves as an ‘eat-me’ signal. Annexin A5 (AnxA5) binds 
reversibly, specifically and with high affinity to PS (15). PS becomes externalized during 
apoptosis, which makes AnxA5 a powerful tool to detect apoptosis (and atherosclerosis) both 
in vitro and in vivo (17). PS is expressed in native atherosclerosis and after revascularisation 
procedures, and circulating AnxA5 binds with high affinity to these cells, and is therefore 
present in high concentrations in atherosclerotic plaques and injured vascular segments. PS 
externalization is normally thought to be associated to apoptosis, but can also be externalized 
in a controlled and reversible way in non-apoptotic cells (18,19). 
Plasma levels of AnxA5 are inversely related to the severity of coronary stenosis and are 
indicative of the extent of atherosclerotic plaques (20), but are also elevated in subjects 
with left ventricular hypertrophy and following myocardial infarction (21,22). It was 
recently shown that systemically administered AnxA5 can prevent vein graft disease and 
vascular inflammation (23) and that the dimer of annexin A5, diannexin, can protect against 
renal ischemia-reperfusion injury and inflammatory cell infiltration into transplanted islet 
grafts (24,25). Patients with hypercholesterolemia and previous coronary heart disease 
(CHD) undergoing PCI for atherosclerosis are most at risk for inflammatory-driven post-
interventional restenosis development. The risk for development of restenosis may partially 
be determined by genetic factors. It has been shown that genetic variations in genes encoding 
inflammatory factors (SNPs) can predict the risk for restenosis after percutaneous coronary 
intervention (PCI) (26). The effects of genetic variation in the AnxA5 gene on clinical 
restenosis after PCI or cardiovascular disease progression have thus far not been elucidated.
In the present study we investigated the association between AnxA5 SNPs and restenosis-risk 
in patients undergoing PCI, followed by in vivo evaluation of the therapeutic effectiveness 
of AnxA5 in a humanized mouse model for post-interventional vascular remodeling using 
ApoE3*Leiden mice. Our findings point to a potential diagnostic and therapeutic clinical role 
for AnxA5 against post-PCI vascular remodeling.
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Materials and Methods
Association between single nucleotide polymorphisms (SNPs) in the AnxA5 gene, extracted 
from the GENDER genome wide association study (GWAS) dataset (27) and restenosis-risk 
following PCI was investigated. 
We performed in vivo intervention studies in which hypercholesterolemic ApoE-/- mice on a 
Western-type diet were subjected to femoral artery cuff placement to induce vascular injury 
and remodeling (28). Cuff placement leads to a localized vascular inflammation, which in 
turn produces concentric intimal lesions that can affect vessel patency. The lesions consist 
of SMCs, connective tissue and infiltrated leukocytes such as macrophages / foam cells 
and are strongly inflammation-dependent (29). In these vascular segments, inflammatory 
cell adhesion, infiltration, intimal thickening and lesion composition were assessed using 
histology, morphometry and immunohistochemistry (IHC), as described previously (29). 
Treatment with vehicle, 0.1, 0.3 and 1.0 mg/kg AnxA5 was given to operated ApoE-/- mice. 
A three day protocol was used to evaluate effects on leukocyte recruitment, and a 14 day 
protocol to evaluate effects on vascular remodeling.  All materials and methods are described 
in detail in the supplemental material.
Results
Annexin A5 SNP as risk marker for clinical restenosis
AnxA5 plasma levels are linked to the severity of coronary stenosis and AnxA5 is a marker 
of cardiovascular disease progress. These data indicate a potential role of AnxA5 in (post-
interventional) accelerated atherosclerosis development. Therefore we investigated the 
association between AnxA5 SNPs and restenosis risk in patients undergoing PCI enrolled in 
the GENDER study, composed of 866 patients (295 cases that developed restenosis following 
PCI and 571 controls that did not develop restenosis). Clinical outcome was linked to genetic 
data obtained through a genome-wide association analysis. 
The allelic association test identified two SNPs, rs4833229 and rs6830321, which are 
significantly associated with restenosis risk after PCI (fig 1A). Both SNPs increased the 
risk for restenosis (rs4833229, odds ratio (OR) =1.29, (95% confidence interval (CI) 1.06-
1.58), pallelic=0.011 and rs6830321, OR=1.35 (95% CI 1.10-1.64), pallelic=0.003), even after 
adjustment for clinical risk factors, such as total occlusion, diabetes, smoking and residual 
stenosis (table 1). The minor allele frequencies for cases and controls from the GENDER 
population are 0.481 and 0.418 for rs4833229 and 0.510 and 0.436 for rs6830321 respectively, 
indicating they are present in a large proportion of the population. The AnxA5 gene linkage 
disequilibrium (LD) plot shows that rs4833229 and rs6830321 are in high LD (r2=0.91, fig 
1B). Haplotype analysis in the gene showed similar association results with restenosis as 
found in the single SNP analysis (haplotype ACAGTTGTT, frequency: 0.427, OR=1.275, 
p=0.018). These data link AnxA5 SNPs to restenosis-risk after PCI and suggest that AnxA5 
genotype functions as risk marker for restenosis. We therefore further explored AnxA5’s 
therapeutic potential using an in vivo model for restenosis and intimal hyperplasia.
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Annexin A5 dose-dependently prevents leukocyte recruitment after vascular injury 
Effects of AnxA5 on leukocyte recruitment to injured arterial segments was investigated in 
the femoral artery cuff model in ApoE-/- mice receiving daily vehicle or 0.1, 0.3 or 1.0 mg/
kg AnxA5 through IP injection. Total plasma cholesterol was not affected by annexin A5 
Figure 1. AnxA5 is a genetic risk marker for clinical restenosis after PCI. Association results for the allelic test for 




Annexin A5 prevents post-interventional accelerated atherosclerosis 
development in a dose-dependent fashion
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Table 1
Association between restenosis risk and SNPs in the ANXA5 gene.
SNP Base position Minor/major allele MAF cases/controls OR (95% CI) p Value
rs2306420 122810925 T/C 0.283/0.309 0.88 (0.71–1.10) 0.2622
rs4833229 122820114 A/G 0.481/0.418 1.29 (1.06–1.58) 0.0114
rs1480287 122821231 A/G 0.481/0.215 0.81 (0.63–1.04) 0.0954
rs17449954 122827178 C/T 0.181/0.067 0.86 (0.57–1.30) 0.4705
rs6534309 122829379 C/T 0.058/0.108 0.75 (0.53–1.06) 0.1040
rs6857766 122830735 A/G 0.083/0.230 0.79 (0.62–1.01) 0.0636
rs6830321 122834205 T/C 0.510/0.436 1.35 (1.10–1.64) 0.0034
rs2306416 122837138 CT 0.139/0.145 0.96 (0.72–1.27) 0.7564
Allelic association results for 8 SNPs included in the annexin A5 gene in the GENDER study. Positions are based on hg18 build. Abbreviations: Chr, chromosome; MAF, minor
allele frequency. ORs are computed for the minor allele from the two by two allele contingency table. Significant association was observed for SNPs rs4833229 and rs6830321
and restenosis-risk with SNPs displaying high linkage.
as found in the single SNP analysis (haplotype ACAGTTGTT, fre-
quency: 0.427, OR = 1.27 , p = 0.018). These data link AnxA5 SNPs
to restenosis-risk after PCI and suggest that AnxA5 genotype func-
tions as risk marker for restenosis. We therefore further explored
AnxA5’s therapeutic potential using an in vivo model for restenosis
and intimal hyperplasia.
3.2. Annexin A5 dose-dependently prevents leukocyte
recruitment after vascular injury
Effects of AnxA5 on leukocyte recruitment to injured arterial
segments was investigated in the femoral artery cuff model in
ApoE−/− mice receiving daily vehicle or 0.1, 0.3 or 1.0 mg/kg AnxA5
through IP injection. Total plasma cholesterol was not affected
by annexin A5 treatment (Supplementary Table I). Three days
after cuff placement there is inflammation in the cuffed arter-
ies, with leukocytes both adherent to the endothelial surface and
with cells that have migrated into the media layer (Fig. 2A). Stain-
ing of arterial lesions at this time point revealed that 0.1, 0.3
and 1.0 mg/kg/d AnxA5-treated animals displayed a reduced per-
centage of endothelial leukocyte adhesion by 26.7% (p = 0.014),
34.9% (p = 0.010) and 48.3% (p = 0.001) respectively (Fig. 2B). For
monocytes/macrophages, this percentage was reduced by 40.0%
(p = 0.029), 66.9% (p = 0.001), and 45.0% (p = 0.037) respectively
(Fig. 2C).
The percentage leukocyte infiltration into the media was
reduced by all AnxA5 treatments by 49.4% (p = 0.008), 53.3%
(p = 0.006) and 49.9% (p = 0.011) respectively (Fig. 2D). The per-
centage medial macrophages was reduced by 61.2% (p = 0.025) by
1.0 mg/kg AnxA5, the other dosages did not significantly affect
monocyte/macrophage extravasation (Fig. 2E). Together, these data
indicate an important role for AnxA5 in low dosages in the preven-
tion of leukocyte recruitment to injured arterial segments.
3.3. Annexin A5 dose-dependently prevents accelerated
atherosclerosis development
The inflammation caused by cuff placement leads to an inflam-
mation driven intimal hyperplasia. Therapeutic effectiveness of
AnxA5 on (neo-)intima development was evaluated 14 days after
cuff placement. Annexin A5 treatment did not affect plasma total
cholesterol concentration (Supplementary Table I). Accelerated
atherosclerotic lesion development was measured on sections
stained with HPS and Weigert’s elastin (Fig. 3A). Vehicle-treated
animals developed intimal thickening, resulting in luminal steno-
sis. Quantitative analysis displayed reduced intimal thickening
(expressed as m2 per cross-section) after 0.1, 0.3 and 1.0 mg/kg
AnxA5-treatment by 54.6% (p = 0.041), 71.2% (p = 0.012) and 66.9%
(p = 0.009) respectively (Fig. 3B). Intimal thickening was 38.1% more
reduced (p = 0.031) by 0.3 compared to 0.1 mg/kg AnxA5.
AnxA5 (0.3 and 1.0 mg/kg) also decreased the absolute medial
surface area (m2) by 30.1% (p = 0.012) and 24.1% (p = 0.025, Fig. 3C)
and intima/media ratio by 62.3% (p = 0.004) and 60.3% (p = 0.007,
Fig. 3D), although the lowest dose was ineffective. Furthermore,
luminal stenosis (%) was reduced by 58.0% (p = 0.001) and 58.8%
(p = 0.0004, Fig. 3E), identifying a potent role for AnxA5 in the
control of inflammatory post-interventional vascular remodeling.
Compared to 0.1 mg/kg, 0.3 mg/kg AnxA5 had increased protective
effects on both the intima/media ratio (by 38.5%, p = 0.016) and
luminal stenosis percentage (by 33.2%, p = 0.042). The total vessel
wall diameter and luminal areas were both similar in all AnxA5
dosages, except for 1.0 mg/kg, which displayed 27.1% (p = 0.043)
reduced total vessel area (Supplementary Fig. IA and B).
IHC showed profound intravascular macrophages/foam cell
areas, which co-localized with AnxA5 (Supplementary Fig. IIA
and B) staining at both 3d and 14d after surgery. AnxA5 in all
dosages strongly reduced the accumulation of the percentage of
macrophages/foam cell area (Fig. 4A) in the tunica media (Fig. 4B,
p = 0.0002, p = 0.028 and p = 0.0005 respectively) and in the tunica
intima (Fig. 4C, p = 0.002, p = 0.011 and p = 0.002 respectively) after
14d. The 78 kDa glucose regulated protein/BiP (GRP78) is an ER
protein and associates permanently with mutant or defective incor-
rectly folded proteins, preventing their export from the ER lumen.
ER stress including upregulation of GRP78 is present in unsta-
ble atherosclerotic lesions. We investigated if annexin A5 affected
GRP78 expression in cuffed femoral arteries. AnxA5 in all dosages
strongly reduced GRP78 BiP expressing cells in the media (Fig. 4D)
by 50.2% (p = 0.006), 66.3% (p = 0.0006) and 68.0% (p = 0.004) respec-
tively, but not in the intima (Fig. 4E).
4. Discussion
This study demonstrates an important therapeutic role for
AnxA5 in post-interventional intimal hyperplasia and accelerated
atherosclerosis development. Association between AnxA5 SNPs
and increased restenosis-risk in patients undergoing PCI was found.
Systemic AnxA5 was effective in preventing intimal thickening
and could dose-dependently reduce leukocyte and macrophage
recruitment to injured arterial segments in ApoE−/− mice in 0.3
and 0.1 mg/kg dosages. Finally, we demonstrate that sustained
therapy reduces accelerated atherosclerosis with fewer infiltrated
macrophages/foam cells and UPR-expressing cells in the injured
arterial wall. Together, these date indicate high diagnostic and ther-
apeutic potential for AnxA5 against post-PCI vascular remodeling.
Association between AnxA5 SNPs and restenosis development
were investigated using a large study population that underwent
PCI, the GENDER population. It has already been shown in this
material that mutations in several genes associated with inflam-
mation were associated to restenosis development (24). Our results
demonstrate that SNPs rs4833229 and rs6830321 show significant
association with increased risk for clinical restenosis (OR 1.29 and
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treatment (supplementary table I). Three days after cuff placement there is inflammation 
in the cuffed arteries, with leukocytes both adherent to the endothelial surface and with cells 
that have migrated into the media layer (fig 2A). Staining of arterial lesions at this time 
point revealed that 0.1, 0.3 and 1.0 mg/kg/d AnxA5-treated animals displayed a reduced 
percentage of endothelial leukocyte adhesion by 26.7% (p=0.014), 34.9% (p=0.010) and 
48.3% (p=0.001) respectively (fig 2B). For monocytes/macrophages, this percentage was 
reduced by 40.0% (p=0.029), 66.9%, (p=0.001) and 45.0% (p=0.037) respectively (fig 2C). 
The percentage leukocyte infiltration into the media was reduced by all AnxA5 treatments 
by 49.4% (p=0.008), 53.3% (p=0.006) and 49.9% (p=0.011) respectively (fig 2D). The 
percentage medial macrophages was reduced by 61.2% (p=0.025) by 1.0 mg/kg AnxA5, 
the other dosages did not significantly affect monocyte/macrophage extravasation (fig 2E). 
Together, these data indicate an important role for AnxA5 in low dosages in the prevention 
of leukocyte recruitment to injured arterial segments. 
Figure 2. Annexin A5 dose-dependently prevents leukocyte recruitment after vascular injury. Representative cross-
sections of cuffed-femoral arteries of ApoE-/- mice treated with vehicle or 0.1, 0.3 or 1.0 mg/kg/d AnxA5 (leukocyte 
and macrophage staining, magnification 80x, arrows indicate positive staining) after 3d (A). Quantification of 
intimal adhering leukocytes (B) and macrophages (C) as percentage of all cells within the internal elastic lamina 























































































































































Annexin A5 dose-dependently prevents accelerated atherosclerosis development
The inflammation caused by cuff placement leads to an inflammation driven intimal 
hyperplasia. Therapeutic effectiveness of AnxA5 on (neo-)intima development was  evaluated 
14 days after cuff placement. Annexin A5 treatment did not affect plasma total cholesterol 
concentration (supplementary table I). Accelerated atherosclerotic lesion development was 
measured on sections stained with HPS and Weigert’s elastin (fig 3A). Vehicle-treated animals 
developed intimal thickening, resulting in luminal stenosis. Quantitative analysis displayed 
reduced intimal thickening (expressed as μm2 per cross-section) after 0.1, 0.3 and 1.0 mg/kg 
AnxA5-treatment by 54.6% (p=0.041), 71.2% (p=0.012) and 66.9% (p=0.009) respectively 
(fig 3B). Intimal thickening was 38.1% more reduced (p=0.031) by 0.3 compared to 0.1 mg/
kg AnxA5. 
AnxA5 (0.3 and 1.0 mg/kg) also decreased the absolute medial surface area (μm2) by 30.1% 
(p=0.012) and 24.1% (p=0.025, fig 3C) and intima / media ratio by 62.3% (p=0.004) and 
60.3% (p=0.007, fig 3D), although the lowest dose was ineffective. Furthermore, luminal 
stenosis (%) was reduced by 58.0% (p=0.001) and 58.8% (p=0.0004, fig 3E), identifying 
a potent role for AnxA5 in the control of inflammatory post-interventional vascular 
remodeling. Compared to 0.1 mg/kg, 0.3 mg/kg AnxA5 had increased protective effects 
on both the intima / media ratio (by 38.5%, p=0.016) and luminal stenosis percentage (by 
33.2%, p=0.042). The total vessel wall diameter and luminal areas were both similar in all 
AnxA5 dosages, except for 1.0 mg/kg, which displayed 27.1% (p=0.043) reduced total vessel 
area (supplementary fig IA, B). IHC showed profound intravascular macrophages/foam cell 
areas, which co-localized with AnxA5 (supplementary fig IIA, B) staining at both 3d and 
14d after surgery. AnxA5 in all dosages strongly reduced the accumulation of the percentage 
of macrophages/foam cell area (fig 4A) in the tunica media (fig 4B, p=0.0002, p=0.028 and 
p=0.0005 respectively) and in the tunica intima (fig 4C, p=0.002, p=0.011 and p=0.002 
respectively) after 14d. The 78 kDa glucose regulated protein/BiP (GRP78) is an ER protein 
and associates permanently with mutant or defective incorrectly folded proteins, preventing 
their export from the ER lumen. ER stress including upregulation of GRP78 is present in 
unstable atherosclerotic lesions. We investigated if annexin A5 affected GRP78 expression 
in cuffed femoral arteries. AnxA5 in all dosages strongly reduced GRP78 BiP expressing 
cells in the media (fig 4D) by 50.2% (p=0.006), 66.3% (p=0.0006) and 68.0% (p=0.004) 
respectively, but not in the intima (fig 4E). 
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Figure 4 next page. 
 Annexin A5 leads to a less-inflammatory phenotype with reduced intravascular signs of ER-stress. Representative 
cross-sections of cuffed arteries of ApoE-/- mice receiving vehicle or 0.1, 0.3 or 1.0 mg/kg AnxA5 (A) after 14d 
(macrophages and GRP78 BiP staining, magnification 40x, arrows indicate positive staining) and quantification of 
medial (B) and intimal (C) macrophage/foam cell area (%) and medial (D) and intimal (E) GRP78 BiP expression 
(%). Results indicated as mean±SEM, n=10. * p<0.05, ** p<0.01.
Figure 3 Annexin A5 reduces accelerated atherosclerosis development in a dose-dependent fashion. Representative 
cross-sections of cuffed arteries of ApoE-/- mice receiving vehicle or 0.1, 0.3 or 1.0 mg/kg AnxA5 (A) after 14d 
(HPS and Weigert’s elastin staining, magnification 40x, arrows indicate internal elastic laminae). Quantification of 
intimal thickening (µm2) (B), medial area (µm2) (C), intima / media ratio (D) and luminal stenosis (%) (E). Results 















































































































































This study demonstrates an important therapeutic role for AnxA5 in post-interventional 
intimal hyperplasia and accelerated atherosclerosis development. Association between 
AnxA5 SNPs and increased restenosis-risk in patients undergoing PCI was found. Systemic 
AnxA5 was effective in preventing intimal thickening and could dose-dependently reduce 
leukocyte and macrophage recruitment to injured arterial segments in ApoE-/- mice in 0.3 
and 0.1 mg/kg dosages. Finally, we demonstrate that sustained therapy reduces accelerated 
atherosclerosis with fewer infiltrated macrophages / foam cells and UPR-expressing cells 
in the injured arterial wall. Together, these date indicate high diagnostic and therapeutic 
potential for AnxA5 against post-PCI vascular remodeling.
Association between AnxA5 SNPs and restenosis development were investigated using a 
large study population that underwent PCI, the GENDER population. It has already been 
shown in this material that mutations in several genes associated with inflammation were 
associated to restenosis development (24). Our results demonstrate that SNPs rs4833229 and 
rs6830321 show significant association with increased risk for clinical restenosis (OR 1.29 





















































































































































































excellent stratification of patients that are most at risk for restenosis development, enabling 
individual tailor-made treatment strategy. Additionally, our results support the notion that 
genetic programming of not only pro-inflammatory mediators, but also the endogenous anti-
inflammatory system exerts a significant role in post-interventional remodeling.
In this study, a perivascular cuff-mediated arterial injury model was applied, which allows 
for quick and reproducible lesion formation with continuous blood flow in a patent vessel 
segment, although the perivascular approach rather differs from clinical endovascular injury 
through balloon inflation and stent deployment during PCI. This perivascular approach could 
affect the amount of exposure of subendothelial thrombogenic material and thrombosis, 
which are important targets for AnxA5.
Therapeutic effects were shown to most likely result from local AnxA5 binding to activated 
cells in the injured vascular segment. Local AnxA5 can reduce adherence of platelets 
leukocytes and eventually prevent their inflammatory activation, with reduced signs of ER-
stress and the UPR within these cells. We found reduced GRP78/BiP expression in the tunica 
media (fig 4D) but not in the intima (fig 4E) Prolonged intracellular cholesterol storage leads 
to increased ER stress in cells, which is more likely to occur in foam cells than in early 
monocyte/macrophages. In this study, such cells should predominantly be found among 
cells that have migrated towards the tunica media, which in turn may explain the difference 
between GRP78/BiP expression between the media and intima layers. 
The fact that clearance of AnxA5 is much slower from the arterial wall than from plasma 
(30) and accumulates in the injured vascular wall after systemic injection (23), supports 
the hypothesis that AnxA5 could act anti-inflammatory in levels lower than originally 
investigated (<1.0 mg/kg). Current results confirm this, with AnxA5 already effective in 
reducing leukocyte (fig 2B) and macrophage (fig 2C) recruitment and intimal thickening (fig 
3B) in dosages 3-10 times lower than previously investigated. This would favour clinical 
application, where undesired side-effects can be kept to a minimum.
In conclusion, this study shows that systemic AnxA5 treatment strongly influences post-
interventional accelerated atherosclerosis development and can dose-dependently prevent 
vascular remodeling. AnxA5 has previously been successfully applied to diagnose 
atherosclerotic patients non-invasively (19). These results therefore may have important 
clinical implications. Immune-mediated interventions directed towards therapeutically 
controlling the leukocyte recruitment and vascular remodeling process could strongly benefit 
from systemic AnxA5, which could be applied in an early phase following revascularization 
or bypass grafting to prevent accelerated atherosclerosis development. AnxA5 SNPs could 
function as biomarkers in the assessment of restenosis risk in patients undergoing PCI, 
improving patient screening. Together, these data indicate high clinical potential for AnxA5 
against post-interventional remodeling.
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The GENetic DEterminants of Restenosis (GENDER) study was designed to investigate 
the association between genetic polymorphisms and clinical restenosis (1). In brief, it is a 
large multicenter prospective follow-up study conducted during 1999-2001 and comprised 
of patients treated successfully by percutaneous coronary intervention (PCI) for an acute 
coronary syndrome. Clinical restenosis was established during a nine-month follow-up 
period for death, myocardial infarction and target vessel revascularization (TVR), which 
occurred in 9.8% of all patients. Eight Single Nucleotide Polymorphisms (SNPs) included in 
the AnxA5 gene were extracted from the GENDER genome wide association study (GWAS) 
dataset (2) composed of 866 patients (295 cases that developed restenosis following PCI 
and 571 controls that did not develop restenosis after PCI). The GWAS was conducted using 
Illumina Human 610-Quad Beadchips (Illumina) and the infinium II assay, following the 
manufacturer’s instructions. After genotyping, samples and genetic markers were subjected 
to a stringent quality control protocol, described in detail elsewhere (2). The open source 
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software PLINK (3) was used to perform genetic association analysis. All p values were 
corrected for multiple testing. For linkage disequilibrium (LD) analyses in terms of r2 and 
haplotype block delineation, we used Haploview software (4).
Mice
All experiments were approved by the Institutional Committee for Animal Welfare of the 
Leiden University Medical Center (LUMC). ApoE-/- mice, purchased from the Jackson 
Laboratory (Bar Harbor) on a C57BL/6J background were used for these studies. All animals 
were 10-12 weeks at the start of a dietary run-in period before surgery. ApoE-/- mice were 
fed a Western-type diet containing 0.15% cholesterol (Lantmännen Lantbruk, diet R638). 
The diet was given three weeks prior to surgery and was continued throughout the entire 
experiment. All animals received food and water ad libitum during the experiment.
Femoral artery cuff mouse model
Mice were subjected to arterial femoral arterial cuff placement to induce intimal thickening 
and accelerated atherosclerosis development, as described previously (5-7). In brief, 
animals were anesthetized before surgery with a combination of intraperitoneally (IP)-
injected Midazolam (5 mg/kg, Roche), Medetomidine (0.5 mg/kg, Orion) and Fentanyl 
(0.05 mg/kg, Janssen). The right femoral artery was isolated and sheathed with a rigid non-
constrictive polyethylene cuff (Portex, 0.40mm inner diameter, 0.80mm outer diameter and 
an approximate length of 2.0mm).  
Animals received vehicle (0.9% sterile NaCl) or AnxA5 (Athera Biotechnologies AB) 
through IP injection. Three and 14 days after cuff placement, mice were anesthetized as 
before and euthanized. At sacrifice, blood was drawn in EDTA collection tubes (Sarstedt 
B.V.) and centrifuged at 6000 r.p.m. for 10 min at 4°C to obtain plasma, which was stored 
at -20°C. Next, the thorax was opened and mild pressure-perfusion (100mm Hg) with 
phosphate-buffered saline for 5 min by cardiac puncture in the left ventricle. After perfusion, 
the cuffed femoral artery was harvested, fixed in 3.7% formaldehyde in water (w/v) and 
paraffin-embedded. Serial cross-sections (5 μm thick) were made from the entire length of 
the artery for analysis.
Biochemical analysis
Total plasma cholesterol (Roche Diagnostics, kit 1489437) concentration was measured 
enzymatically before randomization at surgery. 
Quantification of cuffed femoral artery lesions
Immunohistochemical (IHC) staining was performed using positive and negative tissue-
specific controls as indicated by the antibody manufacturer. Samples were stained with 
hematoxylin-phloxine-saffron (HPS) and specific vessel wall composition was visualized for 
elastin (Weigert’s elastin staining) and with antibodies against GRP78 BiP (1:200, Abcam, to 
identify cells displaying signs of UPR), CD45 for leukocytes (1:200, Pharmingen), MAC3 
for monocytes/macrophages/foam cells (1:200, BD Biosciences) and anti-annexin V for 
injected protein accumulation (1:100, BioVision). Using image analysis software (Leica 
Qwin), total cross-sectional medial area was measured between the external and internal 
elastic laminae; total cross-sectional intimal area was measured between the endothelial cell 
monolayer and the internal elastic lamina, as was GRP78 BiP+ surface area. The luminal 
stenosis is expressed as the percentage of surface area (µm2) within the internal elastic lamina 
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(comprised of the luminal and neointimal areas) that is taken up by neointimal tissue (in µm2). 
The number of leukocytes and monocytes/macrophages attached to the endothelium, within 
the neointimal tissue or infiltrated in the medial layer of the femoral arteries was quantified 
and is displayed as a percentage of the total number of present cells. All quantification in this 
study was performed on six equally spaced (150 µm distance) serial stained perpendicular 
cross-sections throughout the entire length of the vessel and was performed by blinded 
observers.
Statistical analysis
All data are presented as mean± standard error of the mean (SEM). Association between 
clinical outcome and individual SNPs was tested using an allelic association test. Groups 
were compared using a Mann-Whitney sum test for non-parametric data. Total plasma 
cholesterol concentrations in time were compared using a Wilcoxon matched pairs test. All 
statistical analyses were performed with SPSS 17.0 software for Windows or using Prism 
software. P-values <0.05 were regarded as statistically significant and are indicated with an 
asterisk (*).
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Supplemental figures
Annexin A5 prevents post-interventional accelerated atherosclerosis 














































































Figure I. Annexin A5 reduces accelerated atherosclerosis development in a dose-dependent fashion. Quantification 
of total vessel area (µm2) (A) and luminal area (µm2) (B) in ApoE-/- mice receiving vehicle or 0.1, 0.3 or 1.0 mg/kg 
AnxA5 after 14d. Results indicated as mean±SEM, n=10. * p<0.05, ** p<0.01, n.s. not significant.
Figure II. Co-localization of injected AnxA5 at macrophage (3d) and macrophage/foam cell (14d) areas after 3d 
(A) and 14d (B). Representative cross-sections of cuffed arteries of ApoE-/- mice receiving vehicle or 1.0 mg/kg 
AnxA5 (MAC3 and annexin A5 staining, magnification 80x, closed arrows indicate positive macrophage and AnxA5 
staining, open arrows indicate projected macrophages in consecutive slides (5 μm distance) in annexin A5 stained 























Plasma total cholesterol (mmol/L) of ApoE-/- mice receiving vehicle or annexin A5 (1.0, 0.3 or 0.1 mg/kg/d) trough 

















Plasma total cholesterol (mmol/L) of ApoE-/- mice re iving vehicle or annexin A5 (1.0, 
0.3 or 0.1 mg/kg/d) trough IP injection, measured at surgery or at sacrifice (day 3 or 14). 
No significant differences were observed (mean±SEM, n=10). 
 
19.8±1.6 19.3±1.6 0.1 mg/kg annexin A5 
19.2±3.3 19.9±4.1 0.3 mg/kg annexin A5 
17.1±2.7 18.0±2.7 1.0 mg/kg annexin A5 
21.1±2.4 23.7±2.7 Vehicle 
Late time point (14d) 
22.8±2.2 19.6±1.8 0.1 mg/kg annexin A5 
20.0±1.7 16.6±0.6 0.3 mg/kg annexin A5 
19.8±1.6 15.4±0.4 1.0 mg/kg annexin A5 
25.0±0.8 19.5±1.3 Vehicle 
Early time point (3d) 
Sacrifice Surgery   
Total plasma cholesterol (mmol/L) Group 
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     “It always seems impossible until it’s done”
        Nelson Mandela
